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effectiveness of inhaled corticosteroids (ICS) alone and
ICS used in combination with a long-acting beta2
agonist (LABA) in the treatment of chronic asthma in
children aged under 12 years. 
Data sources: Major electronic bibliographic
databases, e.g. MEDLINE and EMBASE, were searched
up to February/March 2006 (and updated again in
October 2006).
Review methods: A systematic review of clinical and
cost-effectiveness studies and economic analyses were
carried out. A flexible framework was used to allow
different types of economic analyses as appropriate,
with either a cost comparison or cost–consequence
comparison conducted.
Results: Of 5175 records identified through systematic
literature searching, 34 records describing 25 studies
were included (16 were fully published randomised
controlled trials, six were systematic reviews, and 
three were post-2004 conference abstracts). The most
frequently reported relevant outcomes in the 16 RCTs
were peak expiratory flow rate (13 trials), FEV1
(13 trials), symptoms (13 trials), adverse events or
exacerbations (13 trials), use of rescue medication 
(12 trials), markers of adrenal function (e.g. blood or
urine cortisol concentrations) (13 trials), height and/or
growth rate (seven trials) and markers of bone
metabolism (two trials). In the trials that compared
low-dose ICS versus ICS and high-dose ICS versus ICS,
no consistent significant differences or patterns in
differential treatment effect among the outcomes were
evident. Where differences were statistically significant
at high doses, such as for lung function and growth,
they favoured formoterol fumarate (FF), but this was
generally in studies that did not compare the ICS at the
accepted clinically equivalent doses. Differences
between the drugs in impact on adrenal suppression
were only significant in two studies. At doses of 200,
400 and 800 g/day, beclometasone dipropionate
(BDP) appears to be the current cheapest ICS product
both with the inclusion and exclusion of
chlorofluorocarbon (CFC)-propelled products. In the
trials comparing ICS at a higher dose with ICS and
LABA in combination, most outcomes favoured the
combined inhaler. Only the combination inhaler,
Seretide Evohaler, is slightly cheaper than the weighted
mean cost of all types of ICS at increased dose except
BDP 400 g/day (including CFC-propelled products).
Both the combination inhalers, Seretide Accuhaler and
Symbicort Turbohaler, are more expensive than the
weighted mean cost for all types of ICS at a two-fold
increased dose. Compared with the lowest cost
preparation for each ICS drug, all the combination
inhalers are always more expensive than the ICS
products at increased dose.
Conclusions: The limited evidence available indicates
that there are no consistent significant differences in
effectiveness between the three ICS licensed for 
use in children at either low or high dose. BDP 
CFC-propelled products are often the cheapest ICS
currently available at both low and high dose, and may
remain so even when CFC-propelled products are
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Abstract
Systematic review and economic analysis of the comparative
effectiveness of different inhaled corticosteroids and their usage
with long-acting beta2 agonists for the treatment of chronic
asthma in children under the age of 12 years
C Main,1* J Shepherd,2 R Anderson,1 G Rogers,1 J Thompson-Coon,1 Z Liu,1
D Hartwell,2 E Loveman,2 C Green,1 M Pitt,1 K Stein,1 P Harris,2 GK Frampton,2
M Smith,2 A Takeda,2 A Price,2 K Welch2 and M Somerville1
1 Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and
Plymouth, Exeter, UK
2 Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research and
Development (WIHRD), University of Southampton, UK
* Corresponding authorexcluded. Exclusion of CFC-propelled products
increases the mean annual cost of all budesonide (BUD)
and BDP , while the overall cost differences between the
comparators diminish. There is very limited evidence
available for the efficacy and safety of ICS and LABAs in
children. From this limited evidence, there appear to be
no significant clinical differences in effects between the
use of a combination inhaler versus the same drugs in
separate inhalers. There is a lack of evidence comparing
ICS at a higher dose with ICS and LABA in combination
and comparing the combination products with each
other. In the absence of any evidence concerning the
effectiveness of ICS at higher dose with ICS and LABA,
a cost–consequence analysis gives mixed results. There
are potential cost savings with the use of combination
inhalers compared to separate inhalers. At present
prices, the BUD/FF combination is more expensive than
those containing FP/SAL, but it is not known whether
there are clinically significant differences between them.
A scoping review is required to assess the requirements
for additional primary research on the clinical
effectiveness of treatment for asthma in children under
5 years old. Such a review could also usefully include all
treatment options, pharmacological and non-
pharmacological, for asthma. A direct head-to-head trial
that compares the two combination therapies of FP/SAL
and BUD/FF is warranted, and it is important to assess
whether the addition of a LABA to a lower dose of ICS
could potentially be as effective as an increased dose of
ICS alone, but also be steroid sparing. There is also a
need for the long-term adverse events associated with
ICS use to be assessed systematically.  Future trials of
treatment for chronic asthma in children should aim to
standardise further the way in which outcome measures
are defined. There should be a greater focus on patient-
centred outcomes to provide a more meaningful
estimation of the impact of treatment on asthma control.
Methods of reporting also require standardisation. 
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ContentsGlossary
Chlorofluorocarbon (CFC) A propellant used
in pressured metered dose inhalers. Currently
being replaced by hydrofluoroalkanes (HFA)
propellants.
Cortisol A corticosteroid hormone that is
involved in the response to stress; it increases
blood pressure and blood sugar levels and
suppresses the immune system.
Ex-actuator Used in reference to drug
delivery. The content per actuation which is
reflected in the labelled strength of the drug.
Ex-actuator means metered – the amount of
drug that is delivered from the mouthpiece to
the patient.
Ex-valve Used in reference to drug delivery.
The content per actuation which is reflected in
the labelled strength of the drug. Ex-valve
means metered – the amount of drug delivered
from the inhaler into the mouthpiece.
Forced expiratory volume (FEV1) The
volume of air exhaled in the second of forced
blowing into a spirometer.
Forced vital capacity (FVC) The total
amount of air that a person can forcibly blow
out after full inspiration, measured in litres.
Hypothalamic–pituitary–adrenal axis (HPA
axis) A major part of the neuroendocrine
system that controls reactions to stress and has
important functions in regulating various body
processes such as digestion, the immune system
and energy usage.
Hydrofluoroalkane (HFA) A propellant used
in pressured metered dose inhalers.
Replacement for chlorofluorocarbon (CFC)
propellant.
I2 A measure used to quantify heterogeneity
in a meta-analysis. It describes the percentage
of the variability in effect estimates that is due
to heterogeneity rather than sampling error
(chance). A value greater than 50% may be
considered to represent substantial
heterogeneity.
Peak expiratory flow rate The maximum
rate at which air is expired from the lungs
when blowing into a peak flow meter or
spirometer.
PC20 The provocative concentration of
methacholine to induce a 20% decline in FEV1.
PD20 A value obtained in methacholine
challenge testing to indicate severity of asthma.
Spacer Device attached to an inhaler to
maximise the delivery of the drug to the lungs.
A spacer consists of a container, usually in two
halves that fit together. One end fits to a
mouth-piece or a face-mask (e.g. for young
children). The other end fits to the inhaler.
Spirometry A pulmonary function test,
measuring lung function.
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Glossary and list of abbreviations
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from
the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the
literature, but the term has a constant meaning throughout this review.List of abbreviations
A&E Accident and Emergency 
ACQ-5 Asthma Control Questionnaire 
AE adverse event 
AMD adjustable maintenance dose 
ANCOVA analysis of covariance 
AQLQ Asthma Quality of Life
Questionnaire 
AZ AstraZeneca 
BDP beclometasone dipropionate 
BMD bone mineral density 
BNF British National Formulary 
BTS British Thoracic Society 
BUD budesonide 
CEA cost-effectiveness analysis 
CFC chlorofluorocarbon 
CI confidence interval 
CMA cost minimisation analysis 
COPD chronic obstructive pulmonary
disorder 
CRD Centre for Reviews and
Dissemination 
CUA cost–utility analysis 
DPI dry powder inhaler 
EMEA European Agency for the
Evaluation of Medicinal Products 
FD fixed dose 
FDA Food and Drug Administration 
FEF25–75% forced expiratory flow 
FEV1 forced expiratory volume in
1 second 
FF formoterol fumarate 
FP fluticasone propionate 
FVC forced vital capacity 
GINA Global Initiative for Asthma 
GSK GlaxoSmithKline 
HFA hydrofluoroalkane 
HPA hypothalamic–pituitary–adrenal 
HRQoL health-related quality of life 
ICER incremental cost-effectiveness ratio 
ICS inhaled corticosteroid (e.g. BUD) 
ITT intention-to-treat 
LABA long-acting beta2 agonist (e.g.
salmeterol or formoterol) 
MDI metered-dose inhaler 
MHRA Medicines and Health Care
Products Regulatory Agency 
NICE National Institute for Health and
Clinical Excellence 
OCS oral corticosteroid 
OR odds ratio 
PAHOM Paediatric Asthma Health Outcome
Measure 
PCA Prescribing Cost Analysis 
PEF peak expiratory flow rate 
pMDI pressured metered-dose inhaler 
PP per protocol 
continued
Glossary and list of abbreviations
viiiList of abbreviations continued
PSA probabilistic sensitivity analysis 
PSC posterior subcapsular cataract 
PSS Personal Social Services 
QALY quality-adjusted life-year 
RCT randomised controlled trial 
RD risk difference 
RR relative risk 
RSV respiratory syncytial virus 
SABA short-acting beta2 agonist (e.g.
salbutamol or terbutaline) 
SAL salmeterol 
SD standard deviation 
SE standard error 
SEM standard error of the mean 
SFD symptom-free day 
SFN symptom-free night 
SIGN Scottish Intercollegiate Guidelines
Network 
SMART Salmeterol Multicentre Asthma
Research Trial 
SMD standardised mean difference 
SNS Salmeterol Nationwide Surveillance 
TCM total cortisol metabolites 
WMD weighted mean difference 
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Current asthma management
Various strategies are used in the prevention and
management of asthma. Pharmacological
management includes, among other drugs, inhaled
corticosteroids (ICS) and short- and long-acting
beta2 agonists (SABAs/LABAs). Both ICS and
LABAs are inhaled controller medications that need
to be taken on a long-term daily basis for maximum
symptom control. The medications can be delivered
via a number of different types of inhaler devices;
these differ in the efficiency with which they deliver
the drug to the lower respiratory tract. 
There are currently three ICS available as licensed
preparations for children aged under 12 years:
beclometasone dipropionate (BDP), budesonide
(BUD) and fluticasone propionate (FP). Two of the
ICS are available as licensed preparations in
combination with LABA: FP used in combination
with salmeterol (SAL) and BUD used in
combination with formoterol fumarate (FF).
Objectives
The aims of this health technology assessment are:
● to identify, appraise and synthesise, where
appropriate, the current evidence base on the
clinical effectiveness and cost-effectiveness of
ICS alone and ICS used in combination with a
LABA in the treatment of chronic asthma in
children aged under 12 years
● to identify the costs associated with the different
treatments
● to provide estimates of cost-effectiveness, where
possible, of the different treatment options.
An accompanying health technology assessment
has been conducted in adults and children over
12 years.
Methods
The assessment was conducted within the context
of the British Thoracic Society (BTS)/Scottish
Intercollegiate Guidelines Network (SIGN)
Guideline on the management of asthma.
The assessment comprises a systematic review of
clinical and cost-effectiveness studies and
economic analyses.
For the assessment of clinical effectiveness, a
literature search was conducted on a number of
electronic bibliographic databases (e.g. MEDLINE,
Cochrane CENTRAL and EMBASE) up to
February/March 2006 (and updated again in
October 2006). Systematic reviews and
randomised controlled trials (RCTs) were
included. Only trials testing different drugs using
the same inhaler device/propellant were included.
Therefore, trials testing, for example, BDP via a
pressurised metered dose inhaler (pMDI) versus
BUD via a dry powder inhaler (DPI) were
excluded, as were trials testing, for example, BDP
via hydrofluoroalkane (HFA)-propelled pMDI
versus BUD via chlorofluorocarbon (CFC)-
propelled pMDI. The scope of the review was to
consider the effectiveness of the inhaled steroids,
as opposed to their delivery devices. Some clinical
trials were specifically designed to evaluate device
effects using clinically inequivalent doses. These
were therefore excluded to reduce the likelihood
of confounding.
A flexible framework was used to allow different
types of economic analyses and a cost comparison
or a cost–consequence comparison was conducted
for each review question identified. 
Results 
Clinical effectiveness review
Of 5175 records identified through systematic
literature searching, 34 records describing 25
studies were included. Of these, 16 were fully
published RCTs, six were systematic reviews, and
three were post-2004 conference abstracts.
Noticeably absent from the evidence base are
studies in children and infants aged under 4 years.
The most frequently reported relevant outcomes
in the 16 RCTs were PEF (13 trials), FEV1 (13
trials), symptoms (13 trials), adverse events or
exacerbations (13 trials), use of rescue medication
(12 trials), markers of adrenal function (e.g. blood
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or urine cortisol concentrations) (13 trials), height
and/or growth rate (seven trials) and markers of
bone metabolism (two trials). The detail of
reporting outcomes varied considerably among
the studies.
ICS versus ICS
Five RCTs were identified that compared the three
ICS with each other at low doses (200–400 µg
BDP/day or equivalent) and seven comparing
them at high doses (800–2000 µg BDP/day or
equivalent). No consistent significant differences
or patterns in differential treatment effect among
the outcomes were evident when single ICS were
compared with each other at either low or high
doses at the accepted clinically equivalent doses.
Where differences were statistically significant at
high doses, such as for lung function  [e.g. forced
expiratory volume in 1 second (FEV1) and
growth], they favoured FP, but this was generally in
studies that did not compare the ICS at the
accepted clinically equivalent doses. Differences
between the drugs in impact on adrenal
suppression were only significant in two studies.
Occurrence of adverse events appeared similar.
ICS versus ICS/LABA
Only one trial was identified that compared ICS at
a higher dose with ICS and LABA in combination.
It included a relatively small proportion (~12%) of
children and reported only growth rate and
adrenal function for the child cohort. Growth rate
significantly favoured the combination inhaler
(FP/SAL) whereas no significant difference in
adrenal function between ICS monotherapy (FP)
and the combination inhaler was observed.
The overall trial results (including adults)
significantly favoured combination therapy in
prolonging the time to first severe and mild
exacerbation compared with ICS alone.
Furthermore, combination treatment was
significantly associated with reduced reliever
medication use, improvements in measures of lung
function and the number of night-time
awakenings relative to monotherapy.
Two large, multi-centre trials were identified that
compared ICS at the same dose with ICS and
LABA in combination. In both trials most
outcomes numerically favoured the combination
inhaler (either FP/SAL compared against FP or
BUD/FF compared against BUD). However, in one
of the studies (FP/SAL), it is unclear whether any
of the differences were statistically significant, and
in the other study (BUD/FF) only lung function
outcomes differed significantly.
ICS/LABA versus ICS/LABA
Only one trial was identified that compared
combination inhalers with the same drugs
delivered in separate inhalers. There were no
statistically significant differences in measures of
lung function between the two treatment regimens.
The mean difference in the morning PEF was
within a defined range for clinical equivalence.
No trials have so far been conducted in children
to compare the clinical effectiveness of the two
combination inhalers.
Economic analysis
Results
ICS versus ICS
A cost comparison was undertaken to compare the
costs of ICS at the starting low dose of 200 µg/day,
the maximum low dose of 400 µg/day and the
assumed median ‘high-level’ daily dose of
800 µg/day (all BDP–CFC equivalent doses).
At daily doses of 200 µg (BDP–CFC
equivalent)/day, CFC-propelled BDP appears to be
the current cheapest ICS product. If CFC-
propelled products are excluded from the
available products, BDP is still usually the
cheapest but at a higher annual cost. At doses of
400 µg/day, BDP remains the cheapest ICS
product available both with the inclusion and
exclusion of CFC-propelled products, although the
cost differences between products are smaller
when CFC-propelled products are excluded.
On average, at doses of 800 µg (BDP–CFC
equivalent)/day, although BDP is the current
cheapest ICS product with both the inclusion and
exclusion of CFC-propelled products, it is only
slightly cheaper than BUD or FP. However,
although the use of weighted averages provides a
useful way to compare the mean annual cost
between the different ICS, at all dose levels it
disguises the often large cost differences between
the different preparations of each ICS.
ICS versus ICS/LABA
Only the combination inhaler, Seretide Evohaler,
is slightly cheaper than the weighted mean cost of
all types of ICS at increased dose except BDP
400 µg/day (including CFC-propelled products).
Both the combination inhalers, Seretide Accuhaler
and Symbicort Turbohaler, are more expensive
than the weighted mean cost for all types of ICS at
a two-fold increased dose. Compared with the
lowest cost preparation for each ICS drug, all the
combination inhalers are always more expensive
than the ICS products at increased dose.
Executive summaryICS/LABA versus ICS/LABA
Taking either FP in combination with SAL
(Seretide Evohaler or Seretide Accuhaler) or BUD
in combination with FF (Symbicort Turbohaler) is
cheaper than taking the relevant ingredient drugs
in separate inhalers.
Based on a comparison of the costs only, BUD in
combination with FF (Symbicort Turbohaler) is
more expensive than both the FP/SAL (Seretide
Evohaler or Seretide Accuhaler) combination
drugs currently available.
Discussion
Limitations of the evidence base
This review identified very few trials including
children under the age of 12 years and none
including children under the age of 5 years. The
methodological quality of the included RCTs
varied considerably, and there was considerable
variation in the way in which outcomes were
defined, measured and reported across the
included trials. This variety of definitions makes it
difficult to compare the therapeutic activity of the
different interventions between the trials, and in
this instance makes combining studies in a meta-
analysis inappropriate.
The aim of the trials varied considerably, with
some primarily assessing safety and others
primarily evaluating efficacy. The included trials
also varied in treatment duration from around
6 weeks to 20 months, with the majority lasting
12 weeks. These trials therefore do not adequately
capture the longer term effects of ICS and LABA
therapy, particularly long-term adverse events and
the impact on growth. Additionally, in the majority
of trials it was not clear what constituted the
minimum clinically significant change for many of
the reported outcomes, such as lung function,
symptoms or exacerbations.
The two other issues that have not formally been
assessed in this report are considerations of the
type of inhaler device and concordance, factors
that are inextricably linked. It is well recognised
that a large proportion of the asthmatic population
has difficulty in using particular inhaler devices.
This difficulty relates particularly to pMDIs and to
a less extent to DPIs. Both require the ability to
coordinate the inhalation with activation of the
device. For paediatric populations, the use of a
pMDI is usually combined with a large volume
spacer. However, within the context of a clinical
trial, only those patients who are able to use the
type of device under evaluation effectively will be
eligible for inclusion in the trial. Evidence for the
effectiveness of inhaled corticosteroids and beta2
agonists for asthma from clinical trials should
therefore be considered carefully for its
generalisability to the typical population with
asthma, as opposed to the subgroup of patients
selected for their ability to use the inhaler
effectively. Furthermore, given the probable
device-related variations in both compliance with
correct inhaler technique and adherence to
recommended daily doses, the rate of concordance
with treatment regimens is likely to be
considerably higher in clinical trials than in
routine practice.
ICS versus ICS
When evaluated in pair-wise comparisons, there
were few statistically significant differences
between the three ICS comparators at both low
and high dose. However, although there were no
clear significant differences in treatment effects
between the comparators, they cannot necessarily
be assumed to be equivalent. Rather, there is a
lack of evidence of differential effectiveness from
the trial evidence available, rather than evidence
of equivalence.
At all doses of ICS licensed for use in children,
BDP, both including and excluding CFC-propelled
products, is the cheapest ICS currently available.
When non-CFC-propelled products only are
considered, the mean annual cost of ICS therapy
increases for all three ICS, but the overall cost
differences between the drugs diminish.
ICS versus ICS/LABA
There is very limited evidence available for the
comparative efficacy and safety of ICS and LABAs
in children. Where significant differences between
ICS compared with ICS and LABA have been
identified, they have favoured the latter. Based on
costs only, the extra annual cost of combination
therapy versus an increased dose of ICS alone
varies enormously, depending on the exact ICS
preparation used. On the whole, only Seretide
Evohaler is slightly cheaper than the weighted
mean cost of all types of ICS, except BDP.
However, the combination inhalers are always
more expensive than the lowest cost preparation
of each ICS drug at increased dose.
Use of a combination inhaler is always cheaper
than taking the same ingredient drugs in separate
inhalers. At the present time, the combination
inhaler containing FP/SAL is cheaper than
combinations containing BUD/FF. However, these
Health Technology Assessment 2008; Vol. 12: No. 20
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direct head-to-head trials, and therefore
differences in clinical effects cannot be ruled out.
Conclusions
The limited evidence available indicates that there
are no consistent significant differences in
effectiveness between the three ICS licensed for
use in children at either low or high dose. BDP
CFC-propelled products are often the cheapest
ICS currently available at both low and high dose,
and may remain so even when CFC-propelled
products are excluded. Exclusion of CFC-propelled
products increases the mean annual cost of all
BUD and BDP, while the overall cost differences
between the comparators diminish.
There is very limited evidence available for the
efficacy and safety of ICS and LABAs in children.
From this limited evidence, there appear to be no
significant clinical differences in effects between
the use of a combination inhaler versus the same
drugs in separate inhalers. There is a lack of
evidence comparing ICS at a higher dose with ICS
and LABA in combination and comparing the
combination products with each other.
In the absence of any evidence concerning the
effectiveness of ICS at higher dose with ICS and
LABA, a cost–consequence analysis gives mixed
results.
There are potential cost savings to the NHS with
the use of combination inhalers compared to
separate inhalers. At present prices, the BUD/FF
combination is more expensive than those
containing FP/SAL, but it is not known whether
there are clinically significant differences between
them.
Research recommendations 
A scoping review is required to assess the
requirements for additional primary research on
the clinical effectiveness of treatment for asthma
in children under 5 years old. Such a review could
also usefully include all treatment options,
pharmacological and non-pharmacological, for
asthma.
There is currently no trial evidence available to
inform the relative effectiveness of the two
combination inhalers of FP/SAL and BUD/FF
within a paediatric population. The results of the
current assessment suggest that for FP/SAL there
are no significant differences in effectiveness in
terms of whether the drugs are delivered in a
single inhaler or concurrently in two separate
inhalers. However, as ease of treatment regimen
may potentially affect concordance then a direct
head-to-head trial that compares the two
combination therapies of FP/SAL and BUD/FF is
warranted.
Given the chronic nature of asthma and that
treatment may be necessary on a long-term basis
from childhood, it is important to assess whether
the addition of a LABA to a lower dose of 
ICS could potentially be as effective as an
increased dose of ICS alone, but also be 
steroid sparing.
There is a need for the long-term adverse events
associated with ICS use to be assessed
systematically. Initial searches undertaken for this
assessment indicate that there are at present no
good-quality systematic reviews available that have
assessed all potential long-term adverse events
associated with the three different ICS
comparators. Future reviews should aim to
examine studies of longer term follow-up and use
appropriate data sources such as cohort and
case–control studies and registry data where
available.
Future trials of treatment for chronic asthma in
children should aim to standardise further the way
in which outcome measures are defined. There
should be a greater focus on patient-centred
outcomes such as HRQoL and symptoms. This will
provide a more meaningful estimation of the
impact of treatment on asthma control. Methods
of reporting also require standardisation. 
Executive summary
xivNatural history of asthma
Definition
Asthma is a chronic inflammatory disorder of 
the airways, leading to airway narrowing from
both inflammatory processes and constriction 
of the smooth muscle in airway walls
(bronchoconstriction). Another characteristic of
the pathology of the disease is a process known as
remodelling. This consists of mucus gland and
smooth muscle hypertrophy and increased
collagen deposition in airway walls. Asthma is
characterised by widespread, variable airflow
obstruction and increased responsiveness of the
airways to various stimuli. Resulting symptoms
include recurring episodes of wheezing,
breathlessness, chest tightness and coughing,
particularly at night or in the early morning.
Common risk factors include respiratory (viral)
infections, allergens such as pollens, moulds,
animal fur and house dust mite, cold and
exercise.1,2
Diagnosis
There is no confirmatory diagnostic test or
investigation for asthma. It is usually diagnosed on
the basis of symptoms (wheeze, shortness of
breath, chest tightness and cough) together with
objective tests of lung function such as peak
expiratory flow rate (PEF) and forced expiratory
volume in 1 second (FEV1). Typical asthma
symptoms tend to be variable, intermittent, worse
at night and provoked by triggers (e.g. allergens
or exercise). Variability of PEF and FEV1, either
spontaneously over time or in response to therapy,
is a characteristic feature of asthma which is also
often used in diagnosis.1
Diagnosis of asthma in young children is difficult.
Objective measurements of lung function are often
difficult to obtain and may be unreliable,
particularly in very young children. The Global
Initiative for Asthma (GINA) Pocket Guide for
Asthma Management in Children suggests that
lung function measurement using either FEV1 or
PEF can greatly enhance diagnostic confidence in
those over 5 years of age.3 The British Thoracic
Society/Scottish Intercollegiate Guidelines
Network (BTS/SIGN) Guideline1 recommends that
the diagnosis of asthma in young children is based
on the presence of key features and careful
consideration of alternative diagnoses (e.g. cystic
fibrosis, developmental anomaly, reflux, recurrent
milk aspiration and tuberculosis), the assessment
of potential co-morbidities and the response to
trials of treatment.
Asthma severity
Assessing asthma severity is difficult and depends
on the level of treatment. GINA classifies asthma
severity as intermittent or persistently mild,
moderate or severe based on combined
assessments of symptoms and lung function
(Table 1) for children over 5 years of age. Severity
Health Technology Assessment 2008; Vol. 12: No. 20
1
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Chapter 1
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TABLE 1 GINA classification of asthma severity in children over 5 years of age
Step Symptoms/day Symptoms/night PEF or FEV1
variability (%)
STEP 1 <once per week <2 times per month 80
Intermittent Asymptomatic and normal PEF between exacerbations <20
STEP 2 >once per week but <once per day >2 times per month 80
Mild persistent Exacerbations may affect activity
20–30
STEP 3 Daily >once per week 60–80
Moderate persistent Exacerbations affect activity >30
STEP 4 Continuous Frequent <60
Severe persistent Limited physical activity >30
Source: Pocket Guide for Asthma Management and Prevention in Children.3varies amongst individuals, does not necessarily
correlate with the frequency or persistence of
symptoms and can change in one individual over
time. When an individual is already on treatment,
the classification of severity is based on the clinical
features present and the daily medication regimen
that the individual is currently on. Under this
classification, the presence of one of the features
of severity is sufficient to place an individual in
that category. Individuals at any level of severity
can have severe exacerbations.3
A cross-sectional study of 12,203 patients from 393
general practices in the UK, performed by Neville
and colleagues in 1994–5, reported that the
majority of individuals with asthma in the UK are
treated at Steps 1 and 2 of the BTS/SIGN
Guideline (Figure 1).4 This appears particularly
true for children, in whom only around 10% were
treated at Steps 4 and 5 of the Guideline,
indicating more severe disease.
Asthma exacerbations
There is no generally accepted definition of an
exacerbation, although they can be regarded as 
“a sustained worsening of the individual’s condition
from the stable state and beyond normal day-to-day
variations in symptoms, that is acute in onset and
necessitates a change in regular medication”.5
Asthma exacerbations are characterised by a
progressive increase in shortness of breath, cough,
wheeze or chest tightness or a combination of
these symptoms, accompanied by a decrease in
PEF. Exacerbations can be triggered by a variety of
stimuli, including allergens, viral infections,
pollutants and drugs. Exacerbations are variable
in severity and frequency both between individuals
and within the same individual over time, and
appropriate treatment will reflect both the severity
and the frequency of exacerbations. Minor
exacerbations may be treated by the individual or
their family using high doses of inhaled SABAs or
an increased dose of ICS, although sometimes a
short course of systemic corticosteroids or other
treatments are also needed.1 More severe
exacerbations, although less common, can
potentially be life-threatening, and may require
hospitalisation, treatment and monitoring until
symptoms have stabilised.
Asthma control
The aims of the pharmacological management of
asthma are the control of symptoms, including
nocturnal symptoms and exercise-induced asthma,
prevention of exacerbations and the achievement
of the best possible lung function, with minimal
side-effects.1 A fixed level of lung function or
symptom control is not normally defined as
individuals may have different treatment goals and
may wish to balance these against potential side
effects. The updated 2006 GINA also provides a
classification of levels of asthma control that can
be used as a basis for ongoing treatment decisions
(Table 2). 
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FIGURE 1 Percentage of individuals at each step of the BTS/SIGN Guideline by age group. From a cross-sectional study performed by
Neville and colleagues in 1994–5.Prognosis
The natural history of wheezing in children is well
documented. Longitudinal population studies that
have followed children into adulthood suggest that
in some young children diagnosed with asthma,
wheezing resolves spontaneously whereas in
others, symptoms persist into adulthood.7–13
Various factors including a family history of atopy
(particularly a maternal history of atopy),
coexistence of atopic disease, gender, bronchiolitis
in infancy, parental smoking, birthweight and
prematurity, age at first presentation, severity and
frequency of episodes and lung function
measurements have been demonstrated to
influence the persistence of asthma into
adulthood.7–11,14
Epidemiologists have suggested that there are
several asthma phenotypes reflecting a
heterogeneous collection of conditions that follow
a common pathway (recurrent reversible airways
obstruction) and that these conditions may have
different prognostic outcomes.12,15–17 Identified
phenotypes include transient early wheezing (up
to age 3 years), non-atopic wheezing in preschool
and school-aged children and IgE-mediated
wheezing/asthma. Transient early wheezing is
associated with reduced lung function, prematurity
and exposure to other siblings/children at daycare
centres and is usually not associated with a family
history of atopy. Non-atopic wheezing in
preschool and school-aged children appears to
be associated with viral infection, most commonly
following respiratory syncytial virus (RSV)
bronchiolitis. Studies suggest that RSV infection is
a risk for subsequent wheezing during childhood,
but that this type of wheezing generally resolves by
the age of 13 years. IgE-mediated
wheezing/asthma is associated with atopy and a
genetic predisposition for sensitisation to allergens
and is more likely to persist into adulthood. Early
allergic sensitisation seems to play an important
role in persistent asthma.15–18
Epidemiological studies of the natural history of
lifetime lung function in healthy subjects show
that FEV1 increases during normal growth in
childhood, followed by a stable phase in
adolescence and early adulthood and a slow
decline in FEV1 after the age of 32 years. The
maximum level of FEV1 achieved and the rate of
decline determine the severity of lung function
impairment later in life in symptomatic adults.
Risk factors associated with smaller increases in
lung function and lower maximally attained levels
of lung function in children and adolescents
include lower respiratory tract infections and
passive and active smoking.19–21 The rate of
decline is generally greater in people who smoke
and in those with asthma than in the general
population,22 possibly as a result of deterioration
in potentially reversible disease or the
development of persistent obstruction following
airway remodelling.23 The natural variability in
maximally achievable FEV1 is reflected in
reference values used to calculate lung function as
a percentage of that predicted for a person of
similar height, sex, age and race (weight is also
sometimes considered) without a diagnosis of
asthma (e.g. FEV1 % predicted).
Epidemiology of asthma
Prevalence in the UK
Asthma UK estimate that there are 5.2 million
people with asthma in the UK; this includes
700,000 people over the age of 65 years and
590,000 teenagers, approximately 2.9 million
women and girls and 2.3 million men and boys.24
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TABLE 2 GINA classification of levels of asthma control
Characteristic Controlled (all the following) Partly controlled  Uncontrolled
(any measure 
present in any week)
Daytime symptoms  None (twice or less per week)  More than twice per week
Limitations of activities None Any
Nocturnal symptoms/awakening  None Any
Need for reliever/rescue medication None (twice or less per week) More than twice per week
Exacerbations  None <80% predicted of 
personal best (if known)
Source: Global Initiative for Asthma.6
Three or more
features of partly
controlled asthma
present in any weekThe Health Survey for England commissioned by
the Department of Health in 1997 included data
on self-reported asthma symptoms and diagnosis
and measurements of lung function obtained from
approximately 7000 children.25 The prevalence of
doctor-diagnosed asthma was 23% in boys and
18% in girls aged between 2 and 15 years
(Figure 2). Approximately 19% of boys and 17% of
girls reported wheezing within the preceding
12 months.25
The 1998 figures from the General Practice
Research Database with a sampling frame of 211
general practices in England and Wales indicated
that the prevalence of treated asthma per 1000
patients was 97.0 [95% confidence interval (CI):
93.8 to 100.2] and 132.1 (95% CI: 129.9 to 134.3)
for boys aged between 0–4 years and 5–15 years,
respectively. For girls the corresponding figures
were 62.5 (95% CI 59.8 to 65.2) and 104.1 (95%
CI: 102.0 to 106.1) for each age group.26
Mortality
Asthma deaths are rare; there were 1266 reported
deaths in the UK due to asthma in 2004 (Figure 3)
Most of these (70%) were in people over the age of
65 years; asthma deaths were more common in
women than in men (64 versus 36%). There was
one reported death due to asthma in 2004 among
children younger than 4 years and 37 in those
between the ages of 5 and 14 years. Slightly more
deaths occurred in boys than in girls (23 versus
15). Several audits and case–control studies of
asthma deaths in the UK have been conducted
and suggest that risk factors fall into four
categories: (1) disease severity, (2) medical care
factors both prior to and during the fatal episode,
(3) health behaviour such as reduced concordance
with prescribed medication, poor inhaler
technique and reduced contact with primary care
services and (4) adverse psychosocial factors.
Therefore, a proportion of deaths due to asthma
are preventable, especially in those under the age
of 65 years.27–31
Impact of asthma on health-related
quality of life in children
Health-related quality of life (HRQoL) refers to
the impact of disease and treatment on daily life.
In contrast to the physiological outcome measures
used to define control, the aim of HRQoL
measurement is to assess the impact asthma has
on a person’s daily functioning and emotional
well-being.33 Studies suggest that individuals with
asthma have impaired HRQoL, and that
morbidity as expressed by HRQoL in individuals
with asthma is substantial.34
When considering the impact of asthma, it is
important to acknowledge the differences that
may exist between control of disease, as defined by
clinical measures, and its impact on HRQoL. It
should not be assumed that meeting clinical
treatment goals will necessarily be meaningful to
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FIGURE 2 Percentage of boys and girls (aged 2–15 years) with a doctor diagnosis of asthma in the Health Survey of England 1997.
Source: Health Survey for England 1997.25individuals with asthma, in terms of improvements
in HRQoL.35
In the Living with Asthma Study performed in
Australia, one in five children with asthma did not
ride a bike, play at school or play with animals,
and one in three did not participate in organised
sports.36 The study also reported that parents of
children with asthma were more anxious than
parents of children who did not have asthma. In a
UK study of children with asthma aged between 5
and 17 years, children reported that asthma
restricted their participation in everyday activities
and caused frequent school absences and night
disturbances.37
The assessment of HRQoL in children is
challenging.38,39 HRQoL measures may not be
appropriate for use in paediatric populations, due
to either lack of content validity or differences in
the measurement process itself.
Adult instruments have been used in studies of
HRQoL in children, and additionally several
instruments have been devised for use within
paediatric populations, including the Childhood
Asthma Questionnaire (CHQ),40 the Paediatric
Asthma Quality of Life Questionnaire (PAQLQ),41
the Asthma Symptoms and Disability
Questionnaire (ASDQ),42 the Life Activities
Questionnaire for Childhood Asthma (LAQCA),43
the Paediatric Asthma Health Outcome Measure
(PAHOM),44 the Paediatric Asthma Impact Survey
(PAIS-6), the DYNHA Paediatric Asthma Impact
Survey,45 the About My Asthma (AMA)
questionnaire46 and the Adolescent Asthma
Quality of Life Questionnaire (AAQOL).33 Chiou
and colleagues have also proposed that the
PAHOM, a multi-attribute measure of health in
asthma, may be used to estimate a single index
measure of health status [a quality-adjusted life-
year (QALY) value].44 There are potential
methodological issues with many of these
instruments which may be specific to particular
age ranges within the paediatric study population.
Current service provision
Asthma management in the UK 
As stated previously, the management of asthma in
the UK is largely based on the BTS/SIGN
Guideline.1 The Guideline is evidence-based and
was developed in collaboration with Asthma UK,
the Royal College of Physicians of London, the
Royal College of Paediatrics and Child Health, the
General Practice Airways Group and the British
Association of Accident and Emergency Medicine
using SIGN methodology adapted for UK-wide
utilisation. The Guideline recommends strategies
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FIGURE 3 Asthma deaths by age and sex, registrations in 2004. Source: Office for National Statistics.32for both non-pharmacological and
pharmacological management of chronic and
acute asthma. Only the pharmacological
management of chronic asthma is relevant to this
appraisal and is described in more detail below.
The Guideline advocates a stepwise approach to
pharmacological management, which aims to
achieve early control and to maintain control by
stepping up treatment when control is poor and
stepping down treatment when control is good.
Recommendations differ slightly depending on
the age of the child (Figures 4 and 5). At all levels,
there is an emphasis on checking inhaler
technique and concordance with existing therapy
and the identification and avoidance of trigger
factors before the level of therapy is increased.
Regular review of treatment level and asthma
control is also recommended at all levels, so that
individuals are maintained at the lowest possible
step of the Guideline.
At Step 1 (mild intermittent asthma), inhaled
short-acting beta2 agonists (SABAs) are
recommended as the agent of choice, to be
prescribed as needed. A review of asthma
management with possible movement to Step 2
(introduction of regular preventer therapy) is
indicated if an individual has had exacerbations 
of asthma in the last 2 years, is using inhaled
Background
6
STEP 3: Add-on therapy
In children aged 2–5 years consider trial of
leukotriene receptor antagonist
In children aged under 2 years consider proceeding to step 4
Refer to respiratory paediatrician
STEP 4: Persistent poor control
STEP 1: Mild intermittent asthma
Inhaled short-acting 2 agonist as required
* BDP or equivalent
† Higher nominal doses may be required if drug delivery is difficult
STEP 2: Regular preventer therapy
Add inhaled steroid 200–400 g/day*†
(or leukotriene receptor antagonist if inhaled steroid cannot be used)
200 µg/day* is an appropriate starting dose for many patients
Start at dose of inhaled steroid appropriate to severity of disease
FIGURE 4 Summary of stepwise management in children aged 0–5 years. Source: BTS/SIGN Guideline.1SABAs three times per week or more or is
symptomatic three times per week or more or
waking on one occasion a week. The exact
threshold at which movement to step 2 should be
considered has not been firmly established and
varies between individuals. The recommended
preventer therapy at Step 2 is an inhaled
corticosteroid (ICS) at a starting dose of
200 µg/day [beclometasone dipropionate (BDP)
equivalent; given as 100 µg twice daily]. The
highest recommended dose at this level is
400 µg/day (BDP equivalent), although higher
doses may be required in children less than 5 years
of age if drug delivery is difficult. The dose should
be titrated to the lowest dose at which effective
control of asthma is maintained. If ICS cannot be
used, a leukotriene receptor antagonist is the next
therapy of choice. If asthma control is not
adequate at this level of treatment, movement to
Step 3 may be necessary. In children less than
2 years of age, referral to a respiratory
paediatrician is the recommended course of
action. A trial of a leukotriene receptor antagonist
may be considered in those between the ages of 
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STEP 5: Continuous or frequent use of oral steroids
Use daily steroid tablet in lowest dose providing adequate control
Maintain high dose inhaled steroid at 800 g/day*
Refer to respiratory paediatrician
STEP 3: Add-on therapy
1.  Add inhaled long-acting 2 agonist (LABA)
2.  Assess control of asthma:
  ■  good response to LABA – continue LABA
  ■  benefit from LABA but control still inadequate – continue LABA and 
    increase inhaled steroid dose to 400 g/day* (if not already on this dose)
  ■  no response to LABA – stop LABA and increase inhaled steroid to 
   400  g/day*. If control still inadequate, institute trial of other therapies (e.g. 
    leukotriene receptor antagonist or SR theophylline)
STEP 4: Persistent poor control
Increase inhaled steroid up to 800 g/day*
STEP 1: Mild intermittent asthma
Inhaled short-acting 2 agonist as required
* BDP or equivalent
STEP 2: Regular preventer therapy
Add inhaled steroid 200–400 g/day*
(other preventer drug if inhaled steroid cannto be used)
200 g* is an appropriate starting dose for many patients
Start at dose of inhaled steroid appropriate to severity of disease
FIGURE 5 Summary of stepwise management in children aged 5–12 years. Source: BTS/SIGN Guideline.12 and 5 years. For children between the ages of 5
and 12 years, the first choice of add-on therapy is
a long-acting beta2 agonist (LABA), although
other agents can be used, such as leukotriene
receptor antagonists, theophyllines and slow-
release beta2 agonist tablets. However, anecdotal
reports suggest that leukotriene receptor
antagonists are becoming more popular than
LABAs as a first choice of add-on therapy. If
asthma control remains suboptimal after the
addition of a LABA, the dose of ICS may be
increased to 400 µg/day (BDP equivalent) with or
without the LABA. If asthma control is still
suboptimal, despite treatment with 400 µg/day of
ICS, other agents should be trialled before moving
to Step 4. Step 4 in the under-fives involves referral
to a respiratory paediatrician. In older children
(between 5 and 12 years old), the dose of ICS may
be increased to 800 µg/day. Step 5 involves referral
to a respiratory paediatrician and the addition of a
daily oral corticosteroid tablet at the lowest dose
possible to provide adequate control. There is no
Step 5 in children under the age of 5 years.
Administration of ICS above 400 µg/day (BDP
equivalent) may be associated with systemic side-
effects (see the section ‘Adverse events’, p. 11) and
therefore the monitoring of growth and adrenal
function is recommended. Once control of asthma
is achieved, it is recommended that treatment be
stepped down to the lowest possible level.1
A large proportion of individuals with asthma are
managed within primary care, often within nurse-
led asthma clinics. As part of the new General
Medical Services contract and Quality Outcomes
Framework in England UK, GPs are encouraged to
perform annual reviews on all registered
individuals with asthma within their practice.47
Figures for England for 2004–5 suggest that most
practices are achieving the targets for asthma set
out within the framework.48
Asthma management plans (action
plans)
The use of written plans to aid individuals in the
self-management of their asthma symptoms has
been shown to lead to reduced utilisation of
healthcare resources, days off work or school and
improvements in nocturnal asthma symptoms49
and to protect against death from asthma.50 The
use of action plans is advocated in the BTS/SIGN
Guideline.1 The aim of such plans is to provide
individuals with information that allows them to
respond to changes in their asthma control either
by changing their level of treatment or by seeking
advice from a health professional at the first signs
of an asthma exacerbation. The evidence for their
efficacy in adults with moderate to severe asthma,
treated primarily within the secondary care
setting, is particularly strong.51–53 Plans based on
symptom scores and on measurements of PEF
have both been found to be effective in adults.54
There have been fewer studies conducted on the
effectiveness of action plans in children and these
are further complicated by the fact that either the
parent/carer or the child themselves may be
responsible for monitoring asthma control and
responding appropriately to the guidance
provided in the action plan. However, there is
evidence that children with a written asthma
management plan are at risk of fewer
exacerbations requiring the need for acute
intervention than those without.55 Anecdotal
reports suggest that most children in the UK have
a written asthma management plan that may be
used by either the parent/carer or the child
themselves. Most of these are based on symptoms
rather than measurements of PEF. Despite this
evidence of effectiveness, there is some indication
in the literature that asthma management plans
are not very popular with health professionals or
with individuals.56 Action plans that incorporate
an individual’s personal experience of their
disease are likely to be more successful.57
Concordance
Improving concordance with ICS therapy is
recognised as an important aim for education and
management. Since the effects of ICS can take
several weeks both to manifest themselves
following initiation of therapy and to decline
following cessation of therapy, there may appear
to be little incentive for individuals to take these
medications, as prescribed, for long periods of
time. Anxiety surrounding the risk of adverse
events (AEs) with ICS may also affect concordance,
especially amongst parents of young children.58 A
systematic review conducted in 2000 by Cochrane
and colleagues identified 10 studies that reported
concordance with ICS measured using electronic
devices contained within the inhaler device.59 All
but one of these studies was conducted in adults.
Overall, subjects took the recommended doses of
medication on 20–73% of days. Average
concordance, measured as the ratio of doses taken
to doses prescribed, ranged from 63 to 92%.59 The
study conducted in children was based on only 14
children, and reported 55% of days when children
used less than 50% of the prescribed dose.60 A
further study conducted amongst children in the
USA, also using an electronic device within the
inhaler, reported an average of 50% concordance
with perfect dosing (100% of prescribed daily dose
taken); when the timing of doses was also
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8considered, the concordance was even lower. 
Non-concordance was highest amongst older
children and adolescents, non-white children and
those with poorer functioning families.61 Non-
concordance was associated with a higher
probability of relapse with a need for treatment
with oral corticosteroids. Concordance measured
in these studies may be better than that seen in
the community since individuals were aware that
their concordance with prescribed treatment
regimens was under scrutiny.
An alternative method of measuring concordance
with prescribed medication is to study the uptake
of repeat prescriptions. A study that used records
from the General Practice Research Database in
the UK and included 284,733 individuals
prescribed ICS over a 10-year study period found
that only 42% of individuals obtained a repeat
prescription for ICS within the expected
timeframe of the preceding prescription.62 A
further UK study, conducted in a general practice
in Nottinghamshire, reported that 39% of
individuals with asthma on regular corticosteroids
had requested less than 80% of the expected dose.
The authors comment that this may be due to
non-concordance or due to individuals adjusting
their ICS dose as a result of improvements in
asthma control.63
Poor concordance is associated with poor asthma
control64 and increased exacerbation frequency65
in children. Concordance is likely to be enhanced
if both the parent/carer and the child are involved
and if using inhalers is part of the household
routine.64 There was also an indication from this
study that some parents are apprehensive about
long-term prophylactic treatment and would
rather treat their children’s asthma as a series of
acute events (often requiring courses of oral
corticosteroids).64 Education programmes have
been shown to improve concordance in adults and
may also play a role in improving concordance
within families.66
Description of technology under
assessment
Inhaled corticosteroids
Products available
There are currently three ICS licensed for use in
children in England and Wales.
● Beclometasone dipropionate (BDP) was the first ICS
available in the UK, introduced in 1972. It is
available in metered-dose inhalers (MDIs) with
chlorofluorocarbon (CFC) propellants in both
proprietary [Becloforte and Becotide (Allen and
Hanburys)] and non-proprietary formulations
[AeroBec (3M), Beclazone Easi-Breathe (IVAX),
Clenil Modulite (Trinity Chiesi), Filair (3M),
Filair Forte (3M), Pulvinal BDP (Trinity Chiesi)],
dry powder inhalers (DPIs) [Asmabec Clickhaler
(Celltech), Becodisks (Allen and Hanburys),
Easyhaler (Ranbaxy)] and hard capsule powder
inhalers [BDP Cyclocaps (APS)].
● Budesonide (BUD) is available in MDIs with CFC
propellants in both proprietary {Pulmicort
[AstraZeneca (AZ)]} and non-proprietary
formulations [Novolizer (Viatris)], DPIs
[Pulmicort Turbohaler (AZ)] and hard capsule
powder inhalers [BUD Cyclocaps (APS)].
● Fluticasone propionate (FP) is available in MDIs
with non-CFC propellants [Flixotide Evohaler
(Allen and Hanburys)] and in DPIs [Flixotide
Accuhaler, Flixotide Diskhaler (Allen and
Hanburys)].
Devices
Several types of inhaler device have been
developed in order to deliver drugs directly to the
airways, rather than rely on absorption of oral
preparations.
MDIs may be breath activated or pressurised
(pMDI). They contain the drug either as a
suspension in a carrier liquid or as a solution
which is delivered through a CFC or
hydrofluoroalkane (HFA) propellant. HFA
propellants were phased in to replace CFC
propellants when it was realised that the latter
may have ozone-depleting properties. Studies
show that HFA propellants deliver a greater
proportion of fine particles than CFC propellants
in the same device, resulting in a greater
proportion of the drug being deposited in the
small airways.67 Use of a spacer device in
conjunction with an MDI can also alter patterns 
of lung deposition by delivering a greater
proportion of fine particles.67 Many devices used
in younger children (especially those below the
age of 5 years) incorporate an MDI and a valved
holding chamber or spacer. Using one of these
devices involves inhalation of the drug by
breathing normally through the spacer, rather
than requiring breath activation or other physical
coordination.
DPIs require less coordination by an individual in
order to achieve correct inhaler technique.
However, lung deposition is flow dependent,
requiring a forceful, deep inhalation to trigger 
the device correctly. The higher the flow rate, 
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lung deposition.68 DPIs are often not appropriate
for children below the ages of 5–6 years.
There is a wide variety of available delivery
systems based on these three types of inhaler
device. Inhaler technique, individual preference
and cost are all factors that may guide healthcare
professionals in their choice of inhaler device.
Although potentially important in the decision as
to which ICS might be best suited to an individual,
the comparison of inhaler devices is beyond the
scope of this appraisal.
Inhaler technique
The ability to use an inhaler correctly is essential if
the anticipated dose of an agent is to be delivered
successfully to the correct area within the lungs. A
systematic review of the assessment of correct
inhaler technique identified 15 studies in adults
that evaluated inhaler technique using a variety of
inhaler devices (including MDIs and DPIs).59
Physicians assessed inhaler technique as ‘good’ in
between 5 and 86% of subjects. Coordination of
MDI activation with onset of inspiration was cited
as a task which individuals found particularly
difficult (17–68% of individuals were unable to do
this in this set of studies).59 In several studies,
education improved technique, but the amount of
improvement was variable (from 6 to 46% in one
study69). Studies in children suggest that this facet
of effective asthma therapy is even more
problematic and that repeated comprehensive
education is necessary to ensure adequate inhaler
technique.70,71
Mechanism of action
ICS suppress inflammation in the lungs and are
the mainstay in the prophylactic treatment of
chronic asthma. Regular treatment with
corticosteroids reduces inflammation, swelling and
mucus production in the lungs, resulting in better
airflow in and out of the airways, fewer
exacerbations, better control of symptoms and
lung function and ultimately a reduction in
hospital admissions and deaths from asthma.72–74
The anti-inflammatory effects may take between 1
to 3 weeks to become apparent and it may take up
to 12 weeks of regular daily treatment before
maximum benefit is seen. However, the length of
time taken to achieve maximal treatment benefit is
dependent on both asthma severity at baseline
and the outcome measure used to assess treatment
effect.75,76 Those with severe asthma when ICS
treatment is started may take longer to achieve
maximal treatment effect than those with mild
asthma.75 ICS are often referred to by individuals
with asthma as ‘preventers’.
Pharmacology
The mechanism of action of corticosteroids in
asthma has not been fully elucidated. However,
corticosteroids are known to exert their effects by
binding to a glucocorticoid receptor located in the
cytoplasm of target cells. Once activated, the
drug–receptor complex moves into the nucleus of
the cell and binds to the DNA and directly or
indirectly regulates the transcription of target
genes. Control of inflammation is believed to be a
result of an increase in the transcription of anti-
inflammatory genes and a decrease in the
transcription of inflammatory genes.77 The
potency of a given corticosteroid is governed by
the affinity of the drug to bind to the
glucocorticoid receptor. Receptor affinity is usually
measured relative to dexamethasone. Of the
corticosteroids currently licensed for use in
children, FP has the highest relative receptor
affinity, followed by the active metabolites of BDP
(BDP 17-monopropionate) (Table 3).
One of the currently available corticosteroids
(BDP) is also a prodrug, i.e. a pharmacologically
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TABLE 3 Pharmacodynamic and pharmacokinetic characteristics of currently available ICS
ICS RRA Oral bioavailability  Pulmonary bioavailability (%)  Comments Refs
(%) (device)
BDP 53 15–20 55–60 (HFA–MDI) 78
17-BMP 1345 26 36 (CFC–MDI) Active metabolite of BDP 78
BUD 935 11 18 (CFC–MDI) 79,80
FP 1800 <1 17 (DPI)
26 (CFC–MDI)
29 (HFA–MDI) 81,82
RRA, relative receptor affinity.inactive compound which is activated by esterases
found only in the lungs.77 This mechanism should
serve to decrease the occurrence of local side-
effects with this agent.
Due to the ubiquitous nature of the glucocorticoid
receptor, corticosteroids act on a wide range of cell
types and are therefore capable of producing
unwanted systemic effects in addition to their anti-
inflammatory actions (see the next section). In
theory, by administering corticosteroids directly to
the airways via inhaler devices, smaller doses of
the drug are required, drug concentrations at the
site of action are higher and the likelihood of
systemic side-effects is reduced. However, the
pharmacokinetics of each individual product will
substantially modify these effects.
The bioavailability of ICS determines the extent of
systemic side-effects and is a measure of the rate
and extent at which the drug reaches the target
site and the systemic circulation. After inhalation,
a large proportion of the dose is swallowed. Oral
bioavailability depends on absorption
characteristics from the gastrointestinal tract and
the extent of first-pass metabolism and ranges
from 1% (FP) to 26% (active metabolite of BDP)
for currently available compounds (Table 3).
Pulmonary bioavailability depends on the amount
deposited in the lungs, will differ for different
delivery devices and ranges from 17% for FP
delivered via a DPI to 55–60% for BDP delivered
via an MDI with HFA propellant. (Table 3).78–82
Once it reaches the circulation, most of the
absorbed drug binds to plasma proteins and only
the unbound fraction is pharmacologically
active.78–84 All currently available ICS are cleared
by the liver.
Adverse events
AEs associated with ICS use can be categorised
into local or systemic events. There appears to be
a wide spectrum of level of concern amongst
clinicians about the occurrence of AEs as a result
of therapy with ICS. Anecdotally, some clinicians
appear to be very aware of the risk of systemic
AEs, whereas others are reassured by the low
frequency at which they are encountered in
practice.
Local AEs with ICS use are less frequently
observed in children than in adults.
● The occurrence of dysphonia or other
noticeable voice changes during treatment with
BUD in children is similar to placebo.209
Additionally, oral candidiasis is reasonably rare,
being observed in ~1% of children treated with
ICS. When this is observed, its prevalence
appears to be positively correlated with total
daily dose and dosing frequency.85,86 Other risk
factors for the development of oral candidiasis
include concomitant antibiotic therapy,
concomitant nasal or systemic corticosteroids
and immunosuppression. Candida overgrowth is
usually the direct result of local corticosteroid
inhibition of the normal host defence functions
of neutrophils, macrophages and T lymphocytes
at the oral mucosal surface. Therefore,
overgrowth can be reduced by use of a spacer
device, decreasing the dosing frequency and
rinsing the mouth after drug administration. 
● The AEs of cough, throat irritation and
bronchoconstriction are thought to be caused
primarily by upper airway irritation by the
propellants or surfactants present in the
aerosol. This reaction, which may be most
marked after upper respiratory tract infections,
can prevent adequate deposition of the inhaled
steroid in the lungs, and thereby cause a
worsening of asthma symptoms. These post-
inhalation symptoms can be reduced by
pretreatment with a bronchodilator, use of a
spacer device, use of a slow inhalation
technique or a change to a dry powder
formulation.87
Systemic AEs occur as a result of the amount of
drug that reaches systemic circulation by
absorption through the lungs or the
gastrointestinal system. As previously outlined, this
is influenced by the pharmacokinetics of the ICS,
the site of deposition and inter-individual
characteristics that may influence the risk of
systemic AEs. Accurate assessment of systemic AEs
associated with ICS use is often confounded by the
concomitant use of other steroid preparations,
such as oral or nasal inhaled steroids.85,88,89 The
most commonly occurring systemic adverse events
potentially associated with long-term ICS use are
adrenal suppression, growth retardation in infants,
children and adolescents, osteoporosis, skin
thinning and easy bruising, cataract formation and
glaucoma.
The effects of ICS on suppression of
hypothalamic–pituitary–adrenal (HPA) function
have been well documented.89–91 In general,
studies have indicated that HPA axis suppression
is associated with the use of doses exceeding the
equivalent of 1500 µg/day of BDP or BUD in
adults (the equivalent of 400 µg/day of BDP or
BUD in children). The effect appears to be more
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ranging studies in adults and children indicate
that single doses of FP exhibit three-fold greater
adrenal suppression than BUD, on a microgram
equivalent basis.97 One randomised controlled
trial (RCT) compared the effects of FP
1500 µg/day and BUD 1600 µg/day with placebo
in both healthy participants and participants with
moderately severe asthma over 7 days.98 The trial
used the outcomes of urinary levels of total
cortisol metabolites (TCM), morning serum
cortisol levels and osteocalcin levels as markers of
corticosteroid absorption. Results indicated that
FP had a greater effect on the two markers of the
HPA axis (TCM and morning serum cortisol
levels) than BUD, although neither difference was
significant. Conversely, BUD was associated with a
significant difference in reduced osteocalcin
concentration levels in both healthy and asthmatic
participants relative to FP.
Further studies conducted in paediatric
populations suggest that between one-quarter and
two-thirds of children on high-dose ICS will show
biochemical adrenal suppression on sensitive
testing.232 Estimates of the prevalence of
suppression have varied somewhat depending on
the populations studied and the methods used to
characterise adrenal suppression, and accordingly
vary between 25%233 and 70%.234
There have also been cases of adrenal crisis
associated with ICS use documented in the
literature.99,100 A survey of the frequency of
adrenal crisis associated with ICS use99 showed
that from an initial 2912 questionnaires, 33 cases
of adrenal crisis were identified. Twenty-eight of
the cases were identified in children and five in
adults. Of these 33 patients who had received ICS
in the range 500–2000 µg/day, 30 (91%) had
received FP, one (3%) FP and BUD and two (6%)
BDP. In all these patients except one, the duration
of oral corticosteroid therapy in the previous
12 months was estimated to be less than 21 days.
Overall, although the biochemical changes in
markers of HPA axis suppression are unequivocal,
their clinical importance remains unclear, and
even at high doses of ICS there remains significant
inter-individual variability, with many patients
demonstrating little or no evidence of adrenal
suppression.92,93
The effect of ICS on growth in children has been
a controversial issue. A number of short-term
studies using knemometry (measurement of 
lower limb length using highly accurate measures)
have demonstrated that high-dose ICS use is
associated with short-term growth
suppression.101–103 Although the exact 
mechanism of action is not known, it is thought 
to be secondary to subnormal androgen secretion
followed by suppression of growth hormone
production.104 However, the majority of studies
have only assessed short-term linear growth and
have not assessed long-term growth and the
effects on final adult height. A number of other
factors also make the assessment of the effects of
ICS use on short-term growth rates difficult,
including the fact that nutritional status, growth
hormones and sex hormones will affect growth to
different extents at various ages, growth can be
slower in winter when the requirement for ICS
treatment may be increased, the type of
inhalation device used may influence lung
deposition and systemic availability, and poorly
controlled asthma is known to inhibit growth
rates.102,105,106 Longer term studies that have
assessed final adult height have indicated that
although growth may temporarily be suppressed,
there was no association between ICS use and
final adult height attained.102,106
One of the major concerns of long-term ICS use is
the potential for AEs on bone turnover, resulting
in an increased risk for osteoporosis and fracture.
This is mediated through the inhibition of
osteoblast function (bone formation) and by
increasing osteoclast function (leading to increased
bone resorption). These act indirectly by
inhibiting intestinal calcium absorption and renal
calcium reabsorption, causing secondary
hyperparathyroidism. A number of studies have
assessed the effects of high dose ICS use on
markers of serum osteoclastin and urinary
hydroxyproline.107,108 These studies have shown
mixed results, with some demonstrating decreased
bone formation and increased bone reabsorption
in a dose-dependent manner,107,108 whereas others
have shown no effects on plasma osteoclastin
concentrations at doses of BDP and BUD as high
as 2000 µg/day.109 Similarly, high doses of both
BDP and BUD have also not shown any effect on
urinary calcium excretion, intestinal calcium
absorption, serum calcium, phosphate or
parathyroid hormone levels.110,111 In relation to
bone density, there is limited evidence from two
studies that high dose ICS use for a duration of
3 years was associated with an 18% reduction in
lumbar spine density111 and a reduction in both
lumbar spine and femoral neck density.112
However, in both of these studies all subjects had
previously received treatment with oral
corticosteroids. Additional evidence from a cross-
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median cumulative dose of 876 µg/day over a 
6-year period, indicated that there was a negative
association between cumulative steroid dose and
bone mineral density (BMD) at the lumbar spine,
femoral neck, Ward’s triangle and trochanter, both
before and after the adjustment for the effects of
age and sex.113 A doubling of the dose of ICS was
associated with a decrease in BMD at the lumbar
spine of 0.16 standard deviation (SD) (95% CI
0.04 to 0.28). Decreases of a similar magnitude
were observed at the femoral neck, Ward’s triangle
and trochanter. The majority of the study
participants were from a primary care population
with relatively mild asthma, so that potentially
neither the underlying disease itself not a
substantial use of oral corticosteroids were
probable confounders. Additionally, the study
participants were between 20 and 40 years of age,
so that the confounding effects of age and
menopausal status were minimised. However, the
exact implications of the findings of an association
between cumulative dose of ICS and reductions in
BMD from the study would need to be verified in
a longitudinal study, particularly since bone loss
with oral corticosteroid therapy is time dependent
and most rapid in the first 12–24 months of
treatment duration.114
Three further studies conducted in children have
shown that doses of BDP and BUD up to
800 µg/day did not affect bone density,115,116 and
the lumbar spine density of children receiving
BDP 300–400 µg/day for 6 months was not
different from that of the control group.117
Overall, the long-term consequences of
administering ICS for many decades from early
childhood are not known.
There is evidence that the use of high-dose ICS is
associated with skin thinning and easy
bruising.118,119 One study showed that skin
thickness measured by an ultrasound scan was
significantly reduced by 15–19% in subjects on
BDP 1000–2250 µg/day compared with controls.118
In addition, the prevalence of bruising was
significantly higher at 48% in this patient
population compared with 12% in the control
population.118 The results of a further survey also
indicated that easy bruising was the commonest
reported symptom, with the use of ICS occurring
in almost half of the individuals.119 The relative
risk of easy bruising was more than double that of
a population of a similar age and sex distribution
not taking ICS. This risk also increased with age,
dose and duration of therapy.119 The presence of
skin bruising can be considered a visible marker of
the AEs of ICS therapy on collagen turnover in
connective tissue. However, it is unclear whether
early susceptibility to skin bruising relates to
effects on collagen in other systemic tissues such
as bone.120 Therefore, the absence of skin bruising
cannot necessarily be taken as a guide to the safety
of a given dose of ICS.
Posterior subcapsular cataract (PSC) is a well-
recognised complication of treatment with oral
corticosteroids, with the incidence increasing with
both dose and duration of treatment.121,122 The
incidence also depends on the individual’s age
(particularly in children) and ethnic origin, with
Hispanic people being more susceptible to
development of PSCs.121 However, the evidence of
an association between ICS use and development
of a PSC is equivocal and often confounded by
previous exposure to oral corticosteroid therapy.
Three studies have reported no association
between long-term low- and high-dose ICS
therapy in adults and the prevalence of
PSCs.123–125 A further population based survey
reported that after adjustment for age and sex, the
relative prevalence ratio for corticosteroid versus
no corticosteroid exposure was 1.9 (95% CI 1.3 to
1.9) for posterior subcapsular, 1.5 (95% CI 1.2 to
1.9) for nuclear, and 1.1 (95% CI 0.9 to 1.3) for
cortical cataracts.126 The relative prevalence ratio
of posterior subcapsular cataracts for a lifetime
dose of BDP of >2000 µg/day was 5.5 (95% CI 2.3
to 13.0).126
As cataracts in children are very rare, even large
increases in risk may be missed in studies of
children and adolescents.127 The results of one
study found no increased risk for the development
of cataracts after an average of 5 years of follow-
up,124 and when cataracts have been found in
studies, participants have had numerous courses of
oral corticosteroids.125
There have also been case reports suggesting that
ICS use may be associated with the development
of ocular hypertension or open-angle
glaucoma.128,129 The results of one case–control
study showed that after adjustment for age, sex,
diabetes, systemic hypertension and the use of
ophthalmic or oral corticosteroids, there was no
association between current use of inhaled or
intranasal corticosteroids and an increased risk for
ocular hypertension or open-angle glaucoma.
However, those individuals who were using high
doses of corticosteroid on a regular basis for
3 months or more were at a small, significantly
increased risk, with an odds ratio (OR) of 1.44
(95% CI 1.10 to 2.06).130
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Products available
There are currently two LABAs licensed for use in
children in England and Wales:
● Salmeterol (SAL) is available in MDIs with CFC
propellants [Serevent (Allen and Hanburys)]
and in DPIs [Accuhaler (Allen and Hanburys)
and Diskhaler (Allen and Hanburys)].
● Formoterol fumarate (FF) (previously known as
eformoterol) is available in MDIs with non-CFC
propellants [Altimos Modulite (Trinity Chiesi)]
and in DPIs [Oxis Turbohaler (AZ) and Foradil
(Novartis)].
Combination products available
Both of these products are licensed for use in
combination with an ICS in the following
combinations:
● BUD combined with FF (BUD/FF) is available
in DPIs [Symbicort Turbohaler (AZ)].
● FP and SAL (FF/SAL) is available in MDIs with
non-CFC propellants [Seretide Evohaler (Allen
and Hanburys)] and DPIs [Seretide Accuhaler
(Allen and Hanburys)].
BUD/FF is licensed for use in children aged over
6 years and FP/SAL in children aged over 4 years.
Mechanisms of action of LABAs
LABAs produce sustained bronchodilation
(relaxation of the airways), improving airflow in
and out of the lungs. In contrast to SABAs (e.g.
salbutamol, terbutaline), which are used for quick
relief of symptoms, these compounds are
administered on a regular basis for long-term
control of symptoms.
Pharmacology
The two currently available LABAs (SAL and FF)
are highly selective beta2 adrenoceptor agonists
which produce a bronchodilator effect lasting for
at least 12 hours after a single inhalation. They act
principally on smooth muscle beta2 adrenoceptors,
which are widely distributed throughout the
bronchial tree; the highest density of beta2
adrenoceptors is found in the alveoli.131 Both
agents are highly potent (i.e. they are effective at
low concentrations). Comparative studies suggest
that the potency ratio is approximately 5:1
(FF:SAL) for both systemic side-effects seen in
healthy volunteers132,133 and bronchodilator effects
seen in people with asthma.134 Onset of
bronchodilation with FF is within 2–3 minutes
whereas the onset of bronchodilation with SAL
takes approximately 10 minutes and the maximal
effect may not be apparent for several hours.135
FF is more lipophilic than SAL and has a much
higher degree of intrinsic agonist activity.136 In
addition to bronchodilator effects, LABAs also
provide protection from a number of stimuli
causing bronchial hyper-responsiveness, such as
methacholine, cold air, exercise, hyperventilation
and histamine.137 Despite some indication of anti-
inflammatory activity in laboratory experiments,
neither SAL nor FF has been shown to have anti-
inflammatory effects in individuals with
asthma,138,139 although preliminary evidence
suggests that LABAs might have some mild anti-
inflammatory effects when given in combination
with ICS (see the section ‘Combination inhalers’,
p. 15) as a result of inadvertent potentiation of the
effects of the ICS.140 The main adverse effects of
LABAs relate to their systemic activity (see the
next section). Both drugs are relatively well
tolerated at recommended doses but their
therapeutic window is fairly narrow.132
Adverse events
Most AEs related to the use of LABAs are a result
of systemic absorption (due to stimulation of beta2
adrenoceptors in the heart, peripheral vasculature
and skeletal muscle) and are dose-related. At
standard doses, AEs such as tachycardia, increase
in the QTc interval, hypokalaemia,
hyperglycaemia and tremor are minimal in most
individuals.137 At higher doses (which may be
relevant during an acute asthma attack), both SAL
and FF produce dose-related effects on heart rate,
diastolic and systolic blood pressure, QTc interval
and plasma potassium levels.132
Tolerance
Tolerance to the effects of regular LABA exposure,
as a result of down-regulation of beta2
adrenoceptors, may result in a diminution of
response and associated worsening of disease
control. This has been the subject of much basic
and clinical research.141–146 Whereas down-
regulation of beta2 adrenoceptors has been
demonstrated in laboratory studies, most large
clinical trials of LABAs have shown that tolerance
to the bronchodilator effects of LABAs is not a
significant clinical problem.136 Tolerance to the
bronchoprotective effects of LABAs against
bronchoconstrictor stimuli such as methacholine
challenge or exercise has been demonstrated in
clinical studies.147–150 Although bronchoconstrictor
challenges are considered to be a surrogate for
conditions during an asthma exacerbation,
whether these laboratory-conducted studies are
relevant to the everyday treatment of asthma with
LABAs is unclear. There is also some evidence to
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might be a reduced response to SABAs, although
some of the studies in this area are difficult to
interpret.136,137
Combination inhalers
Pharmacology
LABAs and ICS affect different aspects of asthma
control; several studies have demonstrated the
superiority of the combination of agents over
increasing the dose of ICS.151–153 Whether the
combined effect is additive or synergistic (i.e. the
combined effect is greater than the sum of the
effects due to the individual agents) has been the
subject of much research, both basic and clinical,
and remains controversial.154–156
There are no apparent differences in systemic
pharmacodynamics or pharmacokinetics when
inhaled SAL and FP are given separately or in
combination.157
Effect of LABAs on life-threatening asthma
attacks and asthma-related deaths
Concerns have been raised in the literature
regarding the potential association between
treatment with a LABA and an increased risk of
death due to asthma. This association, however,
has remained uncertain, since it can be suggested
that a high level of beta2 agonist use is probably
directly correlated with severity of asthma, and
that those with more severe asthma are at greater
risk of death.158 Two post-marketing surveillance
studies have therefore assessed the safety of SAL
and salbutamol versus either each other or
placebo,159,160 and the US Food and Drug
Administration (FDA) has re-analysed data from
three clinical trials161,162 submitted in support of
the approval of Foradil Aerolizer for marketing in
the USA.163 Only one trial has assessed the
association between LABA use and life-threatening
asthma attacks in a paediatric population. This
trial was of FF. No trials have been conducted in
children with SAL alone.
Salmeterol Nationwide Surveillance (SNS) study
The SNS study conducted in the UK in 1990–1,
randomised 25,180 patients with asthma who were
considered to require regular bronchodilator
treatment.159 Patients were randomised to receive
either SAL 50 µg twice daily (n = 16,787) or
salbutamol 200 µg four times daily (n = 8393) in
combination with their previously prescribed
asthma drugs for 16 weeks. Approximately three-
quarters of the patients were taking either an oral
or ICS. The incidence of drug-related serious AEs
was similar in both groups (1.19% versus 1.15%,
respectively), but a significantly lower rate of
severe, non-fatal asthma-related AEs was observed
in the SAL group compared with the salbutamol
group (9.9% versus 1.6%, respectively). The
incidence of the combined trial end-point of
respiratory and asthma-related deaths was not
significantly different between the SAL and
salbutamol treatment groups (0.07% versus 0.02%,
respectively).159
Salmeterol Multicentre Asthma Research Trial
(SMART)
SMART was a randomised, placebo-controlled
study that compared the effects of adding SAL
with usual asthma therapy.160 Patients were
randomised to receive either SAL 42 µg twice daily
via an MDI or placebo twice daily for 28 weeks.
The planned safety interim analysis was conducted
after 26,355 patients had been randomised. At
this point, the trial was terminated as it was found
that the overall rate of death was higher in
patients treated with SAL compared with placebo.
The interim analysis indicated that the occurrence
of the primary outcome (combined respiratory-
related deaths or life-threatening asthma attacks)
was low and not significantly different between the
groups. However, there was a small but significant
increase in respiratory-related deaths (24 versus
11) and asthma-related deaths (13 versus three) in
patients receiving SAL compared with placebo.
Further post hoc analysis showed that compared
with placebo, a higher rate of asthma-related
deaths occurred in the SAL group in both white
(0.01 versus 0.07%) and African Americans (0.04
versus 0.31%). However, the overall estimates of
excess deaths attributable to SAL were greater in
the African American trial patients due to a higher
event rate. It was also observed that the occurrence
of asthma-related deaths and life-threatening
experiences was similar in both groups in those
patients using ICS at baseline (16 versus 13,
respectively). However, overall the trial was not
designed or conducted in a manner that allows for
any conclusions to be drawn regarding whether or
not ICS significantly modify the risk of death or
experiencing a life-threatening episode
purportedly associated with the use of SAL.160
Combined FF trials
Three pivotal randomised, placebo-controlled,
double-blind trials submitted to the FDA by
Novartis Pharmaceuticals in support of the
approval of Foradil Aerolizer for marketing in the
USA have been assessed for reports of serious
asthma exacerbations.161,162 Two of the trials were
conducted in adults and one in a paediatric
population. The two 12-week trials that were
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12 µg twice daily or 24 µg twice daily with either
albuterol 180 µg four times daily or placebo. Both
the 12 and 24 µg twice daily doses of FF were
significantly more beneficial in terms of
improvement in the primary end-point of FEV1 at
the 12-week follow-up. Neither of the trials showed
a statistically significant benefit for FF 24 µg twice
daily compared with FF 12 µg twice daily. However,
the rate of serious asthma exacerbations was higher
in the FF 24 µg twice daily dose group compared
with the groups receiving placebo or albuterol or
the group randomised to 12 µg twice daily of FF.
In the two 12-week trials in adults/adolescents, 9
patients in the FF 24 µg twice daily group
experienced a serious asthma exacerbation, all of
which required hospitalisation. One patient died
due to a cardiorespiratory arrest. In comparison,
two placebo group patients experienced a serious
but non-fatal asthma exacerbation, both of which
required hospitalisation. In the trial that was
conducted in a paediatric population for 1 year, 11
patients in the FF 24 µg twice daily group had a
serious non-fatal asthma exacerbation compared
with eight patients in the FF 12 µg twice daily
group and no patients in the placebo group.
Summary of the risk of mortality or serious
asthma exacerbation associated with LABA use
The results from trials and post-marketing
surveillance studies provide conflicting evidence
on any increased risk of mortality or serious
asthma exacerbations associated with the use of a
LABA. The majority of prospective trials show a
decrease in exacerbation rates with the use of a
LABA either in addition to an ICS or used alone.
Additionally, no significant excess in mortality or
the rate of severe exacerbations is generally
observed. However, the majority of these trials are
relatively short term and are usually not powered
to detect relatively rare AEs. In contrast, post-
marketing surveillance studies have showed mixed
results regarding an increased risk of either severe
AEs or mortality with LABA use. The results of the
SNS159 indicated that there were fewer severe non-
fatal AEs with the use of SAL compared with
salbutamol, and there were no significant
differences in the mortality rates between the
groups. In contrast, the results of SMART160
showed that there was a significantly higher rate of
respiratory and asthma-related deaths in the SAL
group compared with the placebo group. No
difference in the primary composite outcome was
observed between the groups. Likewise, the three
trials that assessed the use of FF indicated that
there is an excess risk of severe exacerbation
associated with higher doses of FF (24 µg twice
daily,) compared with either lower doses of FF
(12 µg twice daily), albuterol or placebo.
Overall, it is difficult to quantify the excess risk of
severe exacerbation associated with the use of
either SAL or FF, but it appears to be reasonably
rare. However, the degree to which this reflects the
use of a LABA alone, and may be attenuated by
the use of combination ICS plus LABA therapy
warrants further investigation in future post-
marketing surveillance studies.
FDA actions on the use of LABAs. The FDA has
recently asked for a ‘black box’ warning to appear
on the labels of products containing SAL. The
labelling includes a warning about a small, but
significant, increased risk of life-threatening
asthma episodes or asthma-related deaths with the
use of SAL. A similar warning has also been
included in the prescribing information. The
labelling for FF remains unchanged.
Economic aspects of asthma
The research literature on economic aspects of
asthma is large and diverse. Although it is
dominated by economic evaluations comparing the
cost-effectiveness of alternative treatments for
asthma, it also includes cost-of-illness studies, cost
analyses of particular treatments, longitudinal
studies, regression analyses of claims databases and
other studies to elicit patient preferences about
different types of treatment and care provision.
Our aim in the following sections is to (1) give a
broad overview of those economic aspects of asthma
that have been identified in the research literature,
focusing especially on studies conducted in the UK
and/or focusing on asthma in children, and (2)
attempt to identify the key causal relationships and
trade-offs that seem to exist between resource use
and the nature of chronic and acute asthma in
children, in order to characterise best the current
decision problem and model structure. It is not,
therefore, intended to be comprehensive in terms
of either the economic issues covered or the
research literature included on each issue.
NHS cost impacts of asthma
Children with asthma place various demands on
the NHS budget, ranging from the cost of
prescribed asthma medications to various levels of
health service use [e.g. GP and nurse
consultations, Accident and Emergency (A&E)
department visits and hospital admissions]. There
is some evidence that children with asthma place
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16relatively greater demands on health services than
adults with asthma.
Cost-of-illness studies of asthma consistently show
relatively high ‘indirect costs’ (including, for
example, the estimated cost of lost days of work or
school) compared with the direct healthcare costs
of service use.164 They sometimes also show the
dominant role of people with severe asthma in
generating the bulk of asthma-related heathcare
costs.
Gupta and colleagues have published the most
recent well-conducted cost-of-illness study of
asthma in the UK.165 Overall, they estimated that
the cost to the NHS of asthma in 2000 was £754
million, of which 78.8% (£594 million) was due to
community-dispensed prescriptions, 12.7% (£96
million) was due to GP consultations and 8.4%
(£63 million) was due to hospital admissions. This
contrasts with most international studies, in which
hospital costs account for a higher proportion of
the costs associated with healthcare use.164 Of the
NHS costs associated with hospital admissions,
over 86% (£54.7 million) were due to non-elective
admissions (i.e. probably to treat asthma
exacerbations). More recent estimates by the UK’s
Lung and Asthma Information Agency (and cited
in the Asthma UK Cymru report ‘Asthma in Wales
today’) suggest that this cost to the NHS has
increased to £889 million annually.166 In a
different study, cited in the same Asthma UK
report, difficult-to-control asthma was estimated to
cost the NHS £680 million per year.
Other data in the study by Gupta and colleagues
suggest that, compared with children, adults (aged
15 years and over) contribute proportionately less
to both primary care and secondary care NHS
costs (Table 4). Among adults there was one
hospital admission for asthma for every 13–15 GP
consultations (for asthma), whereas among
children there was an asthma-related hospital
admission for every eight GP consultations.
The Prescriptions Cost Analysis database167 details
the number and cost of all prescriptions dispensed
in the community in England. Listing of drug
classes (by 317 BNF subparagraphs) shows that
expenditure in 2005 on corticosteroids for
respiratory conditions cost the NHS £436 million.
Although only 15th in terms of the number of
prescriptions, this is the third largest component
of the total cost of community-dispensed drugs in
England (after lipid-regulating drugs £625 million
and proton pump inhibitors £446 million).
Corticosteroids for respiratory conditions cost the
NHS more than double the amount spent on
many other major drug classes, such as
angiotensin-converting enzyme inhibitors,
antipsychotic drugs and intermediate and long-
term insulins.
Of the £436 million spent on respiratory
corticosteroids, £276 million was spent on
combination inhalers (Symbicort and Seretide)
(Figure 6).
Effective drug treatment for asthma relies upon
the correct use of various inhaler devices (see the
section ‘Devices’, p. 9). It is therefore conspicuous
that the cost of related education and support has
usually not been included in economic analyses
comparing drug treatments (for example,
respiratory nurse education on the correct use of
pMDIs). This omission may be particularly
important in younger age groups.
Cost to individuals with asthma, 
their carers and society
Financial cost of medicines
Asthma is not a condition exempt from NHS
prescription charges although, as children aged
under 16 years are exempt from all charges, they
will not be required to pay for asthma
medications. The financial cost of medicines
should therefore not be a factor in children 
not receiving their prescribed dose of 
medication.
Health Technology Assessment 2008; Vol. 12: No. 20
17
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
TABLE 4 GP consultations and hospital admissions for asthma in the UK
Age group (years) Weekly number of GP consultations Annual number of hospital admissions
(per 100,000 in age group) in 2002 (per 100,000 in age group) in 2000–1
0–14 46 292
15–44 25 84
45+ 21 83
Source: Gupta and colleagues.165Other financial costs
Economic evaluations and cost-of-illness studies
have not usually measured the use of resources
such as medical equipment and consumables to
support asthma self-medication and self-
monitoring (such as nebulisers, inhalers and peak
flow meters).168 People with asthma also inevitably
have to pay more of the various costs of attending
more frequent primary care or hospital
consultations, for example for travel, car parking
and child care.
Indirect costs to individuals with asthma, carers
and society
Cost-of-illness studies in a number of countries
suggest that a significant proportion, usually 50%
or more, of all costs due to asthma are due to the
‘indirect costs’ of lost days at work (or school),
which may be estimated by asthma morbidity and
treatment, and/or by premature deaths due to
asthma.164 Adults may lose work days as a result of
their own asthma, or due to looking after children
or other dependents with asthma. Two early
studies estimated the annual number of working
days lost due to asthma in the UK to be 5.7 or 7
million, corresponding to an estimated 50% and
90%, respectively, of all asthma costs.169,170
Other time costs of individuals with asthma and
carers include healthy time lost (either work or
leisure), the time that individuals with asthma put
into the process of receiving healthcare and the
time that carers put into caring for friends and
relatives with asthma.171 Reduced school
attendance due to poor asthma control may also
lead to a reduction in the educational level
achieved and hence the future earning potential of
individuals. These costs are in principle
measurable, but much harder to value; for
example, there is debate surrounding whether
some ‘time costs’, such as lost leisure time, should
be counted as a reduction in quality of life or as a
monetary input.
A costing study by Stevens and colleagues, in the
context of a UK-based RCT, estimated the mean
annual costs per family with preschool children
with asthma to be £562 (comprising £32 for
family-borne costs, £47 for lost non-waged time,
£55 for lost waged time and £428 for health
service costs; 1999 costs).172 Approximately half of
the family-borne costs were due to ‘regular family
expenditure’ (such as extra heating and
childminder costs for caring at home), and one-
third were associated with inpatient stays. Most of
the families’ non-waged time costs were due to
attending primary care consultations or inpatient
stays. In contrast, two-thirds of waged time cost
was associated with inpatient stays. Also, a study
into the loss of work days by caregivers, for French
children with persistent asthma (GINA grade 2+,
aged 6–16 years), showed that almost one-third of
caregivers lost work days during the study year.
About 13% of caregivers lost more than 5 days.173
Healthcare resource use and asthma
severity
There are some published studies which have
specifically examined the relationship between
asthma severity and resource use and costs.
However, we are aware of few UK-based studies
that have studied this relationship. Nevertheless,
the positive association between asthma severity,
whether defined by GINA class or other methods,
and healthcare costs seems strong in a variety of
health systems.174,175
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2005 No. of prescriptions (14.1 million) 2005 net ingredient cost (£436 million)
Beclamethasone
Budesonide
Fluticasone
Mometasone
Ciclesonide
Symbicort
Seretide
FIGURE 6 Number and cost of community-dispensed prescriptions for ICS in England 2005. Source: NHS Health and Social Care
Information Centre.167A study of 713 British children (0–15 years old,
identified with respiratory symptoms through a
postal survey to parents in 1993), 381 of whom
were identified as ‘likely asthmatics’, examined the
incidence of medical consultations for different
reasons.176 In a 2-year reference period, higher
respiratory symptom and allergy history scores
were associated with higher proportions of
children having medical consultations (for upper
and lower respiratory conditions), higher
proportions having home visits and higher
proportions receiving respiratory prescriptions.
These associations remained statistically significant
when data for children aged under 5 years were
analysed separately. The 381 children who were
‘likely asthmatics’ had 934 GP consultations for a
respiratory problem during the 2 years (a mean of
1.23 consultations per child per year).
Unfortunately, this study did not distinguish
routine/review consultations from urgent or
patient-initiated consultations in primary care.
The investigators did, however, highlight the very
low rates of secondary care consultation for
respiratory problems, an indication that in the UK
most exacerbations are managed at home or with
the support of primary care services.
Laforest and colleagues, in a 1-year study of various
factors amongst 261 French children with asthma
(aged 6–16 years), used clear definitions of asthma
severity and control in the same analysis.177
Interestingly they found that within severity
classes, there was only an association between the
cost of medical resource use and asthma symptom
control for children with severe asthma; for children
with mild and moderate asthma severity (in the 
6-month prestudy period) there was no significant
association between control and asthma costs.
Healthcare resource use and asthma
symptom control
Although some asthma medication is prescribed as
prophylactic therapy, and some asthma-related
healthcare consultations are for routine clinical
reviews, a sizeable proportion of medication use
and many consultations occur in response to
worsening symptoms. It is therefore possible that
there might be a strong relationship between
degree of asthma (symptom) control and resource
use. As a result, the level of use of healthcare
resources is sometimes suggested as a possible
measure of effectiveness of asthma treatments.168
A key indicator of poor symptom control is a
greater frequency of use of reliever medication (e.g.
inhaled salbutamol), which has implications for
medication costs. Also, anecdotal reports suggest
that poor asthma symptom control may prompt
better adherence to prophylactic medication.
The key driver of the higher costs of poor
symptom control appears to the resource
consequences of asthma exacerbations.
Exacerbations and healthcare 
resource use
Asthma exacerbations (or asthma ‘attacks’) are one
of the key acute events which lead to the
consumption of additional medications or to
patient-initiated healthcare consultations. They
are also the likely cause of more expensive types of
asthma-related healthcare use, such as A&E
attendances and hospital admissions.
For example, in a UK-wide cohort study of 12,203
people with asthma followed for 1 year, those who
experienced an attack incurred over three times as
much healthcare costs as those who did not (£381
versus £108, 1997 NHS costs).178 Further breakdown
of these costs showed that most of this difference
was due to hospital stays (£169 versus £7, over the
year) and medication costs (£129 versus £75).
It should be noted that many of these published
studies predate the existence of NHS Direct, NHS
Walk-in Centres and GP out-of-hours cooperatives.
In the UK, these services now provide either a new
pathway to some of the more long-standing
providers of acute care (e.g. GPs, A&E
departments), or provide emergency care and
advice in their own right. It is possible that these
services, by being better publicised and more
accessible than traditional models of healthcare
delivery, have made it easier for people with asthma
to obtain care or advice when they experience
symptoms or have other asthma-related queries.
Healthcare resource use and other
factors
In addition to asthma severity and level of asthma
symptom control, there are other published
studies which have documented a relationship
between asthma-related resource use and:
● co-morbidities (such as allergic rhinitis,
diabetes)179,180
● sex (females being more likely to use care for
asthma)
● self-management programmes
● health service organisation and accessibility (e.g.
balance of primary care provided by nurses
versus GPs, availability and use of telephone
advice lines)180,181
● HRQoL.180,182,183
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asthma
● Asthma has considerable economic impacts
beyond the resources used in providing
healthcare. These impacts comprise days lost
from work by individuals with asthma and their
families, and days lost from school among
children.
● Of the costs incurred for providing healthcare
for children with asthma, a high proportion is
associated with the use of hospital services.
Asthma exacerbations, both their frequency and
their severity, appear to be the major driver of
the cost of using health services amongst
children and adults.
● As asthma severity increases and as level of
asthma control decreases, the costs to the health
system increase. There may be interaction
effects, but we are not aware that they have
been explicitly studied (e.g. poorly controlled
severe asthma may lead to more consumption
of healthcare resources than the separate effects
added). People with difficult-to-control asthma
may be another subgroup which generate more
healthcare costs, but they have been less
studied.
● Although there has been a great deal of
research to examine the cost-effectiveness of
switching to alternative treatments for people
with poorly controlled asthma, there do not
appear to have been any economic evaluations
of stepping down treatment in individuals
whose asthma is well controlled.
● In the last 10 years there have been
considerable changes in the range of available
NHS services for people with asthma, especially
those for urgent care and advice – such as NHS
Direct, Walk-in Centres and GP after-hours
cooperatives. These may have changed the
pathways by which people access healthcare,
and perhaps also altered the balance of self-care
and formal care. In addition, the cost and cost-
effectiveness of allergen avoidance strategies to
reduce asthma symptoms have not been
studied.
● There are some dynamic inter-relationships
between resource use (costs) and the level of
actual or perceived symptom control. For
example, patient charges for medication may be
a factor in poor concordance with prophylactic
therapy, and therefore symptom deterioration
(and ultimately higher healthcare costs). Also,
the lack of perceived symptoms may encourage
a gradual reduction in the use of prophylactic
therapies, resulting in a costly exacerbation of
asthma symptoms.
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Assessment aim
The aim of this health technology assessment is to
assess the clinical and cost-effectiveness of ICS,
used alone or in combination with a LABA, for the
treatment of chronic asthma in children under the
age of 12 years and to provide guidance to the
NHS in England and Wales.
Objectives
The objectives were as follows:
● to identify, appraise and synthesise, where
appropriate, the current evidence base which
addresses the specific research questions on
clinical effectiveness listed above
● to identify the costs associated with the different
treatments
● to identify, appraise and synthesise, where
appropriate, the current evidence base which
addresses the specific research questions on
cost-effectiveness listed above
● to provide estimates of cost-effectiveness, where
possible, of the different treatment options.
Definition of the decision
problems
There are three ICS available as licensed
preparations in this population: BDP, BUD and
FP. The drugs may all be administered via
different devices, including pMDIs, with or
without a spacer, and DPIs. Assessment of the
effect of device on the dose of corticosteroid
delivered to the airways and, by extension, the
effect of the device on the clinical effectiveness of
ICS, is not included in this report. Similarly, the
effect of the propellant (CFC versus HFA) used in
the MDIs is not considered.
In addition, two of the corticosteroids under
consideration are available as licensed
preparations in combination with LABA: FP used
in combination with SAL (Seretide) and BUD 
used in combination with FF (Symbicort).
For each ICS, the appropriate comparators are the
other ICS. For each combination inhaler, the
appropriate comparators are ICS alone, ICS and
LABA in separate inhalers and the other
combination inhaler.
The BTS/SIGN Guideline1 is the context in which
the decision problem is set, outlined in the section
‘Asthma management in the UK’ (p. 5). Using the
steps in the Guideline, the following specific
review questions were identified:
Q1. At low doses (200–400 µg BDP per day or
equivalent), which is the most clinically and
cost-effective of the three ICS? (Step 2 of the
Guideline)
The relevant population for which this intervention
should be considered is children with asthma who
have been treated at Step 1 or Step 2 of the
guidelines [i.e. they have either not been treated
with corticosteroids previously or have received low
doses (as defined above) of ICS].
Q2. At high doses (400–800 µg BDP per day or
equivalent), which is the most clinically and
cost-effective of the three ICS? (Step 4 of the
Guideline)
The relevant population for which this intervention
should be considered is children with asthma who
have been treated at Steps 2–3 of the Guideline
(i.e. they have been treated with ICS previously in
conjunction with other treatments such as LABAs).
They should not be steroid-naïve.
Q3. Which is the more clinically and cost-effective
approach to introducing a LABA into a
treatment regimen: 
(a) to increase the dose of ICS alone or to
add a LABA to treatment with ICS?
(Steps 2–3 of the guideline)
(b) to continue with an ICS alone or to add a
LABA to treatment with a similar dose of
ICS using a combination inhaler? (Steps
2–3 of the Guideline)
The relevant population for which this intervention
should be considered is children with asthma who
have been treated at Step 2 of the Guideline (i.e.
they have been treated with low-dose ICS
previously). They should not be steroid-naïve.
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Decision problemsQuestion 3a is viewed as the more clinically
relevant of the two sub-questions, because if
patients remain uncontrolled on lower dose ICS
alone, treatment protocols in line with the
BTS/SIGN Guideline would indicate that either
the ICS dose is increased, or a LABA is added to
the lower dose of ICS. However, the literature
searches conducted for the present assessment also
identified trials in which a LABA was added to the
ICS treatment regimen without the dose of ICS
alone being increased. Although this treatment
strategy is not in line with that advocated in the
BTS/SIGN Guideline for completeness, these
studies are included in the clinical effectiveness
review as a separate sub-question. This sub-
question is not addressed in the cost-effectiveness
evaluation.
Q4. Which is the more clinically and cost-effective
treatment: 
(a) FP and SAL in a combination inhaler or
given in separate inhalers? 
(b) BUD and FF in a combination inhaler or
given in separate inhalers? 
Q5. Which is the more clinically and cost-effective
treatment: FP/SAL in a combination inhaler
or BUD/FF in a combination inhaler? (Step 3
of the Guideline)
The relevant population for which these interventions
should be considered is children with asthma who have
been treated at Step 2 of the Guideline (i.e. they have
been treated with low-dose ICS previously). They should
not be steroid-naïve.
Within the context of the BTS/SIGN Guideline, it
is generally accepted that the following are
clinically equivalent doses: BDP 400 µg, BUD
400 µg, and FP 200 µg. Studies which compare
these drugs at these dose ratios, delivered through
similar devices, are therefore the most appropriate
method for testing this hypothesis.
The clinical effectiveness of treatments for asthma
can be assessed against a wide variety of outcome
measures, which can be broadly divided into the
following categories:
● objective measures of lung function (e.g. FEV1,
PEF)
● symptoms [e.g. nocturnal waking, morning
cough, symptom-free days (SFDs) and
symptom-free nights (SFNs), symptom scores)
● use of rescue medication (e.g. SABAs, short
courses of oral corticosteroids)
● acute exacerbations, defined in a number of
ways (e.g. increase in symptoms, increased use
of rescue medication or contact with health
services)
● AEs
● HRQoL
● mortality.
Although there is some evidence of the minimally
perceived change in PEF considered to be
clinically relevant by patients, for the majority of
the above outcome measures it is unclear for
which, if any, there is a generally accepted
definition of the minimum level of change that is
clinically significant. 
Decision problems
22Methods for reviewing
effectiveness
A peer-reviewed protocol was published in May
2006 on the website of the National Institute for
Health and Clinical Excellence (NICE) and
circulated amongst the consultees, outlining the
agreed scope and methodology for this
assessment.184 This was based on the scope of the
appraisal as published by NICE.185
The scope proposed that the assessment be
conducted within the context of the stepwise
approach as advocated by the BTS/SIGN
Guideline.1 As far as possible, the contents of this
Guideline have been taken into account in the
assessment of clinical effectiveness.
An over-arching philosophy of the assessment of
clinical effectiveness was the need to capitalise,
where possible, on existing evidence syntheses of
the effectiveness of ICS and LABAs for chronic
asthma. A number of systematic reviews have been
published in The Cochrane Database of Systematic
Reviews, some of which are relevant to the scope
of this assessment,186–190 although their aims and
inclusion criteria vary in places from those of the
current assessment. Where relevant, we have built
upon the data presented in those reviews.
Identification of studies
A search strategy for electronic bibliographic
databases was devised and tested by an
experienced information scientist (Appendix 3).
Once finalised, it was applied to a number of
databases, including The Cochrane Database of
Systematic Reviews (CDSR); The Cochrane
Central Register of Controlled Trials; Database of
Abstracts of Reviews of Effectiveness (DARE); the
NHS Economic Evaluation Database (NHS EED);
MEDLINE (Ovid); EMBASE (Ovid); National
Research Register; Current Controlled Trials; ISI
Proceedings (Web of Knowledge); Science Citation
Index (Web of Knowledge); and BIOSIS.
Searches were run up to February/March 2006,
and were restricted to studies published in
English. An update search was conducted in
October 2006 to identify any relevant studies
published since the original search.
The drug manufacturers’ submissions to NICE,
which we received in August 2006, were also
searched for potentially relevant trials.
All identified studies were downloaded into a
Reference Manager database for storage and
retrieval as necessary. A keywording system was
devised to enable each reference to be categorised
according to pre-specified inclusion and exclusion
criteria (see the next section).
Inclusion and exclusion criteria
The inclusion and exclusion criteria were specified
a priori based on the scope issued by NICE,185 as
agreed in the published protocol.184
Intervention
Trials reporting evaluations of the following ICS
were included:
● BDP
● BUD
● FP.
Trials reporting evaluations of the following ICS
combined with LABAs in the same inhaler (i.e.
combination inhalers) were included:
● BUD/FF (in children aged over 6 years)
● FP/SAL (as xinafoate) (in children aged over
4 years).
Trials reporting ICS delivered by pMDIs and 
DPIs were included; those using nebulisers were
excluded.
To be included, the intervention had to last for
more than 4 weeks.
Comparators
● The ICS were compared with each other.
● The combination inhalers were compared with
each other and with ICS only. They were also
compared with ICS and LABAs administered in
separate inhalers.
● Trials testing only different doses of the same
agent were not included as these were outside
the scope of the assessment. (NB. Cochrane
systematic reviews of different doses of BUD,191
BDP192 and FP193 are available). Trials which
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Assessment of clinical effectivenesscompared more than one dose of an ICS with a
different ICS were included.
● Trials testing different drugs by different
inhalers or propellants were not included (e.g.
DPI versus pMDI or HFA pMDI versus CFC
pMDI). The role of delivery device has been
assessed by a published systematic review,194,195
which found that there was no evidence for
differences in effectiveness between different
types of hand-held inhaler. However, some
clinical trials of different ICS identified in our
literature search were specifically designed to
demonstrate superiority of one device over
another, or in some cases that one inhaler
device can be used to achieve comparable
asthma control at a lower ICS dose than an
alternative device. For this reason, we chose to
limit the review to comparisons of different ICS
via the same type of inhaler or propellant in
order to reduce any potential confounding
associated with devices.
● Trials reporting comparisons between ICS and
placebo were sought and included in order
potentially to support economic modelling (e.g.
to provide estimates for model parameters).
Details of these studies are not reported in the
clinical effectiveness review.
Types of studies
● Fully published RCTs or systematic reviews of
RCTs were considered. Double-blinding was not
a prerequisite for inclusion, although blinding
was assessed as part of critical appraisal (see the
Section ‘Critical appraisal strategy’, p. 25).
Indicators of a ‘systematic’ review include
explicit search strategy, inclusion criteria, data
extraction and assessment of quality.
● Trials reported in abstracts or conference
presentations from 2004 onwards were retrieved;
however, their details were not extracted,
critically appraised or analysed (however, details
were extracted where an abstract was available
which provided data supplementary to a fully
published trial report of a particular study; this
occurred in a handful of cases).
● Where unpublished full trial reports were
available (e.g. as supplied by the drug
manufacturers in their submissions to NICE),
these were included.
Population
● Children aged under 12 years diagnosed with
chronic asthma (NB. the mean age of the study
population had to be 12 years or under).
Studies in which the patient group was
asthmatics with a specific related co-morbidity
(e.g. cystic fibrosis) were not included.
● Studies reporting the treatment of acute
exacerbations of asthma were not included.
● Trials reporting the effectiveness of ICS with
LABAs were only included if the patients had
been previously treated with an ICS. Trials
assessing the effectiveness of initiating
treatment with ICS in combination with LABAs
in steroid-naïve patients are not within the
context of the BTS/SIGN Guideline.
Outcomes
At the screening stage, studies reporting one or
more of the following outcomes were included:
● objective measures of lung function (e.g. FEV1,
PEF)
● symptoms (e.g. SFDs and SFNs)
● incidence of mild and severe acute exacerbations
(e.g. mild – requiring unscheduled contact with
healthcare professional; severe – requiring
hospitalisation, systemic corticosteroids or visit
to A&E department).
● use of systemic corticosteroids
● AEs of treatment 
● HRQoL
● mortality.
A list of specific measures for each of these
outcomes was devised for the data analysis (see the
section ‘Narrative synthesis’, p. 26).
Titles and abstracts of studies identified by the
searches were screened by one reviewer based on
the above inclusion/exclusion criteria. A second
reviewer checked a random 10% of these. Any
discrepancies were resolved through discussion
and involvement of a third reviewer where
necessary.
Full papers of studies included on title or abstract
were requested for further assessment. All full
papers were screened independently by one
reviewer and checked by a second. Any
discrepancies were resolved by discussion with
involvement of a third reviewer where necessary.
All included papers were keyworded in the
Reference Manager database as to their
intervention and comparator, and were coded for
the synthesis framework (see the section ‘Methods
of data synthesis, p. 25) to allow efficient retrieval
of subsets of studies for analysis.
As far as possible, all included papers describing a
particular trial were linked together to form a ‘set’
of studies. One of the papers (usually the seminal
journal article reporting the key efficacy and safety
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with the remaining papers classed as secondary
publications.
All included trials were cross-referenced with the
relevant Cochrane reviews to ascertain whether or
not they had already been included in the
reviews.186–190 Those that were included were
keyworded in our Reference Manager database
accordingly. Conversely, the bibliographies of
included studies in the relevant Cochrane reviews
were cross-referenced with our list of included
studies and our inclusion criteria to ascertain
whether there were any relevant studies in those
reviews that had not been identified by our search.
Data extraction strategy
All trials, except those included in the relevant
Cochrane reviews, were fully data extracted. Data
were entered into a structured template by one
reviewer and checked by a second. Any
discrepancies between the data extracted and the
original trial report were resolved and the data
extraction finalised (see Appendix 4). Data on the
studies that met our inclusion criteria and which
were also included in the Cochrane reviews are
available from the reviews themselves.186–190
Critical appraisal strategy
The methodological quality of the trials
supplemental to the Cochrane reviews was
assessed according to criteria specified by the
Centre for Reviews and Dissemination (CRD)196
(see Appendix 4). Quality was assessed by one
reviewer and their judgements were checked by a
second. Where there was disagreement, a third
reviewer was consulted and a final judgement
agreed. Judgements about the quality of the trials
included in the Cochrane reviews can be found by
consulting the relevant review.186–190
Methods of data synthesis
Results of the included trials were synthesised
narratively (see the next section) with use of meta-
analyses where possible and appropriate (see the
section ‘Meta-analyses, p. 26’). A framework was
devised for the analysis and presentation of
results, based on the stepwise approach
recommended in the BTS/SIGN Guideline.1
The review questions were as follows:
1. Which ICS is the most effective at low doses
[200–400 µg/day BDP/BUD equivalent (for FP,
the equivalent doses are 100–200 µg/day
(children aged over 4 years)]? (Step 2 of the
Guideline)
2. Which ICS is the most effective at high doses
[400–800 µg/day BDP/BUD equivalent (for FP,
high dose is up to 200–400 µg/day (children
aged over 4 years)]? (Step 4 of the guideline)
3. Which is more effective: an ICS or a
combination inhaler containing an ICS and a
LABA? (Step 2/Step 3 of the Guideline)
This question is subdivided based on two
categories of trials:
(a) Where the dose of the ICS is higher when
used alone, compared to the dose in the
combination inhaler.
(b) Where the dose of the ICS is the
same/similar in both treatments
4. Which is more effective: an ICS and a LABA
administered in separate inhalers or in a
combination inhaler?
5. Which is the more effective: a combination
inhaler containing FF and BUD, or a
combination inhaler containing SAL and FP? 
Each included trial was coded according to which
of the review questions it was relevant. For
example, a trial comparing 200 µg/day of BDP
with 200 µg/day of BUD was assigned to review
question 1, as it evaluated low-dose ICS. Some
trials were relevant to more than one review
question as they tested multiple doses of inhaled
steroids, some of which were relevant to review
question 1 (i.e. low-dose) and some of which were
relevant to question 2 (i.e. high-dose).
Each review question was stratified according to a
number of pair-wise comparisons of the inhaled
steroids and, where relevant, LABAs (where
evidence allows). In addition, some trials were
included in more than one pair-wise comparison
as they evaluated two or more ICS (e.g. a three-
arm trial comparing FP with BUD and BDP).
Trials were also divided according to whether or
not a parallel-group or cross-over design was
used. It is generally considered inappropriate to
pool these designs together within meta-
analyses.197 Where necessary, trials were then
further divided according to the nominal dose
ratio employed, following the approach used in
the Cochrane review of FP compared with BUD 
or BDP.187 Some trials aimed to test the
equipotency of different inhaled steroids,
particularly newer steroids such as FP compared
with the older steroids such as BDP and BUD.
Therefore, dose ratios of 1:2 or higher are
common in the literature. Separate analysis of the
ratios was necessary to reduce the risk of
confounding associated with comparing trials with
differing doses.
Health Technology Assessment 2008; Vol. 12: No. 20
25
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.In summary, the framework comprised sets of
trials grouped according to which review question,
pair-wise comparison, study design and dose ratio
they related. For example:
1. Review question1: low-dose ICS
(a) pair-wise comparison: BDP versus FP
(i) parallel-group trial 1:1 ratio
(ii) parallel-group trial 1:2 ratio 
(iii) cross-over trial 1:1 ratio 
(iv) cross-over trial 1:2 ratio.
It was expected that this framework would result
in generally smaller sets of studies in each
analysis, as opposed to a larger set with potentially
more statistical power to identify effects. However,
a framework such as this was essential in order to
embed the review within the context of the
BTS/SIGN Guideline1 (as stipulated in the scope
for the appraisal issued by NICE) and to reduce
the likelihood of confounding due to differences
in trial design and dose ratio.
Narrative synthesis
As described above, the narrative synthesis
comprises a framework whereby trials are
summarised according to which review question,
pair-wise comparison, study design and dose ratio
they were relevant. The results sections are
organised according to this framework.
Within each pair-wise comparison, all included
trials were tabulated for their key characteristics,
and described in the text (e.g. trial duration,
patient profile, outcome measures, methodological
quality). In addition, more detailed data on the
trials are available in Appendix 4, for those trials
which were supplemental to the Cochrane reviews
and which underwent full data extraction. Further
details of the remaining studies are available in
the relevant Cochrane reviews. Each outcome
measure is presented in turn and the key results
are reported in the text.
There are numerous ways of measuring and
reporting outcomes from asthma trials. For brevity,
we report only the following measures:
● lung function – FEV1 (litres); FEV % predicted;
morning/evening PEF (litres per minute)
● symptoms – days/nights without symptoms; total
daily symptom scores
● HRQoL – total HRQoL scores 
● use of rescue medication – mean number of
puffs per day of SABA
● exacerbations – number and/or rate of
exacerbations, where the authors’ definition of
exacerbations is not covered by one of our
existing outcomes.
● AEs – number and/or rate of AEs; number
and/or rate of serious AEs; number and/or rate
of withdrawals due to AEs; urinary/serum
cortisol; BMD; growth.
Meta-analysis
The feasibility and appropriateness of meta-
analysis were considered once narrative syntheses
had been completed. The decision to pool was
influenced by the likelihood that the trials were
clinically homogeneous and that the necessary
data were available. Potential clinical heterogeneity
was assumed if there were differences between
trials in
● dose 
● disease severity
● treatment duration.
To some extent, the potential for clinical
heterogeneity was reduced by virtue of the
framework used for the review, whereby studies
were grouped into sets according to whether a
high or a low dose of ICS was used. Nonetheless,
even within the low- and high-dose review
questions the dose ranges can be relatively wide. It
could also be argued that dose is a proxy for
severity, with less severe asthma patients treated
with lower doses, and vice versa, although this is a
generalisation. It was therefore important to
consider severity as a potential source of
heterogeneity. Furthermore, the influence of trial
duration cannot be discounted. Although trials
lasting around 3 months are common, some are
designed to evaluate longer term effects on
asthma control and AEs. Such trials are likely to
have differing aims and, consequently, if they
appeared to be diverse in terms of the above
factors, they were not pooled.
Results
Quantity and quality of research
available
A total of 5175 records of publications were
identified through literature searching. Figure 7
shows the identification of published studies for
inclusion in the systematic review of clinical
effectiveness. Of the identified studies, 4368 were
excluded on title and abstract. Full reports for the
remaining 807 were requested for more in-depth
screening. Of these, 34 records describing 25
studies were included. Searches for this report
were combined with the accompanying report on
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Consequently, a proportion of the 807 papers
screened were included in that report. 
Of the 25 studies:
● Three were conference abstracts published from
2004 onwards (bibliographic details of these are
listed in Appendix 6).
● Six were systematic reviews (of which five were
Cochrane reviews) (these are reported in the
section ‘Cochrane systematic reviews’, p. 60).
● 16 were fully published RCTs (of which 12 had
been included in the Cochrane reviews).
Updated searches conducted in October 2006
yielded a total of 245 records of publications, of
which 26 were inspected on full report. Of these,
two studies (one RCT, one systematic review)
appear relevant and would be eligible for inclusion
in any future update and their bibliographic
details are listed in Appendix 5). In all but one of
the 16 RCTs the mean age was under 12 years, in
line with our inclusion criteria. The exception was
the study by O’Byrne and colleagues,198 in which
mean age was 36 years (range 4–79 years).
Approximately 12% of participants were under the
age of 12 years and results for growth and cortisol
levels are reported separately for this group. The
age range in the RCTs varied, but was generally
from 4 to 19 years. It should therefore be
acknowledged that there is a slight overlap with
some of the studies in adolescents over the age of
12 years included in the accompanying report on
ICS in adults and children over the age of 12.199
Notably absent from the evidence base are studies
in children and infants aged under 4 years.
Tables 5–10 provide a breakdown of the number of
RCTs for each pair-wise comparison between the
three ICS within each review question. There are
equal numbers of trials reporting on low- and
high-dose ICS (seven in each case). There is very
little evidence for the efficacy and safety of ICS in
combination with LABAs.
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Identified on searching
(after duplicates removed)
n = 5175
Titles and abstracts 
inspected n = 5175
Excluded
n = 4368
Full copies retrieved
n = 807
Papers inspected
n = 807
Included 34 records 
describing 25 studies
Excluded
n = 773
FIGURE 7 Flowchart of identification of published studies for
inclusion in the systematic review of clinical effectiveness
TABLE 5 Breakdown of studies for review question 1 – 
low-dose ICS
Pair-wise comparison No. of RCTs included
BDP and BUD 1
FP and BDP 2
FP and BUD 2
Total 5
TABLE 6 Breakdown of studies for review question 2 – 
high-dose ICS
Pair-wise comparison No. of RCTs included
BDP and BUD 1
FP and BDP  3
FP and BUD 3
Total  7
TABLE 7 Breakdown of studies for review question 3a – 
ICS versus ICS + LABA (ICS dose higher when used alone)
Pair-wise comparison No. of RCTs included
BUD vs BUD + FF 1
Total 1
TABLE 8 Breakdown of studies for review question 3b – 
ICS versus ICS + LABA (ICS dose similar in both treatments)
Pair-wise comparison No. of RCTs included
FP vs FP + SAL 1
BUD vs BUD + FF 1
Total 2The 16 RCTs are described in the following
sections in terms of their characteristics and results.
Review question 1 – effectiveness of
low-dose ICS
Low-dose ICS: BDP and BUD 
Study characteristics
Only one RCT, published in 1988, evaluated the
effects of BUD compared with BDP in children200
(Table 11). It was a small, multi-centre study
conducted in six centres in Denmark, and
involving 41 children. The trial was a double-
blind, parallel-group design, containing two arms.
The trial incorporated a stepwise increase in ICS,
and consisted of three 4-week periods with
successive daily doses of 200, 400 and 800 µg of
either BDP or BUD. Thus, the comparison of the
two drugs was at a dose ratio of 1:1 throughout
the study. Although 800 µg is regarded as a high
dose of BDP and BUD, the comparison by
Bisgaard and colleagues200 is included in this (low-
dose) review question as opposed to question 2,
because two-thirds of the treatment duration
involved lower doses (200 and 400 µg), and effects
of the higher dose would not have been
independent of the preceding lower doses. The
drugs were both delivered via an aerosol pMDI
inhaler device (BDP was purchased commercially
and it is not stated explicitly, but it can be
deduced from the text that BUD was provided by
AZ). The treatment period was 3 months in total
(4 weeks for each of three successive doses).
Children who completed the trial were aged
between 5 and 17 years, with a mean age of about
11 years. Although all the children were using
SABAs and almost half were using theophylline
daily, none had used ICS therapy during the
preceding 6 months. The severity of asthma was
not specifically stated and baseline FEV1 %
predicted was not reported.
The rationale of the study was primarily to
evaluate the effect of ICS in varying doses on
adrenal function (as an indicator of systemic
effects). A secondary aim was to investigate
whether BUD offered an improved ratio between
the beneficial ICS effect and undesirable systemic
activity compared to BDP. The primary outcome
was a measure of adrenal function using
biochemical measurements.
In terms of methodological quality, details of the
randomisation procedure were not reported hence
concealment of allocation was unknown. The study
did not perform intention-to-treat (ITT) analysis
as the analysis was only carried out on all children
completing the trial (n = 30). The eligibility
criteria were not adequately specified. The trial
was double-blind although, due to the dose
variation, the trial was blind to drug but not dose.
Results
Lung function
The study did not present any values for lung
function. However, the authors reported that the
morning and evening PEF was not different
between treatment groups [presented as the
average PEF during the last 10 days of the first
trial period (200 µg/day)], nor did it change
significantly with the increase in ICS dose (p > 0.1).
Symptoms
The trial did not report symptom scores as an
outcome measure.
Use of rescue medication
As for lung function, the study did not present any
data for rescue medication use, but did state that
there were no differences between the two drugs.
Similarly, the use of SABAs did not change
significantly with the increase in ICS dose
(p > 0.1).
Exacerbations
The trial did not report the incidence of asthma
exacerbations as a specific outcome measure.
However, two children withdrew from the study
due to a severe exacerbation of asthma (one in
each treatment group).
Adverse events
The authors stated that there were very few AEs in
the two groups, with no dose-related trend. Six of
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TABLE 9 Breakdown of studies for review question 4 –
combination inhaler versus separate inhalers
Pair-wise comparison No. of 
RCTs 
included
FP/SAL (combination) vs FP + SAL (separate) 1
Total  1
TABLE 10 Breakdown of studies for review question 5 –
combination inhaler versus combination inhaler
Pair-wise comparison No. of 
RCTs 
included
FP/SAL (combination) vs BUD + FF (combination) 0
Total 0Health Technology Assessment 2008; Vol. 12: No. 20
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T
ABLE 11
Characteristics of studies (BDP and BUD)
Study
Design
Intervention
P
atients
Outcomes
Bisgaard 
et al.,
1988
200
RCT
Multi-centre
P
arallel-group
Dose-escalation
Double-blind
Drugs:
1. 
BDP stepwise increased doses: 200, 400,
800
µg/daily
2. 
BUD stepwise increased doses: 200, 400,
800
µg/daily 
Successive doses (200, 400, 800
µg/d) were
given for 4-week periods in succession with no
wash-
out between each dose.
Delivery device: 
1. 
pMDI (purchased commercially
, no other
details reported)
2. 
pMDI (Pulmicort, Astra Pharmaceutical
a
)
Duration:
3 months
Run-in period:
2 weeks
Number randomised
41
Age range
7–15 years
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
None during previous 6 months
Outcomes
Adrenal function evaluated by:
24-hour urinary free cortisol
excretion
urinary cortisol metabolites
plasma cortisol 30 minutes post-
125
µg i.v
. tetracosactrin (nmol/l)
PEF % predicted morning and
evening
R
escue SABA use
AEs
a 
Not stated explicitly
, deduced from the text.the 11 children who withdrew from the study did
so because of AEs (two BDP, four BUD).
There was no significant difference (p = 0.207)
between treatments in suppression of diurnal
urinary free cortisol when doses were ignored,
whereas differences between doses were highly
significant when treatment was ignored
(p = 0.004). Data (extracted from a graph by the
reviewers) indicate that the mean urinary free
cortisol concentrations after the treatment with
200-, 400- and 800-µg doses, were (approximately)
82, 72 and 54 nmol/g, respectively, for BDP and
76, 56 and 69 nmol/g, respectively, for BUD. CIs
or error bars were given for these data but cannot
be interpreted as their units were ambiguous.
Summary
Only one small, multi-centre, parallel-group trial
evaluated the effects of BUD compared with BDP
in children. Treatment with increasing doses of
BDP, but not BUD, resulted in a significant decline
of adrenal function, but the overall effect on
adrenal function did not differ significantly
between the groups. The groups were also similar
in terms of the effects on lung function (PEF), use
of rescue medication and safety.
Low-dose ICS: FP and BDP
Study characteristics
There are two trials in this section, by Gustaffson
and colleagues201 and Rao and colleagues202
(Table 12). Both trials were parallel-group studies,
comparing FP 200 µg/day with BDP 400 µg/day
(i.e. a dose ratio of 1:2). The studies both had two
active treatment arms, but the study by Rao and
colleagues202 also had a placebo arm. The
duration of the trials ranged from 6 weeks201 to
20 months.202 The six-week study by Gustafsson
and colleagues201 was a large multi-centre trial 
(32 centres in 11 countries) with 398 children aged
from 4 to 19 years, who were inadequately
controlled on current treatment. The other trial
was smaller and the number of centres was not
reported. Rao and colleagues202 recruited 23
steroid-naïve children with moderately severe
asthma aged 5–10 years.
Participants in both trials used an MDI and spacer
(no further details about the devices were
reported).
Both studies were described as being double-blind
and randomised, but no details were given on the
randomisation procedure, concealment of
allocation or blinding. Only Gustafsson and
colleagues201 reported a power calculation (the
outcome used was PEF) and neither of the trials
stated that they used an ITT analysis. In the study
by Rao and colleagues,202 the three arms ran for
10 weeks. After this period, the placebo arm
merged with the FP arm as it was considered
unethical to continue the placebo for longer, thus
breaking randomisation. Therefore, we only report
results for the first 10 weeks, where data were
available in the trial report. Unfortunately, the
number of children originally randomised to the
three groups was not stated; when merged there
were 15 children in the FP arm and eight in the
BDP arm.
The participants were similar at baseline in the
study by Gustafsson and colleagues201 and
withdrawals were described (nine patients in total,
four from the FP arm and five from the BDP arm).
All patients in Rao and colleagues’ study202
completed the initial 10 weeks and were well
matched (except for immunoglobulin E levels,
which were significantly higher in the BDP group).
The overall aim of the study by Gustafsson and
colleagues201 was to compare the efficacy and
safety of FP with BDP. Rao and colleagues202 were
predominantly interested in comparing the effect
of FP with BDP on growth and bone turnover.
Results
All results refer to parallel 1:2 dose ratio
comparisons. Meta-analysis was not possible due
to different outcomes being reported in each
study.
Lung function
FEV1 (litres). FEV1 at end-point (week 6)
reported by Gustafsson and colleagues201 was 2.19
litres for the FP group (n = 190) and 2.26 litres
for the BDP group (n = 198), but it was not
reported whether this difference between the
groups was statistically significant. No data on
FEV1 during the first 10 weeks were given by Rao
and colleagues.202
Only Gustafsson and colleagues201 reported the
FEV1 change from baseline. This was 0.12 litres in
the FP group and 0.15 litres in the BDP group,
adjusted for baseline, age and country. Neither of
these changes from baseline was statistically
significant. It was not reported whether these
changes from baseline differed significantly
between the groups.
FEV1 % predicted. The FEV1 % predicted
reported by Gustafsson and colleagues201 at end-
point (week 6) was 94.1% in the FP group
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T
ABLE 12
Characteristics of studies (FP and BDP)
Study
Design
Intervention
P
atients
Outcomes
Gustafsson 
et al.,
1993
201
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1. FP 
100
µg b.d. (daily total 200
µg)
2. BDP 200
µg b.d. (daily total 400
µg)
Delivery device: 
1, 2. MDI + large volume spacer (no further
details about devices reported)
Duration:
6 weeks
Run-in period:
2 weeks (usual medication)
Number randomised
398
1. 197
2. 201
Mean age (range) (years)
1. 10 (4–19)
2. 11 (4–18)
Mean baseline FEV
1
% predicted
1. 88.9
2. 87.8
P
revious ICS treatment (drug and dose)
Either received ICS up to 400
µg or received
a bronchodilator
, ketotifen or sodium
cromoglycate but asthma inadequately
controlled
Outcomes
Change in FEV
1
(litres) 
Change in FEV
1
% predicted
Change in clinic PEF % predicted
Change in morning and evening 
PEF % predicted
Diurnal variation in PEF
% SFDs
% SFNs
% SABA
-free days
AEs
R
ao 
et al., 1999
202
RCT
P
arallel-group
Double-blind
Drugs:
1. FP 
100
µg b.d. (daily total 200 
µg)
2. BDP 
200
µg b.d.
(daily total 400
µg)
3. 
Placebo (for 10 weeks before merging with
the FP arm)
Delivery device: 
1, 2. MDI + spacer (no further details about
devices reported)
Duration:
20 months
Run-in period:
2 weeks
Number randomised
23 (not broken down by group)
Mean (SEM) age (age) (years)
1. 6.68 (0.57) 
2. 6.93 (0.61) 
3. 6.77 (0.61) 
Mean (SEM) baseline FEV
1
% predicted
1. 90.8 (4.7) 
2. 79.3 (5.5) 
3. 94.4 (4.7) 
P
revious ICS treatment (drug and dose)
Steroid-naïve
Outcomes
FEV
1
% predicted
FEF
25–75%
P
ost-exercise fall in FEV
1
Morning plasma cortisol
Log PC20 for histamine (the
provocative concentration of
histamine causing a 20% fall in FEV
1
)
Daily asthma symptom score
BMD by dual-energy X
-ray
absorptiometry
Serum and urine markers of bone
turnover
Height assessment
SEM, standard error of the mean.(n = 190) and 94.1% in the BDP group (n = 193).
These identical mean values imply no difference
between the groups (no statistics were reported for
this comparison).
Rao and colleagues202 presented the FEV1 %
predicted data in a graph, from which the data at
10 weeks have been extracted by the reviewers
(after 10 weeks, the FP group was merged with the
placebo group). In the FP group, the baseline
mean ± standard error of the mean (SEM) was
estimated to be 90 ± 10% and the end-point 
(10-week) value was 96 ± 12%. In the BDP group,
the corresponding baseline and end-point values
were 80 ± 12% and 81 ± 12%, respectively. No
statistical tests of the difference between groups at
10 weeks are available.
Morning PEF (l/minute). In the study by
Gustafsson and colleagues,201 the mean baseline
morning PEF and the change in morning PEF
from baseline for the FP group were 318 and
24 l/minute, respectively. For the BDP group, the
respective values were 329 and 19 l/minute. No
variances or p-values for these differences were
presented. Rao and colleagues202 did not report
this outcome measure.
Evening PEF (l/minute). In the study by
Gustafsson and colleagues,201 the mean baseline
evening PEF and the change in evening PEF from
baseline for the FP group were 326 and
21 l/minute, respectively. For the BDP group, the
respective values were 340 and 16 l/minute. As
with the morning PEF, no statistical information
was provided for these differences. Rao and
colleagues202 did not report this outcome measure.
Symptoms
Rao and colleagues202 presented daily summary
scores for the entire 82-week study period but not
for the initial 10-week period of interest. Gustafsson
and colleagues201 did not present daily summary
scores as an outcome measure, but did report that
there were no statistically significant differences
between treatments in the percentage of SFDs or
SFNs (no data or significance values were reported).
Use of rescue medication
Neither of the studies presented data in terms of
mean number of inhalations per day.
Exacerbations
Only Gustafsson and colleagues201 reported this
outcome. They did not present the total number
of exacerbations; however, three patients from
each group withdrew because of exacerbations.
Adverse events
In the study by Gustafsson and colleagues,201
99 patients reported 155 AEs (three described as
serious) in the FP group and 95 patients reported
153 AEs (two described as serious) in the BDP
group. Rao and colleagues202 did not present any
data on AEs. They measured growth and bone
density and reported a significantly higher growth
rate in the FP-treated group (difference
0.81 cm/year, 95% CI 0.45 to 1.16 cm/year, no 
p-value given). However, the timing of these
measurements is not relevant to the initial 10-week
period of interest (bone density was measured over
20 months), or was unclear (the timing of the
growth measurements was not stated).
Gustafsson and colleagues201 found no significant
difference between the two treatments in the effect
on plasma cortisol. They reported that the ratio of
FP to BDP [sic] was 1.00 (95% CI 0.91 to 1.09;
p = 0.989), but the meaning of this statement is
unclear. In the study by Rao and colleagues,202
there was a significant drop in the plasma cortisol
from baseline to 10 weeks in the BDP group (95%
CI for the difference 44.64 to 254.50 nmol/l,
p = 0.010), although the absolute values were still
within the normal range. The corresponding 95%
CI for the difference in the FP group was –149.91
to 260.25, p = 0.52. Statistics for the between
group differences were not presented.
Summary
Two studies compared the efficacy and safety of FP
and BDP in children. These studies differed
considerably in their size and patient populations:
one was with steroid-naïve patients, the other with
patients on ICS that inadequately controlled their
asthma. The studies tended to report different
outcomes, which precluded meta-analysis. Only
one of them presented statistical information
about differences between the drugs. Overall,
these studies do not appear to support the
superiority of either FP or BDP. The AE profiles
appear similar for the two drugs, although one
study found a statistically significant drop in
plasma cortisol levels in the BDP arm (but with
absolute values within the normal range), but a
similar change was not seen in the BDP arm.
Low-dose ICS: FP and BUD
Study characteristics
Two RCTs, by Agertoft and Pedersen in 1977203
and Altintas and colleagues in 2005,204
investigated the effectiveness of BUD versus FP in
children (Table 13). Both trials used a parallel-
group design (assumed from the text rather than
explicitly stated in one trial204). The trials varied
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T
ABLE 13
Characteristics of studies (FP and BUD)
Study
Design
Intervention
P
atients
Outcomes
Agertoft and
P
edersen, 1997
203
RCT
P
arallel-group
Double-blind 
Double-dummy
Drugs:
1. 
FP 100 or 200
µg b.d.
a
(daily total 200 or
400
µg)
2. 
BUD 100 or 200
µg b.d.
a
(daily total 200
µg
or 400
µg)
Delivery device: 
1. Diskhaler 
DPI 
2. T
urbuhaler 
DPI 
No further details about devices were reported
Duration:
V
aried among patients up to 15 weeks. Data
for most outcomes reported for 5 weeks.
Run-in period:
2 weeks
Number randomised
217
Mean age (range) (years)
1. 9.9 (5–15) 
2. 10.1 (5–16) 
Mean ±
SD baseline FEV
1
% predicted
1. 91.9 ±
14.6
2. 93.8 ±
13.3
P
revious ICS treatment (drug and dose)
BUD 400 or 800 
µg/day from pMDI
with large volume spacer
(Nebuhaler)
Outcomes
Morning and evening PEF
FEV
1
FEF
25–75%
Dose reduction steps from baseline
Minimal effective ICS dose (µg daily)
Asthma symptom scores
R
escue SABA use
Urine cortisol excretion
Altintas 
et al.,
2005
204
RCT
P
arallel-group
Drugs:
1. FP 250
µg/q.d.
2. BUD 400
µg/day
3. (Non-randomised) control group
Delivery device: 
1, 2. No details of device reported
Duration:
12 months
Run-in period:
Not reported
Number randomised
30
Mean age (range) (years)
1. 9.6 ±
2.4
b
(6–12)
2. 10.6 ±
2.1
b
(7–13)
Mean baseline FEV
1
% predicted
1. 60.6 ±
9.4
b
2. 60.6 ±
9.4
b
P
revious ICS treatment (drug and dose)
Children with moderate asthma
Outcomes
Anthropometric measurements:
Body mass index
Growth rate
Pulmonary functions:
FVC
PEF
FEV
1
Bone metabolism:
Serum calcium
Serum phosphorus
Serum ALP
BMD
Adrenal functions:
Basal a.m. serum cortisol level
F
ree cortisol in 24-hour urine collection
Urine and calcium creatinine ratio
A
CTH stimulation test
Symptom score
A
CTH
, adrenocorticotrophic hormone. 
a 
After 5 weeks reduced to 100
µg b.d. – reduced by 50% every 5 weeks until deterioration in asthma control or acceptable asthma control achieved.
b 
Statistics (not stated) are assumed to be SD.in sample sizes from 30 to 217 patients, and both
were single-centre studies.
Altintas and colleagues204 conducted a three-
armed study, using a control group, but no details
were supplied about the group. The study by
Agertoft and Pedersen203 contained two arms. 
The former study204 compared total daily doses 
of 250 µg of FP and 400 µg of BUD,
approximating a nominal dose ratio of 1:2. The
latter study203 used a starting total daily dose of
200 or 400 µg for both drug treatments,
equivalent to a 1:1 ratio, with dose reductions of
50% at 5-week intervals.
Altintas and colleagues204 used pMDI devices for
both drugs (no further details on devices were
reported). The Agertoft and Pedersen203 study
used a Turbuhaler for BUD and a Diskhaler for
FP (both branded forms of DPI). The former
study204 had a treatment duration of 12 months,
but the duration of the latter203 varied among
patients, with dose reductions by 50% at 5-week
intervals until deterioration in asthma control or
acceptable asthma control was seen. Data on most
of the outcomes reported in that study were
presented only for the first 5 weeks.
There was some variation in terms of the aims of
the studies. Altintas and colleagues204 did not
specifically state whether the intention was to
assess equivalence or superiority between
treatments. Rather, the focus was on the AEs of
ICS therapy on growth in children. Agertoft and
Pedersen203 aimed to determine the equipotency
of the inhaled steroids, while also defining the
minimal effective doses with these delivery
systems.
The age range of children in the RCTs was
5–16 years and mean ages were in the range
9.6–10.6 years. Agertoft and Pedersen203 reported
children as having been treated previously with
either 400 or 800 µg of BUD, but no previous
treatment details were reported by Altintas and
colleagues.204 The mean baseline levels for FEV1
ranged from 60%204 to around 90%.203 One trial
included children with moderate asthma,204 but
the other did not report asthma severity.203
Neither of the studies specifically stated their
primary outcomes.
The study by Agertoft and Pedersen203 reported
an adequate method of randomisation, but no
details of the randomisation procedure were
reported by Altintas and colleagues.204 Neither of
the studies reported an ITT analysis.
Results
Lung function
Both of the trials reported measures of lung
function. However, pooling results for meta-
analysis was not possible due to the differences in
study design and methodology.
Parallel 1:1 dose ratio studies. Agertoft and
Pedersen203 reported a mean change from baseline
to the end of the first treatment period (5 weeks)
in FEV1 of 0.1 litres for the FP group and
<0.1 litres for the BUD group. This difference
between the groups was not statistically significant
(95% CI –0.07 to 0.03, p = 0.77).
The change in PEF from baseline was presented as
the difference between the mean PEF at baseline
and the mean PEF during the last 2 weeks of the
first 5 weeks of treatment (i.e. treatment weeks 4
and 5). The change from baseline in morning PEF
was 7.6 l/minute for FP recipients and 1.9 l/minute
for BUD recipients. This difference between
groups was not statistically significant (95% CI
–12.0 to 0.7, p = 0.06). The corresponding results
for evening PEF were 5.1 l/minute for FP recipients
and –0.7 l/minute for BUD recipients. This
difference between groups was also not statistically
significant (95% CI –12.1 to 0.6, p = 0.06).
Parallel 1:2 dose ratio studies. Altintas and
colleagues204 provided data showing
improvements after 1 year in FEV1 % predicted
for both BUD and FP. However, due to an error in
reporting (identical data were presented for both
groups), these results cannot be used.
Symptoms
Parallel 1:1 dose ratio studies. Agertoft and
Pedersen203 measured day- and night-time
symptom scores on a four-point scale (0 = none,
3 = severe, no reference supplied). The change
from baseline in symptom scores was presented as
the difference between the mean score at baseline
and the mean score during the last 2 weeks of the
first 5 weeks of treatment (i.e. treatment weeks 4
and 5). The change in daytime asthma symptom
scores was –0.11 for the FP group and –0.05 for
the BUD group. This difference between the
groups was not statistically significant (95% CI
–0.08 to 0.20, p = 0.37). The change in night-time
asthma symptoms was –0.04 for patients on FP
and –0.03 for patients on BUD. This difference
between the groups was also not statistically
significant (95% CI –0.07 to 0.09, p = 0.75).
Parallel 1:2 dose ratio studies. Altintas and
colleagues204 provided data showing
Assessment of clinical effectiveness
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both BUD and FP. However, due to an error in
reporting (identical data were presented for both
groups), these results cannot be used.
Use of rescue medication
Only Agertoft and Pedersen203 reported the use of
rescue medication as an outcome. They presented
data on the daily use of SABAs, but did not state
whether these were the number of inhaler sessions
per day or the number of puffs per day. The
change from baseline was reported as the difference
between the mean SABA use at baseline and the
mean use in weeks 4 and 5. SABA use remained
relatively unchanged, with values of 0.02 for the FP
group and 0.01 for the BUD group. This difference
between the groups was not statistically significant
(95% CI –0.20 to 0.18, p = 0.87).
Exacerbations
Neither of the trials reported exacerbations of
asthma as an outcome measure.
Adverse events
Neither of the studies reported the number of AEs
experienced by each treatment group, but other
measures of safety or side-effects were reported.
Parallel 1:1 dose ratio studies. Agertoft and
Pedersen203 reported the change in 24-hour urine
cortisol excretion from baseline to 5 weeks. This
was 6.6 nmol for the FP group and 1.8 nmol for
the BUD group. The difference between the
groups is not statistically significant (95% CI –10.9
to 1.3, p = 0.13).
Parallel 1:2 dose ratio studies. Altintas and
colleagues204 reported growth rate (centimetres in
1 year). Growth increased at a similar rate and did
not differ significantly between the groups (FP 8.2
cm/year, BUD 8.4 cm/year, p > 0.05). In the same
study, morning serum cortisol levels decreased in
both groups at 12 months, with no statistically
significant difference between BUD and FP
(p > 0.05). BMD was also comparable between
groups, with no statistically significant difference
(p > 0.05).
Summary
Two studies compared the efficacy and safety of FP
and BDP among children. These RCTs had
different designs and used different nominal dose
ratios (1:1 and 1:2). The more detailed of these
studies was only 5 weeks in duration, with some
outcomes reported as mean values for weeks 4 and
5. No statistically significant differences were
observed in measures of lung function when
patients were treated with FP compared with
treatment with BUD. Only one of the studies
reported reliable symptom scores and a measure
of safety (urine cortisol). Neither of these
outcomes differed significantly between the
treatment groups.
Summary of Q1: relative effectiveness of 
low-dose ICS
Summaries of the results are given in Tables 14–16.
Review question 2 – effectiveness of
high-dose ICS
High-dose ICS: BDP and BUD 
Study characteristics
Only one study, by Pedersen and Fuglsang205
published in 1988, compared the effects of BUD
and BDP in children (Table 17). It was a small,
single-centre study conducted in Denmark,
involving 31 children. The trial was an open-label,
cross-over design with no wash-out period,
containing two arms. It focused on systemic AEs
rather than clinical effectiveness.
The total daily dose of ICS varied between 800 and
1200 µg/day, with a mean of 900 µg/day. The dose
was equal to that normally used by the child, and
was the same in both the BUD and BDP treatment
periods. Thus the comparison of the two drugs was
at a dose ratio of 1:1 throughout the study. The
drugs were both delivered via an MDI, with or
without a volume spacer (make or manufacturer of
device not reported). The aim of the study was to
determine if there were any differences between
the two drugs in adverse systemic effects on
adrenal function. For this purpose, cortisol
excretion was chosen as the primary outcome (it
was not explicitly stated whether the intention was
to test equivalence or superiority). The treatment
duration was two 6-week periods with no wash-out
in between. However, the authors reported that no
carry-over effects were found.
The trial included boys and girls aged between 5
and 15 years, with a mean age of 10 years. All the
children had previously received high-dose ICS
therapy with either BUD or BDP. The severity of
asthma was not specifically stated and baseline
FEV1 % predicted was not reported. However, it
may be assumed that the participants’ asthma was
severe in light of the high-dose ICS therapy.
The trial reported a randomisation procedure that
assured true random assignment to treatment
groups (a computer-generated algorithm), and
which was also adequately concealed. However,
these details were obtained by the authors of the
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T
ABLE 14
BDP versus BUD (1 RCT)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
Stepwise 
Bisgaard,
200
increased 
12 weeks
BDP
2 withdrawals
doses: 200, 
(3 
×
4 weeks),
C
C
C
NSD
400, 
parallel-group, 
800
µg/day
double-blind,
BUD
4 withdrawals
MDI; 
n
=4
1
C, stated to be comparable between trial arms but no tests of statistical significance reported; 
n, number of events; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-
free nights; SS, symptom score (varies between studies); blank cells signify no data reported on that outcome.Health Technology Assessment 2008; Vol. 12: No. 20
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T
ABLE 15
FP versus BDP (2 RCT
s)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
Gustafsson
a
,
201
6
weeks,
FP
50% (3 serious)
parallel-group, NSD
NSD
NSD
double-blind, 
BDP
F
c
47% (2 serious)
200
µg vs 
MDI; 
n
=
398
400
µg
Ra
o
a
,
202
20
months,
FP
b
F
F
parallel-group, 
double-blind,
BDP
MDI; 
n
=2
3
F
, results appear to favour treatment group, but no tests of statistical significance reported; 
n, number of events; NSD, no significant difference between trial arms; NW
, nocturnal
waking; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); blank cells signify no da
ta reported on outcome.
a 
Gustafsson 
et al. reported within-group differences for measures of lung function, rather than between-group comparisons. R
ao 
et al. presented FEV
1
data graphically with no
between-group comparisons; only symptom scores for the entire period (not for the initial 10-week period of interest) were repo
rted; AE outcomes were related to growth and
bone turnover
, therefore no usable data can be reported in the table.
b 
This study had a third arm where patients received placebo for 10 weeks and were then merged with the FP arm.
c 
R
efers to FEV
1
(litres). Study also reports data for FEV
1
% predicted, where the values were identical in both groups.Assessment of clinical effectiveness
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T
ABLE 16
BUD versus FP (2 RCT
s)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
200 or 
Agertoft,
203
FP
400
µg vs 
variable
a
,
200 or 
parallel-group, NSD
NSD
NSD
NSD
NSD
NSD
400
µg
a
double-blind, 
BUD
DPI; 
n
=
217
Altintas
b
,
204
12
months,
FP
250
µg vs 
parallel-group,
NSD
400
µg
device not 
reported, BUD
n
=3
0
n, number of events; NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, sympt
om-free nights; SS, symptom score (varies
between studies); blank cells signify no data reported on that outcome.
a 
Starting daily dose of 200 or 400
µg for 5 weeks with dose reductions by 50% at 5-week intervals.
b 
Altintas 
et al. did not analyse differences between groups; the focus was on the AEs of ICS therapy on growth, therefore no usable data can b
e reported in the table.Health Technology Assessment 2008; Vol. 12: No. 20
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T
ABLE 17
Study characteristics (BDP and BUD)
Study
Design
Intervention
P
atients
Outcomes
P
edersen and
F
uglsang, 1988
205
RCT
Single-centre
Cross-
over (no
wash-
out)
Open label
Drug(s): 
1. BDP total 800–1200 µg/day
2. BUD total 800–1200 µg/day
T
aken b.d. as BDP 50, 100 or 250 
µg per
actuation, BUD 50 or 200 
µg per actuation and
remaining constant throughout the trial
Delivery device: 
1, 2. MDI ±
spacer (V
olumatic or Nebuhaler
,
no other details about devices reported)
Duration:
2 
×
6 weeks
Run-in period:
None
Number randomised
31
Mean age (years)
10.2 (range 5–15)
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
BDP or BUD 800–1200 µg/day
Outcomes
Adrenal function (as measured by 
24-hour free cortisol excretion in
urine)
FEV
1
AEsCochrane review in which this trial was included,
and not reported in the original paper. Although
the trial was open label, the outcome assessors
were blind to the experimental dose regimen. It is
not known whether the study performed an ITT
analysis.
Results
Lung function
Pedersen and colleagues205 reported limited data
on efficacy in terms of lung function parameters as
this was not the main purpose of the study. The
authors reported that FEV1 at the end of each
period was 2.35 litres (range 0.9–3.8 litres) for
BDP compared with 2.26 litres (range
0.8–3.9 litres) for BUD. The difference was not
statistically significant.
Symptoms, use of rescue medication, exacerbations
The trial did not report symptoms, use of rescue
medication or exacerbations as outcome measures.
Adverse events
The authors stated that no side-effects were
reported. However, one participant during the
period on BUD was withdrawn from the study
because of an acute exacerbation of asthma.
The excretion of urinary cortisol was statistically
significantly higher during BUD treatment [76.3
(range 25–215) nmol/day] than during BDP
treatment [53.7 (range 6–118) nmol/day)
(p < 0.01)]. The difference was reported to be
more pronounced in children treated with
1000–1200 µg/day (n = 8) than in those treated
with 800 µg/day (n = 22). Cortisol excretion was
below the normal range during the period on
BDP for four children and during the period on
BUD one child.
Summary
Only one small, single-centre, cross-over trial
evaluated the effects of BUD compared with BDP
in children receiving high-dose ICS therapy. The
study focused on adverse systemic effects on
adrenal function but also reported FEV1 at the
end of each period. The FEV1 did not differ
significantly between the BDP and BUD periods.
However, treatment with BUD resulted in
significantly higher 24-hour free cortisol excretion
compared with BDP.
High-dose ICS: FP and BDP
Study characteristics
Three RCTs compared the effects of high doses of
FP and BDP in children. These trials, published
between 1997 and 2001, were by Yiallouros and
colleagues,206 Fitzgerald and colleagues207 and de
Benedictis and colleagues208 (Table 18). One study
used a parallel-group design,208 whereas the other
two studies used a cross-over design. The study
sizes ranged from 34206,207 to 343 patients.208 Two
of the trials were single-centre studies206,207 and
one trial was a multi-centre study.
All three RCTs contained two arms. There was
variability in the doses used in the trials. Fitzgerald
and colleagues207 used a daily dose of 750 µg of FP
and 1500 µg of BDP. In the study by Yiallouros and
colleagues,206 participants had been receiving
between 400 and 900 µg/day of BUD/BDP (median
519 µg/m2/day BUD, 588 µg/m2/day BDP). They
were randomised to receive either an equal dose of
BDP or an equipotent (half the dose) of FP daily.
The trial by de Benedictis and colleagues208 used a
daily dose of 400 µg for both FP and BDP. Thus,
two studies used dose ratios of 1:2206,207 (FP:BDP)
and one study used a dose ratio of 1:1.208 Two of
the trials used MDI devices with spacers206,207 (the
only device details provided are by Yiallouros and
colleagues, in that the devices were provided by
Glaxo Group Research), and the third trial used a
dry powder Diskhaler (no further details about the
device were reported).208 Two RCTs treated for 12
weeks206,207 and the third RCT lasted for 52
weeks.208 A range of efficacy outcomes were
measured, and also safety, with two measuring
adrenal function206,207 (one of which was powered
specifically to detect differences on this
outcome207) and one measuring growth.208
All three RCTs contained two arms. There was
variability in the doses used in the trials.
Fitzgerald and colleagues207 used a daily dose of
750 µg of FP and 1500 µg of BDP, Yiallouros and
colleagues206 used a daily dose of 200 µg of FP
and 400 µg of BDP and de Benedictis and
colleagues208 used a daily dose of 400 µg for both
FP and BDP. Hence, two studies used a dose ratio
of 1:2206,207 and one study 1:1.208 Two of the trials
used MDI devices with spacers206,207 (the only
device details provided are by Yiallouros and
colleagues, in that the devices were provided by
Glaxo Group Research) and the third trial used a
dry powder Diskhaler (no details about the device
were reported).208
Two RCTs had a treatment duration of
12 weeks206,207 and the third RCT lasted
52 weeks.208 Two of the studies measured adrenal
function206,207 and the third measured growth.208
The age range of children included in the RCTs
varied from 4 to 15 years, with mean ages 
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T
ABLE 18
Study characteristics (BDP and FP)
Study
Design
Intervention
P
atients
Outcomes
Fitzgerald 
et al.
1998
207
RCT
Cross-
over (no 
wash-
out)
Double-blind
Drugs:
1. FP 375
µg/b.d. (daily total 750
µg)
2. BDP 750
µg/b.d. (daily total 1500
µg)
Delivery device: 
1, 2. MDI + volume spacer 
(no further details about devices reported)
Duration:
12 weeks
Run-in period:
4 weeks
Number randomised
34
Mean ±
SD age (range) (years)
1. 10.5 ±
2.5 (6–15) 
2. 9.4 ±
2.9 (5–13) 
Baseline FEV
1
% predicted (range)
1. 86 (82–90) 
2. 86 (82–90) 
P
revious ICS treatment (drug and dose)
FP 750
µg/day or BDP 1500
µg/day
P
rimary outcomes
PEF (morning and evening)
Symptom scores (day and night)
Secondary outcomes
24-hour urinary cortisol levels
Growth
AEs:
No. of asthma exacerbations
No. of asthma exacerbations 
requiring oral steroids
P
atient-assessed efficacy scale
Physician-assessed efficacy scale
Plasma A
CTH
8 a.m. plasma cortisol
Plasma cortisol 1
hour post-synthetic
A
CTH (Synacthen) (0.5
µg per 
1.73
m
2
body surface area)
Y
iallouros 
et al.,
1997
206
RCT
Cross-
over (no 
wash-
out)
Double-blind
Drugs:
1. 
BDP
: dose equal to prestudy ICS 
2. 
FP at half daily µg dose of prestudy ICS 
Delivery device: 
1, 2. MDI + spacer (GlaxoSmithKline
a
)
Duration:
12 weeks
Run-in period:
2 weeks
Number randomised
34 (comprising 2 groups, A and B, before
randomisation)
Median age (range) (years)
A. 7.3 (5–12.4)
B. 8.8 (6–13.1)
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and median dose)
A. BUD 519
µg/day
B. BDP 588
µg/day
(for 
3 months before randomisation)
Outcomes
Urinary cortisol
Urinary cortisol metabolites
PEF (morning and evening)
Symptom sores
R
escue SABA use (day and night)
continuedAssessment of clinical effectiveness
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ABLE 18
Study characteristics (BDP and FP) (cont’d)
Study
Design
Intervention
P
atients
Outcomes
de Benedictis 
et al.,
2001
208
RCT
Multi-centre
P
arallel-group
Double-blind
1. FP 200
µg/b.d. (daily total 400
µg)
2. BDP 200
µg /b.d. (daily total 400
µg)
Delivery device:
1. DPI (Flixotide Diskhaler
, GSK
a
)
2. DPI (Diskhaler
, GSK
a
)
Duration:
52 weeks
Run-in period:
2 weeks
Number randomised
343
Mean ±
SD age (range) (years)
1. 7.6 ±
1.7 (4–11)
2. 7.6 ±
2.0 (4–11)
Baseline FEV
1
% predicted
No reported
P
revious ICS treatment (drug and dose)
FP 100–200
µg/day or
BDP or BUD 200–500
µg/day
P
rimary outcome
Growth velocity
Secondary outcomes
Symptom scores
R
escue medication
PEF (morning and evening)
FEV
1
A
CTH
, adrenocorticotrophic hormone; GSK, GlaxoSmithKline.
a 
Not stated explicitly
, but deduced from the text.from 7206,208 to 9 years.207 One trial reported
children as having been previously treated with
1000–2000 µg daily of BDP or BUD207 and the
second trial reported a daily median dose of
519 µg BUD or 588 µg BDP.206 In the third trial,
children had previously been treated with
100–200 µg daily of FP or 200–500 µg daily of
BDP or BUD.208 Fitzgerald and colleagues207
reported mean baseline levels for FEV1 at 80%.
The other two studies reported measuring
baseline levels for FEV1, but provided no further
details.206,208 The study by de Benedictis and
colleagues208 described children as suffering with
mild to moderate asthma, whereas the other two
trials described children as suffering with
persistent severe207 or severe chronic asthma.206
The report by de Benedictis and colleagues208
specified their primary outcome as growth velocity,
whereas Fitzgerald and colleagues207 specified
their primary efficacy variables as PEF, and also
day and night symptom scores. Yiallouros and
colleagues206 did not specify a primary outcome.
Fitzgerald and colleagues207 powered their study
to detect a mean daily difference in PEF of 5%
(15 l/minute in 10-year-old children) whereas de
Benedictis and colleagues powered their study to
detect a difference in growth rate of 1 cm/year.
Yiallouros and colleagues206 did not report
statistical power or details of their randomisation
procedure, and allocation concealment was also
unclear in two of the studies.206,207 Only two of the
studies reported an ITT analysis207,208 and only
one study208 reported the proportion of eligible
patients that were not randomised (20/403, of
which 10 were due to AEs, four for failure to
return and six for withdrawal of consent). Both of
the cross-over trials206,207 had no wash-out period
between treatments due to asthma severity;
however, both of these trials reported that there
were no carry-over effects.
Results
Lung function
Parallel design, 1:1 dose ratio. The following data
were obtained by the reviewers from the primary
publication208 and, in some cases, also from the
Cochrane review.187 The study by de Benedictis
and colleagues208 reported mean ± SD end-point
data for FEV1 in the FP group to be 1.75 ±
0.29 litres and in the BDP group to be 1.63 ±
0.31 litres. This was shown to be statistically
significantly different in favour of FP, p < 0.001.
Mean ± SD morning PEF in this trial was 251.30
± 29.81 l/minute at end-point in the FP group
compared with 242.80 ± 31.38 l/minute in the
BDP group. The difference between groups
(8.5 l/minute) was statistically significant (95% CI
2.8 to 14.2, p = 0.004). Mean ± SD evening PEF
was 255.10 ± 28.52 l/minute at end-point in the
FP group compared with 246.50 ± 30.08) l/minute
in the BDP group, with the difference between
groups (8.6 l/minute) also statistically significant
(95% CI 3.0 to 14.1, p = 0.003).
Cross-over design, 1:2 dose ratio. Fitzgerald and
colleagues207 demonstrated no statistically
significant differences between FP and BDP in
mean morning PEF [FP 311 l/minute, BDP
308 l/minute, treatment difference 2.6 l/minute
(95% CI –1.8 to 7.0 l/minute)]. Results in the trial
were adjusted to take account of a significant
period effect and patient differences in the
sequence groups. To investigate a possible carry-
over effect, the analysis was repeated for the last
month of treatment (month 3). The results were
similar with no differences demonstrated between
the two treatment groups. Yiallouros and
colleagues206 also demonstrated no statistically
significant differences between FP and BDP in
mean morning PEF (both groups 268 l/minute).
The trial also reports that no statistically
significant carry-over effect was detected
(p = 0.144).
Similarly, no statistically significant differences
between the two groups were shown in mean
evening PEF [FP 316 l/minute, BDP 312 l/minute,
treatment difference 4.2 l/minute (95% CI –1.2 to
9.5 l/minute)] in Fitzgerald and colleagues’ trial.207
Results were adjusted to take account of a
significant period effect and patient differences in
sequence groups. Yiallouros and colleagues206 also
reported that there was no statistically significant
difference between the two drugs for the mean
evening PEF [no results were presented but they
commented that there was a trend towards a carry-
over effect (p = 0.096)].
Symptoms/health related quality of life
Parallel design, 1:1 dose ratio. The study by 
de Benedictis and colleagues208 reported no
significant differences between treatment groups
with respect to diary-card symptoms, but no data
were presented to support this.
Cross-over design, 1:2 dose ratio. Symptom scores
were reported on a four-point scale (0 = no
symptoms, 3 = unable to carry out activities due
to shortness of breath) in the trial by Fitzgerald
and colleagues207 (no reference supplied). Day-
and night-time symptom scores (adjusted to take
account of a significant period effect and patient
differences in sequence groups) were reported
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significantly different at end-point between the FP-
treated patients and the BDP-treated patients. The
daytime scores were 0.3 for FP and 0.4 for BDP,
with a treatment difference of –0.1 (95% CI –0.8 to
0.02). Night-time symptom scores were 0.3 for
both drugs, with a treatment difference of –0.05
(95% CI –0.14 to 0.03).
Use of rescue medication
Parallel design, 1:1 dose ratio. The study by 
de Benedictis and colleagues208 reported no
significant differences between treatment groups
with respect to the need for rescue medication, but
no data were presented to support this.
Cross-over design, 1:2 dose ratio. Yiallouros and
colleagues206 reported that there were no
statistically significant differences between FP and
BDP treatments with respect to the need for
rescue medication, but no data were presented to
support this.
Exacerbations
Parallel design, 1:1 dose ratio. The total number
of exacerbations in the FP group was 47 compared
with 52 in the BDP group in de Benedictis and
colleagues’ trial.208 The percentage of patients
experiencing at least one exacerbation was 16% in
the FP group compared with 19% in the BDP
group. No statistical significance testing was
reported for these outcomes.
Cross-over design, 1:2 dose ratio. The total
number of exacerbations in the trial by Fitzgerald
and colleagues207 was 33 during treatment with FP
and 35 during treatment with BDP. This is
reported to be not statistically significant although
no p-value is reported. Overall the study reports
that 16 of these exacerbations were in the group
who received FP first whereas 52 exacerbations
were in the group who received BDP first. This
difference was shown to be statistically significant
(p < 0.001) and the authors suggest that a greater
proportion of less stable cases were placed in this
latter treatment sequence.
Adverse events
Parallel design, 1:1 dose ratio. AEs were
experienced at similar rates in the FP and BDP
arms of the trial by de Benedictis and colleagues208
(around 80% in both groups). Mean ± SEM growth
rates for the ITT populations were 4.76 ±
0.28 cm/year in the FP-treated group and 4.06 ±
0.29 cm/year in the BDP-treated group. This
difference (0.7 cm/year) was statistically significant
(95% CI 0.13 to 1.26 cm/year, p < 0.02).
In the same study,208 there were no statistically
significant differences in changes from baseline
morning serum cortisol levels between treatment
groups (FP 8.1 µg/dl; BDP 7.1 µg/dl, p = 0.12).
There were no statistically significant differences in
changes from baseline overnight urinary cortisol
levels (FP 14.0 µg/dl; BDP 12.6 µg/dl, p = 0.32).
Cross-over design, 1:2 dose ratio. Fitzgerald and
colleagues207 reported that there were no differences
in the number of AEs between the FP and BDP
treatment phases in their study, but no data were
presented. Similarly, Yiallouros and colleagues206
reported that the incidence of AEs was similar in the
two groups, but no data were presented.
One patient discontinued during treatment with
FP and three during treatment with BDP in
Yiallouros and colleagues’ trial.206
Fitzgerald and colleagues207 commented that there
was no evidence of growth suppression (based on
height SD scores) and no evidence of a significant
effect of drug treatment on growth, which
remained normal (no p-values were provided).
There were no statistically significant differences in
adjusted mean urinary free cortisol levels between
the FP and BDP treatment groups in the Fitzgerald
and colleagues207 trial (25.3 nmol per 24 hours FP
versus 25.2 nmol per 24 hours, treatment
difference –0.1 (95% CI –6.0 to 6.3). Similarly, in
the Yiallouros and colleagues206 trial, there were no
statistically significant differences in adjusted total
cortisol between the two study medications (FP
1315 µg/dl, BDP 1254 µg/dl, p = 0.55).
Summary
Parallel design, 1:1 dose ratio
Patients treated with FP improved more than
patients treated with BDP on measures of lung
function. However, differences between the groups
on measures of symptoms, use of rescue
medication and exacerbations were not statistically
significant, although reported data were limited on
these outcomes. Similar rates of AEs were noted
between the two treatments, except that the BDP-
treated group had a significantly lower growth rate.
Cross-over design, 1:2 dose ratio
On measures of lung function, no significant
differences were observed between groups treated
with FP and groups treated with BDP. No
differences between the two treatments were
observed on symptoms, use of rescue medications
or exacerbation rates where data was reported.
The AE profiles of the two drugs were similar.
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Study characteristics
Three parallel group RCTs210–213 evaluated the
effectiveness of BUD compared with FP, published
between 1996 and 2002 (Table 19). One study212
reported additional data in a secondary
publication.213
Two studies were multi-centre studies where study
sample sizes ranged between 229 and 333
participants;210,211 the third study was a single-
centre pilot study where the sample size was
60.212,213 Only one of the trials reported
undertaking a power calculation, where adequate
power in the sample was met.211
All three included trials had two-arm comparisons
of BUD versus FP. One trial compared FP 400 µg
with BUD 400 µg, a nominal dose ratio of 1:1.210
Two trials compared FP with BUD at a nominal
dose ratio of 1:2.211–213 One compared 400 µg/day
of FP with 800 µg/day of BUD211 and the second
compared FP 500 µg/day with BUD
800 µg/day.212,213 The latter study reduced doses
after 2 months to 200 and 400 µg/day, respectively.
This study also had a third, non-randomised
comparison group, who were prescribed cromones
(not discussed here). The devices used in all three
studies were DPIs for BUD respectively
[Diskhalers: Flixotide, GlaxoSmithKline (GSK);
Turbuhalers: Pulmicort, AZ). The treatment
duration in the 1:1 dose ratio study was
8 weeks.210 The treatment duration for the two 1:2
dose ratio studies were similar at 16 weeks and
20 weeks for the studies by Kannisto and
colleagues212,213 and Ferguson and colleagues,211
respectively.
All three included trials aimed to compare the
clinical efficacy of the two drugs, administered in a
DPI. The outcomes used to measure clinical
efficacy differed between the groups. The one trial
using equal doses of the two comparator drugs210
aimed to compare the efficacy and effects on
serum cortisol and serum and urinary indices of
bone metabolism. The trial by Ferguson and
colleagues211 was reported to be an equivalence
trial, assessing morning PEF as their primary
outcome. The third trial,212,213 reported as a pilot
study, aimed to measure clinical efficacy using
FEV1 as the primary outcome.
The ages of participants in the trials are likely to
be similar. Two trials report age ranges that lie
between 4 and 15 years210–213 and one trial reports
mean ages between 7.9 and 8.2 years.211 The
severity of asthma varied across the three studies.
In the 1:1 dose ratio study, participants were
described as mild to moderate in severity.210 In
the two 1:2 dose ratio studies, participants were
described as moderate to severe211 and newly
diagnosed.212,213 In the trials by Hoekx and
colleagues210 and Ferguson and colleagues,211 all
patients were already prescribed ICS. Baseline
FEV1 % predicted was reported in only one of the
included trials and was similar across the
comparison arms at 92%.212,213
The method of randomisation and allocation
concealment was assessed to be adequate in the
trial by Hoekx and colleagues.210 In the trials by
Ferguson and colleagues211 and Kannisto and
colleagues,212,213 no method of randomisation was
reported and allocation concealment was also
unclear. These two factors reduce the risk of
selection bias and therefore care is required when
interpreting the last two trials. Only the trial by
Ferguson and colleagues211 reported that data
were analysed using an ITT principle, although,
as it appears that some participants were excluded
from the data analysis, reporting is not considered
accurate.
Results
Lung function
Parallel design, 1:1 dose ratio. Hoekx and
colleagues210 presented data on morning and
evening PEF as the mean of available data during
a period of 1–8 weeks of treatment. They also
presented this as an adjusted mean to account for
differences in baseline gender, age and country.
During the treatment period (weeks 1–8) the
adjusted mean morning PEF was 274 l/minute in
the FP group compared with 267 l/minute in the
BUD group, which was statistically significant
(p = 0.019). The adjusted mean evening PEF did
not differ significantly between the groups (FP
279 l/minute, BUD 273 l/minute, p = 0.054). No
measures of variance were reported.
Parallel design, 1:2 dose ratio. After 20 weeks of
treatment, the adjusted mean morning PEF for
the FP group in the trial by Ferguson and
colleagues211 was 271 (± SD 82) l/minute
compared with 259 (± SD 75) l/minute in the
BUD arm. The treatment regimens were shown
not to be equivalent, as determined by an a priori
calculation of the 90% CI. The difference was
shown to be statistically significantly different,
p = 0.002 in favour of FP. Evening PEF was not
statistically significantly different between the two
groups [FP 271 (± SD 104) l/minute, BUD 259 
(± SD 103) l/minute, mean difference 12 (95% CI
–11.12 to 35.12)].
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T
ABLE 19
Characteristics of studies (BUD and FP)
Study
Design
Intervention
P
atients
Outcomes
Hoekx 
et al.,
1996
210
RCT
Multi-centre
P
arallel-group
Double-blind
Drugs:
1. FP 
100
µg 2 puffs b.d. (daily total 400
µg) +
placebo
2. BUD 
200
µg 1 puff b.d. (daily total 400
µg) +
placebo 
Delivery device:
1. DPI Diskhaler (Flixotide, GSK)
2. DPI T
urbuhaler (Pulmicort, AZ)
Duration:
8 weeks
Run-in period:
2 weeks
Number randomised
229
Age range (years)
4–13 years
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
Mild-to
-moderate asthma (all taking ICS
but no details of drug or dose)
Outcomes
FEV
1
Clinic PEF
PEF (morning and evening)
Daytime asthma symptom score
% SFDs
% SFNs
Days missed from school (patients)
Days missed from work (parents)
P
arent completed, patient-centred
assessment of physical and social activity
Morning serum cortisol
Biochemical markers of bone turnover
Ferguson 
et al.,
1999
211
RCT
Multi-centre 
P
arallel-group
Double-blind
Drug(s): 
1. FP 400
µg daily
2. BUD 800
µg daily
Delivery device: 
1. DPI Diskhaler (Flixotide, GSK) 
2. DPI T
urbuhaler (Pulmicort, AZ) 
Duration:
20 weeks
Run-in period:
2 weeks
Number randomised
333
Mean age (years)
1. 8.2 ±
2
2. 7.9 ±
2
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
All taking ICS but no details of drug or
dose
Outcomes
Morning PEF
Change in day
- and night-time symptom
score 
Daytime SABA use
Change in height compared 
Change in morning plasma cortisol 
Asthma exacerbations
Oro
-pharyngeal side-effects
Height assessment
K
annisto 
et al.,
2002
212,213
RCT
P
arallel-group
Open-label
Drugs:
1. FP 
250 
µg b.d. (daily total 500
µg) – 200
µg/day
after 2
months
2. BUD 
400
µg b.d. (daily total 800
µg) –
400
µg/day after 2
months
3. Cromolyn 
200
µg t.d.s. (daily total 600
µg) or
Nedocromil 40
µg t.d.s. (daily total 120
µg)
Only groups 1 and 2 relevant here
Delivery device: 
1. DPI Diskus (Flixotide, GSK)
2. DPI T
urbuhaler (Pulmicort, AZ)
Duration:
16 weeks
Run-in period:
Not reported
Number randomised
60 for groups 1 and 2 
(75 in total)
Age range (years)
5.5–14.7 years
Baseline FEV
1
% predicted (±
SD)
1. 92 ±
1
1
2. 92 ±
1
5
P
revious ICS treatment (drug and dose)
None
Outcomes
FEV
1
% change from baseline
Number with fall in FEV
1
R
escue medication usage: doses/week
Changes in heightFerguson and colleagues211 reported a comparable
improvement from baseline to end of treatment in
FEV1 between the groups [FP 1.74 (± SD 0.51),
BUD 1.66 (± SD 0.44), p = 0.183]. Kannisto and
colleagues212,213 reported that change in FEV1 %
predicted was 5.5% (± SD 11.83) for the FP group
and 6.7% (± SD 13.25) for the BUD group. These
changes from baseline were reported to be not
statistically significantly different but no p-value
was reported.
Symptoms/health-related quality of life
Parallel design, 1:1 dose ratio. Although Hoekx
and colleagues210 reported some data on
symptoms, inadequate information was provided
for the purposes of the present review.
Parallel design, 1:2 dose ratio. Ferguson and
colleagues211 reported that there were no
differences between the FP and BUD groups on
change in daytime symptom scores, but no data
were presented to support this.
Use of rescue medication
Parallel design, 1:1 dose ratio. No data on use of
rescue medication in terms of puffs per day were
reported in the included trial210 in this category.
Parallel design, 1:2 dose ratio. Ferguson and
colleagues211 reported that there were no
differences between the FP and BUD groups on
the need for rescue medication, but no data were
presented to support this. Kannisto and
colleagues212,213 showed at end-point that rescue
medication usage in terms of puffs per day was
lower in the FP group [1.70 (± SD 3.45)]
compared with the BUD group [3.75 (± SD 7.50)],
but this was not statistically significantly different
[mean difference –2.05 (95% CI –5.00 to 0.90)].
Exacerbations
Parallel design, 1:1 dose ratio. No data on
exacerbation rates were reported in the included
trial in this category.
Parallel design, 1:2 dose ratio. No data on
exacerbation rates were reported in either
included trial in this category.
Adverse events
Parallel design, 1:1 dose ratio. The proportion of
patients with an AE 5% were similar in the FP
and BUD groups in the trial by Hoekx and
colleagues210 (63% versus 69%, respectively). Two
patients from the FP group and three from the
BUD group in this trial discontinued due to AEs.
One patient from each treatment group had a
serious AE. The mean value of serum cortisol
concentration rose from 248 nmol/l (baseline) to
291 nmol/l (after 8 weeks) for those on FP
treatment, and from 214 nmol/l (baseline) to
246 nmol/l (after 8 weeks) for those on BUD
treatment. An FP/BUD ratio of change in mean
cortisol level was shown to be statistically
significantly different between the two groups at
4 weeks (p = 0.022) but not statistically
significantly different between the two groups at
8 weeks (p = 0.074).
Parallel design, 1:2 dose ratio. Ferguson and
colleagues211 reported that there were no
significant differences in the number of children
who experienced an AE between the two treatment
groups [FP 144/166, BUD 145/167 patients, OR
0.99 (95% CI 0.53 to 1.87)]. Serious AEs were
experienced by 4/166 children in the FP group
and 10/167 children in the BUD group. Four
patients in the FP treatment group and one in the
BUD treatment group discontinued due to AEs.
The study by Kannisto and colleagues212 did not
report proportions of patients experiencing AEs
other than growth and serum cortisol changes.
Kannisto and colleagues212,213 reported that the
decrease in height SD scores differed significantly
between the treatment groups (p < 0.05). In the
FP group, eight patients (27%) experienced a
decrease in the height SD score (absolute risk
increase 7%, 95% CI 13 to 67%). In the BUD
group, the decrease affected 18 patients (60%)
(absolute risk increase 40%, 95% CI –19 to 33%).
In the study by Ferguson and colleagues,211 the
adjusted mean growth from end of run-in to
20 weeks was 3.31 cm in FP-treated subjects and
1.99 cm in BUD-treated subjects. This difference
(1.32 cm) was statistically significant (90% CI 0.48
to 2.17, p = 0.002).
Kannisto and colleagues212,213 reported that the
cortisol response decreased in five patients (17%)
in the FP group (absolute risk increase 17%, 95%
CI 4 to 30%) and in nine patients (30%) in the
BUD group (absolute risk increase 30%, 95% CI
14 to 47%). This difference between the drugs is
not statistically significant (p > 0.05).
In the study by Ferguson and colleagues,211
adjusted geometric mean serum cortisol
concentrations at the end of treatment were
199 mmol/l in the FP-treated group and
183 mmol/l in the BUD-treated group. The ratio
of these means (1.09) does not differ significantly
from 1.0 (95% CI 0.98 to 1.21, p = 0.172).
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Parallel design, 1:1 dose ratio
Limited available data suggest that on measures of
lung function there were greater improvements in
the FP-treated groups than the BUD-treated
groups, although this was not always statistically
significant. Rates of AEs and discontinuations were
similar between the two treatment groups.
Parallel design, 1:2 dose ratio
On measures of lung function, one trial
demonstrated superiority of FP over BUD on
morning PEF, but similarity between the two
groups on evening PEF. The other trial showed
comparable improvement between groups on
FEV1. No differences between FP and BUD were
seen on measures of symptoms or use of rescue
medication. Growth was significantly lower in
BUD-treated patients in both trials and more AEs
were experienced by BUD-treated children in one
of the trials. The AE profiles, including changes in
cortisol concentrations, were otherwise similar
between the two drugs. Data on most outcomes
were limited.
Summary of Q2: relative effectiveness of 
high-dose ICS
Summaries of the results are given in Tables 20–22.
Review question 3a – ICS/LABA or
higher dose ICS
No RCTs of this comparison with an exclusively
child patient population were identified. However,
one RCT, included in our accompanying report on
inhaled corticosteroids,199 included around 12% of
patients under the age of 12 years.198 Results for
growth and plasma cortisol only are reported
separately for children and are presented here. 
A further brief summary of the results from the
overall trial population for both adults and
children is also presented.
The study by O’Byrne and colleagues198 (Table 23)
was published in 2005 and evaluated the
combination of BUD/FF in a single inhaler with
higher doses of BUD alone. It was a multi-centre
study conducted in 246 centres across 22
countries. Of the 2760 participants, 341 (12%)
were children aged 4–11 years. The trial was a
double-blind parallel-group design, containing
three arms. The first arm was 80 µg BUD/4.5 µg
FF twice daily with the combination inhaler as
reliever, the second arm was 80 µg BUD/4.5 µg FF
twice daily with terbutaline as reliever and the
final arm was 320 µg BUD twice daily with
terbutaline as reliever. Children were given half
the maintenance dose once daily at night. All
study medication was delivered by Turbohaler
(BUD, Pulmicort Turbuhaler, AZ).
The rationale of the trial was to test the
superiority of combined treatment and the
treatment duration was 12 months. The time to
first severe asthma exacerbation was the primary
outcome measure. The age range of all patients
was from 4 to 79 years, with a mean of around
36 years. The mean baseline FEV1 % predicted
was 73%. Prior to entry, children had to be treated
with 200–500 µg/day of inhaled corticosteroid.
The trial was of reasonable methodological quality.
A computer-generated random number list was
used (they were randomised in balanced blocks
and there were separate lists for children and
adults), and the treatment delivery devices were
indistinguishable – no other details were available.
The study reported using ITT analysis.
The majority of results (pertaining to adults) are
presented in our accompanying assessment report
on the efficacy and safety of ICS in adults.199
However, for clarity a summary of the overall results
is presented here for the total trial population and
the safety results which were reported separately for
children are reported in full.
Summary of trial results for overall population
Treatment with BUD/FF combination used as
maintenance and reliever therapy significantly
prolonged the time to first severe and mild
exacerbation compared with treatment with either
BUD/FF plus terbutaline or BUD plus terbutaline.
Furthermore, treatment with combination therapy
as both maintenance and reliever was associated
with significantly reduced reliever medication use,
improvements in both morning and evening PEF
and FEV1 and the number of night-time
awakenings compared with the two other
treatment groups.
Adverse events
Children in both BUD/FF groups grew
significantly more than those in the BUD group.
There was an adjusted mean difference in growth
of 1.0 cm between children treated with BUD/FF
as maintenance and reliever compared with BUD
(95% CI 0.3 to 1.7, p = 0.0054), and a difference
of 0.9 cm between BUD/FF with terbutaline
reliever compared with BUD (95% CI 0.2 to 1.6,
p = 0.0099).
Data were also presented for mean change in
morning plasma cortisol. The between-group
differences were 11% (95% CI –7 to 33%) for
BUD/FF with terbutaline reliever versus BUD, 1%
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T
ABLE 20
BDP versus BUD (1 RCT)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
P
ederson,
205
BDP
+
12
weeks,
800–1200
µg
a
cross-
over
, NSD
open-label, 
BUD
MDI; 
n 
= 31
NSD, no significant difference between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, 
symptom score (varies between studies); 
+, statistically significant difference between trial arms; blank cells signify no data reported on that outcome.
a 
Same in each group and remaining constant throughout the study period.Assessment of clinical effectiveness
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ABLE 21
FP versus BDP (3 RCT
s)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
Fitzgerald,
207
BDP
81%
1500 vs 
12 weeks,
750
µg
cross-
over
, NSD
NSD
NSD
a
NSD
NSD
double-blind,
FP
80%
MDI, 
n
=3
4
Y
iallouros,
206
BDP
400 vs 
12
weeks,
200
µg
cross-
over
, NSD
NSD
NSD
C
NSD
double-blind, 
FP
MDI, 
n
=3
4
de Benedictis,
208
BDP
400 vs 
52
weeks,
400
µg
parallel,
NSD
b
NSD
C
C
double-blind, 
FP
+
+
+
DPI, 
n
=
343
C, stated to be comparable between trial arms but statistical tests not reported; NSD, no significant difference between trial 
arms; NW
, nocturnal waking; SFD, symptom-free days;
SFN, symptom-free nights; SS, symptom score (varies between studies); +, indicates results significantly favour this trial arm;
 blank cells signify no data reported on that outcome.
a 
Day
-time symptom scores.
b 
Diary card symptoms.Health Technology Assessment 2008; Vol. 12: No. 20
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ABLE 22
FP versus BUD (3 RCT
s)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
Hoekx,
210
BUD
69%
400 vs 
8
weeks,
400
µg
parallel, 
NSD
double-blind,
FP
+
F
c
63%
DPI, 
n
=
229
Ferguson,
211
BUD
800 vs 
20 weeks,
400
µg
parallel, NSD
NSD
C
d
C
NSD
NSD
double-blind,
FP
+
DPI, 
n
=
333
K
annisto,
212,213
16
weeks,
BUD
800 vs 
parallel, 
NSD
NSD
NSD
NSD
500
µg
a
open-label, 
DPI, 
n 
= 60 
FP
b
(75 total)
C, stated to be comparable between trial arms but statistical tests not reported; 
n, number of events; NSD, no significant difference between trial arms; NW
, nocturnal waking; 
SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); +, indicates results significantl
y favour this trial arm; blank cells signify no data
reported on that outcome.
a 
Doses reduced after 2 months to 400
µg BUD vs 200
µg FP
.
b 
This study had a third non-randomised arm receiving cromones.
c 
Borderline statistical significance (
p
=
0.054).
d 
Day
-time symptom scores.Assessment of clinical effectiveness
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ABLE 23
Study characteristics (BUD versus BUD + FF)
Study
Design
Intervention
P
atients
Outcomes
O
’Byrne 
et al.,
2005
198
RCT
Multi-centre
P
arallel-group
Double-blind
1. 
BUD + FF 80
µg + 4.5
µg b.d. plus 80
µg +
4.5
µg as needed (daily total 160
µg + 9
µg) +
combination inhaler as reliever
2. 
BUD + FF 80
µg + 4.5
µg b.d. (daily total
160
µg + 9
µg) + terbutaline as reliever as
needed
3. BUD 
320
µg b.d. (daily total 640
µg) +
terbutaline as reliever as needed
Children were given half the maintenance dose
once daily
Delivery device:
1, 2, 3. DPI (Pulmicort T
urbuhaler
, AZ)
Duration:
12 months
Run-in period:
14–18 days
Number randomised
2760 (341 children)
Mean age (range) (years)
1. 35 (4–77)
2. 36 (4–79)
3. 36 (4–79)
Baseline mean FEV
1
% predicted (range)
1. 73 (43–108)
2. 73 (46–108)
3. 73 (49–100)
P
revious ICS treatment (drug and dose)
Adults 400–1000
µg q.d., children
200–500
µg q.d.
P
rimary outcome
The time to first severe asthma
exacerbation.
Secondary outcomes
FEV
1
PEF (morning and evening)
Asthma symptom scores (day/night)
A
wakenings
R
eliever medication use
SFDs
R
escue medication-free days
Asthma control days
Study drug use
AEs
Height (children)
Morning plasma cortisol
Mild exacerbations
NB. This trial also examines the effects of the combination inhaler as a reliever
. 12% are children (4–11 years).(95% CI –15 to 21%) for BUD/FF as maintenance
and reliever versus BUD, and –9% (95% CI –23 to
9%) for the two BUD/FF groups. The differences
were not statistically significant.
Summary of Q3a: ICS/LABA or higher dose ICS
A summary of the results is presented in 
Table 24.
Review question 3b – ICS/LABA or
similar dose ICS
FP/SAL versus FP
Study characteristics
Only one RCT, published in 2005, evaluated the
combination of SAL and FP compared with FP
alone214 (Table 25). It was a multi-centre study
conducted in 79 sites across the USA and Canada,
and involving 203 children. The trial was a
double-blind, parallel-group design, containing
two arms.
The total daily dose of FP was 200 µg and was the
same in both arms. The total daily dose of SAL
was 100 µg. The drugs were both delivered via a
Diskus inhaler device (FP, Flovent, GSK), with the
FP/SAL drugs delivered in combination via a
single inhaler (Advair, GSK).
The rationale of the study appeared to be whether
the addition of a LABA to the ICS (as opposed to
increasing the dose of ICS) is as safe as treatment
with ICS alone. It is not explicitly stated whether
the intention was to test equivalence or superiority
of safety measures. The treatment period of the
trial was 12 weeks.
The study included boys and premenarcheal girls
aged between 4 and 11 years, with a mean age of
8 years. All patients had previously received a
range of ICS therapy at a consistent dose, with FP
being the most commonly used ICS in each group
(70–74% of patients used FP). The severity of
asthma was not specifically stated, but the mean
baseline FEV1 % predicted was approximately 80%.
Although the primary objective of the trial was to
compare the safety profile of the two treatments,
some measures of efficacy were obtained. However,
these were reported in separate abstract
publications.215,216
On the whole, the study was of adequate quality
with regard to the reporting of methodological
details. The study used an ITT analysis which
included all subjects who received at least one
dose of the study drug. However, details of the
randomisation procedure and concealment of
allocation were lacking. The eligibility criteria
were adequately specified, and the supplemental
paper216 described withdrawals and drop-outs,
with reasons and numbers reported for each
treatment group.
Results
Lung function
The main publication for this trial214 did not report
any values for lung function as this was a safety
study and was not designed to evaluate efficacy
differences between treatment groups. However, the
authors did report that the FP/SAL group showed
greater improvements in FEV1 and in morning and
evening PEF compared with FP alone.
In one of the abstract publications for the study,215
FEV1 (litres) at end-point was reported for a
subgroup of children aged 6–11 years, and was
1.88 versus 1.77 litres for FP/SAL versus FP,
respectively. No p-values were reported. A second
abstract linked to this study216 reported a mean
change [± standard error (SE)] from baseline in
morning PEF (l/minute) of 21.5 ± 2.79 versus
16.9 ± 2.85 and evening PEF of 21.5 ± 2.43
versus 15.1 ± 2.83 for FP/SAL and FP, respectively.
Again, statistical significance was not reported.
Caution is advised as these data are taken from
conference abstracts and have not been subjected
to academic journal peer review.
Symptoms
Daytime asthma symptom scores were based on a
Likert scale, which is a five-point rating scale
(0 = none, 5 = severe, no reference supplied), and
were recorded by the parent or guardian on a
daily diary card. The asthma symptom scores
improved to a similar degree in both treatment
groups [–0.6 ± 0.10 versus –0.5 ± 0.12
(mean ± SE) for FP/SAL versus FP, respectively].
Use of rescue medication
The mean reduction from baseline in the use of
albuterol (number of puffs per day) was similar in
both treatment groups [–0.5 ± 0.22 versus
–0.4 ± 0.19 (mean ± SE) for FP/SAL versus FP,
respectively].
Exacerbations
The trial reported that children treated with
FP/SAL had a lower incidence of asthma
exacerbations than children treated with FP 
alone, occurring in three (3%) and eight (8%)
patients, respectively. Withdrawal from the study
due to asthma exacerbations occurred in 
two (2%) children treated with FP/SAL and five
(5%) children treated with FP alone.
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T
ABLE 24
BUD versus BUD/FF (1 RCT)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
O
’Byrne 
1. BUD
et al.,
198
parallel,
NSD
12 months, 
2. BUD/FF
a
2 vs 1
DPI, 
n 
= 2760
3 vs 1
(341 children)
3. BUD/FF
b
NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); blank cells
 signify no data reported on that outcome.
a 
BUD/FF with terbutaline as a reliever when needed.
b 
BUD/FF used for both maintenance and relief
.
T
ABLE 25
Study characteristics (FP versus FP + SAL)
Study
Design
Intervention
P
atients
Outcomes
Malone 
et al.
2005
214
RCT
Multi-centre
P
arallel-group
Double-blind
Active-controlled
Drugs:
1. FP/SAL 
100/50
µg b.d. (total dose 200/100
µg)
2. FP 100
µg b.d. (total dose 200
µg)
Delivery device:
1. Diskus (Advair
, GSK)
2. Diskus (Flovent, GSK)
Duration:
12 weeks
Run-in period:
2 weeks
Number randomised
203
Mean age (years)
1. 8.0
2. 8.1
Baseline FEV
1
% predicted
1. 80.9
2. 80.0
P
revious ICS treatment (drug and dose)
BDP 252–336
µg/day
, triamcinolone
acetonide 600–1,000
µg/day
, flunisolide
1,000
µg/day
, FP 88–250
µg/day
, or BUD
200–400
µg/day consistent dose for
1
month prior to study
P
rimary outcome
Safety measures (AEs)
Secondary outcomes
FEV
1
(for aged 6–11
years)
PEF (morning and evening)
2-hour serial post-dose FEV
1
(for those
aged 6–11 years) or 2-hour serial post-
dose PEF (for those aged 4–5
year) after
the first dose of study medication on
treatment day 1
Daytime asthma scores 
24-hour rescue medication use
Asthma exacerbations or worsening
asthmaAdverse events
The overall incidence of AEs was similar in the
two treatment groups, with 59% in the FP/SAL
group compared with 57% of FP treated patients
experiencing any AE (occurring at a rate of 3%
during treatment). Slightly more patients in the
FP/SAL group experienced at least one AE that
was potentially related to the study drug 
(13 versus 9% for FP/SAL and FP, respectively).
Similarly, addition of a LABA resulted in three
(3%) patients having AEs leading to premature
study withdrawal compared with none with FP
alone. There were no serious drug-related AEs in
either group.
Summary
Only one multi-centre, parallel group trial
evaluated FP compared with SAL and FP delivered
in combination via a single inhaler. Children in
the SAL/FP group showed apparent greater
improvements in lung function compared with FP
alone, although no statistical data were reported.
Furthermore, addition of a LABA to FP appeared
to be as safe as treatment with FP alone.
ICS versus ICS + LABA (BUD vs BUD/FF)
Study characteristics
The study by Tal and colleagues217 was the only
RCT which evaluated the effectiveness of the
combination of FF and BUD compared with BUD
alone in children (Table 26). It was an international,
multi-centre study conducted in 48 centres in seven
countries (Belgium, Czech Republic, Hungary,
Israel, South Africa, Spain and the UK), 
and involving 286 children. The trial was a
double-blind, parallel-group design, containing
two arms.
Patients in the BUD/FF group received 80/4.5 µg,
compared with BUD 100 µg, both taken as two
puffs twice daily. The doses of BUD in each
treatment group were equivalent (differences are
explained by labelling changes for new inhaled
drugs which require the delivered dose rather than
the metered dose to be reported). The total daily
dose of BUD was 400 µg in each group, and 
both groups used the Turbuhaler device
(Symbicort and Pulmicort, both AZ) for drug
administration. The hypothesis of the study 
was that the combination of BUD/FF would 
lead to improved lung function compared with
treatment with BUD alone. The treatment 
period of the trial was 12 weeks.
The trial included asymptomatic children aged
4–17 years, with a mean age of 11 years. All the
children had previously received a range of 
ICS therapy at a constant dose. The severity of
asthma was described by the authors as moderate,
and the mean baseline FEV1 % predicted was
approximately 75%.
The primary outcome was morning and evening
PEF, and this reflected the rationale of the study,
which was that addition of a LABA to ICS would
lead to improved lung function compared with
ICS therapy alone.
Methodological quality was generally adequate.
The trial reported a randomisation procedure that
assured true random assignment to treatment
groups (a computer-generated block-
randomisation list), and which was also adequately
concealed. A double-dummy technique was used
for drug administration, and also a double-blind
procedure, and the study used an ITT analysis
with all available data.
Results
Lung function
Relative to baseline, children treated with 
BUD/FF exhibited significantly greater increases
in FEV1 % predicted compared with BUD alone
(86.77 versus 83.02%, p < 0.05). A beneficial effect
of adding a LABA was further seen in terms of
improvement in morning PEF (% predicted), with
the mean increase from baseline being
significantly greater in the BUD/FF group
compared with BUD alone (7.22 versus 3.45%,
p < 0.001). Evening PEF also increased
significantly with BUD/FF (6.13 versus 2.73%,
p < 0.001).
Symptoms
The severity of daytime and nocturnal asthma
symptoms were recorded using a four-point rating
scale (0 = none, 3 = severe, no reference
supplied). There were no significant differences 
in asthma symptoms between the two groups 
at the end of treatment. The percentage of 
SFDs (defined as a night and day without
symptoms and no asthma-related nocturnal
awakenings) was determined as an overall 
measure of symptom control. The percentage 
of SFDs was slightly greater in the BUD/FF 
group (77.5%) compared with the BUD 
group (75.1%), but this difference was not
significant.
Use of rescue medication
Similar improvements in the use of inhaled
terbutaline or salbutamol (number of puffs 
per day) were observed in both treatment 
groups.
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T
ABLE 26
Study characteristics (BUD versus BUD/FF)
Study
Design
Intervention
P
atients
Outcomes
T
al 
et al.,
2002
217
RCT
Multi-centre
P
arallel-group
Double-blind
Double-dummy
Drugs:
1. BUD/FF 
80/4.5
µg 2 puffs b.d. actuation (daily
total 400/18
µg)
2. BUD 
100
µg 2 puffs b.d (daily total 400
µg)
Delivery device: 
1. T
urbuhaler (Symbicort, AZ)
2. T
urbuhaler (Pulmicort, AZ)
Duration:
12 weeks
Run-in period:
2–4 weeks
Number randomised
286
Mean age (range) (years)
1. 11 (4–17) 
2. 11 (5–17)
Baseline FEV
1
% predicted (range)
1. 74 (40–114)
2. 76 (40–100)
P
revious ICS treatment (drug and dose)
ICS at constant dose for at least 6 weeks
prior to study (400 
µg BUD T
urbuhaler
,
600 
µg BUD via pMDI, 
375 
µg FP or
600 
µg CFC–BDP)
Outcomes
PEF (morning and evening)
FEV
1
Symptom scores
Daily use of rescue medication
AEsExacerbations
Tal and colleagues217 did not report asthma
exacerbations as a specific outcome measure.
However, it was reported that five children in the
BUD/FF group had an exacerbation of asthma
that was classed as a serious AE requiring
admission to hospital. It is assumed from the text
that there were no asthma exacerbations in the
BUD group.
Adverse events
The two treatment groups were reported to be
similar in terms of AE profiles, with similar
proportions of patients in each group
experiencing the most common AEs. Seven
patients (4.7%) in the BUD/FF group had a
serious AE requiring admission to hospital. A total
of 18 children withdrew from treatment – nine
children (6.1%) in the BUD/FF group and nine
(6.5%) in the BUD group.
Summary
Only one trial evaluated the effectiveness of
BUD/FF delivered in combination via a single
inhaler compared with BUD alone. It was a large,
international, multi-centre study, of parallel-group
design and high methodological quality. The
combination of FF and BUD resulted in
statistically significant improvements in lung
function compared with BUD therapy alone. The
safety profile of the two groups appeared to be
similar, as was the improvement in symptoms and
use of rescue medication.
Summary of Q3b: ICS/LABA or similar dose ICS
Summaries of the results are given in Tables 27
and 28.
Review of question 4 – ICS/LABA
administered in separate or
combination inhalers
FP/SAL in combination inhaler versus FP + SAL in
separate inhalers
Study characteristics
One parallel group RCT218 evaluated the
effectiveness of FP/SAL in combination compared
with FP plus SAL taken concurrently and was
published in 2000 (Table 29). This study was a
multi-centre trial with 35 centres and the study
sample size was 257 participants. No power
calculation to ascertain an adequate sample size
was reported.
The trial compared FP/SAL 200/100 µg/day via
Diskus inhaler (Seretide, GSK) in one trial arm
with FP 200 µg/day plus SAL 100 µg/day also via
Diskus inhalers (it is not explicitly stated, but can
be deduced from the text, that devices were
supplied by GSK) in the second trial arm. The
treatment duration was 12 weeks. The aim of the
study was to compare the safety and efficacy of a
combination of the two groups with those of the
two drugs separately in children with asthma that
was poorly controlled by ICS alone.
The mean age of the participants in the trial was
7.6 years. The children were all poorly controlled
by ICS therapy alone (BDP or BUD or flunisolide
400–500 µg/day or FP 200–250 µg/day). The mean
baseline FEV1 % predicted was 86% in the
combination therapy arm and 84% in the
concurrent therapy arm.
The quality of reporting and methodology of the
study was generally inadequate. The method of
randomisation and allocation concealment was not
reported. The study did, however, report that data
were analysed on an ITT population, but the
method undertaken to achieve this was assessed to
be inadequate.
Results
Lung function
Van den Berg and colleagues218 presented data on
the adjusted mean change from baseline in FEV1.
At 12 weeks this was 0.21 litres in the SAL/FP
combination group and 0.13 litres in the FP plus
SAL group (difference –0.08 litres, 95% CI –0.14
to –0.01, p = 0.052), suggesting that the difference
is of borderline significance.
For morning PEF, the adjusted mean change from
baseline was 33 l/minute in the combination
therapy group compared with 28 l/minute in the
concurrent therapy group. The mean difference
between groups (separate inhalers – combination
inhaler) (–5 l/minute, 90% CI –10 to 0.1/minute,
p = 0.103) was shown to be within the defined
limits for equivalence (the criterion being
±15 l/minute). Similar, non-statistically significant
differences were seen with adjusted mean change
in evening PEF (FP/SAL 29 l/minute, FP plus SAL
25 l/minute, p = 0.164).
Symptoms/health-related quality of life
SFDs were reported to be similar between groups
in the trial by Van den Berg and colleagues,218 but
no data were reported to support this.
Use of rescue medication
Van den Berg and colleagues218 reported that there
were no differences between the FP/SAL and the FP
plus SAL groups on the need for rescue medication,
but no data were presented to support this.
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T
ABLE 27
FP versus FP/SAL (1 RCT)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
Malone,
214
FP
200 vs 
12
weeks,
200/100
µg
parallel, 
C
a
CC
double-blind,
FP/SAL
F
F
F
F
DPI, 
n 
= 203
C, stated to be comparable between trial arms but statistical tests not reported; F
, results favour this trial arm but statisti
cal tests not reported; NW
, nocturnal waking; 
SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); blank cells signify no data repor
ted on outcome.
a 
Day
-time symptom scores.
T
ABLE 28
BUD versus BUD/FF (1 RCT)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
T
al,
217
12 
BUD
400 vs 
w
e
eks, parallel,
NSD
a
NSD
C
C
400/18
µg
double-blind, 
BUD/FF
+
+
+
DPI, 
n
=
286
C, stated to be comparable between trial arms but statistical tests not reported; 
n, number of events; NSD; no significant difference between trial arms; NW
, nocturnal waking; 
SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between studies); +, indicates results significantl
y favour this trial arm; blank cells signify no data
reported on that outcome.
a 
Defined as a night and day without symptoms and no asthma-related nocturnal awakenings.Health Technology Assessment 2008; Vol. 12: No. 20
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ABLE 29
Study characteristics (FP/SAL combination versus separate inhalers)
Study
Design
Intervention
P
atients
Outcomes
V
an den Berg
et
al., 2000
218
RCT
Multi-centre 
P
arallel-group
Double-blind
Drugs:
1. FP/SAL 
100/50
µg b.d. (daily total 200/100
µg) +
placebo
2. 
FP + SAL 100 + 50
µg b.d. (daily total 200 +
100
µg)
Delivery device: 
1. 
Diskus (Seretide, GSK
a
) + Diskus
2. 
Diskus (Flixotide, GSK
a
)
Duration:
12 weeks
Run-in period:
2 weeks
Number randomised
257
Mean age (years)
7.6 (4–11)
Baseline FEV
1
% predicted
Not reported
P
revious ICS treatment (drug and dose)
BDP
, BUD 400–500
µg/day
, flunisolide
200–250
µg/day constant for 4
weeks
prior to study
Outcomes
FEV
1
Mean PEF (morning and evening)
AEs
a
Not stated explicitly
, but deduced from the text. Exacerbations
No data on exacerbations were reported.
Adverse events
There were 13 children with AEs in the FP/SAL
group and six in the FP + SAL group. No analysis
for statistical significance was undertaken on this
data.
Summary
In this multi-centre trial, no differences between
treatment with FP/SAL in a combination inhaler
and FP plus SAL in separate inhalers were
observed on measures of lung function, symptoms,
use of rescue medication or AEs.
Summary of Q4: ICS/LABA administered in
separate or combination inhalers
A summary of the results is given in Table 30.
Review question 5 – combination
inhaler compared with combination
inhaler
No RCTs of this comparison were identified.
Cochrane systematic reviews
Five Cochrane systematic reviews186–190 evaluating
various ICS treatments for chronic asthma in
adults and children were identified in searches.
The reviews were published between 2000 and
2006 and are briefly described individually 
below.
It is important to note that these reviews had
slightly different inclusion criteria to the current
assessment (e.g. when comparing ICS and LABA
to ICS alone, the former could be delivered in
separate inhalers in addition to combination
inhalers). Further, only a relatively small
proportion of the included studies in each review
comprised children under 12 years. Their results
are provided here as context within which to
interpret the results of the current assessment.
Adams and colleagues187 – FP versus BDP or
BUD
This review187 evaluated the effectiveness and
safety of three inhaled corticosteroids – FP was
compared with either BDP or BUD. The review
was first published in Issue 1, 2001, and was last
updated in May 2005 (searches up to January
2005). The review included prospective RCTs of
parallel or cross-over design in both adults and
children (aged >2 years) with chronic asthma. The
interventions included any dose of FP compared
with any dose of BDP or BUD, with a treatment
period of 1 week or longer.
The review found 57 studies which met the
inclusion criteria, involving 12,614 participants.
Fourteen of the studies were in children, with the
remaining studies conducted in adolescents and
adults. The asthma severity of the participants in
the trials varied from mild (eight studies), mild to
moderate (12 studies), moderate (12 studies),
moderate to severe (16 studies), severe (six
studies), and mild to severe (two studies), with
severity being unclear in one trial. In the majority
of studies, some or all of the participants were
using regular inhaled corticosteroids at the time of
enrolment.
Results
Dose ratio 1:2
FP resulted in a significantly greater absolute FEV1
compared with BDP/BUD (mean difference 0.09
litres, 95% CI 0.03 to 0.15 litres). However, when
reported as change from baseline, there was no
significant difference between groups (mean
difference 0.01 litres, 95% CI –0.02 to 0.05 litres).
Similarly, there was no significant difference
between groups in absolute FEV1 % predicted
(mean difference 0.50%, 95% CI –1.28 to 2.28%)
or change from baseline FEV1 % predicted (mean
difference –1.04%, 95% CI –3.55 to 1.47%).
Treatment with FP led to a significantly greater
morning PEF compared with BDP/BUD (mean
difference 9.32 l/minute, 95% CI 5.96 to
12.69 l/minute), but not evening PEF (mean
difference 4.67 l/minute, 95% CI –1.36 to
10.7 l/minute). When reported as change from
baseline, there was no significant difference
between groups (mean difference 1.68 l/minute,
95% CI –1.93 to 5.29 l/minute).
Symptoms and rescue medication use were widely
reported but differences in the reporting of these
outcomes precluded the pooling of data for meta-
analysis. The review only reported on specific AEs,
and data on morning plasma cortisol and 24-hour
urinary cortisol were limited. No significant
differences were observed between FP and
BDP/BUD for trial withdrawals (OR 0.76, 95% CI
0.53 to 1.09, 12 studies), or in the likelihood of
experiencing an asthma exacerbation (OR 0.75,
95% CI 0.52 to 1.08, three studies).
Dose ratio 1:1
A significant difference in absolute FEV1 was
found in favour of FP (mean difference 0.09 litres,
95% CI 0.02 to 0.17 litres). However, when
reported as change from baseline, there was no
significant difference between groups (mean
difference 0.04 litres, 95% CI –0.03 to 0.11 litres).
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T
ABLE 30
FP/SAL versus separate FP + SAL (1 RCT)
Study
, 
R
esults
design, 
duration, ICS 
Lung 
function
Symptoms
device,
in each 
AEs
Daily
number trial
PEF
PEF 
R
escue
(% 
of
Adrenal
dose
randomised
arm
FEV
1
morning
evening
NW
SFD
SFN
SS
HRQoL
medication
Exacerbations
patients)
markers
200/100
µg 
V
an den 
FP/SAL
vs 
Berg,
218
12 
NSD
200 + 
weeks, parallel,
N
S
D
a
NID
NSD
C
C
C
100
µg
double-blind,
FP + SAL
DPI, 
n 
= 257
C, stated to be comparable between trial arms but statistical tests not reported; 
n, number of events; NID, non-inferiority/equivalence demonstrated; NSD, no significant difference
between trial arms; NW
, nocturnal waking; SFD, symptom-free days; SFN, symptom-free nights; SS, symptom score (varies between s
tudies); blank cells signify no data reported on
that outcome.
a 
p 
= 0.052.Morning PEF was significantly better with FP
compared with BDP (mean difference
8.78 l/minute, 95% CI 5.14 to 12.41 l/minute).
Evening PEF was also significantly better with FP
(mean difference 6.37 l/minute, 95% CI 2.75 to
9.99 l/minute).
Treatment with FP resulted in a significant
reduction in the odds of an asthma exacerbation
(OR 0.77, 95% CI 0.59 to 0.99, four studies).
However, when a random effects model was
applied to the meta-analysis due to study
heterogeneity, the difference became insignificant.
No significant differences were observed between
FP and BDP/BUD for trial withdrawals (OR 0.72,
95% CI 0.38 to 1.35, five studies). Differences in
the reporting of measures of symptoms and rescue
medication use meant that only limited studies
could be included in a meta-analysis. There was
no significant difference between groups in the
proportion of SFDs (three studies), day- or night-
time score (two studies), the number of
participants experiencing SFDs or SFNs (two
studies) or the use of rescue medication use (two
studies).
Lasserson and colleagues190 – FP versus HFA–BDP
for chronic asthma in adults and children
This review190 aimed to determine the efficacy of
FP compared with HFA–BDP. The review was 
first published in Issue 4, 2005, and was last
updated in January 2006 (searches up to 
January 2006). The review included RCTs of
parallel or cross-over design in both adults and
children with chronic asthma. The interventions
included CFC– or HFA–FP compared with
HFA–BDP.
The review found eight studies which met the
inclusion criteria, involving 1260 participants.
Only one of the studies was conducted in children.
The HFA–BDP used in all the studies was extra
fine, and all the studies had a nominal dose ratio
of 1:1. Treatment duration ranged from 3 to
12 weeks. The majority of participants were adults
with baseline symptoms and lung function
indicating moderate asthma.
Results
Parallel trials
No significant difference in change in FEV1 was
observed between the HFA–BDP and FP groups
[weighted mean difference (WMD) 0.04 litres, 95%
CI –0.03 to 0.11]. Similarly, no significant
difference was observed in change from baseline
in morning PEF (WMD –2.31 l/minute, 95% CI
–12.53 to 7.91).
Differences in the way in which data were reported
meant that meta-analysis was not undertaken for
most of the other outcome measures. Individual
studies reported no significant differences between
treatment groups for symptom scores, HRQoL or
asthma exacerbations. Whereas three trials found
no difference in the use of rescue medication
(reported in various ways), one trial reported a
significant difference in the medians which
favoured FP (0.28 versus 0 puffs/day, p = 0.04). No
significant difference was found in the rate of any
AE [relative risk (RR) 0.88, 95% CI 0.72 to 1.08].
Cross-over trials
Of the three RCTs of cross-over design, one was a
fully published paper and two were conference
abstracts only. Therefore, there are limited data to
report in this category.
One trial reported no significant difference
between FP and HFA–BDP in FEV1 % predicted or
morning PEF. One trial also reported in the text
that there were no differences between treatment
groups in FEV1 or morning PEF but did not
present any data. The third study did not indicate
whether reported FEV1 data were significantly
different.
The trials in this category did not report any data
on symptoms, HRQoL, rescue medication use,
asthma exacerbations or withdrawals.
Ni Chroinin and colleagues189 – LABAs versus
placebo in addition to ICS in children and adults
with chronic asthma
This review189 assessed the effectiveness and safety
of adding a LABA to inhaled corticosteroids
compared with inhaled corticosteroids alone. The
review was first published in Issue 4, 2005, and
was last updated in June 2005 (searches up to
April 2004). The review included RCTs of parallel
or cross-over design in both adults and children
(aged >2 years) with chronic asthma who had
previously received ICS therapy. The interventions
included a LABA (SAL or FF) or placebo
administered daily for at least 30 days, added to
ICS (e.g. FP, BDP, BUD, triamcinolone acetonide).
The dose of ICS had to be the same in both the
LABA and ICS alone groups.
The review included 26 studies involving 8147
participants which met the inclusion criteria and
provided data in sufficient detail. Eight of the
studies were in children, with the remaining
studies conducted in adolescents and adults.
LABA was added to BUD in seven trials, to BDP
in three trials, to BDP or BUD in one trial and to
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11 studies. Most of the studies used separate
inhaler devices for ICS and LABA (n = 19) and the
study duration was 4 months or less in most trials.
Participants in the majority of trials had inadequate
asthma control, and the severity of asthma was mild
(n = 8 trials) or moderate (n = 18 trials). In adult
studies the mean age of participants ranged from
35 to 48 years and in children the mean age ranged
from 8.5 to 14 years.
Results
Compared with ICS alone, the addition of LABA
to ICS provided a significantly greater
improvement in change from baseline FEV1
(WMD 0.170 litres, 95% CI 0.11 to 0.24 litres) and
change in FEV1 % predicted (WMD 2.79%, 95%
CI 1.89 to 3.69%). Similarly, treatment with LABA
+ ICS led to a significantly greater improvement
in change from baseline in morning PEF (WMD
23.28 l/minute, 95% CI 18.38 to 28.18 l/minute)
and evening PEF (WMD 21.33 l/minute, 95% CI
14.53 to 28.12 l/minute).
Use of LABA + ICS significantly reduced daytime
symptoms [standardised mean difference (SMD)
–0.34, 95% CI –0.44 to –0.23, five studies], night-
time symptoms (SMD –0.18, 95% CI –0.31 to
–0.05, two studies) and overall 24-hour symptoms
(SMD –0.28, 95% CI –0.45 to –0.11, two studies).
The addition of LABA was also significantly more
favourable in terms of change from baseline in
SFDs (WMD 17.21%, 95% CI 12.06 to 22.36%, six
studies) and SFNs (SMD 0.51, 95% CI 0.28 to
0.74, four studies). There were no significant
differences between groups in change in
percentage of nights with no awakenings or in
night-time awakenings.
The addition of LABA to ICS significantly
reduced the need for rescue medication use in
terms of the change in overall 24-hour use (WMD
–0.81 puffs/day, 95% CI –1.17 to –0.44, eight
studies). The addition of LABA also significantly
reduced the risk of asthma exacerbations
requiring systemic steroids by 19% (RR 0.81, 
95% CI 0.73 to 0.90, 17 studies). There was no
group difference in the risk of overall AEs 
(RR 0.98, 95% CI 0.92 to 1.05, 11 studies),
serious AEs (RR 1.16, 95% CI 0.30 to 4.42, 
four studies) or withdrawals due to AEs 
(RR 1.29, 95% CI 0.96 to 1.75, 23 studies).
Adams and colleagues186 – BDP versus BUD for
chronic asthma
This review assessed clinical outcomes in studies
which compared BDP with BUD delivered at the
same nominal daily dose. The review was
published in Issue 1, 2000, and was last 
updated in November 1999 (searches up to 1999,
month not specified). The review included 
RCTs of either parallel-group or cross-over 
design. Studies were eligible for inclusion if 
they included adults or children over 2 years old
with chronic asthma. The drugs could be delivered
by different devices (pMDI, MDI + spacer, 
DPI), and there does not appear to have been 
any restriction on the length of treatment 
period.
The review found 24 studies (five parallel-group
and 19 cross-over trials) published between 1982
and 1988 which met the inclusion criteria. Four of
these were only available in abstract form and did
not report any outcome data. Two of the citations
were not assessed for the review as they required
translation. Eighteen of the studies were
conducted in adults and six studies were in
children, with a total of 1174 participants in the
included trials. The level of asthma control at
randomisation was not well described in the
majority of studies, and asthma severity at baseline
was not well documented. One study stated that
patients had asthma of moderate severity, one
described patients as having fairly severe asthma
and two reported severe asthma. In 20 of the
studies, patients were not previous regular users of
oral corticosteroids (OCSs). In three of the studies,
prior OCS use was an inclusion criterion, and a
proportion of patients in another trial had
received OCS treatment at the time of enrolment.
Twelve studies lasted from 2 to 4 weeks, 10 treated
patients from 6 to 12 weeks and one study treated
patients for 2 years. One of the studies had a
complex trial design with treatment periods of
variable length. Only two of the cross-over trials
had a wash-out period. The majority of trials
assessed daily doses of 400 µg/day (n = 10) or
800 µg/day (n = 7), although one study assessed
doses of 200 µg/day and two studies used higher
doses of 1500–1600 µg/day. An MDI device was
used to deliver both drugs in eight of the studies,
but the other 16 used different delivery devices for
each drug.
Results
Meta-analysis by Adams and colleagues186 found
no statistically significant differences between BDP
and BUD for any of the outcome measures
relevant to the present review. Results were
presented separately for cross-over trials with no
prior OCS, parallel-group trials, and cross-over
trials with prior OCS. Comparisons reported
below were for BDP versus BUD.
Health Technology Assessment 2008; Vol. 12: No. 20
63
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.FEV1 was reported by six cross-over studies of
people with no prior OCS and two parallel-group
studies. The WMD was –0.08 litres (95% CI –0.27
to 0.12) in the cross-over studies of people with no
prior OCS and –0.02 (95% CI –0.23 to 0.20) in
the parallel-group studies. FEV1 predicted was also
reported by two cross-over studies of people with
no prior OCS [WMD –5.04 litres (95% CI –11.98
to 1.89)]. Morning and evening PEF reported in
diary cards also showed no statistically significant
difference between the two drugs. The pooled
cross-over trials where patients had no prior OCS
had a WMD of –2.99 l/minute (95% CI –28.43 to
22.45) for morning PEF (six trials) and
–5.47 l/minute (95% CI –31.50 to 20.56) for the
five trials reporting evening PEF. Similar, non-
statistically significant differences were observed in
three cross-over trials whose patients had
previously received OCS. Corresponding analysis
for one parallel-group RCT found a WMD of
–18.00 l/minute (95% CI –54.76 to 18.76) for
morning PEF and –8.00 l/minute (95% CI –49.29
to 33.29) for evening PEF.
The studies reported asthma symptoms using a
range of measures, and no significant differences
between treatments were reported for any of these
measures. Meta-analysis of daily symptom score in
five studies found no statistically significant
difference between BDP and BUD [SMD 0.08
(95% CI –0.22 to 0.39)]. Similarly, use of rescue
medication was not reported to differ statistically
significantly between the two drugs. AEs were not
pooled due to lack of clear reporting in the
original trials. One parallel-group study 
reported an RR of 1.76 (BDP versus BUD) for
withdrawal due to an asthma exacerbation 
(95% CI 0.44 to 7.10).
Greenstone and colleagues188 – combination of
LABA and ICS versus higher dose ICS in children
and adults with persistent asthma
This review assessed clinical outcomes in studies
which compared combination treatment of twice
daily LABA and ICS against the use of a higher
dose of ICS. The review was published in Issue 4,
2005, and was last updated in July 2005 (searches
up to April 2004). The review included RCTs of
adults or children over 2 years old with chronic
asthma, with a minimum duration of 30 days’
treatment.
The review found 42 studies published as 26 full-
text papers and 16 abstracts, 13 of which provided
insufficient data to be included in the meta-
analysis. One of the trials had two intervention
groups compared with a control group, and these
were analysed as separate trials, so the review 
was therefore based on data from 30 trials with a
total of 9509 participants. One trial was a cross-
over study and the rest were of parallel-group
design. The majority of trials (n = 27) were based
on adult participants and three focused on
children. Participants’ asthma was generally of
moderate severity and was inadequately controlled
at baseline in all but two of the studies. Patients
were required to have used ICS for at least
1–3 months before entry to all but one of the
trials.
SAL was used as the LABA in 24 of the trials, with
FF being used in the other eight trials. Standard
doses of LABA were used in the majority of trials
(n = 27). Most of the trials (n = 25) used the same
ICS in both the LABA and control groups; 11
used CFC–BDP, four used BUD and ten used FP.
Three trials compared FP and LABA with
CFC–BDP, BUD or HFA–BDP. One study
compared the combination of LABA and the
patients’ usual ICS to additional FP in the higher
ICS study arm, and one study compared BUD and
LABA with FP. The median ICS dose in the
combined LABA group was 400 µg/day (range
200–1000 µg/day) and 1000 µg/day (range
400–2000 µg/day) in the higher ICS dose group.
ICS and LABA drugs were delivered via separate
devices in 22 trials, but eight trials used a single
device to deliver the drugs. Most of the trials
lasted for 12 or 24 weeks (n = 14, n = 9), with
others lasting 4 weeks (n = 1), 6 weeks (n =1 ) ,
52 weeks (n = 3) or 54 weeks (n =1 ) .
Results
The review’s main outcome measure was the risk
of exacerbation requiring systemic corticosteroids,
and this was reported by 15 of the trials. Pooled
data gave an RR of 0.88 (95% CI 0.77 to 1.02),
with no significant group difference [risk
difference (RD) 2% (95% CI 0 to 4%)]. Although
the similarity between treatments did not meet
Greenstone and colleagues’ a priori definition of
equivalence,188 the upper CI was reported to
exclude the likelihood of a higher rate of
exacerbations in patients who received LABA.
Planned subgroup analyses found no effect of age
group (children versus adults), average baseline
severity, type of LABA ICS dose difference
between groups, ICS dose associated with LABA
and trial duration. However, meta-regression of 
13 trials found two independent variables which
significantly reduced the risk of exacerbation [low
ICS dose used in combination with LABA
(p = 0.046) and trial duration of 24 weeks or less
(p = 0.01)].
Assessment of clinical effectiveness
64Lung function showed a statistically significantly
greater improvement in the combination LABA
and ICS groups than in the high-dose ICS group.
Using pooled data from nine trials, the weighted
mean difference in FEV1 at end-point was
0.13 litres (95% CI 0.08 to 0.19). Similarly, change
from baseline FEV1 showed a WMD of 0.10 litres
(95% CI 0.07 to 0.12; n = 7 trials) and FEV1 %
predicted at end-point had a WMD of 3.93% (95%
CI 1.33 to 6.53; n = 4 trials). The WMDs for
morning and evening PEF at end-point were
27.33 l/minute (95% CI 21.39 to 33.26; n =1 4
trials) and 20.18 l/minute (95% CI 12.75 to 27.62;
n = 3 trials), respectively.
Patients treated with a combination of ICS and
LABA had statistically significantly better changes
from baseline total asthma symptom scores. Data
from five trials were pooled, giving an SMD of
–0.23 (95% CI –0.41 to –0.05). The percentage of
SFDs at end-point also favoured combination
therapy in pooled analysis of eight trials
(WMD = 11.9%, 95% CI 7.37 to 16.44). Change in
rescue inhalations over 24 hours favoured the
combination treatment group (ICS + LABA) over
the high-dose ICS group. Data from eight trials
were pooled to give an SMD of –0.22 (95% CI
–0.29 to –0.14). There were no statistically
significant differences between the groups in day-
time symptoms at end-point, night-time symptoms,
percentage of SFDs at end-point, change from
baseline in night-time awakenings and quality of
life as measured by the Juniper Questionnaire.
There were no group differences in overall side-
effects [RR = 0.93 (95% CI 0.84 to 1.03); n =1 5
trials], serious AEs [RR = 1.54 (95% CI 0.72 to
3.21); n = 5 trials] or withdrawals due to AEs 
[RR = 0.94 (95% CI 0.71 to 1.24); n = 18 trials].
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The purpose of this chapter is to:
1. Summarise existing published economic
evaluations that are relevant to the decision
problems specified in the project scope and
protocol.
2. Summarise the industry-submitted economic
evaluations provided as part of the NICE
appraisal process, with particular focus on
critically appraising those that are relevant to
the decision problems specified in the project
scope. 
3. Describe the methods of the new economic
evaluation(s), cost comparisons and other
economic information which has been
generated to try and help consider the ‘value
for money’ implications for the NHS of
alternative guidance on the use of
corticosteroids in children with asthma.
Additionally, we outline the approach we have
taken to assessing the cost-effectiveness or, more
broadly – given the lack of clear evidence of
differential effectiveness for all but one of the cost-
effectiveness research questions – the ‘value for
money’ to the NHS of the alternative asthma
treatments evaluated.
Systematic review of 
cost-effectiveness studies
A systematic review of existing cost-effectiveness
studies was undertaken.
Search strategy and critical appraisal
methods
MEDLINE, EMBASE and the Cochrane Library
(Issue 1, 2006) were searched for cost-effectiveness
studies that assessed the cost-effectiveness of BDP,
BUD or FP used alone or in combination with a
LABA, SAL or FF within their licensed indications
and the appropriate step of the BTS/SIGN
Guideline.1 The full search strategy is shown in
Appendix 3.
A total of 723 titles and abstracts were screened
for inclusion in the review. These included studies
that were potentially relevant to the present
assessment and also those relevant to a linked
assessment on the effectiveness and cost-
effectiveness of inhaled corticosteroids and LABAs
for the treatment of chronic asthma in adults. Of
the titles and abstracts screened, 58 were ordered
as full papers and assessed in detail.
Inclusion and exclusion criteria
Cost-effectiveness analyses (CEAs), cost–utility
analyses (CUAs), cost–benefit analyses and
cost–consequence analyses were eligible for
inclusion in the cost-effectiveness review. In
addition, separate submissions were received from
GSK, AZ, Meda Pharmaceuticals and Trinity-
Chiesi Pharmaceuticals as part of the NICE
technology appraisals process.
Published cost-effectiveness studies 
No cost-effectiveness studies for the relevant
comparators in the treatment of chronic asthma 
in children less than 12 years of age were
identified.
Cost-effectiveness studies
provided by industry
Four submissions to NICE included CEA analysis.
Two of these included CEA and two included cost
minimisation analysis (CMA). Submissions were
made by GSK, AZ, Meda Pharmaceuticals and
Trinity-Chiesi Pharmaceuticals. Table 31 shows a
summary of the submissions received by industry
through the appraisal process.
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Chapter 4
Economic analyses
TABLE 31 Summary of the submissions received by industry
through the appraisal process
Manufacturer Product Type  of 
analysis 
GSK Becotide CEA
Flixotide
Seretide
AZ Pulmicort CEA
Symbicort
Meda Pharmaceuticals Novolizer CMA
Trinity-Chiesi Pharmaceuticals Modulite CMABelow, an outline review of each of the
manufacturer’s submissions (CEA, CMA) is
presented. This outline review is based on a
checklist suggested for critical appraisal CEA by
Drummond and colleague219 and the
requirements of NICE for submissions on CEA
(reference case),220 and where appropriate a
suggested guideline for good-practice in cost-
effectiveness models by Philips and colleagues.221
Review of the submission by
GlaxoSmithKline
Overview
The submission by GSK to NICE includes an
economics commentary and CEA to support three
GSK products; BDP (Becotide), FP (Flixotide) and
a combination inhaler containing FP/SAL
xinafoate in combination) (Seretide).
The submission includes some commentary on the
clinical equivalence of ICS products and the
presentation of some price estimates. The
submission does not include any CEA for BDP and
FP versus other ICS products, with a CMA
approach assumed due to clinical equivalence
across these products. This is justified in the
submission on the basis of assumed equivalence.
The submission also does not include any CEA for
Seretide versus Symbicort, as the submission states
there is an absence of head-to-head comparisons
of the clinical effectiveness of these products.
The submission is focused on four specific
research questions:
● Q1: For patients taking ICS alone, is FP the
most clinically effective ICS?
● Q2: For patients uncontrolled on ICS alone, is
switching to Seretide more clinically effective
than remaining on the same dose or increasing
the dose of ICS alone?
● Q3: Where a LABA and ICS are to be co-
prescribed, is Seretide more clinically effective
than ICS and LABA delivered in separate
inhalers?
● Q4: In patients where combination therapy is
appropriate, what is the relative clinical
effectiveness of Seretide compared with
Symbicort?
The submission presents outline detail of a
systematic search of the literature on CEAs for the
treatment of asthma. Appendix 9 of the
submission provides information on this review,
but the literature is not considered relevant. The
submission presents specific cost-effectiveness
analyses, and a generic cost-effectiveness model to
address questions 2 and 3. Question 1 is not
covered further (as above, a CMA approach is
assumed) and question 4 is addressed via a
comparison of product costs only.
Model on cost-effectiveness of Seretide
In the submission, a new model is developed by
GSK to estimate the cost-effectiveness of the
alternative treatment scenarios. A common model
is used for the analysis of both adult and child
treatment for asthma. Below we outline the
approach taken for the GSK model and provide an
outline review.
The model presented is a simple two-state model
applying effectiveness data on the percentage of
symptom-free days (% SFDs), cost and outcome
data associated with the two health states of
‘symptom-free’ and ‘with symptoms’. The model is
essentially a spreadsheet calculation to estimate
cost-effectiveness from these related data across
alternative treatments. In the model, at a given
point in time, patients are either (1) symptom-free
or (2) with symptoms. Death is not included in the
model (due to an assumption of no differential
effect of treatments). Exacerbations are not
included in the model. The model is not a disease
progression model, and does not involve
transitions between the two health states over
time. The model presents a scenario, showing
occupancy of states “conditional on treatment
choice” on the basis of a meta-analysis of the %
SFDs at the trial end-point. This end-point is
chosen as it was (1) commonly reported and
considered, (2) based on clinical opinion, and 
(3) judged to be more appropriate than lung
function for representing patients’ clinical
response to treatment. This reported end-point 
(% SFDs) was taken to represent the proportion of
time spent in the symptom-free state. The model
used effectiveness data from four trials: two for
Seretide versus the same dose of FP, one for
Seretide versus an increased dose of FP and one
for Seretide versus the same dose delivered via
separate products.
The model is based on a range of assumptions,
including the assumptions that:
● Alternative therapies have the same mortality
profile and the same toxicity profile (including
long-term effects).
● The differential proportion of time patients
spend in the symptom-free state over their
treatment lifetime would be the same as the
Economic analyses
68differential proportion observed during the trial
period (even though clinical trials are mainly
12 weeks).
● Trial-based data are generalisable to wider
patient populations.
● There is no difference in the effectiveness
between different inhaler devices.
The submission states that the time horizon is
“nominally 1 year, corresponding to the duration
of the GOAL trial used to estimate costs and
utilities”. However, given the nature of the model,
it is a ‘snap-shot’ or cross-sectional approach to
estimating CEA.
The model uses health state values of 0.97 for the
‘symptom-free’ health state and 0.85 for the ‘with
symptoms’ health state, a utility decrement of 0.12.
These values are cited from the CEA study for the
GOAL RCT reported by Briggs and colleagues.222
However, this study does not provide information
on the methods used for estimating utility weights,
citing a personal communication only, for a study
mapping Asthma Quality of Life Questionnaire
(AQLQ) to EQ-5D. The model works by placing
proportions of patients (or patient time) in each
health state, according to the effectiveness data,
and calculating QALY differences as the product
of these data [e.g. a 12.29% difference in % SFDs
(low-dose Seretide versus FP 200 µg/day) results in
a difference in QALYs between treatments of
0.014748].
Although the data from the GOAL clinical trial are
based on an adult patient group, the GSK
submission states that these data are considered to
be the most appropriate for use in the paediatric
analysis. No justification is provided in the
submission to support this.
Costs are comprised of mean acquisition costs for
products and an estimate of the annual mean
‘other health service’ costs for symptom-free time
and time with symptoms. The latter ‘other’ cost
excludes primary treatment costs. The cost
estimates used for the health states are based on
data from the GOAL clinical trial, which
comprised resource use against secondary care
visits, primary care visits and rescue medication
used. The submission uses a linear regression
model to estimate a mean annual cost, which is
£79.83 for the health state ‘with symptoms’ and
£1.57 for ‘symptom-free’. The cost differences
between alternatives is as per the above example
for QALY differences, with estimated difference in
costs for strategies multiplied by the percentage
difference in SFDs.
The model is developed for use in both adult and
child patient groups, and is arranged around 21
specific cost-effectiveness questions (five for
children, 16 for adults). All costs are reported in
UK£ 2006.
Model/cost-effectiveness results
The CEA is arranged around the comparison of
Seretide (FP 200/SAL 100 µg/day) with (i) the
same dose of ICS alone (FP), (ii) a higher dose of
ICS alone (FP 400 µg/day) and (iii) ICS + LABA
in separate inhalers (at same dose). The analysis
also considers a comparison with Symbicort (at
BUD 400/FF 100 µg/day). The submission reports
results for different product costs for Seretide 
(for Evohaler and Accuhaler) and against two
different ICS product costs (FP and BDP).
Therefore, the analysis results in approximately 10
different summary statistics. These are
summarised below:
● Q1: Seretide 200/100 µg/day versus the same
dose of ICS minus a LABA (FP 200 µg/day) –
incremental cost-effectiveness ratio (ICERs)
range: Seretide £31,388 (Evohaler, versus
comparator price at £91.31) to £72,702 per
additional QALY. For all scenarios the
incremental effect is 3.61% in % SFDs,
incremental QALYs are 0.0043 and ‘other costs’
are reduced by –£2.83. Incremental
drug/treatment costs range from £138 to £317.
● Q2: Seretide 200/100 µg/day versus a higher
dose ICS alone (FP 400 µg/day) – ICER range:
Seretide at £15,739 (Evohaler, versus
comparator price at £178.97) to Seretide at
£63,736 per QALY (with comparator price at
£178.97). For all scenarios the incremental
effect is 2.60% in % SFDs, incremental QALYs
are 0.0031 and ‘other costs’ are reduced by
–£2.03. Incremental drug/treatment costs range
from £51 to £201.
● Q3: Seretide 200/100 µg/day versus FP
200 + SAL 100 µg/day (separate inhalers) –
ICERs: Seretide dominates for all comparisons
(cost saving and greater effect). For all scenarios
the incremental effect is 1.90% in % SFDs,
incremental QALYs are 0.0023 and ‘other costs’
are reduced by –£1.49. Drug/treatment costs for
comparators are all lower for Seretide, from
–£47.48 to –£226.45.
● Q4: Seretide 200/100 µg/day versus Symbicort
[BUD 400 µg/day, (inhaler type100/6)] – no
CEA undertaken, acquisition cost comparisons
only, with Seretide Evohaler at £230.11 versus
£401.78, and Accuhaler at £379.86 versus
£401.78, both presented as Seretide being cost
saving (acquisition costs).
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(e.g. dose, price), resulting in a range of cost-
effectiveness results. The TAR team suggest that
policy makers should take note of the specific
inputs for analysis and consider the interpretation
of results. For example, estimated cost savings and
estimated incremental QALYs are very small, and
some consideration should be given to their
significance and/or meaningfulness.
Outline appraisal of the cost-
effectiveness analysis undertaken
A critical appraisal checklist is given in Table 32
and NICE reference case requirements in Table 33.
Economic analyses
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TABLE 32 Critical appraisal checklist of economic evaluation by GSK
Item  Critical appraisal  Reviewer comment 
Is there a well-defined  Yes 4 clinical questions stated (2 of which covered in CEA)
question?
Is there a clear description  Yes Seretide versus comparators (various options stated with 
of alternatives? comparisons against the same dose of FP alone, an increased dose of
FP alone, single versus combination inhaler and Symbicort. Analysis
against comparable dose of BDP alone was presented as a sensitivity
analysis)
Has the correct patient  Partial  Children under 12 years old is the patient group under consideration; 
group/population of  however, many of the data are from adult patient groups (aged
interest been clearly stated? 12+ years)
Is the correct comparator  Yes Sensitivity analysis undertaken for BDP versus Seretide. This is 
used? appropriate as it is the other single comparator under consideration
with the same inhaler and propellant type (i.e. pMDI with HFA)
Is the study type reasonable? Yes CEA model used (CUA results presented)
Is the perspective of the  Yes Perspective stated as UK NHS
analysis clearly stated?
Is the perspective employed  Cost: yes Submission appears to adopt a UK NHS and PSS perspective for 
appropriate? Outcomes: partial costs (consistent with NICE reference case). Perspective on
outcomes is that of the patient, but not all effects considered
Is effectiveness of the  Yes The CEA is based on clinical effectiveness data from a small number 
intervention established? of trials reporting the chosen economic end-point (% SFDs) – mainly
over 12 weeks. Although the study demonstrates effectiveness over
this one end-point, it does not discuss, in the context of CEA, the
other effectiveness end-points across treatments. The study assumes
that differences seen in trials can be generalised to the lifetime
treatment period
Has a lifetime horizon been  No Nominal 1-year time horizon used (not lifetime)
used for analysis (has a  ICERs are based on 1-year cost and QALY differences
shorter horizon been 
justified)?
Are the costs and  Partial  Costs appear to be consistent with perspective employed, but 
consequences consistent  limited justification provided.
with the perspective  Consequences limited to consequences of SFDs?
employed?a
Is differential timing  No Nominal 1-year time frame used
considered?
Is incremental analysis  Yes
performed?
Is sensitivity analysis  Yes Yes, sensitivity analysis included, including probabilistic sensitivity 
undertaken and presented  analysis. No scenario analyses undertaken to consider different mean 
clearly? input  parameters
PSS, Personal Social Services.
a More on data inputs for costs and consequences is given in the review of modelling methods below.Model structure/assumptions
The model structure is based around the clinical
end-point in the GOAL trial of differences in the
% SFDs, and this is assumed, in the submission, to
be a reasonable reflection of relative treatment
effectiveness. This may not be a reasonable
assumption, as this end-point only reflects part of
the effectiveness profile of asthma treatments.
Other important elements of asthma control
include night-time disturbances (and data
presented in the submission indicate that
differences between % SFNs may be smaller than
% SFDs), lung function and exacerbations. The
model presented does not directly capture these
items The model structure used is stated to be
based on the CEA for the GOAL clinical trial
presented by Briggs and colleagues.222 However,
the model differs from the approach of Briggs and
colleagues in a number of ways. First, the model
presented by Briggs and colleagues uses patient-
level data to derive transition probabilities;
second, their study uses a composite measure of
asthma control; and third, they also model the
state of exacerbation. The estimates of cost-
effectiveness presented by GSK are simple
spreadsheet calculations combining data on %
SFDs and data estimated for relative costs and
QALYs for patients in the health states used. The
model uses a two-state approach covering time in
a symptom-free state and time with symptoms.
This is a simplification of the disease process for
asthma, and is stated to be driven by the
availability of data for comparative purposes and
on a review of the general literature on modelling
asthma treatment. However, it may be that the
end-point chosen is more favourable for
comparison of Seretide with other alternative
strategies. For example, the effect of Seretide will
be more immediate on SFDs than it will be from
ICS alone (where any treatment benefit will accrue
more slowly over time). No discussion of other
outcomes, in the context of the CEA, is provided
for the discussion on the model structure,
although a brief statement on the potential use of
lung function as an alternative approach is
provided.
When considering the above points, it is important
to acknowledge that the literature on modelling
cost-effectiveness in asthma treatment is sparse,
and although there are guidelines for the
treatment of asthma (e.g. the BTS/SIGN
Guideline), it is generally difficult (given the
current evidence base) to structure and populate a
model which reflects such guidelines.
Data inputs
The primary data inputs for effectiveness, costs
and outcomes are presented in the submission. In
the analysis, there is a lack of transparency in the
calculations for ‘other costs’, and there are
concerns with the methods used to identify and
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TABLE 33 NICE reference case requirements – GSK submission
NICE reference case requirement Reviewer comment
Decision problem: as per the scope developed by NICE (especially technologies  Partial
and patient group)
Comparator: alternative therapies routinely used in the UK NHS Yes
Perspective on costs: NHS and PSS Yes
Perspective on outcomes: All health effects on individuals No Only SFDs were used to
consider QALY values
Type of economic evaluation: CEA Yes
Synthesis of evidence on outcomes: based on a systematic review Yes
Measure of health benefits: QALYs Yes
Description of health states for QALY calculations: use of a standardised  Unclear Method for estimating 
and validated generic instrument health state utilities is
unclear
Method of preference elicitation for health state values: choice-based  Unclear Method of preference 
method (e.g. TTO, SG, not rating scale) elicitation is not reported 
Source of preference data: representative sample of the UK public Unclear
Discount rate: 3.5 per year for costs and health effects NA
NA, not applicable; PSS, Personal Social Services; SG, standard gamble; TTO, time trade-off.measure the ‘other costs’. The data used on the
resource for ‘other costs’ are taken from one
clinical trial, the GOAL trial, by Bateman and
colleagues,223 but the specific data used are not
presented in the submission. Furthermore, the
generalisability of this study (a multi-national
RCT, covering 44 countries) to the current analysis
is not discussed. The GOAL CEA used data on
resource use from all 44 countries in the trial,
using a UK indicator variable in the analysis
presented. However, the issue of how generalisable
the GOAL study is to the UK context and also to a
paediatric population is not discussed in the
context of the current analysis. Unit costs for the
resource use are taken from appropriate data
sources. The submission uses a regression model
to estimate other costs, based on an expected cost
per week of £1.53 for people with asthma
symptoms, a mean annual cost of £79.83. Where
people with asthma are symptom-free, this is
reduced to £0.03, a mean annual cost of £1.57.
These cost estimates appear to be very low and the
submission does not offer the opportunity to
consider the appropriateness of the resource use
to the UK treatment group. The submission has
referred to the economic evaluation undertaken
alongside the GOAL trial;222 however, the
publication for that particular evaluation does not
offer detail on resource use. The regression
analysis employed in the submission also differs
from that presented by Briggs and colleagues.222
The cost for Seretide is based on its availability in
two different inhaler devices (Accuhaler and
Evohaler), with both prices from the Drug Tariff,
together with an average price, used to generate a
range of data on cost-effectiveness. A drug ‘cost
per day’ is estimated for all treatment options. For
example, in the model the estimated costs per day
for Seretide 200/100 µg/day via Accuhaler and
Seretide 200/100 µg/day via Evohaler + spacer are
set at £1.04 and £0.63, respectively. For Symbicort
400 (100/6 µg/day), and ICS alone (FP
200 µg/day), the daily costs are estimated at £1.10
and £0.25, respectively. There are a range of
approaches that can be taken to estimate daily
costs, and the approach taken in the submission
appears reasonable for the current analysis
(Appendix 9 of the submission presents the
methods used).
There is a lack of transparency over the
calculation of health state utilities used in the
model (with a citation to a personal
communication). The general literature available
to inform on health state values for asthma is
sparse and undeveloped, and although the values
used for symptom-free in the analysis seem
relatively high (compared with some general
population age-related values), the important 
issue is the incremental difference of 0.12 used
between the health state of with symptoms and
symptom-free.
The effectiveness data used in the CEA are from a
limited number of available trials (as above, two
for Seretide versus the same dose of FP, one for
Seretide versus increased dose of FP and one for
Seretide versus the same dose of separate
products), and this is justified in the submission on
the basis of a lack of consistency in the reporting
of common outcomes across relevant trials. The
use of these limited data may introduce bias to the
estimates used, but this has not been discussed or
considered in the sensitivity analysis. Effectiveness
data from the trials presented are assumed to be
generalisable to the treatment group in England
and Wales that are the focus of policy analysis.
Likewise, the treatment effect from short-term
trials (mainly of 12 weeks’ duration) is assumed to
be appropriate over longer periods (e.g. 1 year).
Assessment of uncertainty
Uncertainty in the analyses is addressed using
probabilistic sensitivity analysis (PSA). The PSA
considered parameter uncertainty for the mean
treatment effect and for ‘other cost’ and utility
model inputs. The report submitted does not
present discussion on the results of the PSA
(additional material was submitted, providing a
cost-effectiveness plane and cost-effectiveness
acceptability curve for each of the 80+ analyses
undertaken). Additionally, the report does not
present any deterministic sensitivity analysis or
address structural uncertainties via sensitivity
analyses. Also, heterogeneity of the treatment
group has not been considered against any
defined subgroups.
Model validation 
The submission states that checks were undertaken
to consider the validity of the model, with a
rebuild undertaken using a different software
package. This presents evidence of the internal
consistency (logic) of the model structure and data
structure used.
Summary of general comments on the
submission
1. The focus on % SFDs as a measure of asthma
control and treatment effect may be limited
and may not capture other important aspects of
asthma control and/or effectiveness data (e.g.
exacerbations, quality of life).
Economic analyses
722. A limited evidence base is used to populate the
model (e.g. only six trials used to derive
effectiveness estimates).
3. The assumptions over the generalisability of
trial data on effectiveness to a UK paediatric
population and extrapolation of the treatment
effect are not discussed.
4. There are concerns over the methods used and
estimates used for ‘other costs’.
5. There are concerns over the lack of
transparency in estimating health state utilities
and other cost estimates.
6. Data are assumed to be generalisable to a
paediatric analysis, and it is assumed that:
(a) Resource use data from the GOAL clinical
trial are generalisable to a UK treatment
group (aged under 12 years).
(b) Health state utility values cited from the
GOAL CEA222 are generalisable to a UK
treatment group aged under 12 years.
Review of the submission by
AstraZeneca (AZ)
Overview
The submission by AZ to NICE includes
economics commentary and CEA to support two
AZ products; Pulmicort (BUD) and Symbicort
(BUD/FF in combination).
The submission includes some commentary on the
clinical equivalence of BUD with other ICS
products and the presentation of some price
estimates. It does not include any CEA for BUD
versus other ICS products. There is limited
discussion of the relative cost-effectiveness of
different ICS products, with a CMA approach
taken due to assumed clinical equivalence between
products.
The CEA presented in the submission is to
support the use of Symbicort (BUD/FF in
combination). The submission refers to Symbicort
fixed dose (FD), and Symbicort adjustable
maintenance dose (AMD). The submission uses
Symbicort FD as the base case for the CEA,
working on the basis that Symbicort AMD has
been shown to be superior to Symbicort FD. The
submission compares Symbicort (Symbicort FD
and AMD) with the use of ICS alone (high-dose),
BUD and FF in separate inhalers and with
Seretide (GSK combination product). However, no
CEA is presented for Symbicort versus Seretide.
The submission consists of a brief discussion on
the relevant literature (covering CEAs and
modelling studies), and the presentation of the
methods and results for a cost-effectiveness model
developed for the submission to NICE.
A literature search is reported that aimed to
identify CEAs on Symbicort. Nine studies were
identified, all of which are stated to show
Symbicort AMD or Symbicort SMART (Symbicort
as both maintenance and reliever therapy) at an
equivalent or increased efficacy compared with
Symbicort FD (four studies), separate inhalers
(three studies), high-dose FP (ICS alone) (one
study) or Seretide (one study). All except one of
these identified studies is stated to show cost
savings from the use of Symbicort. None of the
identified studies covered the population of
children aged 4–11 years.
Model on cost-effectiveness of
Symbicort
The submission states that the approach presented
by Price and Briggs224 was most appropriate for
the analysis of Symbicort. However, it is also stated
to have a number of limitations and a new model
is developed by AZ for their submission. Below we
outline the approach taken for the AZ model and
provide an outline review.
A model was developed to capture the difference
in exacerbations between comparisons and the
difference in time spent in a non-exacerbation
health state. It is a Markov-type model with four
health states: non-exacerbation, mild
exacerbation, severe exacerbation and treatment
change. The last state is a form of absorbing state
which reflects withdrawal from the treatment
allocated. Where patients withdraw from treatment
(undergo treatment change), they are subject to a
second-line treatment regimen and are modelled
in a parallel process to the main (first-line) model.
When treatment is changed, it is in line with
recommendations in the BTS/SIGN Guideline.
The model uses a cycle of 4 weeks, and has a time
horizon of 1 year (with a 5-year time horizon
considered in sensitivity analysis). The model uses
transition probabilities derived from two clinical
trials, by Pohunek and colleagues225 and Tal and
colleagues.217 One of these trials225 is available as
a published abstract only. The trials were both 
12-week RCTs conducted in children aged
4–11 years225 and children and adolescents aged
4–17 years.217 Transition probabilities were from
combined data from trial arms of Symbicort FD
and the BUD + FF arm (administered as separate
inhalers) assuming equivalent efficacy. Data on the
relative effect (RRs for severe exacerbation, mild
exacerbation and treatment change) of ICS alone
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trial data for these comparators (two RCTs for ICS
alone).217,225 Patient-level trial data (over
12 weeks) allow the use of different transition
probabilities for Symbicort over months 1–3, and
thereafter a constant transition probability matrix
is used based on events occurring during months
1–3. Analysis is presented for an asthma treatment
group aged under 12 (4–11 years). In the model
all persons start in the ‘non-exacerbation’
(controlled) health state. The perspective of the
analysis is stated as UK NHS and Personal Social
Services (PSS). Prices for asthma treatment are at a
2005–6 price year.
Health state utilities used for the model are based
on EQ-5D tariff values. Health state descriptions
covering the health states used in the model were
collected from a sample of asthma patients, and
EQ-5D tariff values for these states were applied
(the submission cites Kind and colleagues 1999,
for tariff values).235 Values were presented for
‘non-exacerbation’ (no SABA use), ‘non-
exacerbation’ (SABA use) (with proportions for
SABA and non-SABA use applied to calculate a
weighted utility value), ‘mild exacerbation’ and
‘severe exacerbation’ health states (all utility values
applied are commercial-in-confidence). The model
assumes that exacerbations affect costs and utilities
for 1 week only, with the remaining 3 weeks in that
cycle based on non-exacerbation status. Therefore,
utility values for the mild and severe exacerbation
states were weighted accordingly (data are
commercial-in-confidence), based on 1 week of the
exacerbation related value, plus 3 weeks at a non-
exacerbation value.
A monthly cost is applied in the model based on
asthma medication costs and health service
consultations and hospitalisations. Primary care
NHS resource use (consultations) are assumed to be
the same for each of the treatment options and are
not included in the model. The cost of managing
a mild exacerbation is estimated at £49.46 and
severe exacerbation between £333 and £1751.
Model/cost-effectiveness results
The submission presents summary results for
outcomes and costs separately, in Tables 9 and 10
(p. 28), respectively, and in an incremental analysis
in Table 11 (p. 29).
The submission presents results indicating that over
a 12-month period Symbicort FD is dominated by
the ICS alone treatment option (Symbicort with
greater cost and less QALYs), dominated by
Seretide (no difference in effect and Symbicort with
greater cost), and Symbicort is dominant over
ICS + LABA in separate inhalers (no difference in
effect and Symbicort with lower cost).
In the opinion of the TAR team, it appears that
any comparison rests on the incremental costs
associated with ‘maintenance costs’
(drug/treatment acquisition costs).
Outline appraisal of the cost-
effectiveness analysis undertaken
A critical appraisal checklist is given in Table 34
and NICE reference case requirements in Table 35.
Model structure/assumptions
The model structure is driven by the use of
exacerbation data, and the characterisation of a
‘non-exacerbation’ health state, using clinical trial
data. The structure is not discussed and justified
in the context of a coherent theory of asthma, and
the model is essentially based around the
availability of data surrounding exacerbations for
Symbicort and comparators. It may be that AZ
have adopted this approach due to the more
positive profile of Symbicort (against exacerbation
rates), when the use of an outcome related more
directly to control, such as % SFDs, may have
seemed more favourable for comparator products
(e.g. Seretide). The submission indicates that a
review of published modelling studies was
undertaken, but no discussion is presented on
alternative approaches. Given the prominence in
the clinical and economic literature of outcome
measures around lung function and symptoms, it
would have been useful for some discussion of
competing approaches for the modelling of
asthma treatment and cost-effectiveness to have
been presented.
The non-exacerbation health state presented is
made up of patients who are without symptoms
and those patients with symptoms, but not
requiring any intervention from a healthcare
professional. However, it is not clear how the data
have been interpreted from different clinical trials,
where the trial methods may not have been
homogeneous. Much of the data to inform the
model transitions have been taken from a limited
evidence base, with citations to two published
RCTs, with data on patient location in those RCTs
over time being presented in commercial-in-
confidence format only.
The cycle length and time horizon are justified (in
the submission) on the basis of data available and
an assumption that mortality effects (longer term
outcomes) are similar across comparison
Economic analyses
74treatments. Both of these assumptions seem
reasonable. However, treatment effect is based
primarily on 12-week trial data, and the
submission does not discuss the assumption that
this treatment effect is assumed to continue for the
period of the model (1 year in the base-case
analysis), or the generalisability of the trial data to
the broader treatment population.
Although not stated in the submission,
assumptions are made regarding the toxicity
profile for treatments, and longer term AEs (data
commercial-in-confidence).
There is no statement in the submission on the
evaluation of the internal consistency of the
model.
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TABLE 34 Critical appraisal checklist of economic evaluation by AZ
Item Critical appraisal Reviewer comment
Is there a well-defined question? Yes
Is there a clear description of alternatives? Yes Symbicort versus comparators (various options stated).
Has the correct patient group/population  Yes  Children 4–11 years
of interest been clearly stated? All patients in model start in non-exacerbation state
(this may not be the case in practice, with a proportion
of patients being in an ‘uncontrolled’ asthma state)
Is the correct comparator used? Yes Comparators used are all appropriate; however, other
additional comparators could also be used
Is the study type reasonable? Yes CEA model used (CUA results presented)
Is the perspective of the analysis  Yes Perspective stated as UK NHS and PSS
clearly stated?
Is the perspective employed appropriate? Partial Submission appears to adopt a UK NHS and PSS 
Cost: yes perspective for costs (consistent with NICE reference 
Outcomes: partial  case)
Perspective on outcomes is that of the patient, but not
all effects considered (the focus is on ‘non-
exacerbation’ state, and exacerbation events, with no
symptom-based measures used) 
Is effectiveness of the intervention  Partial The CEA is based on clinical effectiveness data from a 
established? limited number of trials reporting the chosen economic
endpoint (exacerbation related states/outcomes) –
mainly over 12 weeks. Primary effectiveness data from
2 RCTs form model transits. The study assumes that
differences seen in trials can be generalised to the
lifetime treatment period
Has a lifetime horizon been used for  No 1-year time horizon used (not lifetime)
analysis (has a shorter horizon been  ICERs are based on 1-year cost and QALY differences
justified)? 5-year horizon in sensitivity analysis
Are the costs and consequences  Partial Costs appear to be consistent with perspective 
consistent with the perspective  employed, but limited justification provided, and may 
employed?a not include all relevant costs (e.g. primary care not
included)
Consequences limited to exacerbations and non-
exacerbation months. Interpretation of non-
exacerbation state from limited clinical evidence
Is differential timing considered? No 1-year time frame used – no discounting. (in sensitivity
analysis 3.5% discount rate used)
Is incremental analysis performed? Yes
Is sensitivity analysis undertaken and  Yes Yes, sensitivity analysis is undertaken, probabilistic 
presented clearly? analysis
a More on data inputs for costs and consequences is given in the review of modelling methods (p. 74).When interpreting the above points, it is also
important to acknowledge that the literature on
modelling cost-effectiveness in asthma treatment is
indeed sparse, and although there are guidelines
for the treatment of asthma (e.g. the BTS/SIGN
Guideline), it is generally difficult (given the
current evidence base) to develop and populate a
model which is driven by such guidelines.
Data inputs
The primary data inputs for effectiveness, costs
and outcomes are presented in the submission.
Medication costs are based on trial data for the
number of inhalations per day and drug costs from
the Drug Tariff or eMIMs, and a weighted average
cost per inhalation was estimated across the various
drug formulations [mean inhalations per day for
Symbicort FD (100/6), dose of 400/24 µg, was 3.86,
same data for ICS (400 µg/day), and ICS + LABA
(400 µg/24 µg/day)]. The ‘base-case’ mean cost per
day applied for Symbicort FD was £1.06, with cost
per day for Seretide (200 µg/100 µg), ICS alone
(400 µg), and ICS + LABA (separate inhalers),
presented (data commercial-in-confidence). Data
on ‘other costs’ are presented clearly, and
although including a number of assumptions, the
methods used appear reasonable. The estimated
cost for managing a mild exacerbation was £49.46.
The estimated cost for the management of a
severe exacerbation ranged between £333 and
£1751 (depending on need for hospitalisation).
Although there may be some methodological
limitations with the health state utility study (as
with many studies of this nature) presented to
inform the model, data on health state utilities are
consistent with the preferred approach of NICE,
and commercial-in-confidence data are provided
in support. The general literature available to
inform the health state values for asthma is sparse
and undeveloped.
When considering methods for the calculation of
transition probabilities, a small clinical evidence
base has been used, and within the trial data used
there are only a small number of reported events
occurring (from a sample of n = 565). One of the
two RCTs used to estimate transition probabilities
is available in abstract form only.225 Data
presented indicate that in the trial populations
there were a very small number of events requiring
hospitalisations, OCSs or severe exacerbations
(presumably hospitalisations) reported (data
commercial-in-confidence; Appendix 6). Relative
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TABLE 35 NICE reference case requirements – AZ submission
NICE reference case requirement Reviewer comment
Decision problem: as per the scope developed by NICE  Yes
(especially technologies and patient group)
Comparator: alternative therapies routinely used in  Yes
the UK NHS
Perspective on costs: NHS and PSS Yes
Perspective on outcomes: all health effects on individuals Partial Health effects were limited to effect of treatment
on exacerbation status/rate
Type of economic evaluation: CEA Yes
Synthesis of evidence on outcomes: based on a  Yes
systematic review
Measure of health benefits: QALYs Yes
Description of health states for QALY calculations:  Unclear Method for estimating health state utilities is 
use of a standardised and validated generic instrument unclear
Method of preference elicitation for health state values:  Partial  Method of preference elicitation is explicit, but a 
choice-based method (e.g. TTO, SG, not rating scale). choice-based method was not used
Source of preference data: representative sample of  Yes
the UK public
Discount rate: 3.5% per year for costs and health effects NA Base case is 1-year analysis and therefore no
discounting is necessary. Sensitivity analysis at 
5 years, with 3.5% rate used for costs and effects
NA, not applicable; SG, standard gamble; TTO, time trade-off.treatment effect is estimated for the ICS-alone
treatment comparison, from two RCTs (as above,
one available as an abstract only). There is no
assessment of relative treatment effect for
Symbicort versus Seretide.
Assessment of uncertainty 
Uncertainty is addressed in the submission using
deterministic sensitivity analysis and PSA. PSA has
addressed parameter uncertainty in a number of
cases (number of inhalations, utility values,
transition probabilities, RRs). However, although
the choice of distributions would seem to follow
accepted methods, in many cases the uncertainty
around parameter inputs is very small, with SEs
(around the mean) being very small (data
commercial-in-confidence). The report (Appendix
6) refers to the use of probabilistic methods for
transition probabilities. However, it is unclear how
probabilities were sampled (whether they were
either rescaled to sum to 1.00 or sampled via a
correlation matrix) and the submission only
reports that they were “normalised to give a sum
of one” (p. 99).
The assessment of uncertainty does not address
any issue of heterogeneity in the treatment group,
and certain structural and methodological
uncertainties are not addressed in the sensitivity
analysis (e.g. impact of exacerbations on patients).
The deterministic analysis presented indicates very
little difference in the summary status on cost-
effectiveness comparisons; however, the variations
in many of the parameter inputs are often very
small.
Summary of general comments on the
submission
● The focus on exacerbation (rate) and non-
exacerbation defined control status may not
capture other important aspects of asthma
control and/or effectiveness data (e.g. broader
symptoms, quality of life, lung function).
● The use of a limited evidence base for
effectiveness to populate the model (the
transition probabilities were derived from data
from only two trials, in which the event rate was
low, with one of the trials being reported in
abstract form only).
● The relative treatment effect applied for the
ICS alone comparator option was also based on
the data from only two RCTs conducted in
children, one including children aged
4–11 years and the other including children
and adolescents aged 4–17 years. In addition,
no relative treatment effect and no CEA for
Symbicort versus Seretide was presented (due to
lack of head-to-head data).
● Assumptions over the generalisability of the
trial data and extrapolation of treatment effect
are not discussed.
● The analysis contains a large amount of data
that are classified as ‘in confidence’, some of
which are not transparent in the submission.
Review of the submission by 
Meda Pharmaceuticals
Overview
The submission by Meda Pharmaceuticals to NICE
includes evidence summaries of the Novolizer DPI
device’s technical performance, tolerability and
acceptability to patients and also general
discussion on the burden of asthma and the role
of BUD in asthma treatment. The emphasis
throughout their report, including in the CMA, is
on the documented or estimated patient benefits
and NHS savings of the Novolizer device
compared with its main DPI competitor product,
the Turbohaler. The majority of the submitted
material, and the whole of the economic analysis,
are therefore outside the scope of the NICE
appraisal, which is focused on ICS drug
compounds and selected ‘add-on’ therapies, rather
than different formulations of the same compound
and different delivery devices.
Nevertheless, the submission does provide further
useful insight into the mediating role of inhaler
devices in the effectiveness of ICS and other
inhaled asthma medications.
For completeness, Tables 36 and 37 outline the
approach taken in the submission and provide an
outline review.
Review of the submission by
Trinity-Chiesi Pharmaceuticals
Overview
The submission by Trinity-Chiesi Pharmaceuticals
to NICE focuses on clinical effectiveness and cost
of Clenil Modulite, an HFA-propelled BDP
product for use with pMDIs.
Clenil Modulite
The submission includes some discussion of the
clinical equivalence of this product and the main
CFC-propelled equivalent product that is licensed
for use in children and the presentation of some
price estimates. There is also some discussion on
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TABLE 36 Critical appraisal checklist of economic evaluation by Meda Pharmaceuticals
Item Critical appraisal Reviewer comment
Is there a well-defined question? No Implicitly compare the two device types
Is there a clear description of alternatives? Yes Novolizer (BUD) vs Turbohaler (BUD) both at a
dose of 400 µg daily (or 200 µg b.d.)
Has the correct patient group/population of  Yes Implicitly children from daily doses
interest been clearly stated?
Is the correct comparator used? No Comparison of devices not a part of NICE scope
Is the study type reasonable? Yes – CMA Assuming that claim of therapeutic equivalence
with Turbohaler is valid
Is the perspective of the analysis clearly stated? No But implicitly NHS perspective
Is the perspective employed appropriate? Yes
Is effectiveness of the intervention established? Yes (?) Depending on the quality of RCT by Chuchalin
et al. Respiration 2002;69:502–8.
Has a lifetime horizon been used for analysis  No CMA projects 1 year costs
(has a shorter horizon been justified)?
Are the costs consistent with the perspective  Yes Only drug provision costs are included
employed?
Are the consequences consistent with the  NA
perspective employed?
Is differential timing considered? NA
Is incremental analysis performed? Yes Calculates per person annual NHS savings of
switching from Turbohaler to Novolizer
Is sensitivity analysis undertaken and  No
presented clearly?
NA, not applicable.
TABLE 37 NICE reference case requirements – Meda Pharmaceuticals submission
NICE reference case requirement Reviewer comment
Decision problem: as per the scope developed by NICE  No Inhaler devices compared, (i.e. not BUD with other 
(especially technologies and patient group) ICS or ICS + LABAs)
Comparator: alternative therapies routinely used in  Yes But assessing inhaler devices outside NICE scope
the UK NHS
Perspective on costs: NHS and PSS Yes Implicitly (source of costs = eMIMS)
Perspective on outcomes: all health effects on individuals NA CMA
Type of economic evaluation: cost-effectiveness analysis CMA
Synthesis of evidence on outcomes: based on a  Yes (?) PubMed search obtained 1 trial; no stated inclusion 
systematic review or exclusion criteria
Measure of health benefits: QALYs NA CMA
Description of health states for QALY calculations:  NA CMA
use of a standardised and validated generic instrument
Method of preference elicitation for health state values:  NA CMA
choice-based method (e.g. TTO, SG, not rating scale)
Source of preference data: representative sample of  NA CMA
the UK public
Discount rate: 3.5% pa for costs and health effects No
NA, Not applicable.
a Health effects – just SFDs used to consider QALY values.
b Method for estimating health state utilities is unclear.the changing regulatory environment for these
and related products, specifically the progressive
banning of CFC-propelled asthma medications
under the Montreal Protocol.226,227
The submission is based on a systematic search of
the literature on a range of topics that include
clinical effectiveness, tolerability and safety and
costs-effectiveness of the product. Appendix 9 of
the submission provides information on this
review. The literature is deemed unhelpful for the
current submission, and the submission presents
specific cost comparisons for selected products.
For completeness, an outline review of the
approach taken in the submission is presented.
Analysis of cost of Clenil Modulite (BDP)
Based on evidence summarised elsewhere in the
submission (one published study, two unpublished
Phase III studies) the cost-effectiveness section
assumes the clinical equivalence of Clenil
Modulite with Becotide, which is the main
alternative BDP preparation for children that is
for inhalation via pMDI devices. It then proceeds
with a cost comparison between Clenil Modulite
and the following three BDP products that are
licensed for use in children in the UK:
● Becotide (= BDP, via CFC pMDI)
● Asmabec (= BDP, via Clickhaler DPI)
● Becodisks (= BDP, via Diskhaler DPI).
The submission uses a time horizon of 1 year and
calculates the per patient incremental (NHS)
medication costs of Clenil Modulite, Asmabec and
Becodisks compared with Becotide, at both 100 µg
twice daily and 200 µg twice daily (Tables 12 and
13 in the submission’s Appendix).
Given regulatory changes towards the banning of
CFC-propelled ICS, it is questionable whether the
cost or cost-effectiveness of any products should
now be compared with CFC-propelled products
such as Becotide. More appropriate comparators
would be products which combine other well-
established ICS compounds (such as BUD or FP)
that similarly use HFA propellants for use with
pMDI devices.
Cost-effectiveness results
Table 38 summarises the annual incremental cost
of the three comparator BDP preparations with
Becotide.
Appraisal of the submitted cost-minimisation
analysis
A critical appraisal checklist is given in Table 39
and NICE reference case requirements in Table 40.
Summary of the cost-effectiveness
submissions made by the
manufacturers
Our review of the industry submissions highlights
a number of concerns in relation to providing a
comprehensive and reliable evidence base for
considering the present decision problem.
None of the submissions compared the cost-
effectiveness of all three of the ICS products
licensed for use in children (and which are the
scope for this assessment). All four submissions
presented a CMA with a general assumption of an
equivalent level of clinical effectiveness across ICS
products being made. The submissions by Meda
Pharmaceuticals and Trinity-Chiesi
Pharmaceuticals were both limited to a
presentation of the costs of their respective BDP
products, Novolizer and Modulite, respectively.
The submissions by GSK and AZ for the cost-
effectiveness of ICS products were limited to a
CMA. The cost-effectiveness of the products
included in the current appraisal was not
apparent. Moreover, the methods used for
estimating the product costs varied across the
submissions and were not transparent. This is
particularly pertinent, as the majority of the
different ICS named preparations are usually sold
in a variety of dose strengths (e.g. 100, 200 or
400 µg per dose). Therefore, there are a number
of ways of achieving any given daily dose of a
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TABLE 38 Annual incremental cost of the three comparator BDP preparations with Becotide
Product At 100 g b.d. At 200 g b.d. 
Annual cost (£) Incremental cost (£) Annual cost (£) Incremental cost (£)
Becotide 10.18 – 29.71 –
Clenil Modulite 28.18 18.00 61.43 31.72
Asmabec 35.81 25.63 71.61 41.90
Becodisks 73.00 62.82 139.13 109.42particular drug, with the method used to derive
the dose affecting cost.
For the combination therapies of Seretide (FP + S;
GSK) and Symbicort (BUD + FF; AZ), more
complex cost-effectiveness models were presented.
However, once again both of the models were
developed from a product-specific view of CEA.
The model developed by GSK was presented as a
‘generic’ model, but the focus was entirely on
Seretide, with no formal comparison being made
with Symbicort. Conversely, the model developed
by AZ was based only on trial data for Symbicort,
and again no formal comparisons were made with
Seretide. In both submissions the lack of direct
head-to-head trial evidence between Seretide and
Symbicort in children was highlighted.
Approach to modelling cost-
effectiveness for this review
As discussed above, the review of the cost-
effectiveness literature on asthma did not identify
any studies that were applicable to the research
questions of interest in the UK context. Similarly,
the limitations of published models of asthma
meant they were not applicable in the context of
this review. We therefore developed our own
model to address the specific research questions
outlined previously, in the context of a UK
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TABLE 39 Critical appraisal checklist of economic evaluation by Trinity-Chiesi Pharmaceuticals
Item Critical appraisal Reviewer comment
Is there a well-defined question? No But the implicit question is: which of the currently
licensed non-CFC-propelled BDP products for use in
children is the cheapest?
Is there a clear description of alternatives? Yes However, although equivalence is demonstrated with
Becotide, the cost comparison includes two other BDP
products that are delivered by DPI (Asmabec
Clickhaler and Becodisk Diskhaler)
Has the correct patient group/population  No Although implicitly their analysis applies to children 
of interest been clearly stated? aged under 12 years (or 6 years and over, which is the
licence for some of the products compared)
Is the correct comparator used? No Both in terms of accordance with NICE scope and the
fact that the proper comparator should probably be
other ICS compounds delivered via pMDIs using HFA
propellants
Is the study type reasonable? Yes
Is the perspective of the analysis clearly  No But implicitly NHS perspective (implied by source of 
stated? unit costs)
Is the perspective employed appropriate? Yes
Is effectiveness of the intervention  Yes Equivalence to Becotide, but not to the other two 
established? products included in the cost comparison
Has a lifetime horizon been used for  No CMA for 1 year
analysis (has a shorter horizon been 
justified)?
Are the costs consistent with the  Yes
perspective employed?
Are the consequences consistent with  NA
the perspective employed?
Is differential timing considered? NA
Is incremental analysis performed? NA
Is sensitivity analysis undertaken and  NA
presented clearly?
NA, not applicable.paediatric population and of the BTS/SIGN
Guideline.1
To use the model to estimate the relative cost-
effectiveness of the three ICS drugs at low or high
dose required an estimate of their relative
treatment effects. Despite the number of trials
identified, it was not possible to derive such an
estimate, either from direct trial evidence of head-
to-head comparisons of the three ICS, from meta-
analyses combining the trial data or from
synthesising the data using a mixed treatment
comparison model. The trial data have been
presented in the clinical effectiveness review and
the reasons for this lack of an overall treatment
effect are discussed in detail in the discussion
below. Briefly, our inability to pool or compare
treatment effects lies in the heterogeneous nature
of the trials and lack of consistency in measuring
and reporting outcomes, making comparison and
combination extremely difficult.
For questions 1 and 2, as the clinical effectiveness
review did not establish any consistent differences
in treatment effect or safety parameters across the
range of outcomes assessed within the trials at
their accepted clinically equivalent doses, a cost
comparison was undertaken (see the sections
‘Review question 1 – effectiveness of low-dose ICS’,
p. 28, and ‘Review question 2 – effectiveness of
high-dose ICS’, p. 35).
For question 3, no trials were identified that
assessed the treatment strategy of either increasing
the dose of ICS alone if control remained
inadequate at doses within the Step 2 range of the
Guideline, or the addition of a LABA to a lower
dose of ICS in children.
As it is improbable from a clinical view point that
the two treatment strategies would provide
comparable benefits in terms of treatment effect
and associated AEs, equivalence in outcomes
between the two strategies could not be assumed.
We were therefore unable to undertake a cost
comparison for the costs associated with these two
treatment strategies due to lack of relevant clinical
trial evidence. An exploratory cost-offset analysis
based on costs only was therefore undertaken for
the higher dose ICS compared with each of the
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TABLE 40 NICE reference case requirements – Trinity-Chiesi Pharmaceuticals
NICE reference case requirement Reviewer comment
Decision problem: as per the scope developed by NICE  No Product was compared with same ICS with different
(especially technologies and patient group) pMDI propellant (Becotide) and with same ICS for
use with DPI devices (Asmabec Clickhaler and
Becodisk Diskhaler). Therefore, it is outside the
scope of the present appraisal
Comparator: alternative therapies routinely used in  Yes (See above). However, Becotide will soon be 
the UK NHS obsolete due to implementation of Montreal
Protocol, so rationale for this being the main
comparator for cost-effectiveness purposes is
questionable
Perspective on costs: NHS and PSS Yes
Perspective on outcomes: all health effects on individuals No CMA
Type of economic evaluation: CEA CMA
Synthesis of evidence on outcomes: based on a  Search criteria supplied
systematic review
Measure of health benefits: QALYs NA CMA
Description of health states for QALY calculations:  NA CMA
use of a standardised and validated generic instrument
Method of preference elicitation for health state values:  NA CMA
choice-based method (e.g. TTO, SG, not rating scale)
Source of preference data: representative sample of  NA CMA
the UK public
Discount rate: 3.5% per year for costs and health effects No
NA, not applicable, SG, standard gamble; TTO, time trade-off.available combination preparations in a dose ratio
of 2:1 for the ICS dose delivered either alone or
in combination. The assumption was made that
this represented the most usual clinical decision
facing clinicians when considering options for
treating children whose asthma is inadequately
controlled on low-dose ICS alone.
For the comparison of both combination inhalers
with the same drugs delivered in separate
inhalers, clinical equivalence between the
treatment strategies could be assumed from the
results of the clinical effectiveness analysis. A cost
comparison was therefore undertaken and is
presented in the section ‘Cost comparison analysis
results’ (p. 84).
For question 5, no trials were identified that
compared the effectiveness of a combination
inhaler containing BUD/FF with a combination
inhaler containing FP/SAL in children. Due to the
lack of evidence on the relative cost-effectiveness
of using either combination inhaler, a cost
comparison was undertaken. This was deemed
appropriate due to the lack of evidence of non-
equivalence between the two comparators. The
methods employed and results of the cost
comparison are presented in the next section. 
Methods for cost comparison
Rationale
Cost comparison analysis should normally be used
when there is valid and reliable evidence of
equivalent effectiveness of the alternative
technologies being compared.219 However, as
previous sections of this report have concluded,
among different ICS for asthma there is little
conclusive evidence of equivalence, and more
often instead, inconclusive evidence concerning
differential effectiveness. Furthermore, the
evidence of differential effectiveness due to adding
a LABA to treatment with ICS is also ambiguous,
and largely restricted to studies in adults.
However, performing a cost comparison analysis is
not straightforward, as it is far from simple to
derive a single ‘representative’ cost figure for each
ICS. This is because each drug is typically
available in a range of named preparations (e.g.
from different manufacturers or for different
inhaler devices), and also because each named
preparation is usually sold in a variety of dose
strengths (e.g. 100, 200 or 400 µg per dose).
There can therefore be a wide variety of ways of
achieving any given daily dose of a particular
drug. This is especially an issue for long-
established drugs such as BDP and BUD.
In order to generate single cost figures for each
drug, we have made use of standard assumed
ratios regarding dose equivalence and made some
other simplifying assumptions to allow pooling 
of cost estimates. Also, given the likely withdrawal
of CFC-containing products in the near future, we
have also calculated cost estimates both including
and excluding currently available CFC-containing
products (this is an issue for BDP and BUD
preparations only). During the period when 
CFC-containing products are withdrawn from sale
in the UK, it is likely that the relative market
shares of different named preparations will also
alter, because many patients will need to switch
between products, new products may
simultaneously enter the market and pack prices
may also change.
Given the issues outlined above, what we present
below should be viewed as an exploration of the
current and future relative costs of different classes
of ICS and combination products.
Methods
First, we have calculated the mean annual per
patient cost of taking each specific named
preparation of each drug (or each combination of
drugs), in order to achieve a given level of daily
dosage. For each named preparation, this is
calculated as:
£ per dose × doses per day × No. days in year =
(BNF £ pack price ÷ doses per pack) × (target
daily dose ÷ µg BDP–CFC equivalent per dose) 
× 365
where ‘BNF £ pack price’ is the specific BNF per
pack price for a specific preparation (e.g. 50, 100
or 200 µg per dose). The ‘doses per day’ are the
number of doses of a given preparation needed to
achieve a particular target daily dose level (e.g.
400 µg/day of BDP–CFC equivalent ICS; see
below).
Assumptions about target daily dosage
For child patients with asthma, we have estimated
costs for two ‘low levels’ and one ‘high level’ of
daily dosage of ICS. The low-level dosages we
have costed are:
LDstart: low-dose starting dosage = 200 µg
CFC–BDP (or equivalent) per day
LDmax: low-dose maximum dosage = 400 µg
CFC–BDP (or equivalent) per day 
Economic analyses
82These equate to, respectively, the recommended
starting dose for child patients stepping up from
mild intermittent asthma managed primarily by
SABAs (i.e. those changing from Step 1 to Step 2
of the BTS/SIGN Guideline) and the
recommended maximum daily dose of ICS for
children before an add-on therapy (such as a
LABA) should be tried (i.e. Step 3, ‘Add-on
therapy’).
The ‘high-level’ daily dosage we have costed is
800 µg BDP–CFC (or equivalent) per day. This is
assumed to approximate to the median ICS dose
of people being treated at Step 4 of the BTS/SIGN
Guideline.
Assumptions about number of doses per day/dose
of preparations
For simplicity, and unless recommended otherwise
in the BNF, we assumed that the required daily
dose of an ICS was achieved as either one dose
taken twice daily or two doses twice daily. These
base-case assumptions are summarised in Table 41.
Assumptions about dose equivalence with
CFC–BDP
In order to compare the cost of alternative ICS
preparations, it is necessary to make some
assumptions about the likely equivalent dose that
would be required if controlled patients were
switching between preparations. Because of
product ‘potency’ characteristics, related to
particle size and mode of action, the same
quantities of different active ingredients achieve
different clinical effectiveness. For the practical
purposes of informing dosage decisions when
switching patients between ICS products, both the
GINA Guidelines and the BTS/SIGN Guideline
have published ratios of dose equivalence. These
are shown in Table 42.
It should be noted that these effectiveness
equivalence ratios are fairly crude ‘rules of thumb’,
for the main purpose of aiding doctors in
deciding the starting dose of any new ICS drug
when switching between drug types. They may not
necessarily, therefore, reflect the relative doses
actually used in the body of trials that have
examined the clinical effectiveness of the different
ICS drugs. Nor would they be likely to reflect
possible differences in de facto effectiveness within
and between drugs due to different concordance
or ease of use associated with different inhaler
devices. In any case, it should be remembered that
after a switch between drug treatments, clinical
guidelines recommend that the dose be adjusted
upwards or downwards until the minimum dose
required to maintain effective control is found.
However, to perform a cost comparison analysis
we have to make use of these assumptions about
how much of alternative ICS preparation people
would probably need to take in order to maintain
the same level of symptom control.
Health Technology Assessment 2008; Vol. 12: No. 20
83
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
TABLE 41 Daily patterns of ICS dose-taking to achieve target daily dose
Daily dosage (BDP–CFC equivalent) (g) Taken either as Or as
200 50 µga × 4 doses 100 µga × 2 doses
400 100 µga × 4 doses 200 µga × 2 doses
800 200 µga × 4 doses 400 µga × 2 doses
a BDP–CFC or equivalent (see multipliers in Table 42).
TABLE 42 Published and assumed dose equivalence ratios of different ICS preparations
Drug Equivalent amount of BDP–CFC Ratio used in CMA
BTS/SIGN Guidelines GINA Pocket Guide to Asthma
BDP HFA-propelleda ×2 ×2 ×2
BUD ~ ×1 Not shown ×1
BUD–DPI ~ ×1b ~ ×1 ×1
FP ×2 ×2 ×2
Sources: Section 4.2.3 of BTS/SIGN Guideline and Figure 7 (p. 19) of the GINA Pocket Guide 2005.
a Except Clenil Modulite, which has been designed to have equivalent potency to BDP–CFC preparations.
b Despite some evidence that BUD–DPI via Turbohaler is more effective than same dose of BDP–CFC.Assumptions about the mix of brands/named
preparations within each ICS drug class
For some of the ICS drug (notably BDP), there is a
wide range of named preparations, available in
different physical forms (aerosol versus dry
powder), for different inhaler devices, and either
propelled by CFC-containing or non-CFC-
containing propellants (e.g. HFA preparations). To
compare between ICS drugs, it is therefore
necessary to generate a single, average cost for a
given level of daily dosage.
We have used two methods for doing this: (1)
using an unweighted mean annual cost and (2)
using a weighted mean annual cost, weighted
according to the current (2005) market share in
terms of quantity of doses sold (in BDP–CFC
equivalent units).
The unweighted mean annual cost is calculated as
follows. First, for a given dose level (e.g. LDstart =
200 µg BDP–CFC equivalent), calculate the annual
cost of achieving this daily dosage (e.g. all
products available as 50 µg BDP–CFC equivalent
doses and/or 100 µg BDP–CFC equivalent doses).
Second, sum the annual costs for these
preparations. Third, divide by the number of
preparations available at these doses (i.e. the
number of annual costs summed in step two).
The weighted mean annual cost is calculated as
follows. First, the adjusted annual quantity sold of
each product for each drug is calculated. For a
product sold in 200-dose packs, in a drug where
most products are available in 200-dose packs, this
will simply be the quantity of packs sold (in
thousands, as listed in the Prescribing Cost Analysis
(PCA) database for 2005). However, for a product of
this drug sold in a 100-dose pack, this PCA quantity
sold will be multiplied by 0.5 (= 100/200); similarly,
for any products sold in 120-dose packs, the PCA
quantity sold will be multiplied by 0.6 (= 120/200).
Second, using these adjusted sale quantities, total
quantities are summed for each drug. For each
drug, total quantities are also calculated for three
groupings of products: CFC-propelled aerosols
(pMDI–CFC), HFA-propelled aerosols
(pMDI–HFA) and products for DPIs. These total
quantities are used as the denominators for the
weighted mean percentages and to calculate the
proportion of adjusted sales of each subgroup of
products (e.g. pMDI–HFA only, DPI only)
accounted for by each product.
This has allowed the calculation of several
different (weighted and unweighted) mean annual
costs by broad inhaler type, and also according to
whether the product contains a CFC propellant or
not. This is particularly critical for estimating the
mean annual cost of BDP and BUD, since CFC-
containing products account for a substantial
market share of these drugs. However, these
products will probably be withdrawn from the
market in the near future.
For each of the three ICS drugs that are licensed
for use in children, and for each of the three dose
levels, we have therefore estimated both a
weighted and an unweighted mean annual cost of:
● all relevant CFC-propelled (pMDI) products
(where they exist)
● all relevant HFA-propelled (pMDI) products
(where they exist)
● all relevant dry powder (capsule and loose
powder) products
● all relevant products for the ICS (including
CFC-propelled products)
● all relevant products for the ICS (excluding
CFC-propelled products).
By ‘relevant’ products we mean those that achieve
the specified daily dose in two or four doses 
per day.
Note that because the combination inhaler
products are only available in two named
preparations (Symbicort and Seretide), and only
the lowest dose strength of each product is
recommended in children, we have simply
calculated the cost for each low-dose product.
Cost comparison analysis results
Research question 1: what is the
cheapest ICS at Step 2?
The cost comparison results presented below are
justified on the basis that we found no consistent
evidence of differential effectiveness in trials
comparing the three comparators of interest (see
the section ‘Summary of Q1: relative effectiveness
of low-dose ICS’, p. 35).
Tables 43 and 44 summarise the unweighted and
weighted mean annual cost of taking the three
main ICS drug classes, by inhaler and propellant
type, at the typical starting daily dose for
children of 200 µg BDP–CFC (equivalent) per day.
Figures 8 and 9 then summarise some of these
data, together with data on the cheapest and most
expensive drug in each ICS drug class for
achieving these target daily dosage.
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TABLE 43 Unweighted mean annual cost of ICS by drug if on 200 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations in drug class 
propellant type (2006 £) (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 26 28 48 32 42
BUD 54 NA 68 61 68
FP NA 33 85 68 68
NA, not applicable.
TABLE 44 Weighted mean annual cost of ICS by drug if on 200 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations in drug class 
propellant type (2006 £) (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 28 NAa 60 30 60
BUD 54 NA 68 64 68
FP NA 33 85 44 44
NA, not applicable.
a There is currently only one pMDI with HFA product recommended for use in children (Clenil Modulite); its current
market share is not known.
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FIGURE 8 Annual cost of 200 µg ICS per day by drug class, and including all products. Cheapest in class products: BDP = Becotide
100 µg (200 D); BUD = Pulmicort L.S. 50 µg (200 D); FP = Flixotide Evohaler 50 µg (120 D). Most expensive in class products: 
BDP = Becodisks Disk 100 µg (120 D Ref.); BUD = Pulmicort Turbohaler 100 µg (200 D); FP = Flixotide Disk 50 µg (60 D Ref.). 
D = number of doses in pack; Ref. = refill pack price (where the same preparation is also available with inhaler device included).They show that overall BDP appears to be the
current cheapest class of ICS drug at starting low
doses for children (200 µg BDP–CFC equivalent
per day), costing on average £30 per year (weighted
mean) or £32 per year (unweighted mean). If CFC-
propelled products are excluded from the available
products, BDP is still the cheapest but at a higher
annual cost. Excluding CFC-propelled products,
and using current prices, cause a significant
increase in the mean annual cost of taking BDP at
this dose level since CFC-propelled products still
account for over half of the product types and
quantities of BDP sold. In contrast for FP, no
currently available products are CFC propelled, so
their exclusion does not alter the calculated mean
annual cost. BUD is the most expensive of the class
of drug when weighted means are considered.
When CFC-propelled products are excluded, FP is
significantly cheaper (weighted means) than either
BDP or BUD; this is because there is a relatively
cheap HFA-propelled preparation of FP (Flixotide
Evohaler 50 µg, £5.44 for 120-dose pack = £33 per
year), which accounts for a large proportion (79% of
50-µg FP doses) of current sales of the three 50-µg
FP products available to children.
Tables 45 and 46 summarise the unweighted and
weighted mean annual cost of taking the three
main ICS drug classes, by inhaler and propellant
type, at the typical maximum daily dose for
children of 400 µg BDP–CFC (equivalent) per day.
Figures 10 and 11 then summarise some of these
data, together with data on the cheapest and most
expensive drug in each ICS drug class for
achieving this target daily dosage.
They show that, overall at this dose level, BDP
appears to be the current cheapest class of ICS
drug, costing on average £63 per year (weighted
mean) or £68 per year (unweighted mean). If
CFC-propelled products are excluded from the
available products, BDP is still the cheapest
according to both the unweighted and unweighted
means. Excluding CFC-propelled products, and
using current prices, cause a substantial increase in
the weighted mean annual cost of taking BDP at
this dose level, since typically cheaper CFC
propelled products still account for over half of
the product types and quantities of BDP sold. In
contrast for FP, no currently available products are
CFC propelled, so their exclusion does not alter
the calculated mean annual cost. Overall, under
most assumptions, FP products are the most
expensive drug class (weighted/unweighted means
when including CFC-propelled products), except
that they are similar in cost to CFC-free BUD
products. In fact, if only non-CFC-propelled
products are considered, the weighted mean
annual cost of the three ICS drug classes varies
between only £122 and £133.
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FIGURE 9 Annual cost of 200 µg ICS per day by drug class, and excluding CFC-propelled products. Cheapest in class products: 
BDP = Clenil Modulite 50µg (200 D); BUD = Pulmicort Turbohaler 100 µg (200 D); FP = Flixotide Evohaler 50 µg (120 D). Most
expensive in class products: BDP = Becodisks Disk 100 µg (120 D Ref.); BUD = Pulmicort Turbohaler 100 µg 200; FP = Flixotide
Disk 50 µg (60 D Ref.). D, Ref.: see Figure 8.Health Technology Assessment 2008; Vol. 12: No. 20
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FIGURE 10 Annual cost of 400 µg ICS per day by drug class and including all products. Cheapest in class products: BDP = Becotide
100 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Accuhaler 100 µg (60 D with device). Most expensive in class
products: BDP = Becodisks Disk 100 µg (120 D Ref.); BUD = Pulmicort Turbohaler 100 µg (200 D); FP = Flixotide Disk 100 µg 
60 D Ref.). D, Ref.: see Figure 8.
TABLE 45 Unweighted mean annual cost of ICS by drug if on 400 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations in drug class 
propellant type (2006 £) (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 47 56 98 68 92
BUD 76 NA 113 106 113
FP NA NA 128 128 128
NA, not applicable.
TABLE 46 Weighted mean annual cost of ICS by drug if on 400 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations in drug class 
propellant type (2006 £) (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 51 NAa 122 63 122
BUD 76 NA 134 120 134
FP NA NA 133 133 133
NA, not applicable.
a There is currently only one pMDI with HFA product recommended for use in children (Clenil Modulite); its current
market share is not known.Research question 2: what is the
cheapest ICS at Step 4?
The cost comparison results presented below are
justified on the basis that we found no consistent
evidence of differential effectiveness in trials
comparing the five comparators of interest at
this dose level (see the section ‘Summary of Q2:
relative effectiveness of high-dose ICS’, p. 48).
For this question, we have assumed that for
children a maximum daily dose of ICS when at
treatment Step 4 of the BTS/SIGN Guideline is
800 µg BDP–CFC equivalent. Since the new BDP
product Clenil Modulite is listed in the BNF
under standard-dose inhalers, we have assumed
that this product is not currently recommended
for use in children at these high doses.
Tables 47 and 48 summarise the unweighted and
weighted mean annual cost of taking the three
main ICS drug classes for children, by inhaler and
propellant type, at the typical maximum daily
dose for children of 800 µg BDP–CFC (equivalent)
per day. Figures 12 and 13 then summarise some
of these data, together with data on the cheapest
and most expensive drug in each ICS drug class
for achieving this target daily dosage.
They show that, overall at this dose level, BDP
appears to be the current cheapest class of 
ICS drug, costing on average £142 per year
(weighted mean) or £143 per year (weighted
mean). If CFC-propelled products are excluded
from the available products, BDP is still the
cheapest according to both the weighted and
unweighted means. Excluding CFC-propelled
products, and using current prices, cause a
substantial increase in the weighted mean annual
cost of taking BDP at this dose level, since the
cheaper CFC-propelled products still account for
over half of the product types and quantities of
BDP sold (for children and adults). In contrast 
for FP, no currently available products are 
CFC propelled, so their exclusion does not 
alter the calculated mean annual cost. Overall,
under most assumptions, FP products are
currently the most expensive drug class
(weighted/unweighted means when including
CFC-propelled products). However, FP products
are similar in cost to CFC-free BUD products
when weighted according to current market share.
If only non-CFC-propelled products are
considered, the weighted mean annual cost of the
three ICS drug classes varies between only £247
and £266.
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FIGURE 11 Annual cost of 400 µg ICS per day by drug class excluding CFC-propelled products. Cheapest in class products: BDP =
Clenil Modulite 100 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Accuhaler 100 µg (60 D with device). Most
expensive in class products: BDP = Becodisks Disk 100 µg (120 D Ref.); BUD = Pulmicort Turbohaler 100 µg (200 D); FP = Flixotide
Disk 100 µg (60 D Ref.). D, Ref.: see Figure 8.Health Technology Assessment 2008; Vol. 12: No. 20
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FIGURE 12 Annual cost of 800 µg ICS per day by drug class and including all products. Cheapest in class products: BDP = Beclazone
200 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Accuhaler 100 µg (60 D with device). Most expensive in class
products: BDP = Becodisks Disk 200 µg (120 D Ref.); BUD = Pulmicort Turbohaler 200 µg (100 D); FP = Flixotide Disk 100 µg 
60 D Ref.). D, Ref.: see Figure 8.
TABLE 47 Unweighted mean annual cost of ICS by drug if on 800 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations in drug class 
propellant type (2006 £) (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 59 NA 199 143 199
BUD 153 NA 212 197 212
FP NA NA 257 257 257
NA, not applicable.
TABLE 48 Weighted mean annual cost of ICS by drug if on 800 µg BDP equivalent per day
Drug Preparations with same inhaler and  All preparations in drug class 
propellant type (2006 £) (2006 £)
pMDI with CFC pMDI with HFA DPI Including CFC-propelled Excluding CFC-propelled
BDP 59 NAa 247 142 247
BUD 153 NA 269 216 269
FP NA NA 266 266 266
NA, not applicable.
a There is currently only one pMDI with HFA product recommended for use in children (Clenil Modulite); its current
market share is not known.Research question 3: increase ICS dose
or add LABA to a lower ICS dose?
We have not performed a cost comparison 
analysis of this research question because we
found no reliable evidence that would enable us
to conclude, or reasonably assume, equivalence
between ICS and ICS plus a LABA (see the
section ‘Review question 3a – ICS/LABA or 
higher dose ICS’, p. 48). Therefore, below we set
out the costs and cost differences between
products and present the results of a speculative
threshold analysis to examine the number of
exacerbations that would need to be avoided for
the more expensive product to achieve NHS cost
savings.
Exploratory cost savings analysis of combination
inhalers versus ICS monotherapy
Given the lack of any evidence on the relative
effectiveness of combination inhalers compared
with an increased dose ICS, but also the known
differences in costs between different products, it
is possible to calculate some threshold levels of
effectiveness – in terms of exacerbations avoided –
that would need to be achieved for the more
expensive product to achieve NHS cost savings.
These are based on an estimated mean cost of a
hospital-managed exacerbation of £1056 (assumed
range £500–2000) or the estimated cost of a GP-
managed exacerbation of £24 (assumed range
£20–40). (The estimation of these costs is shown in
Tables 53 and 54, p. 95.) In general, therefore,
averting one hospital-managed exacerbation is
much more likely to generate cost savings than
averting a GP-managed exacerbation.
The calculations for these exploratory analyses are
shown in Tables 49–52. Tables 49 and 50 compare
the cost of Seretide and Symbicort products with
the weighted mean cost of an increased dose of
each type of ICS drug. Tables 51 and 52 compare
the cost of Seretide and Symbicort products with
an increased dose of the cheapest product for each
ICS drug. Where the annual cost of either Seretide
or Symbicor exceeds the cost of the increased dose
ICS, we have calculated the annual number of
either hospital-managed exacerbations or the
annual number of GP-managed exacerbations that
would have to be averted in order to compensate
for the additional costs of the combination
preventer medication.
Only the combination inhaler, Seretide Evohaler
(100 µg/50 µg FP/SAL per day) is slightly cheaper
than the weighted mean cost of all types of ICS at
increased dose except BDP 400 µg/day (including
CFC-propelled products). Compared with
BDP–CFC products at 400 µg/day, taking Seretide
Evohaler costs £52 extra per year. If the cost of a
hospital-managed exacerbation lies somewhere
Economic analyses
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FIGURE 13 Annual cost of 800 µg ICS per day by drug class excluding CFC-propelled products. Cheapest in class products: 
BDP = Beclomet Dipropionate 200 µg (200 D); BUD = Novolizer 200 µg (100 D Ref.); FP = Flixotide Accuhaler 100 µg (60 D with
device). Most expensive in class products: BDP = Becodisks Disk 200 µg (120 D Ref.); BUD = Pulmicort Turbohaler 200 µg (100 D);
FP = Flixotide Disk 100 µg 60 D Ref.). D, Ref.: see Figure 8.Health Technology Assessment 2008; Vol. 12: No. 20
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T
ABLE 49
Exploratory cost-savings analysis: annual exacerbations avoided to cover extra cost of FP/SAL compared with weighted mean cost 
of ICS
W
eighted mean 
Seretide Evohaler 
Cost difference 
Cost of a hospital-managed 
Cost of a GP
-managed 
annual cost of 
100 g/50 
g 
per year
e
xacerbation (£)
e
xacerbation (£)
ICS (£)
FP/SAL per day
(£)
500
1056
2000
20
24
40
BDP 400/day
63
115
52
0.1
0.05
0.03
2.6
2.2
1.3
BUD 400/day
120
115
–
5
Seretide Evohaler cheaper than higher dose ICS
FP 200/day (all CFC
-free)
133
115
–15
Seretide Evohaler cheaper than higher dose ICS
BDP 400/day (excluding 
122
115
–
7
Seretide Evohaler cheaper than higher dose ICS
CFC
-propelled)
BUD 400/day (excluding 
134
115
–19
Seretide Evohaler cheaper than higher dose ICS
CFC
-propelled)
Seretide Accuhaler 
100 
g/50 
g
FP/SAL per day
BDP 400/day
63
190
127
0.25
0.12
0.06
6.35
5.29
3.18
BUD 400/day
120
190
70
0.14
0.07
0.04
3.50
2.92
1.75
FP 200/day (all CFC
-free)
133
190
57
0.11
0.05
0.03
2.85
2.38
1.43
BDP 400/day (excluding 
CFC
-propelled)
122
190
68
0.14
0.06
0.03
3.40
2.83
1.70
BUD 400/day (excluding 
CFC
-propelled)
134
190
56
0.11
0.05
0.03
2.80
2.33
1.40Economic analyses
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T
ABLE 50
Exploratory cost-savings analysis: annual exacerbations avoided to cover extra cost of BUD/FF compared with weighted mean cost 
of ICS
W
eighted mean 
Seretide T
urbohaler
Cost difference 
Cost of a hospital-managed 
Cost of a GP
-managed 
annual cost of 
200 g/12 
g 
per year
e
xacerbation (£)
e
xacerbation (£)
ICS (£)
BUD/FF per day
(£)
(100 
g/6 
g inhaler) (£)
a
500
1056
2000
20
24
40
BDP 400/day
63
201
138
0.28
0.13
0.07
6.90
5.75
3.45
BUD 400/day
120
201
81
0.16
0.08
0.04
4.05
3.38
2.03
FP 200/day (all CFC
-free)
133
201
68
0.14
0.06
0.03
3.40
2.83
1.70
BDP 400/day (excluding 
122
201
79
0.16
0.07
0.04
3.95
3.29
1.98
CFC
-propelled)
BUD 400/day (excluding 
134
201
67
0.13
0.06
0.03
3.35
2.79
1.68
CFC
-propelled)
a 
Costs for Symbicort T
urbohaler are based on the inhaler 100
µg/6
µg. Symbicort 200
µg/6
µg and 400
µg/12
µg are not recommended in children aged under 12 years. 
T
ABLE 51
Exploratory cost-savings analysis: annual exacerbations avoided to cover extra cost of FP/SAL compared with cheapest ICS produc
t for each drug
Annual cost of
Seretide Evohaler 
Cost difference 
Cost of a hospital-managed 
Cost of a GP
-managed 
cheapest ICS
100 
g/50 
g 
per year
e
xacerbation (£)
e
xacerbation (£)
(£)
FP/SAL per day
(£)
500
1056
2000
20
24
40
BDP 400/day
20
115
95
0.19
0.09
0.05
4.75
3.96
2.38
BUD 400/day (all CFC
-free)
70
115
45
0.09
0.05
0.02
2.22
1.88
1.13
FP 200/day (all CFC
-free)
109
115
6
0.01
0.005
0.003
0.30
0.25
0.15
BDP 400/day (excluding 
56
115
59
0.12
0.06
0.03
2.95
2.46
1.48
CFC
-propelled)
Seretide Accuhaler 
100 
g/50 
g
FP/SAL per day
BDP 400/day
20
190
170
0.34
0.16
0.09
8.50
7.08
4.25
BUD 400/day (all CFC
-free)
70
190
120
0.24
0.11
0.06
6.00
5.00
3.00
FP 200/day (all CFC
-free)
109
190
81
0.16
0.08
0.04
4.05
3.38
2.03
BDP 400/day (excluding 
56
190
134
0.27
0.13
0.07
6.70
5.58
3.35
CFC
-propelled)Health Technology Assessment 2008; Vol. 12: No. 20
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T
ABLE 52
Exploratory cost-savings analysis: annual exacerbations avoided to cover extra cost of BUD/FF compared with cheapest ICS produc
t for each drug
Annual cost of
Seretide T
urbohaler
Cost difference 
Cost of a hospital-managed 
Cost of a GP
-managed 
cheapest ICS
200 
g/12 
g 
per year
e
xacerbation (£)
e
xacerbation (£)
(£)
BUD/FF
(£)
per day (£)
a
500
1056
2000
20
24
40
BDP 400/day
20
201
181
0.36
0.17
0.09
9.05
7.54
4.53
BUD 400/day (all CFC
-free)
70
201
131
0.26
0.12
0.07
6.55
5.46
3.28
FP 200/day (all CFC
-free)
109
201
92
0.18
0.09
0.05
4.60
3.83
2.30
BDP 400/day (excluding 
56
201
145
0.29
0.14
0.07
7.25
6.04
3.63
CFC
-propelled)
a 
Costs for Symbicort T
urbohaler are based on the inhaler 100 
µg/6 
µg. Symbicort 200
µg/6 
µg and 400
µg/12
µg are not recommended in children aged under 12 years. between £500 and £2000, then in order to be cost
saving Seretide Evohaler would need to avert at
least one hospital-managed exacerbation in
between 10 and 39 people who are using these
inhalers compared with BDP. However, treatment
with this specific combination inhaler would
annually need to avert between 1.3 and 2.6 GP-
managed exacerbations per person to cover the
extra drug treatment costs.
Both of the combination inhalers, Seretide
Accuhaler and Symbicort Turbohaler, are more
expensive than the weighted mean annual cost for
all types of ICS at a two-fold increased dose.
Compared with the lowest cost preparation for
each ICS drug, the combination inhalers are
always more expensive than these ICS products at
increased dose. The greatest cost difference is
between taking Symbicort Turbohaler
(200 µg/12 µg/day = £201 per year) and BDP
400 µg/day (as Becotide 100 µg = £20 per year).
To compensate for these extra annual medication
costs, the combination inhaler would annually
need to avert at least one hospital-managed
exacerbation in between 3 and 11 people taking
the drug. In contrast, between 4.5 and 9 GP-
managed exacerbations per person would need 
to be averted annually to compensate for the 
extra cost of taking this combination inhaler,
compared with increasing the dose of Becotide to
400 µg/day.
However, since Becotide and other CFC-propelled
products will soon be withdrawn from sale in the
UK, it is now probably more realistic to compare
the cost of the combination inhalers with CFC-free
ICS products. Compared with the cheapest CFC-
free products of each ICS drug, the combination
inhalers are between £6 and £145 more costly per
year (see Tables 51 and 52). With a £6 extra annual
cost of Seretide Evohaler 100 µg/50 µg/day over
FP 200 µg/day, only a GP-managed exacerbation
would have to be avoided every 2–4 years to cover
the additional drug cost. In contrast, to cover the
£145 extra annual cost of Symbicort Turbohaler
(200 µg/12 µg/day) compared with increasing the
dose of BDP (CFC-free) to 400 µg/day, at least one
hospital-managed exacerbation would have to be
avoided per year for every 3–14 patients on the
combination inhaler.
In summary, the extra annual cost to the NHS of
combination inhalers compared with an increased
dose of the different ICS drugs as monotherapy
varies enormously depending on the exact ICS
product used. When the more expensive ICS
preparations are considered (derived by use of the
weighted mean cost of all ICS preparations), then
only the combination inhaler Seretide Evohaler is
generally cheaper than an increased dose of ICS
alone. However, for the cheapest ICS products, the
additional cost implied by using a combination
inhaler (instead of increasing the ICS dose) will
often be £100 or more per year. Although this
does not, perhaps, appear to be a large difference,
this exploratory analysis shows that to achieve cost
savings the combination inhaler would need to at
least avert approximately four GP-managed
exacerbations or avert one hospital-managed
exacerbation among 10 people on the drug for a
year.
We appreciate that this basic ‘cost savings’ or ‘cost
offset’ analysis does not take into account the
other important benefits to individuals and their
families of avoiding exacerbations or having
generally improved asthma control in between
exacerbations. Nor does it capture the longer term
cost impact of avoiding exacerbations on reducing
the likelihood over time of treatment step-up.
However, given the paucity of other reliable
sources of effectiveness data, we hope that it is a
useful illustration of how much more effective
combination inhalers would need to be in order to
be cost saving compared with increasing ICS dose.
This illustration should also be read in the context
of how likely these absolute differences in
exacerbation rates could be for each of the different
treatment options under consideration, given
background exacerbation rates which may already
be low. The results from the clinical effectiveness
review highlighted that there are currently no trials
that have compared the effectiveness of increasing
the dose of ICS alone to the addition of a LABA
with a lower dose of ICS in a paediatric population.
Therefore, it is impossible to comment on the likely
exacerbation rates associated with each of the
treatment options, except to say that in adults these
rates are typically fairly low.
Estimated costs of hospital- and GP-managed
exacerbations are given in Tables 53 and 54.
Research question 4: combination
versus separate inhalers at Step 3?
The cost comparison results presented below are
justified on the basis that we found no consistent
evidence of differential effectiveness in trials
comparing the comparators of interest (see the
section ‘Review question 4 – ICS/LABA
administered in separate or combination 
inhalers’, p. 57).
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TABLE 53 Estimated cost of a hospital-managed exacerbation for children with asthma
Resource type Unit cost (£) Source % patients % patients Cost (£)
Oral steroids (prednisolone 2 × 25 mg/day for 10 days,  0.1727  BNF 20 doses 3.45
as per BTS/SIGN Guideline) per dose
Child asthma patients discharged from A&E:
% of those with exacerbations who are discharged 39%a
Arriving by ambulance/paramedic services 169 NSRC 39% 23%a 15.10
A&E other high-cost investigations 100 NSRC 39% 11%a 4.30
A&E low-cost investigations 74 NSRC 39% 18%a 5.20
A&E no investigations 62 NSRC 39% 71%a 17.22
Post-discharge GP follow-up 20 UCHSC 39% 64%a 4.97
Child asthma patients admitted from A&E:
% of those with exacerbations who are admitted to  28%a
hospital via A&E department
Arriving by ambulance/paramedic services 169 NSRC 28% 41%a 19.50
A&E other high-cost investigations 151 NSRC 28% 18%a 7.65
A&E low-cost investigations 118 NSRC 28% 14%a 4.63
A&E no investigations 112 NSRC 28% 68%a 21.46
Hospital episode for treating asthma (paediatric) 721 NSRC 28% 202.75
ICU costs (3 bed-days in ICU, for 25% of those  1910 NSRC 28% 3a × 25%a 403.01
admitted via A&E)
Child asthma patients admitted following GP referral:
% admitted to hospital via GP referral 33%a
GP appointment 20 UCHSC 33% 6.60
Hospital episode for treating asthma (paediatric) 721 NSRC 33% 237.77
ICU costs (mean = 1 bed-day in ICU, for 10% of those  1910 NSRC 33% 1a × 10%a 63.01
admitted via GP referral)
All child asthma patients admitted to hospital:
Post-discharge GP follow-up 20 UCHSC 61% 50%b 6.11
Post-discharge hospital outpatient follow-up 111 NSRC 61% 50%b 33.83
NHS cost per hospital-managed exacerbation 1056.56
BNF, British national Formulary No. 51 (March 2006);228 ICU, intensive care unit; NSRC, National Schedule of Reference
Costs 2005;229 UCHSC, Unit Costs of Health and Social Care 2005.230
a Administrative records of Royal Devon and Exeter NHS Trust and/or Southampton University Hospitals Trust.
b Authors’ assumption.
TABLE 54 Estimated cost of a GP-managed exacerbation for children with asthma
Resource type Unit cost (£) Source % patients % patients Cost (£)
Oral steroids (prednisolone 2 × 25 mg/day for 5 days,  0.1727  BNF 10 doses 1.73
as per BTS/SIGN Guideline) per dose
% of consultations that are in surgery hours: 80%a
In-hours GP visit (half see GP) £20 UCHSC 80%a 50%a 8.00
In-hours GP visit (half see practice nurse) £9 UCHSC 80%a 50%a 3.60
Out-of-hours GP telephone consultation (all out-of-hours) £22 UCHSC 20%a 100%b 4.40
Out-of-hours GP visit (half of those calling out-of hours) £59 UCHSC 20%a 50%b 5.90
NHS cost per GP-managed exacerbation 23.63
BNF, British National Formulary No. 51 (March 2006);228 UCHSC, Unit Costs of Health and Social Care 2005.230
a Clinical expert opinion/estimate.
b Authors’ assumption.Tables 55 and 56 show, for both of the currently
available combination products (Seretide and
Serevent), that the combination ICS with LABA
product is always cheaper than taking the same
drugs in separate inhalers. For taking BUD with
FF, using Symbicort via Turbohaler is always
cheaper than taking Pulmicort via Turbohaler (at
the same BUD dose) and taking FF separately.
The estimated annual savings vary between £57
and £190 depending on the exact preparation of
FF used and the daily dose of BUD required.
For taking FP with SAL, using Seretide via
Accuhaler is always cheaper than taking Flixotide
Accuhaler (at the same FP dose) and SAL
separately. The estimated annual savings vary
from £132 (if on 200 µg FP per day) to £244 (if on
100 µg FP per day). Similarly, using Seretide via
Evohaler is always either £189 or £274 cheaper
than taking Flixotide via Evohaler (at the same FP
dose) and taking SAL separately.
Comparisons with SAL delivered as Serevent
Diskhaler are not shown. However, two blisters of
Serevent Diskhaler per day costs £428 per year
(£72 more than Serevent Accuhaler or Serevent
inhaler), and therefore the difference in annual
cost between separate and combination inhalers
would be even greater.
Research question 5: FP/SAL versus
BUD/FF at Step 3?
The cost comparison results presented below are
justified on the basis that we found no evidence
Economic analyses
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TABLE 55 Annual cost of combination versus separate inhalers: BUD with FF added
Combination or BUD FF Annual cost (£) by daily dose of BUD
200 g/day 400 g/day
Symbicort Turbohaler (combination product) 201 402
Separate inhalers: Oxis 4.5 µg (or 9 µg)a 369 437
Pulmicort Turbohaler, plus Foradil 12 µg 391 458
Difference in annual cost (separate less combination):
Separate inhalers:
Pulmicort Turbohaler, plus Oxis 4.5 or 9 µg +169 +35
Foradil 12 µg +190 +57
a Oxis 4.5 and 9 µg are the same price per dose.
TABLE 56 Annual cost of combination versus separate inhalers: FP with SAL added
Preparation Taken as Annual cost (£) by daily dose of FP
100 g/day 200 g/day
As dry powder:
Flixotide Accuhaler 2 blisters/day 78 155
Serevent Accuhaler (or aerosol inhaler)a 2 blisters/dayb 356 356
Both (total) 434 511
Seretide Accuhaler (FP and SAL combined) 2 blisters/dayb 190 379
Difference in annual cost +244 +132
As aerosol:
Flixotide Evohaler 4 puffs/day 33 66
Serevent aerosol Inhaler 4 puffs/dayb 356 356
Both (total) 389 422
Seretide Evohaler (FP and SAL combined) 4 puffs/dayb 115 233
Difference in annual cost +274 +189
a Seretide Accuhaler and aerosol inhaler are the same price per µg.
b Each blister contains 50 µg of SAL and each puff contains 25 µg of SAL.of differential effectiveness in trials comparing
the comparators of interest (see section ‘Review
question 5 – combination inhaler compared with
combination inhaler’, p. 60).
Table 57 compares the cost of taking ICS with
LABA in the two currently licensed combination
inhalers, Seretide and Symbicort. In making the
comparison between these products we have
assumed that 200 and 400 µg of BUD are
equivalent to 100 and 200 µg of FP, respectively.
Symbicort is more expensive than both of the
Seretide preparations that are recommended for
use in children. The estimated annual savings to
the NHS of using Seretide instead of Symbicort
may be between £11 and £172. However, these
differences rely heavily on the assumed 2:1 dose
equivalence between BUD and FP, which is a
rather crude rule of thumb (and not, for example,
derived from a meta-analysis of trials of the
relevant products in children). It should also be
noted that the assumed equivalence of Symbicort
to Seretide at half the ICS dose is based on only
four head-to-head trials in adults, and in all these
trials the Seretide comparator product was
Seretide Diskus (which is marketed as Accuhaler in
the UK) and all the trials were in adults and of
doses that would not be recommended in children
(typically comparing 500 µg/100 µg FP/SAL per
day with 800, 1600 or 400 µg/12 µg of BUD/FF
per day).
Summary of cost comparisons
What is the cheapest type of ICS?
For research question 1, the weighted mean
annual cost of taking an ICS drug at 200 µg
BDP–CFC (or equivalent) varies from £30 for BDP
to £64 for BUD. In contrast, the weighted mean
annual cost of taking an ICS drug at a higher dose
of 400 µg BDP–CFC (or equivalent) varies over
two-fold from £63 for BDP to £133 for FP. At this
higher dose level, currently available BUD
preparations cost on average £120 per year, only
slightly less expensive than FP.
CFC-containing products are often considerably
cheaper than the dry powder or HFA-propelled
alternatives within the same drug class. As a
consequence, and assuming that pack prices and
relative market shares remain the same, when
CFC-containing products are withdrawn the
weighted mean annual cost of taking BDP will
increase from £30 to £60 (at a 200 µg ICS/day
dose level) and from £63 to £122 (at a 400 µg
ICS/day dose level). Although the difference in
mean price between CFC-containing and non-
CFC-containing BUD products is also substantial
(weighted means £76 versus £159), the CFC-
containing products currently account for a much
smaller proportion of BUD product sales and the
dry powder products are relatively cheap. As a
consequence, the exclusion of CFC-containing
products causes an increase in the weighted mean
annual cost of BUD (at 400 µg/day) of only £14
(from £120 to £134).
What these weighted averages often conceal,
however, is very wide variations in the cost of
individual preparations within each class of drug.
For example, currently the cheapest way of
obtaining 400 µg of BDP per day is by taking
Becotide 100 µg four times daily (£0.0139 per
dose = £20.37 per year); the most expensive way
is to use Becodisks 100 µg four times daily
(£0.0952 per dose = £138.94 per year). Similarly,
for obtaining 400 µg of BUD per day, the cheapest
product is Novolizer BUD 200 µg taken twice daily
(£0.0959 per dose = £70.00 per year) and the
most expensive product is Pulmicort Turbohaler
100 and 200 µg (£0.0925 and 0.185 per dose =
£135.05 per year).
Which is cheapest – taking ICS with
LABAs in combination or separate
inhalers?
Overall, taking ICS with LABAs as either of the
two currently available combination products is
Health Technology Assessment 2008; Vol. 12: No. 20
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TABLE 57 Comparison of the cost of currently available combination products
Combination product Taken as 200 g BUD/day 400 g BUD/day
Symbicort Turbohaler (100 µg:6 µg of BUD:FF combined) 1 or 2 puffs/day 201 402
100 g FP/day 200 g FP/day
Seretide Accuhaler (100 µg:50 µg of FP:SAL combined) 1 or 2 blisters/day 190 379
Seretide Evohaler (50 µg:25 µg of FP:SAL combined) 2 or 4 puffs/day 115 233cheaper than taking the relevant ingredient drugs
in separate inhalers. Taking Symbicort Turbohaler
instead of the same drugs in separate inhalers
saves the NHS between £35 and £190 per patient
per year. Taking Seretide Accuhaler or Evohaler
instead of the same drugs in separate inhalers
saves the NHS between £132 and £274 per patient
per year.
Which combination inhaler is the
cheapest?
Noting that this comparison crudely assumes that
200 and 400 µg of BUD are equivalent to 100 and
200 µg of FP, respectively, and also that 12 µg/day
of FF has effectiveness equivalent to 100 µg/day of
SAL, the Seretide Evohaler appears considerably
cheaper than either Seretide Accuhaler or
Symbicort Turbohaler. At the lower daily dose of
200 µg BUD or 100 µg FP per day, Seretide
Evohaler is over £74 cheaper per year than 
both Seretide Accuhaler and Symbicort
Turbohaler, and when taking 400 µg BUD or
500 µg FP per day, it is over £148 cheaper than
these alternatives.
All of the comparisons described above have
involved a number of simplifying assumptions,
including (1) the relative doses of different
products which are assumed to have equivalent
effectiveness, (2) the combinations of products
which are used to achieve any particular daily dose
level of ICS or ICS with LABA and (3) using 2005
community prescription sales as a way of
producing a weighted mean annual cost for 
each class of drugs. For these reasons, and because
the range of available ICS and combination
products is currently undergoing considerable
change (with CFC-containing products being
phased out and some new HFA-propelled
products recently entering the market), the
conclusions should be viewed with appropriate
caution. 
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sthma is one of the most common chronic
conditions in the UK, with a prevalence of
approximately 5.2 million.24 Therefore, the
economic burden of asthma regarding both direct
and indirect costs to the NHS is high. In 2005,
expenditure on corticosteroids for respiratory
conditions cost the NHS £436 million. Although it
was only 15th in terms of the number of
prescriptions issued, it is the third largest
component of the total cost of community-
dispensed drugs in England.
Estimates of the prevalence of treated asthma in
children vary somewhat according to the source
used to obtain them. However, estimates from the
General Practice Research Database indicate that
the prevalence of children being treated for
asthma ranges from approximately 9.5 to 13.5%
for boys and from 6.0 to 10.5% for girls. In both
cases the age ranges used in these estimates were
0–4 and 5–15 years, and in both sexes the
prevalence increased with increasing age. It is not
clear from these data what percentage of these
children are currently using ICS or ICS plus
LABA. Estimates quoted in the background, from
Neville and colleagues,4 suggest that around one-
third of children under 5 years old and 20–25% of
children aged 5–15 years are treated at Step 1 of
the BTS/SIGN Guideline or below. These very
rough estimates suggest that the majority of
children with asthma are treated with ICS, either
alone or in combination with other drugs. As these
data are fairly old (1994–5), it is likely that this
proportion is currently higher.
Children with asthma place various demands on
the NHS budget, ranging from the cost of
prescribed asthma medications to various levels of
health service use, including GP and nurse
consultations, A&E department visits and hospital
admissions. Each of these is associated with a
varying level of cost.
ICS therapy alone
The cost comparisons presented in this review
indicate that there are currently considerable
differences in the mean annual cost between the
different ICS preparations, and also large cost
differences between individual products of each
ICS drug. However, as highlighted from the
limited evidence available, there appear to be few
if any significant differences in effect between the
different ICS which would offset the additional
cost of the more expensive treatment options.
There are potential cost savings to be made for
the NHS if patients who are currently treated with
the more expensive ICS drugs or preparations
were switched to a cheaper option. Currently the
largest cost savings would be associated with
switching all patients to BDP CFC-propelled
devices at all dose ranges. However, this is not a
realistic treatment strategy as CFC-propelled
devices are due to be phased out in the near
future, and there are additional GP consultation
costs associated with a review to switch patients
between treatment strategies and drugs. With the
phasing out of CFC-propelled products, the cost
of providing ICS therapy to the NHS is likely to
increase. Additional costs will be associated with
switching patients who are currently on CFC-
propelled formulations to new preparations and
the higher costs associated with all non-CFC-
propelled preparations of ICS. The exact cost
implications to the NHS are difficult to project, as
it is likely that as CFC-propelled formulations are
removed from the market, the relative market
share of non-CFC formulations will change and
new products will enter the market. In order to
realise any potential cost savings, it may be
important to review patients’ ICS therapy in
routine GP or nurse consultations and examine
whether switches can potentially be made to
cheaper preparations of the same product, which
obviously has an associated cost in terms of patient
education, follow-up and any further treatment
changes that may need to be made if the
treatment regimen is unsuitable.
Additionally it must be noted that any potential
cost savings of switching patients between either
products or preparations can easily be offset by
the costs incurred by potentially higher
exacerbation rates. The BTS/SIGN Guideline
states that patients and clinicians should choose
the preparation that most suits the individual
patient. This will be based not only on the
preparation, but also the device and the
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Chapter 5
Factors relevant to the NHS and other partiescomplexity of the treatment regimen. It is
therefore necessary that any potential switches to
cheaper preparations should be done bearing in
mind the patient’s ability to use different inhaler
types. This is particularly pertinent within a
paediatric population as a higher percentage of
exacerbations are managed either within an A&E
department or by an inpatient hospital stay
compared with the adult population. Both of these
incur considerable costs to the NHS.
ICS plus LABA
There are potential direct savings to the NHS with
a switch to combination ICS/LABA products
delivered in the same inhaler from the same drugs
delivered in separate inhalers. Taking Symbicort
via Turbohaler is associated with an estimated
annual saving between £57 and £190 depending
on the exact preparation of FF used and the daily
dose of BUD required compared with taking
Pulmicort via Turbohaler and taking FF
separately.
Taking Seretide via Accuhaler is associated with an
estimated annual saving of between £132 and
£244 (depending on the dose of FP) compared
with taking Flixotide via Evohaler and taking SAL
separately. Likewise, using Seretide via Evohaler is
between £185 and £270 cheaper than taking the
constituent drugs separately.
However, it is not clear to what extent the drugs
are currently prescribed in separate inhalers.
Given the concerns that the clinicians consulted
for this report have expressed about the potential
hazards of using LABAs without ICS, it is likely
that most ICS plus LABA therapy is now
prescribed in combination inhalers and so the
potential for cost savings in this area may be
limited.
We are also aware from discussions with clinicians
for this report that there is an increasing tendency
to prescribe ICS and LABA in combination
inhalers instead of ICS alone at Step 2 of the
BTS/SIGN Guideline. Reasons given for this
practice include ease of use for patients, to get
both preventer and reliever therapy in one device
and concerns about over-use of reliever
medication, particularly LABAs, on their own. As
this practice is not in line with the Guideline,
assessing the effectiveness and cost-effectiveness of
this treatment strategy is outside the scope of this
report and has not been investigated. It is likely,
however, that a significant proportion of current
prescribing cost may reflect ICS and LABA use
that is not strictly according to the Guideline,
making the estimation of potential cost savings
more difficult.
Factors relevant to the NHS and other parties
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ndertaking this assessment has highlighted
the difficulties in assessing intervention
effects for the treatment of asthma. In the most
part these are a reflection of the complex nature
of the disease and the way that by necessity
outcomes are defined and measured within clinical
trials. In the sections below a brief summary of
these issues is outlined. 
Assessing the effectiveness of
interventions for asthma
Asthma is a common chronic condition with a
number of definitions based on disease process,
clinical symptoms and their pattern over time and
response to external stimuli. Each definition
defines different populations in terms of severity,
the underlying pathological process and the likely
disease trajectory. No one objective test can be
used definitively to diagnose asthma in children
and the diagnosis may only be made after a
period of observation and trials of treatment,
particularly in very young children. Asthma is also
partly defined by the variation of symptoms over
time, thus making the detection of changes due to
interventions more difficult to identify.
In terms of outcomes of treatment for asthma,
death is very uncommon and so is not an
informative outcome measure for assessing the
effectiveness of treatment at levels of severity
within the scope of this report. The wealth of
other outcome measures that are commonly
reported can broadly be divided into the
categories of lung function, symptoms, acute
exacerbations, use of rescue medication and AEs,
but no standardised measures are used consistently
in trials. Measures of lung function such as FEV1
and morning and evening PEF are among some of
the most commonly reported outcomes. However,
such measures are less useful in children as
objective measures of lung function are often
difficult to obtain and may be unreliable,
particularly in young children. Additionally,
although FEV1 is widely reported in trials, it may
be expressed as absolute changes or % predicted,
thus preventing clear comparison between the
results of different studies. Symptoms are also
widely reported, but trials do not use consistent
methods for scoring symptoms or defining
measures such as SFDs or SFNs. For example,
SFDs were defined as diversely as “a 24-hour
period with a symptom score of zero” and
“percentage of days without
cough/wheeze/shortness of breath/chest tightness”.
Very few studies provided any indication of
whether symptom measurement instruments had
been validated. Similarly, definitions of
exacerbations are highly heterogeneous, ranging
from those defined as a fall in PEF of at least 30%
on two consecutive days to those necessitating
emergency treatment at a healthcare institution.
Very few trials report HRQoL, which, in addition
to being important in its own right, is needed to
inform CUAs. Additionally, the way in which AEs
are defined is often poorly reported, and it is
often unclear as to which events are measured and
the severity of these. This limits the degree to
which comparisons of differences in the type and
rate of AEs can be made between trials.
Although lung function provides the most
objective assessment of response to treatment, and
probably more closely reflects the underlying
disease process, the clinical significance of
reported changes in lung function is not clear.
Disease severity also relates to the underlying
disease process, reflected in lung function and
symptoms, but is most commonly defined by level
of medication. Patients on substantial amounts of
medication may be classified as having moderate
or severe disease, but this classification will give no
indication of their level of symptoms, which may
be well or poorly controlled.
The aim of treatment is to control symptoms and
enable patients to lead as normal a life as possible,
so well-controlled asthma is a composite concept
that varies between patients and professionals. It is
dependent on any given patient’s expectations for
their lifestyle (e.g. being active versus sedentary or
willingness to avoid known trigger factors), in
addition to their acceptance of a regular treatment
regimen. Each individual therefore must balance
these factors to allow them to achieve an
acceptable level of symptoms and medication. Part
of this balance is the extent to which patients will
adhere to a medication regimen when they are
symptom free; many will adhere while they are
Health Technology Assessment 2008; Vol. 12: No. 20
101
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Chapter 6
Discussionsymptomatic, but choose to reduce treatment
levels once symptom free. This step down in
treatment may be appropriate in response to
symptoms, but it may happen too quickly and lead
to a return of symptoms or an exacerbation. Mild
exacerbations may either be managed by the
patient alone by increasing medication use, or be
managed within a primary care setting, leading to
the wide variation in definition referred to above.
From the perspective of assessing cost-
effectiveness, however, it is particularly important
to be able to identify the healthcare resource use
associated with more severe exacerbations. These
are usually defined as those exacerbations
requiring hospital admissions or attendance in
emergency departments, but many non-clinical
factors influence admission to hospital,
particularly for young children.
Assessing differences in healthcare costs for the
treatment of asthma is difficult, because of the
difficulty in deriving a single representative cost
for each drug. There are a range of alternative
products, available in a range of doses and
delivered by different devices for each drug.
Therefore, there can be a number of ways of
achieving any given daily dose of a particular
drug, with significant consequences for the cost of
delivering that dose. In order to make any
comparisons in terms of costs between the
different drugs, assumptions have to be made
regarding dose equivalence and the way in which
the target daily dose is achieved.
A further assumption must be made regarding the
context of the BTS/SIGN Guideline for assessing
intervention effects of the different comparators
under consideration. Although the Guideline is
well established and has been used for a number
of years within the UK, it is clear that many
clinical trials are not set within its context, and the
treatment regimens assessed do not fit neatly into
the Guideline steps. Additionally, the effects of
concomitant medication use, such as the addition
of a leukotriene receptor antagonist or
theophylline, for patients treated at Step 4 of the
Guideline has not been reviewed, despite the fact
that most patients would not be treated on high-
dose ICS alone at this step.
The two other areas that have not been formally
assessed in this assessment report are the issues of
device type and concordance, issues which are
inextricably linked. It is well recognised that a
large proportion of the asthmatic population has
difficulty in using particular inhaler devices. This
difficulty relates particularly to pMDIs and to a
lesser extent to DPIs. Both require the ability to
coordinate inhalation with activation of the
inhaler. However, within the context of a clinical
trial, only those patients who are able to use the
type of device under evaluation effectively will be
eligible for inclusion in the trial. Evidence for the
effectiveness of inhaled corticosteroids and beta2
agonists for asthma from clinical trials should
therefore be considered carefully for its
generalisability to the typical population with
asthma, as opposed to a subgroup of patients
selected for their ability to use the inhaler
effectively. Additionally, given the probable device-
related variations in both compliance with correct
inhaler technique and adherence to recommended
daily doses, the rate of concordance with
treatment regimens is likely to be considerably
higher in clinical trials than in routine practice.
Although concordance rates were not formally
assessed in the clinical effectiveness review,
concordance rates were around 70–95% in the
trials where reported. This is considerably higher
than the rates observed in practice, for which it is
generally observed that approximately 50% of
patients take the full amount of prescribed
medication (see Chapter 1). This figure is likely to
vary considerably depending on the level of
support patients receive in primary care and from
asthma specialist nurses and their ability to use
their prescribed inhaler devices.
Limitations of the evidence base
This review identified a very limited evidence base
of trials including children under the age of
12 years and none including children under the
age of 5 years. We have identified only eight trials
that have been conducted solely on child
populations under the age of 12 years: the rest
include a proportion of children aged over
12 years, and none are exclusive to children under
5 years old. In those trials with a mixed child and
adolescent population, the results are not reported
separately. The trials that have been identified are
generally of short duration (less than 6 months),
with a treatment period of 12–24 weeks. These
trials generally do not capture long-term
outcomes, such as growth and impact on BMD
that may be of most interest to clinicians and
patients. A number of trials report various
measures of adrenal function, but it is not clear
how these results can be extrapolated to periods of
treatment lasting years or decades rather than the
weeks that the trials last. It is also not clear in the
trials what constitutes the minimum clinically
significant change for many of the reported
Discussion
102outcomes, such as lung function, symptoms or
exacerbations. Lung function probably reflects the
underlying disease process more closely than
symptom measures of HRQoL, and exacerbations
are probably only triggered when lung function
drops below a certain threshold. Hence it is likely
that lung function changes may still be detectable
at a point in the disease process when patients
have few, if any, symptoms.
The wide range of possible outcome measures,
most with no widely accepted and standardised
method of measuring them, makes comparison
across studies difficult and combining studies in a
meta-analysis inappropriate. Trials have also been
conducted for a variety of reasons and are not
necessarily powered to detect superiority of one
ICS over another. It is also not always clear how
well blinding is maintained when drugs are
delivered through different devices, although
some trials report the use of placebo devices.
Reporting of baseline population characteristics
and outcome measures is frequently poor or
selective.
Review of clinical effectiveness
Of the 16 RCTs identified as relevant to this
assessment, 12 have been included in published
Cochrane systematic reviews. This assessment adds
to this body of evidence, providing a systematic
synthesis of these drugs within the context of a
comprehensive and recognised care pathway.
Below we discuss the key findings according to
Steps 2–4 of the Guideline, embedded within our
five review questions.
Review question 1: which inhaled
corticosteroid is the most effective at
low doses? (200–400 g/day BDP/BUD
equivalent) (Step 2 of the BTS/SIGN
Guideline)
Note that for FP the equivalent doses are 100 to
200 µg/day (children aged over 4 years).
Five relevant RCTs of the efficacy and safety of
ICS at doses up to 400 µg/day (BDP/BUD or
equivalent, corresponding to the BTS/SIGN
Guideline1) were included.
In general, all three of the ICS were associated
with favourable changes across a range of
outcomes. However, limited findings are reported,
particularly in terms of statistical significance tests.
Where such tests were reported, there were few
statistically significant differences between them
when evaluated in pairwise comparisons. The
steroids might therefore be considered generally
equivalent in clinical terms, although few studies
explicitly aimed to assess clinical equivalence/non-
inferiority.
The BTS/SIGN Guideline notes that BDP and
BUD are approximately equivalent in clinical
practice.1 Similarly, the Cochrane review of BDP
and BUD186 noted few significant differences
between them. In the current assessment, only one
small trial of BUD compared with BDP was
included. The trial was designed to evaluate the
impact of stepwise increases in doses on adrenal
function, as opposed to efficacy outcomes. That
said, the trial did report that the treatments were
comparable in terms of morning and evening PEF
and use of rescue medication, although no
statistical tests were reported. There was no
significant difference between the groups in
suppression of diurnal urinary free cortisol
(irrespective of dose).
The BTS/SIGN Guideline also notes that FP
provides equal clinical activity to BDP and BUD at
half the dose.1 This is based on a reported higher
potency for FP. In the Cochrane review of FP
compared with BDP or BUD187 (of which 14 of the
57 included RCTs were in children), the only
significant differences between the drugs when
administered at a 1:2 dose ratio (FP:BDP/BUD)
were for FEV1 and morning PEF, in favour of FP.
There were few differences between the drugs on
other outcome measures, although limitations in
the reported data prohibited meta-analysis of
these outcomes. Only two studies comparing FP
with BDP were included in the current assessment
(a further three were included in the ‘high’ dose
comparison of the two drugs, discussed under
review question 2, below). Both of them tested the
drugs in a 1:2 dose ratio (FP:BDP). Differences
between them in size, length and outcomes
measured make it hard to draw comparisons. The
findings generally do not support the superiority
of either drug. Where statistical comparisons were
reported, they showed no significant differences
between groups. This was the case for SFDs and
SFNs, and for plasma cortisol. The proportion of
patients experiencing an AE was similar between
the treatments in the one trial that reported this
outcome.
There were only two studies comparing FP with
BUD (again, a further three were included in the
‘high’ dose comparison, below). One was a large
study in which the dose of both drugs (dose ratio
1:1) was reduced by 50% every 5 weeks until
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smaller trial focusing on long-term safety over
12 months (dose ratio 1:2). There were no
statistically significant differences between the
treatments on any of the outcomes, including
safety measures such as 24-hour urine cortisol,
BMD and growth over 12 months.
In summary, from the limited evidence available,
low-dose ICS, when evaluated in pairwise fashion,
appear similar in effects, with no statistically
significant differences between them where
statistical tests have been reported.
Review question 2: which inhaled
corticosteroid is the most effective at
high doses? (400–800 g/day BDP/BUD
equivalent) (Step 4 of the BTS/SIGN
Guideline)
Note that for FP high dose is greater than
200 µg/day.
Seven RCTs of the efficacy and safety of ICS at
‘high’ doses in excess of 400 µg/day (BDP/BUD or
equivalent, corresponding to the BTS/SIGN
Guideline1) were included. Although in general
doses were within the 400–800 µg dose range, in
some studies they reached as high as 1500 µg/day
for BDP, 1200 µg/day for BUD and 750 µg/day 
for FP.
The results of comparisons of ICS at high doses
were similar to those of comparisons of ICS at low
doses in demonstrating few statistically significant
differences between the steroids.
For the comparison of BDP with BUD, there was
just one small short-term cross-over RCT. The
primary outcome was to examine any differences
in systemic effects, principally adrenal function.
Urinary cortisol excretion was statistically
significantly higher with BUD. There was no
significant difference between the drugs for FEV1.
Three RCTs compared FP with BDP, ranging from
12 weeks to 1 year in length. Results for lung
function were inconsistent between different dose
ratios, although for one of the dose ratios there
was only one trial. When compared at a nominal
1:1 dose ratio (as measured in one trial), FP was
significantly favourable for FEV1, and also
morning and evening PEF. There were no
significant differences for symptoms or use of
rescue medication. The incidence of exacerbations
was similar and there were no statistically
significant differences between the drugs for
changes in morning serum cortisol and overnight
urinary cortisol levels. There was a significant
difference in growth rates, favouring FP. At a
nominal 1:2 dose ratio (FP:BDP), measured in two
small cross-over trials, there were no statistically
significant differences between the drugs on any
efficacy measures, including exacerbations. Rates
of AEs appeared similar, and there were no
statistically significant differences in mean urinary
free cortisol levels and total cortisol levels.
There were also three RCTs comparing FP with
BUD. In common with the comparison of FP with
BDP, there was one nominal 1:1 dose ratio
comparison and two 1:2 dose ratio comparisons
(FP:BUD). Results were mixed, with FP
significantly better in terms of lung function at
dose ratio of 1:1 (one trial, not the accepted
clinically equivalent dose ratio), but not for other
outcomes. At a dose ratio of 1:2, one trial also
reported a significantly favourable outcome for FP
in terms of morning PEF, but not for other
outcomes. The proportion of patients
experiencing AEs was similar between the 
drugs, with no significant differences in one trial.
There was no significant difference in changes 
in serum cortisol between groups in the one 
trial that reported this measure. FP was
significantly favourable in terms of changes in
growth/height.
In summary, when evaluated in pairwise fashion,
there were few statistically significant differences
between the high-dose ICS in efficacy outcomes.
Where significant differences did exist they tended
to favour FP, but this is largely at 1:1 dose ratios.
Where only comparisons of the accepted clinically
equivalent dose ratios are considered, even fewer
significant differences are reported. There was no
consistent pattern in effects across different dose
ratios, although the small number of trials limits
what can be concluded about this. Perhaps more
importantly, there were few significant differences
between the ICS in measures of adrenal
suppression, which is of particular interest when
ICS are prescribed at high doses in children.
However, the trials did not appear to be
adequately powered to detect differences on this
outcome and clinical trials may not be the best
type of study to measure this.
Review question 3: which is more
effective: an ICS or a combination
inhaler containing an ICS and a LABA?
(Step2/Step 3 of the BTS/SIGN
Guideline)
The clinical effectiveness review concentrated on
the comparison of ICS alone versus ICS and
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arm was higher than in the combination arm, as
this comparison appeared to be most relevant to
the clinical decision at Step 2 of the Guideline (i.e.
whether to increase the dose of ICS or add in a
LABA). However, the review also identified trials
comparing ICS alone with combination ICS and
LABA where the ICS doses are similar in each
arm. They are commented on below.
(a) ICS + LABA where the dose of the ICS is
higher when used alone, compared with the dose
in the combination inhaler
For patients who are inadequately controlled on
low-dose ICS, the options include increasing the
dose of the ICS, either within or beyond the
400 µg/day dose threshold, or adding in a
supplemental treatment. The BTS/SIGN
Guideline1 recommends a trial of an add-on
therapy for such patients, before increasing the
ICS dose. In children aged 5–12 years, the first
choice is a LABA. For children aged 2–5 years, a
trial of a leukotriene receptor agonist is
recommended. However, the scope of this
assessment does not include add-on therapies
other than LABAs and therefore we cannot
comment on the efficacy and safety of such
strategies in children of this age group.
Only one trial where the dose of ICS was higher
than the dose in the combination inhaler arm was
identified and included. This was a large multi-
centre trial of over 2000 patients. However, only
around 12% were children aged under 12 years.
The only results that are reported separately for
children are for growth rates and plasma cortisol
(our accompanying assessment report in adults
and children aged over 12 years reports the
efficacy results for the full population). There was
a significant difference in favour of the
combination inhaler for growth, but there were no
significant differences for plasma cortisol.
A Cochrane review of this treatment modality188
found that combination therapy led to greater
improvement in lung function, symptoms and use
of rescue medication. It was also associated with
fewer withdrawals due to poor asthma control.
There was no significant difference between
treatments in terms of reducing exacerbations
requiring systemic corticosteroids. However,
caution is advised in any extrapolation from this
evidence base as only three of the 30 studies were
in paediatric populations, and only eight of the
studies used a combination inhaler (the remaining
studies using separate inhalers to deliver ICS and
LABA). Clearly, more RCTs evaluating this
treatment strategy are needed in children, with a
particular focus on impact on exacerbations,
HRQoL and long-term safety.
(b) ICS + LABA where the dose of ICS is similar
in both treatment arms
As discussed, the BTS/SIGN Guideline
recommends either increasing the dose of ICS or
adding in a supplemental drug, such as a LABA,
for patients uncontrolled on low doses of ICS.
However, a body of evidence exists, mainly in
adult patients, comparing ICS with ICS and 
LABA where the ICS dose is similar in both
strategies. These trials were conducted to 
evaluate the safety and efficacy of the combination
inhalers compared with standard treatment 
with ICS.
In this assessment, two such trials were included,
both multi-centre trials of reasonable size. One
compared FP against FP/SAL in a combination
inhaler and the other compared BUD against
BUD/FF in a combination inhaler.
The trial that compared FP against FP/SAL was
designed primarily to evaluate safety. The limited,
unpublished, data for efficacy outcomes suggested
that the combination inhaler was favourable for
lung function outcomes and exacerbations,
although it is not clear whether there were
statistically significant differences. The treatments
appeared similar for symptoms and use of rescue
medication and AEs.
When BUD was compared against BUD/FF in a
combination inhaler, the latter was statistically
significantly more favourable for changes in FEV1,
and morning and evening PEF. For other
outcomes, such as symptoms, use of rescue
medication and AEs, the combination inhaler was
either favourable or the treatments appeared
similar, but no significance testing was reported.
Review question 4: ICS and LABA
administered in a combination inhaler
compared with separate inhalers
The scope for this assessment, as set by NICE,
includes the use of ICS and LABA in a
combination inhaler, but not in separate inhalers.
It should therefore be acknowledged that there is
a wider evidence base for the use of ICS and
LABA in separate inhalers compared with ICS
alone, although mainly in adults, as summarised
by the Cochrane Collaboration.188,189 The scope
does, however, cover the use of ICS + LABA in a
combination inhaler compared with the two in
separate inhalers.
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identified, a multi-centre RCT of over 200
children. The key findings were that there were no
statistically significant differences between the two
treatment modalities for measures of lung
function, and the mean difference in morning PEF
was within a defined range for clinical
equivalence. They were similar for symptoms, use
of rescue medication and exacerbations, but no
statistical data were reported.
In practice, decisions about whether a
combination inhaler or separate inhalers are used
will be based on factors such as ease of use,
convenience and the likelihood of concordance.
Expert clinical opinion suggests that one of the
advantages of combination inhalers is that the risk
of patients failing to take their ICS is reduced.
When ICS and LABA are prescribed separately, it
is suggested that the rapid symptom relief
provided by the LABA may mean that some
patients are less likely to take their ICS routinely.
The LABA will not have reduced the underlying
inflammation and patients may be at increased
risk of exacerbation. The BTS/SIGN Guideline1
makes it clear that LABAs should not be used
without ICS.
Review question 5: combination inhaler
compared with combination inhaler?
(FP/SAL versus BUD/FF) 
No trials were identified which compared the two
combination trials head-to-head in children. We
are therefore unable to comment on the relative
efficacy and safety of the two inhalers. Clearly
RCTs assessing the two combination inhaler
therapies head-to-head with a focus on
exacerbation rates, SFDs and safety are needed.
Estimates of costs
It was not possible to develop a valid and credible
cost–utility model for the treatment of asthma with
an ICS used either alone or in combination with a
LABA at the appropriate step of the BTS/SIGN
Guideline in a paediatric population. The main
reason for this was the lack of direct head-to-head
trial data for the three ICS comparators
considered in questions 1 and 2, ICS versus other
ICS, and the lack of relevant trial data in
questions 3–5. Poor reporting of trial results,
where they existed, meant that the reported data
could not be used because of incomplete
information. We therefore adopted a cautious
approach to the economic analysis for this report,
and present for each question either a cost
comparison or an exploratory cost offset analysis.
These two different methods of analysis were used
appropriately in relation to the findings from the
accompanying clinical effectiveness review. A cost
comparison of the different ICS and ICS plus
LABA preparations was undertaken where the
clinical effectiveness review showed no consistent
evidence of differential treatment effects between
the comparators. An exploratory cost offset
analysis was undertaken where the clinical
effectiveness review indicated that there were
significant differences in effects between the two
comparators. This examined the number of
hospital- or GP-managed exacerbations that would
need to be avoided in order to offset any cost
differences between the different treatment
strategies.
Cost comparisons
These cost comparisons have been shown in
Chapter 4. They relied on a range of assumptions
for arriving at each mean annual cost of taking a
particular ICS or combination inhaler. In
particular, they used the conventional (GINA and
BTS/SIGN) dose equivalence ratios for different
ICS drugs and/or propellants, and used the 2005
community-dispensed prescription sales data for
weighting the cost of different products within
each drug type. For these reasons, they should
probably be viewed as a form of illustrative
economic ‘what if ’ analysis: ‘If they were equally
effective, what would be the likely differences in
the annual cost of treatment?’
ICS versus ICS
There are considerable differences in weighted
mean annual cost between the different ICS, and
also large cost differences between different
preparations of the same ICS. The annual cost
varies seven-fold between different preparations of
BDP to less than three-fold between different FP
preparations. The cost differences between
different BDP preparations are smaller, however, if
the (typically cheaper) CFC-propelled
preparations are excluded from the analysis. Our
systematic review of the published research
evidence has highlighted the fact that there is little
demonstrated difference in effectiveness between
the different ICS comparators under trial
conditions. Therefore, there appears to be little
justification for the sometimes considerable cost
differences between different products containing
the three licensed drugs. However, other
differences between the products, for example
inhaler device characteristics and propellant taste,
will probably influence how effectively or easily
they are used. Yet in most clinical trials assessing
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who are already able to use the inhaler device type
being trialled effectively and who are willing to
tolerate other properties of the propellant will
actually be eligible for inclusion.
It is well recognised that a large proportion of the
asthmatic population has difficulty in using
particular inhaler devices. This difficulty relates
particularly to pMDIs and to a lesser extent to
DPIs. Both require the ability to coordinate
inhalation with activation of the inhaler. All trial
evidence of the effectiveness of inhaled treatment
for asthma should therefore be considered
carefully for its generalisability to the general
population with asthma rather than the subgroup
able to use the trial devices.
In applying these cautions on the ease of use of
inhaler devices to the results of the cost
comparison analysis, the cost savings that could be
realised by using the cheapest ICS via the cheapest
device (a pMDI) might well result in an increase in
other healthcare resource use through an increase
in exacerbations resulting from poorer control of
asthma from lack of adherence to treatment
regimens or inability to use a pMDI. Although we
cannot quantify this likely increase, concordance
with treatment in trials is around 80%, but in the
general population of children with asthma it may
be that fewer than 50% take the full amount of
prescribed medication (see Chapter 1). Addition
of a spacer device to the pMDI, or choosing a
more expensive delivery device that the patient
prefers and is able to use easily, might well
improve concordance, thus minimising other
healthcare resource use.
Summary of the cost analyses
At present, it is clear that BDP CFC-propelled
products are the cheapest product available for the
treatment of asthma in children. However, as CFC-
propelled products are phased out, the cost of ICS
treatment is likely to increase considerably. When
non CFC-propelled products are considered, then
there is less variation in the costs between the
three ICS, although BDP still appears to be
marginally cheaper than either BUD or FP. When
considering the cost-effectiveness of increasing the
dose of ICS alone or adding a LABA to a lower
dose of ICS, it is clear that the extra annual cost of
combination therapy varies enormously
depending on the exact ICS product used. For the
more expensive ICS products, their use at higher
dose is more expensive than some of the
combination inhaler products, whereas the use of
cheaper ICS products in preference to a
combination inhaler will be cost saving. Overall, it
should be noted that although the use of weighted
averages can provide a useful way of representing
the major differences between the different ICS
drugs and LABAs, they conceal the wide variations
in the cost of individual products. This means that
any generic conclusions about cost-effectiveness, at
the level of each ICS drug either versus another
ICS or an ICS/LABA combination, are not
possible as they are confounded by the sheer
number and differences in price of the products
available for each drug.
All of the comparisons described above have also
involved a number of simplifying assumptions,
including (1) the relative doses of different
products which are assumed to have equivalent
effectiveness, (2) the combinations of products
which are used to achieve any particular daily dose
level of ICS or ICS with LABA and (3) using 2005
community prescription sales as a way of producing
a weighted mean annual cost for each group of
drug preparations. For these reasons, and because
the range of available ICS and combination
products is currently undergoing considerable
change (with CFC-containing products being
phased out and some new HFA-propelled products
recently entering the market), the conclusions
should be viewed with appropriate caution.
Strengths and limitations of 
the review
Strengths and limitations of the
systematic review of clinical
effectiveness
In terms of strengths, this assessment has followed
transparent and accepted methods for conducting
systematic reviews. A protocol outlining the scope
and methods was agreed and published early on
in the process. An expert advisory group
comprising clinicians specialising in respiratory
medicine, GPs and health economists has provided
advice throughout the assessment and commented
on a draft of this report.
The effect of inhaler devices was outside the scope
of the present assessment. However, in order to
reduce any potential confounding in the
assessment of the different comparators under
consideration, only trials in which the inhaler type
and propellant were the same in each of the trial
arms were included in the systematic review.
In terms of limitations, it was not possible to
report every outcome measure reported in each of
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numerous ways of measuring and reporting
measures of asthma control. To achieve brevity, we
prioritised key measures from each of the relevant
outcomes. For example, of the various ways of
measuring lung function, we only reported FEV1
and morning and evening PEF, as these appeared
to be the most commonly used and clinically
meaningful. Consequently, in some trials the
primary outcome has not been reported in this
assessment if it was not a measure that had been
prioritised. Furthermore, some of the outcomes
that have been reported here may have been
secondary outcomes for which trials were not
necessarily powered to detect differences. This
should be borne in mind when interpreting the
findings.
It was not possible to conduct meta-analysis in
order to provide a quantitative estimate of
treatment effect. This would have provided greater
statistical power to show any potential differences.
Consequently, much of the assessment of clinical
effectiveness has been reported narratively.
The quality of reporting in the trial reports was
poor in places. For example, the brand name for
the inhaled steroids and the devices used to
dispense them were not always mentioned. Where
possible, we contacted authors for further
clarification, but time did not allow for this to be
conducted routinely.
As discussed earlier, in order to avoid duplication,
this assessment aimed to build upon previously
published evidence syntheses of the efficacy and
safety of ICS. The Cochrane Airways Review group
kindly made available data from their systematic
reviews. We performed data extraction and quality
assessment only on the trials that met our
inclusion criteria that were supplemental to the
Cochrane reviews. The completed data extraction
and quality assessment forms for these
supplemental studies are available in Appendix 4.
Further details of the remaining studies can be
found in the Cochrane reviews.73,187–190
The majority of the included trials tended to be of
short duration, and so do not provide data on the
long-term consequences of treatment for chronic
asthma or the longer term side-effects associated
with therapy.
No trials of treatment in children aged under
5 years have been identified for this review.
Conducting trials in young children can be
problematic in terms of obtaining consent and
assessing outcomes such as lung function and
symptoms. Since asthma in this population may
well respond differently to ICS and other
treatment options, it is of concern that there does
not appear to be a direct formal evidence base on
which to base clinical decisions. It was therefore
not possible to provide a stratified analysis to
examine the effects of ICS and/or LABA use in
infants and young children as requested in the
assessment scope.
No trials have been conducted in a paediatric
population that have assessed the effectiveness of
a combination inhaler containing FP/SAL versus
BUD/FF. Therefore, it is not possible to compare
the relative effectiveness and cost-effectiveness of
these treatments for chronic childhood asthma.
Grounding the review within the context of the
BTS/SIGN Guideline placed a number of
limitations on the comparisons between different
treatment strategies that could be assessed. For
example, the strategy of adding a LABA to an ICS
at Step 2 rather than Step 3 was outside the scope
of the present assessment. Such a strategy would
involve the instigation of combination therapy in a
potentially steroid-naïve population that have
been treated predominantly with a SABA. At
present such strategies are outside the
recommended guidance in the BTS/SIGN
Guideline.
Strengths and limitations of the
economic evidence and analyses
Economic analysis has been severely restricted as
we were unable to populate the cost–utility model
from the relevant trial data available to assess
cost–utility. Ideally, an economic evaluation in
asthma should capture the quality of life and cost
impacts both of different levels of control and
exacerbation severity and frequency, and also be
able to compare all potential treatments
concurrently. To some extent, therefore, all
existing evaluations, including those submitted by
industry sponsors to NICE, are limited.
Evaluations based solely on SFDs, for example,
may not adequately capture the full spectrum of
costs and disutility associated with other indicators
of poor control and exacerbations. Conversely,
evaluations dominantly based on exacerbations as
an outcome may not fully reflect differences in
costs and utility associated with varying levels of
‘non-exacerbation’ asthma control. In the absence
of established models that can include all relevant
technologies in a single evaluation and also
capture the consequences of differences in all
levels of control, most comparisons have focused
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mean annual treatment costs for each ICS and
LABA drug.
Strengths
The cost comparison approach that we adopted
was a pragmatic response to the lack of evidence
of differential clinical effectiveness for some
research questions. In the absence of a formal
model-based CUA or CEA, these comparisons
clearly illustrate the wide variation in possible
costs for each ICS drug, and how these vary by
product type/strength, daily dose and inhaler type.
Although we have chosen to show averages for
each ICS, we have put them in context by showing
both weighted and unweighted means and also the
cheapest and most expensive product for each ICS
at each dose level. With a view to other changes
currently taking place in the UK market for
asthma drugs, we have also generated estimates
with and without CFC-propelled products
included. 
Limitations
The main limitation of our economic analyses is
that they do not include a model-based CUA
which integrates all relevant cost and effectiveness
evidence relevant to the decision problems. This
omission is partly due to the nature of the
published trial evidence base for these decision
problems, but is also to do with the inherent
challenges of modelling the full spectrum of
asthma outcomes, from symptom control and
quality of life impacts to severe exacerbations.
All of the cost comparisons discussed above have
involved a number of necessary simplifying
assumptions including (1) the relative doses of
different ICS drugs which are currently assumed
to have equivalent effectiveness, (2) the exact mix
of products which would probably be used to
achieve any particular daily dose level of ICS or
ICS with LABA and (3) using 2005 community
prescription sales as a way of producing a
weighted mean annual cost for each group of drug
preparations. For these reasons, and because the
range of available ICS and combination products
is currently undergoing considerable change (with
CFC-containing products being phased out and
some new HFA-propelled BDP products recently
entering the market), the conclusions should be
viewed with appropriate and substantial caution.
Other considerations
As already discussed, the relevance to decision-
makers of trial-based evidence on the clinical
effectiveness of asthma treatments is often limited
by a range of factors to do with the characteristics
of the patients in the trials, or the inevitably
partial selection of drugs and inhaler devices 
that have mostly been compared. The evidence
base may therefore be on comparisons between
technologies that are not relevant within 
current clinical guidelines, focus on efficacy 
and safety rather than ‘real-world’ (e.g. 
adherence-diminished) effectiveness and be
conducted in patients who are specially selected 
to be able to comply or who are monitored 
more thoroughly than would be the case in 
routine clinical care. Furthermore, the fact that
most choices between different asthma drugs
involve a simultaneous choice of inhaler type 
(or, choice of inhaler device may effectively
determine the asthma drug ‘chosen’), creates
further difficulties in using an evidence base which
is largely aimed at comparing either drugs or
devices.
In addition to these difficulties, it may be that 
the average effectiveness results that clinical 
trials mainly produce are inappropriate in 
another more fundamental way. Asthma drug
treatment decisions are inherently reversible. 
Also, the drugs themselves are, in general, safe
(certainly at the low to moderate doses with 
which most people are managed). This is why
asthma treatment guidelines are implicitly 
based on an iterative approach of ‘trying out’ 
what works best in achieving symptom control 
for individual patients. Given such a clinical
context, with the possibility of multiple reversible
clinical decisions, there may be a legitimate
argument for retaining the current variety in
products, in terms of both drug types and 
inhaler devices, given acceptable variations in
average effectiveness and costs. In addition to
variations in people’s ability and willingness 
to use different inhaler devices effectively, it may
be that there are subtle differences in people’s
response to the different ICS drugs themselves 
(or to the addition of a LABA to an ICS) 
which mean that some individuals, for example,
respond more to particular ICS compounds than
others.
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he literature on the clinical and cost-
effectiveness of the three inhaled
corticosteroids, BUD, BDP and FP, used alone or
in combination with a LABA in the treatment of
chronic asthma in children aged under 12 years is
limited. The RCTs included in this review were
predominantly of one ICS comparator versus
another, used at doses within the range of Steps
2–4 of the BTS/SIGN Guideline. There was no
evidence available on whether the addition of a
LABA to a dose of ICS at a range within Step 2 of
the Guideline is more effective than increasing the
dose of ICS alone. No trials were identified that
assessed the relative effectiveness of the
combination treatments of ICS plus LABA
(Symbicort and Seretide) currently licensed for use
in children.
No evidence is available on the clinical
effectiveness of any of these treatments for
children under the age of 5 years.
ICS versus ICS
From the available evidence, the clinical
effectiveness and short-term safety of the three
inhaled corticosteroids, used at either low (Step 2)
or high (Step 4) dose is similar. As no cost–utility
model could be used to estimate cost-effectiveness
across all technologies, cost comparisons were
undertaken between the different ICS drugs. At the
starting dose of 200 µg/day, BDP tends to be the
cheapest ICS available, although when CFC-
propelled products are excluded FP products can
be the cheapest. At the higher doses of 400 and
800 µg/day, it remains the cheapest. When non-
CFC-propelled products are considered, the mean
annual cost of ICS therapy increases for all three
ICS, but overall cost differences between the drugs
diminish. However, the use of weighted averages to
represent the cost associated with each ICS tends to
conceal the wide variations in costs apparent
between the individual preparations of each drug
and the wide overlap in costs between the drugs.
ICS versus ICS + LABA
No evidence is available on clinical effectiveness of
ICS on its own versus ICS + LABA at a lower dose
of ICS. There is limited evidence that
ICS + LABA in a combination inhaler is more
effective than the same dose of ICS on its own.
When the weighted mean cost of all types of ICS
at increased dose is considered, only one of the
combination inhaler preparations (Seretide
Evohaler) is slightly cheaper than ICS at a 
two-fold increased dose. Compared with the 
lowest cost preparation for each ICS drug, 
both the combination inhalers are more 
expensive than the ICS products at increased
dose.
ICS plus LABA versus ICS plus
LABA
From the limited evidence available, there were no
significant differences in the clinical effectiveness
of ICS plus LABA delivered concurrently
compared with delivery in separate inhalers. Cost
comparison between the two regimens showed that
taking an ICS with a LABA as either of two
currently available combination products
(Symbicort and Seretide) is usually cheaper than
taking the relevant ingredient drugs in separate
inhalers.
The use of single inhaler therapy not only
provides a simpler treatment regimen, but may
also enhance concordance with maintenance ICS
therapy and diminish the potential use of a LABA
on its own. From this review, there appear to be no
significant clinical differences in effects between
the two modes of treatment delivery, and potential
cost savings to the NHS with use of a combination
inhaler compared with separate inhalers.
Based on a comparison of the costs only, BUD in
combination with FF (Symbicort Turbohaler) is
more expensive than both the FP/SAL (Seretide
Evohaler or Seretide Accuhaler) combination
drugs currently available.
Research recommendations
There is a clear lack of research in a number 
of areas that have been covered in the 
present assessment on the effectiveness and 
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Chapter 7
Conclusionscost-effectiveness of ICS used alone or in
combination with a LABA for the treatment of
chronic asthma in children under 12 years of age.
The diagnosis of asthma in young children is
extremely difficult, as viral wheeze is common in
young children. However, a scoping review, using
broad inclusion criteria, followed by research
synthesis as appropriate, is required to assess the
requirements for additional primary research on
the clinical effectiveness of treatment for asthma
in children aged under 5 years. Such a review
could also usefully include all treatment options,
pharmacological and non-pharmacological, for
asthma.
There is currently no trial evidence available to
inform the relative effectiveness of the two
combination inhalers of FP/SAL and BUD/FF
within a paediatric population. The results of this
assessment suggest that for FP/SAL there are no
significant differences in effectiveness in terms of
whether the drugs are delivered in a single inhaler
or concurrently in two separate inhalers. However,
as ease of treatment regimen may potentially
affect concordance, then a direct head-to-head
trial that compares the two combination therapies
of FP/SAL and BUD/FF is warranted.
No trials have assessed the relative effects of
increasing the dose of ICS or adding a LABA to a
lower dose of ICS if control is not maintained at
doses within Step 2 of the BTS/SIGN Guideline. It
is therefore important that the relative effects of
these two treatment strategies are compared
within a paediatric population, particularly given
concerns about the AEs of long-term ICS use.
Given the chronic nature of asthma and that
treatment may be necessary on a long-term basis
from childhood, it is important to assess whether
the addition of a LABA to a lower dose of ICS
could potentially be as effective as an increased
dose of ICS alone, but also be steroid sparing.
There is a need for the long-term AEs 
associated with ICS use to be assessed
systematically. Initial searches undertaken for 
this assessment indicate that there are at present
no good-quality systematic reviews available that
have assessed all potential long-term AEs
associated with the three different ICS
comparators. Published reviews have tended to
focus on the use of short-term RCT safety data
with a length of follow-up between 1 and 2 years.
Therefore, to assess adequately the longer term
sequel of ICS use, future reviews should aim to
examine studies of longer term follow-up, and use
appropriate data sources such as cohort,
case–control studies and registry data where
available.
Need for standardisation of outcome
measures and reporting
The evidence base that was assessed in this 
review was highly heterogeneous in terms of 
both the way in which outcome measures had 
been defined and measured and also in the 
detail in which results were reported. Future 
trials of treatment for chronic asthma in 
children should aim to standardise further the 
way in which outcome measures are defined.
There should be a greater focus on patient-
centred outcomes such as HRQoL and 
symptoms. This will provide a more meaningful
estimation of the impact of treatment on asthma
control.
Methods of reporting also require standardisation.
In particular where statistical results are presented,
means and SDs should be provided. This will
enable such studies to be included in quantitative
meta-analysis. The statistical methods of analysis
should also be explicitly stated. In addition, the
overall trial methods should be explicitly
documented and reported with adherence to the
CONSORT statement231 standard of reporting
being made a priority. 
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Expert advisory groupTechnology Assessment Report
commissioned by the NHS R&D
HTA Programme on behalf of the
National Institute for Health and
Clinical Excellence – Final
Protocol. 4 May 2006
1. Title of the project 
Inhaled corticosteroids and long-acting beta2
agonists for the treatment of chronic asthma in
children under the age of 12 years
2. Name of TAR teams and ‘leads’ 
Southampton Health Technology Assessment
Centre (SHTAC); Peninsula Technology
Assessment Group (PenTAG).
3. Plain English summary 
Chronic asthma is a condition that affects around
5 million children and adults in the UK. The
symptoms can include wheezing, shortness of
breath and general difficulties in breathing, and
can significantly disrupt daytime activity and the
ability to sleep well at night. Symptoms occur as a
result of tightening of the muscles surrounding
the airways and inflammation of the airway lining.
People with asthma need to maintain good control
of the condition to prevent worsening of
symptoms or ‘asthma attacks’. This can be
achieved by following a healthy lifestyle, reducing
contact with substances likely to aggravate asthma
and regular and correct use of prescribed drugs.
People with mild asthma can usually manage the
condition through use of an inhaler device
containing a short-acting beta2 agonist (e.g.
salbutamol) on an as-needed basis. Short-acting
beta2 agonists are known as bronchodilators and
work by relaxing the airway muscles to improve
the passage of air into the lungs. When this is not
enough to prevent worsening of symptoms,
patients may be prescribed one of the five
available corticosteroids, usually via a hand-held
inhaler. A corticosteroid works to reduce
inflammation in the airways. The corticosteroid is
usually inhaled twice per day for a given period of
months or longer (in addition to the inhaled
short-acting beta2 agonist, as needed) until asthma
is stabilised, at which time it may be gradually
reduced. Often a low, regular dose of inhaled
corticosteroid is needed to control symptoms.
Where asthma symptoms continue to be difficult
to control, the daily dose of inhaled corticosteroid
may be increased, or a third drug may be
prescribed. Inhaled long-acting beta2 agonists, of
which there are two, are commonly used in these
situations. They may be given separately or in a
combined inhaler containing the inhaled
corticosteroid. Other drugs may be given in cases
where control is still not adequate.
There are a number of different inhaled
corticosteroids and long-acting beta2 agonists
available, in different combinations and via
different inhalers. This study will systematically
summarise the results of clinical trials which
compare the different inhaled corticosteroids with
each other; trials which compare inhaled
corticosteroids combined with long-acting beta2
agonists with use of inhaled corticosteroids only;
and trials which compare the two different
combinations of inhaled corticosteroids and long-
acting beta2 agonists. The report will include an
economic evaluation, to compare the costs and
benefits of the different drugs to indicate whether
they represent good value for money from the
NHS and Personal Social Services (PSS)
perspective. 
4. Decision problem
The aim of this health technology assessment is to
assess the clinical-effectiveness and cost-
effectiveness of inhaled corticosteroids (ICS), and
inhaled corticosteroids in combination with long-
acting beta2 agonists (LABA), in the treatment of
chronic asthma in children aged under 12 years.
4.1. Background to asthma
Asthma is a condition characterised by
inflammation and narrowing of the bronchial
airways leading to wheezing, cough, chest
tightness, shortness of breath and general
difficulties in breathing. Symptoms vary from mild
intermittent wheezing or coughing to severe
attacks requiring hospital treatment. Severity can
be defined on the basis of symptoms, lung
function and incidence of exacerbations.
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Assessment protocolDefinitions vary but a classification system has
been proposed by the Global Initiative for Asthma
(GINA).P1,P2 Asthma can be triggered by a number
of stimuli, including allergens (e.g. animals, house
dust mite), environmental factors (e.g. dust,
pollution, tobacco smoke) and exercise. Family
history of asthma and low birth weight may
predispose people to the condition. Other risk
factors include increasing age, lower social class
and urban dwelling.P3 Although common in
children and young adults, asthma can affect
people at any time of life.
Asthma is distinguished from other related
conditions such as chronic obstructive pulmonary
disease (COPD) or emphysema through reversible
rather than progressive airway narrowing
(although evidence is emerging that people with
asthma do have some degree of decline in lung
function over time). In young children, it is often
not possible to measure lung function in order to
confirm variable airway obstruction; diagnosis is
then usually made on careful clinical history and
examination.
Prevalence has increased considerably over recent
decades, in both developed and developing
countries. Reasons are complex, reflecting
environmental and lifestyle factors. In the UK
there are 5.2 million people (9%) with asthma,
including 590,000 teenagers. In England and
Wales the number of people affected is around
4.7 million. Although severe exacerbations of
asthma may cause death, mortality from the
condition is relatively low compared with other
respiratory diseases such as COPD. Respiratory
disease accounts for greater mortality in the UK
(24% of total deaths) than coronary heart disease
(21%) or non-respiratory cancer (19%). However,
asthma is responsible for only 1% of respiratory
deaths.P3
4.2. Management
The management of asthma includes several inter-
linked approaches including medication (e.g.
bronchodilators, corticosteroids), lifestyle
modification, environmental changes (e.g.
minimising the impact of allergens in the home or
workplace), patient education (e.g. to encourage
self-management and improve concordance with
medication) and regular monitoring to assess
disease control. Management is primarily the
responsibility of the GP in collaboration with the
patient, although specialist intervention may be
required in severe cases. The aims of treatment are
to relieve symptoms (e.g. wheeze, cough), improve
health-related quality of life (including ability to
work, study or sleep), improve lung function [i.e.
forced expiratory volume 1 (FEV1); peak
expiratory flow rate (PEF)], minimise the
requirement for relief (e.g. short-acting beta2
agonists) and rescue (oral corticosteroids)
medication and reduce adverse effects associated
with medication.
The British Thoracic Society (BTS), in
collaboration with the Scottish Intercollegiate
Guidelines Network (SIGN), have published
clinical guidelines on asthma.P4,P5 The guidelines
cover a variety of aspects of management,
including pharmacological management. They
propose a stepwise approach to achieving
symptom control (Appendix 9.1). Treatment is
initiated at the step most appropriate to the initial
severity of asthma and the person’s day-to-day
needs, with the aim of achieving early control of
symptoms. Control is maintained by stepping up
treatment as necessary and stepping down when
control is good.
First-line treatment in mild intermittent asthma is
with an inhaled short-acting beta2 agonist, as
required for symptom relief (e.g. salbutamol or
terbutaline). Treatment is stepped up with the
introduction of regular preventer therapy with ICS
in addition to symptomatic use of an inhaled
short-acting beta2 agonist (Step 2). If necessary, a
long-acting beta2 agonist (LABA) is added (but not
in children under the age of 4 years, for whom a
leukotriene receptor agonist should be considered,
and in children under 2 years old, where referral
to a respiratory paediatrician should be
considered) (Step 3). If control is still not
adequate, the dose of the inhaled corticosteroid
can be increased, in addition to introduction of a
fourth drug such as a theophylline or a
leukotriene receptor agonist (children aged
5–12 years) (Step 4). For children aged under
5 years, Step 4 involves referral to a respiratory
paediatrician. For children aged 5–12 years, if
response remains poor specialist care may be
initiated with regular use of oral corticosteroids
(e.g. prednisolone), in addition to the other drugs
(Step 5).
In 2000, NICE issued guidance to the health
service in England and Wales on the use of inhaler
devices in children with chronic asthma aged
under 5 years (Guidance No. 10), and in 2002
guidance for older children (aged 5–15 years,
Guidance No. 38).
For children under the age of 5 years with chronic
stable asthma, both corticosteroids and
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delivered by a pressurised metered dose inhaler
(pMDI) and a spacer system, with a facemask
where necessary. Where this combination is not
clinically effective for the child and depending on
the child’s condition, nebulised therapy may be
considered. In the case of children aged 3–5 years,
a dry powder inhaler (DPI) may also be
considered.
For children aged 5–15 years, a press-and-breathe
pMDI and suitable spacer device are
recommended as the first-line choice for the
delivery of inhaled corticosteroids. If adherence is
likely to be poor, then other alternatives should be
considered. For bronchodilators, a wider range of
devices should be considered to take account of
their more frequent spontaneous use, the greater
need for portability and the clear feedback that
symptom response provides to the device user.
Over-arching principles when choosing an inhaler
include the therapeutic need for the particular
drug, the ability of the child to develop and
maintain an effective technique with the specific
device and the suitability of a device for the child’s
and carer’s lifestyles, considering factors such as
portability and convenience and the child’s
preference for and willingness to use a particular
device.
A planned update of both sets of guidance in 2005
was not undertaken as it was found that little new
evidence had emerged since the first guidance.
They have both now been moved to the Institute’s
‘static’ list of appraisals, which will not routinely be
updated.
4.2.1. Inhaled corticosteroids (ICS)
ICS work to reduce bronchial inflammation. They
are recommended for prophylactic treatment of
asthma when patients are using a short-acting
beta2 agonist more than three times per week or if
symptoms disturb sleep more than once per week,
or if the patient has suffered exacerbations in the
last 2 years requiring a systemic corticosteroid or a
nebulised bronchodilator. Corticosteroid inhalers
should be used regularly for maximum benefit.
There are currently three ICS licensed in the UK
for children (see Appendix 9.2 for details of
delivery devices. NB. High-dose inhalers are not
licensed in children):
● beclometasone dipropionate [AeroBec (3M),
Asmabec Clickhaler (Celltech), Beclazone Easi-
Breathe (IVAX), Becloforte (Allen and
Hanburys), Beclometasone Cyclocaps (APS),
Becodisks (Allen and Hanburys), Becotide
(Allen and Hanburys), Easyhaler (Ranbaxy),
Filair (3M) and Pulvinal Beclometasone
Dipropionate (Trinity)]
● budesonide [Budesonide Cyclocaps (APS),
Easyhaler (Ranbaxy), Novolizer (Viatris) and
Pulmicort (AstraZeneca)]
● fluticasone propionate [Flixotide (Allen and
Hanburys)]. 
Beclometasone dipropionate, budesonide and
fluticasone propionate have been used for some
time, whereas ciclesonide is relatively new.
Ciclesonide [Alvesco (Altana)] is included in the
scope issued by NICE with the expectation that it
may receive an extension to its marketing
authorisation to include children under the age of
12 years within the time frame for the appraisal.
There are a variety of delivery systems including
pressurised metered-dose inhalers (pMDI), breath-
activated pMDIs, dry powered formulations and
nebulisers. Chlorofluorocarbons (CFCs) have been
the traditional propellant in pMDIs, but with the
phasing out of CFCs they are being replaced by
ozone-friendly hydrofluoroalkanes (HFAs). Spacer
chambers can be attached to pMDIs to make them
easier to use and improve drug delivery to the
lungs.
Standard daily recommended doses of ICS in
children are 100 micrograms (µg) twice daily for
budesonide and beclometasone dipropionate and
50 µg twice daily for fluticasone propionate.P6 The
BTS recommends titrating to the lowest dose at
which effective control is maintained.P5,P7 In
children this can be up to 400 µg/day (for
budesonide or beclometasone dipropionate).P5
Fluticasone is considered clinically equivalent to
budesonide or beclometasone dipropionate at half
the dose (however, HFA-propelled beclometasone
dipropionate is regarded as clinically equivalent to
fluticasone at the same dose).
If maintenance therapy with an ICS does not
adequately control symptoms, there are a number
of potential treatment options. One is to continue
with the ICS but to increase the dose to the higher
end of the recommended range (e.g. up to 400 µg
in children aged 5–12 years or 200 µg in children
younger than 5 years). However, this increases the
risk of adverse effects (such as growth and adrenal
suppression). An alternative is to add a LABA to
ICS (but not in children younger than 4 years
old). Adding a LABA may be preferential as
results of dose–response studies suggest that
higher doses of ICS may worsen the overall
therapeutic ratio (that is, the ratio of the
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minimally curative or effective dose).P8
4.2.2. Long-acting beta2 agonists (LABA)
Two LABAs are licensed for use in the UK,
salmeterol (Serevent) and formoterol (Foradil;
Oxis). Like short-acting beta2 agonists, LABAs
have a bronchodilatory action, expanding the
bronchial airways to improve the passage of air.
They are recommended in addition to existing
inhaled corticosteroid therapy, rather than
replacing it. They can be used in combination with
inhaled corticosteroids in separate inhalers or
combined in one inhaler. There are two licensed
combination inhalers in the UK:
● budesonide + formoterol fumarate (Symbicort) 
● fluticasone propionate + salmeterol (as
xinafoate) (Seretide).
Budesonide and formoterol fumarate can be used
only in children aged over 6 years, whereas
fluticasone propionate and salmeterol can be used
in children as young as 4 years old. The two
LABAs differ chemically, with formoterol
associated with a more rapid onset of action.
A typical dose of fluticasone propionate/salmeterol
in children over 4 years old is 100/50 µg/day,
titrated up to 200/100 µg/day if necessary. 
A typical dose of budesonide/formoterol in
children over 6 years old is 80/4.5 µg once daily,
titrated up to 320/18 µg/day in severe cases.
Given the vast range of options available in the
pharmacological management of chronic asthma,
an assessment of clinical effectiveness and cost-
effectiveness of the various strategies is required.
Specifically, an assessment is needed of the relative
benefits and adverse effects of the different ICS,
and of the two ICS and LABA combination
inhalers. It is also necessary to assess the benefits
and adverse effects of combined treatment with an
ICS and a LABA compared with continuing ICS
alone (including increasing the dose of the ICS) in
situations of worsening asthma control.
5. Report methods for synthesis of
evidence of clinical effectiveness 
5.1. Search strategy 
● A search strategy will be devised and tested by
an experienced information scientist. The
strategy will be designed to identify two
different types of study: (1) studies reporting
the clinical effectiveness of inhaled
corticosteroids and long-acting beta2 agonists;
and (2) studies reporting the cost-effectiveness
of inhaled corticosteroids and long-acting beta2
agonists. The draft search strategy for
MEDLINE is given in Appendix 9.3.
● A number of electronic databases will be
searched, including: The Cochrane Database of
Systematic Reviews (CDSR); The Cochrane
Central Register of Controlled Trials; NHS
CRD (University of York) Database of Abstracts
of Reviews of Effectiveness (DARE) and the
NHS Economic Evaluation Database (NHS
EED); MEDLINE (Ovid); EMBASE (Ovid);
National Research Register; Current Controlled
Trials; ISI Proceedings; Web of Science; and
BIOSIS. Bibliographies of related papers will be
assessed for relevant studies where possible. 
● The manufacturers’ submissions to NICE will be
assessed for any additional studies. 
● Experts will be contacted to identify additional
published and unpublished references. 
● Searches will be carried out from the inception
date of the database until February/March 2006
(for clinical effectiveness and cost-effectiveness
studies). All searches will be limited to the
English language. The searches will be updated
around October 2006. 
● Searches for other evidence to inform cost-
effectiveness modelling will be conducted as
required (see Section 6.5.2).
5.2. Inclusion and exclusion criteria
5.2.1. Intervention
Studies reporting evaluations of the following
inhaled corticosteroids will be included:
● beclometasone dipropionate
● budesonide
● ciclesonide (subject to licensing)
● fluticasone propionate.
Studies reporting evaluations of the following
inhaled corticosteroids combined with long-acting
beta2 agonists in the same inhaler (i.e.
combination inhalers) will be included:
● budesonide + formoterol fumarate (in children
aged 6 years and over)
● fluticasone propionate + salmeterol (as
xinafoate) (in children aged 4 years and over). 
Studies reporting treatment duration of 4 weeks or
less will not be included.
5.2.2. Comparators
● The inhaled corticosteroids will be compared
with each other. 
● The combination inhalers will be compared
with each other and with inhaled corticosteroids
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corticosteroids and long-acting beta2 agonists
administered separately in terms of any adverse
events likely to impact on costs and cost
effectiveness. 
● Studies testing different doses of the same agent
or the same agent delivered by different inhaler
devices will not be included. 
5.2.3. Types of studies
● Fully published randomised controlled trials
(RCTs) or systematic reviews of RCTs. Double
blinding is not a prerequisite for inclusion,
although blinding will be assessed as part of
critical appraisal (see Section 5.3). Indicators of
a ‘systematic’ review include an explicit search
strategy and inclusion/exclusion criteria.
● Studies published as abstracts or conference
presentations from 2004 onwards will be
included in the primary analysis of clinical and
cost-effectiveness only if sufficient details are
presented to allow an appraisal of the
methodology and assessment of results. 
5.2.4. Population
● Children aged under 12 years with chronic
asthma. Studies in which the patient group is
asthmatics with a specific related co-morbidity
(e.g. cystic fibrosis) will not be included. 
● Where data are available, clinical effectiveness
and cost-effectiveness will be reported for
patient subgroups, in terms of disease severity
and age. Concordance according to different
patient sub-groups will be assessed where data
allow.
● Studies reporting the treatment of acute
exacerbations of asthma will not be included. 
5.2.5. Outcomes
● Studies reporting one or more of the following
outcomes will be included:
– objective measures of lung function (e.g.
FEV1, PEF)
– symptom-free days and nights
– incidence of mild and severe acute
exacerbations (e.g. mild – requiring
unscheduled contact with healthcare
professional; severe – requiring
hospitalisation, short-term ‘rescue’ use of
systemic corticosteroids or visit to accident
and emergency department)
– adverse effects of treatment (e.g. growth
suppression)
– health-related quality of life
– mortality.
● Titles and abstracts of studies identified by
searching will be screened by one reviewer
based on the above inclusion/exclusion criteria.
A second reviewer will check a random 10% of
these with any discrepancies resolved through
discussion and involvement of a third reviewer
where necessary.
● Full papers of studies which appear potentially
relevant on title or abstract will be requested for
further assessment. All full papers will be
screened independently by one reviewer and
checked by a second, and a final decision
regarding inclusion will be agreed. Any
discrepancy will be resolved by discussion with
involvement of a third reviewer where necessary. 
5.3. Critical appraisal and data extraction 
● A number of recently updated Cochrane
systematic reviews of the effectiveness of
comparisons of ICSP9–P11 and ICS with LABAP12
have been published. Where possible, these and
other high-quality systematic reviews will be used
to assess clinical effectiveness. RCTs published
since the reviews were last updated would be
prioritised for full data extraction and critical
appraisal. The findings of the systematic reviews
and the supplemental RCTs will be used together
to inform the assessment of clinical effectiveness. 
● Data extraction and critical appraisal will be
performed by one reviewer using a standardised
data extraction form (see Appendix 9.4). A
second reviewer will check the form for accuracy
and completeness. Discrepancies will be
resolved by discussion, with involvement of a
third reviewer where necessary.
● The quality of included RCTs and systematic
reviews will be assessed using NHS CRD
(University of York) criteriaP13 (see
Appendix 9.5).
5.4. Methods of analysis/synthesis
● Clinical effectiveness studies will be synthesised
through a narrative review with tabulation of
results of included studies.
● Where data are of sufficient quantity, quality
and homogeneity, a meta-analysis of the clinical
effectiveness studies will be performed, using
appropriate software. 
● To minimise clinical heterogeneity, the synthesis
will seek to group together studies reporting
similar populations and interventions.
– For example, comparisons of different ICS
delivered via pMDI may be considered
separately to those comparing different ICS
delivered by dry powder formulations. 
– Similarly, comparisons of ICS where a CFC-
propelled pMDI is used may be grouped
separately to those where the propellant is
HFA, given suggested differences in potency.P11
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account as far as the evidence allows,
particularly where a study compares a CFC
pMDI ICS with an HFA pMDI ICS. 
6. Methods for synthesising evidence of
cost-effectiveness 
6.1. Search strategy
Refer to Appendix 9.3 for details of the draft
search strategy for MEDLINE. The sources to be
searched are similar to those used in the clinical
effectiveness review (see Section 5.1). All searches
will be limited to the English language.
6.2. Inclusion and exclusion criteria
The inclusion and exclusion criteria for the
systematic review of economic evaluations will be
identical with those for the systematic review of
clinical effectiveness, except that:
● Non-randomised studies may be included (e.g.
decision model based analyses or analyses of
patient-level cost and effectiveness data
alongside observational studies).
● Full cost-effectiveness analyses, cost–utility
analyses, cost–benefit analyses and
cost–consequence analyses will be included.
(Economic evaluations which only report
average cost-effectiveness ratios will only be
included if the incremental ratios can be easily
calculated from the published data.)
Based on the above inclusion/exclusion criteria,
study selection will be made independently by two
reviewers. Discrepancies will be resolved by
discussion, with involvement of a third reviewer
when necessary.
6.3. Study quality assessment
The methodological quality of the economic
evaluations will be assessed using accepted
frameworks such as the international consensus-
developed list of criteria developed by Evers and
colleaguesP4 and Drummond and colleagues.P14
For any studies based on decision models we will
also make use of the checklist for assessing good
practice in decision analytic modelling of 
Philips and colleagues.15 We will examine recent
published studies which are carried out from 
the UK NHS and PSS perspective in more 
detail.
6.4. Data extraction strategy
Data will be extracted by one researcher into two
summary tables: one to describe the study design
of each economic evaluation and the other to
describe the main results.
● The following data will be extracted into the
study design table: author and year; model type
or trial based; study design [e.g. cost-
effectiveness analysis (CEA) or cost–utility
analysis (CUA)]; service setting/country; study
population; comparators; research question;
perspective, time horizon and discounting;
main costs included; main outcomes included;
sensitivity analyses conducted; and other
notable design features.
● For modelling-based economic evaluations a
supplementary study design table will record
further descriptions of model structure (and
note its consistency with the study perspective,
and knowledge of disease/treatment 
processes), sources of transition and chance
node probabilities, sources of utility values,
sources of resource use and unit costs, 
handling of heterogeneity in populations and
evidence of validation (e.g. debugging,
calibration against external data, comparison
with other models).
● For each comparator in the study, the following
data will be extracted into the results table:
incremental cost; incremental
effectiveness/utility and incremental cost-
effectiveness ratio(s). Comparators excluded on
the basis of dominance or extended dominance
will also be noted. The original authors’
conclusions will be noted, and also any issues
they raise concerning the generalisability of
results. Finally, the reviewers’ comments on
study quality or generalisability (in relation to
the NICE scope) will be recorded.
6.5. Synthesis of evidence on costs and effectiveness
6.5.1. Published and submitted economic
evaluations
Narrative synthesis, supported by the data
extraction tables, will be used to summarise the
evidence base from published economic
evaluations and sponsor submissions to NICE.
6.5.2. Economic modelling 
A new cost-effectiveness analysis will be carried out
from the perspective of the UK NHS and PSS
using a decision analytic model. The evaluation
will be constrained by available evidence. If
possible, the incremental cost-effectiveness of the
intervention drug classes and the specified
comparators will be estimated in terms of cost per
quality-adjusted life-year (QALY) gained, as well as
the cost per acute exacerbation avoided.
Model structure will be determined on the basis 
of research evidence and clinical expert 
opinion of:
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in children (i.e. knowledge of the natural
history of the disease)
● the main diagnostic and care pathways for
patients in the UK NHS context [both with and
without the intervention(s) of interest] and
● the disease states or events that are most
important in determining patients’ clinical
outcomes, quality of life and consumption of
NHS or PSS resources.
For example, we will need to consider developing
a natural history model of chronic asthma which
could reflect factors such as: patient age, asthma
severity (e.g. FEV1, PEF, frequency of acute
exacerbations), whether their asthma is
predominantly self-managed or GP/primary care
nurse managed. The extent to which the model is
able to reflect these various factors fully will
depend on the available research literature. The
extent to which the model needs to reflect these
factors will depend on how plausible it is that they
impact on either the effectiveness or cost impacts
of the interventions.
Parameter values will be obtained from relevant
research literature, including our own systematic
review of clinical-effectiveness. Where required
parameters are not available from good-quality
published studies in the relevant patient group we
may use data from sponsor submissions to NICE
or expert clinical opinion. Sources for parameters
will be stated clearly.
Resource use will be specified and valued from the
perspective of the NHS and PSS in 2005 (this is
the most recent year for which NHS National
Schedule of Reference Cost data will be available).
Cost data will be identified from NHS and PSS
reference costs or, where these are not relevant,
they will be extracted from published work or
sponsor submissions to NICE as appropriate. If
insufficient data are retrieved from published
sources, costs may be obtained from individual
NHS Trusts or groups of Trusts.
To capture health-related quality of life effects,
utility values will be sought directly from 
the relevant research literature. Ideally utility
values will be taken from studies that have been
based on ‘public’ (as opposed to patient or
clinician) preferences elicited using a choice-based
method.
Analysis of uncertainty will focus on cost–utility,
assuming the cost per QALY can be estimated.
Uncertainty will be explored through one-way
sensitivity analysis and, if the data and modelling
approach permit, probabilistic sensitivity analysis
(PSA). The outputs of PSA will be presented both
using plots on the cost-effectiveness plane and
cost-effectiveness acceptability curves.
The simulated population is likely to be separate
birth cohorts of children aged between 2 and
11 years. Where possible, the base-case results will
be presented separately for grouped age bands, at
least for 2–4-year-olds and 5–11-year-olds. The
time horizon for our analysis will be between 1
and 5 years, sufficiently long to reflect both the
chronic nature of the disease and estimate
differences in rare outcomes, such as asthma-
related deaths.
Searches for additional information regarding
model parameters, patient preferences and 
other topics not covered within the clinical
effectiveness and cost-effectiveness reviews will 
be conducted as required (e.g. health-related
quality of life, epidemiology and natural history).
This is in accordance with the methodological
discussion paper produced by InterTASC in
January 2005.
7. Handling the company submission(s) 
All information submitted by the
manufacturers/sponsors as part of the NICE
appraisal process will be considered if received by
the TAR team no later than 2 August 2006.
Information arriving after this date will not be
considered.
Economic evaluations included in sponsors’
submission will be assessed against the NICE
guidance for the Methods of Technology
Appraisals220 and will also be assessed for clinical
validity, reasonableness of assumptions and
appropriateness of the data used.
Incremental cost-effectiveness ratios (ICERs)
estimated from consultee models will be compared
with results from the Assessment Group’s analysis,
and reasons for large discrepancies in estimated
ICERs will be explored and, where possible,
explained.
Any ‘commercial-in-confidence’ data taken from a
company submission will be underlined and
highlighted in the assessment report (followed by
an indication of the relevant company name, e.g.
in brackets).
8. Competing interests of authors 
There are no competing interests. 
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9.1. SIGN/BTS pharmacological management
pathway for chronic asthma.
9.2. Inhaled steroids and devices.
9.3. MEDLINE search strategy.
9.4. Data extraction form (RCTs and systematic
reviews).
9.5. Quality assessment criteria (RCTs and
systematic reviews).
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134Clinical effectiveness search
strategy: corticosteroids in
asthma 
The following databases were searched:
The Cochrane Database of Systematic Reviews
(CDSR)
The Cochrane Central Register of Controlled
Trials
CRD (University of York) Database of Abstracts of
Reviews of Effectiveness (DARE), NHS
Economic Evaluation Database (NHS EED)
MEDLINE (Ovid)
EMBASE (Ovid)
National Research Register
Current Controlled Trials
Web of Knowledge Science Citation Index and ISI
Proceedings
BIOSIS
Ovid MEDLINE 1966–2006. Run on 15 February
2006; update search run on 26 September 2006:
1 exp asthma/
2 asthma.ti,ab. 
3 1 or 2
4 exp randomized controlled trials/
5 exp random allocation/ 
6 controlled clinical trials/
7 randomized controlled trial.pt.
8 controlled clinical trial.pt.
9 exp double blind method/
10 exp single blind method/ 
11 (randomiz$ or randomis$). 
12 placebo.ti,ab.
13 (singl$ or doubl$ or tripl$ or trebl$ or
blind$).ti,ab. 
14 (trial$ or study or studies or method$).ti,ab. 
15 13 or 14
16 meta analysis/
17 (meta analys?s or metaanalys?s).ab,pt,ti.
18 (systematic$ adj2 (review$ or overview$)).ti,ab.
19 or/16-18 28348
20 or/4-12,15,19
21 (letter or editorial or comment).pt.
22 20 not 21
23 3 and 22
24 beclomethasone/
25 bdp.ti,ab.
26 budesonide/
27 (beclomet?asone or budesonide or ciclesonide
or fluticasone or mometasone).mp.
28 (asmabec or belclazone or cyclocaps or
becodisks or becotide or filair or qvar or
pulvinal or pulmicort or flixotide or aerobec or
becloforte or novoliser or viatris or alvesco or
asmanex or novolizer or easyhaler or
symbicort or seretide or serevent or atimos or
foradil).mp.
29 exp glucocorticoids/
30 (corticosteroid$ or glucocorticoid$ or
steriod$).ti,ab. 
31 or/24-30
32 31 not 21
33 23 and 32
34 limit 33 to (humans and english language)
35 or/24-28
36 35 not 21
37 23 and 36
38 limit 37 to (humans and english language)
Cost-effectiveness search strategy:
corticosteroids in asthma
The search strategy was translated and run in:
MEDLINE (Ovid) 
MEDLINE in Process (Ovid)
EMBASE (Ovid)
Cochrane Database of Systematic Reviews 
(CDSR)
Cochrane Central Register of Controlled Trials
(CCTR)
Science Citation Index (Web of Knowledge)
CRD NHS Economic Evaluation Database, DARE
and HTA databases and EconLit.
Ovid MEDLINE 1966 to March Week 1 2006.
Searched on 9 March 2006; update search on 
6 October 2006:
1 exp Asthma/)
2 asthma.ti,ab 
3 1 or 2 
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Appendix 3
Search strategies and databases searched for the 
clinical and cost-effectiveness reviews4 exp ECONOMICS/ 
5 exp ECONOMICS, HOSPITAL/ 
6 exp ECONOMICS, PHARMACEUTICAL/ 
7 exp ECONOMICS, NURSING/ 
8 exp ECONOMICS, DENTAL/ 
9 exp ECONOMICS, MEDICAL/ 
10 exp "Costs and Cost Analysis"/ 
11 Cost-Benefit Analysis/ 
12 VALUE OF LIFE/ 
13 exp MODELS, ECONOMIC/ 
14 exp FEES/ and CHARGES/ 
15 exp BUDGETS/ 
16 (economic$ or price$ or pricing or financ$ or
fee$ or pharmacoeconomic$ or pharma
economic$).tw. 
17 (cost$ or costly or costing$ or costed).tw. 
18 (cost$ adj2 (benefit$ or utilit$ or minim$ or
effective$)).tw. 
19 (expenditure$ not energy).tw. 
20 (value adj2 (money or monetary)).tw. 
21 budget$.tw. 
22 (economic adj2 burden).tw. 
23 "resource use".ti,ab.
24 or/4-22 
25 news.pt. 
26 letter.pt. 
27 editorial.pt. 
28 comment.pt. 
29 or/25-28 
30 24 not 29 
31 3 and 30 
32 Beclomethasone/ 
33 budesonide/ 
34 bdp.ti,ab. 
35 (beclometasone or beclomethasone or
budesonide or ciclesonide or fluticasone or
mometasone).mp. 
36 (pulmicort or flixotide or asmanex or novoliser
or becotide or asmabec or belclazone or
cyclocaps or becodisks or filair or qvar or
pulvinal or aerobec or becloforte or viatris or
alvesco).mp. 
37 32 or 33 or 34 or 35 or 36 
38 31 and 37 
39 limit 38 to (humans and english language)
Quality of life search strategy:
asthma in adults and children
This search strategy was translated and run in:
MEDLINE (Ovid)
MEDLINE in Process (Ovid)
EMBASE
Cochrane Database of Systematic Reviews and
Cochrane Central Register of Controlled Trials
(CDSR and CCTR)
Ovid MEDLINE 1966 to May Week 1 2006.
Searched on 11 May 2006; update search run on 
6 October 2006:
1 exp Asthma/
2 asthma.ti,ab. 
3 1 or 2 
4 value of life/
5 quality adjusted life year/ 
6 quality adjusted life.ti,ab. 
7 (qaly$ or qald$ or qale$ or qtime$).ti,ab. 
8 disability adjusted life.ti,ab. 
9 daly$.ti,ab. 
10 health status indicators/ 
11 (sf36 or sf 36 or short form 36 or shortform 36
or sf thirtysix or sf thirty six or shortform
thirstysix or shortform thirty six or short form
thirty six or short form thirtysix or short form
thirty six).ti,ab. 
12 (sf6 or sf 6 or short form 6 or shortform 6 or sf
six or sfsix or shortform six or short form
six).ti,ab. 
13 (sf12 or sf 12 or short form 12 or shortform 12
or sf twelve of sftwelve or shortform twelve or
short form twelve).ti,ab. 
14 (sf16 or sf 16 or short form 16 or shortform 16
or sf sixteen or sfsixteen or shortform sixteen
or short form sixteen).ti,ab.
15 (sf20 or sf 20 or short form 20 or shortform 20
or sf twenty or sftwenty or shortform twenty or
short form twenty).ti,ab. 
16 (euroqol or euro qol or eq5d or eq 5d).ti,ab. 
17 (hql or hqol or h qol or hrqol or hr qol).ti,ab. 
18 (ACQ or asthma control questionnaire$).ti,ab.
19 (AQLQ or asthma quality of life
questionnaire$).ti,ab. 
20 (SGRQ or (St George$ adj5 Respiratory
Questionnaire$)).ti,ab. 
21 (hye or hyes).ti,ab. 
22 health$ year$ equivalent$.ti,ab. 
23 health utilit$.ab. 
24 (hui or hui1 or hui2 or hui3).ti,ab. 
25 disutil$.ti,ab. 
26 rosser.ti,ab. 
27 quality of well being.ti,ab. 
28 quality of wellbeing.ti,ab. 
29 qwb.ti,ab. 
30 willingness to pay.ti,ab. 
31 standard gamble$.ti,ab. 
32 time trade off.ti,ab. 
33 time tradeoff.ti,ab. 
34 tto.ti,ab. (221)
35 (index adj2 well being).mp. 
36 (quality adj2 well being).mp. 
37 (health adj3 utilit$ ind$).mp. [mp=title,
original title, abstract, name of substance word,
subject heading word] 
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13638 ((multiattribute$ or multi attribute$) adj3
(health ind$ or theor$ or health state$ or
utilit$ or analys$)).mp. 
39 quality adjusted life year$.mp. 
40 (15D or 15 dimension$).mp. 
41 (12D or 12 dimension$).mp. 
42 rating scale$.mp. 
43 linear scal$.mp. 
44 linear analog$.mp.
45 visual analog$.mp. 
46 (categor$ adj2 scal$).mp. 
47 or/4-46
48 (letter or editorial or comment).pt. 
49 47 not 48 
50 3 and 49
51 limit 50 to english language 
Adverse events searches:
corticosteroids for asthma
This search strategy was translated and run in:
MEDLINE (Ovid) 
MEDLINE in Process (Ovid)
EMBASE
Cochrane Database of Systematic Reviews 
Cochrane Central Register of Controlled Trials
and DARE.
Database: Ovid MEDLINE 1966 to May Week 3
2006. Searched 26 May 2006:
1 exp Asthma/ 
2 asthma.ti,ab. 
3 1 or 2 
4 (beclometasone or beclomethasone or
budesonide or ciclesonide or fluticasone or
mometasone).mp. 
5 (pulmicort or flixotide or asmanex or novoliser
or becotide or asmabec or belclazone or
cyclocaps or becodisks or filair or qvar or
pulvinal or aerobec or becloforte or viatris or
alvesco).mp. 
6 Beclomethasone/ae, po, to 
7 budesonide/ae, po, to 
8 Adrenal Cortex Hormones/ad, ae, po, to
[Administration & Dosage, Adverse Effects,
Poisoning, Toxicity] 
9 exp *Pregnenediones/ae, to [Adverse Effects,
Toxicity] 
10 steroid$.ti,ab. 
11 (inhal$ or oral).ti,ab. 
12 (toxicity or poisoning or adverse effects).fs. 
13 10 and 11 and 12 
14 4 and 12 
15 5 and 12 
16 6 or 7 or 8 or 9 or 13 or 14 or 15 (
17 (safe or safety).ti,ab. 
18 side effect$.ti,ab. 
19 tolerability.ti,ab.
20 toxicity.ti,ab. 
21 (adverse adj3 (effect or effects or reaction or
reactions or event or events or outcome or
outcomes or consequence$)).ti,ab. 
22 exp Dose-Response Relationship, Drug/
23 17 or 18 or 19 or 20 or 21 or 22 
24 long term.ti,ab. (296250)
25 short term.ti,ab. (79427)
26 16 and 23 and 24 and 3 
27 16 and 23 and 25 and 3
Healthcare resource use and
asthma severity or symptom
control searches
This search strategy was translated and run in
Ovid MEDLINE, Ovid MEDLINE in Process and
Ovid EMBASE.
Ovid MEDLINE 1966 to July Week 4 2006.
Searched 2 August 2006:
1 "healthcare resource use".mp. 
2 exp Health Care Costs/ 
3 economics/ or exp resource allocation/ 
4 hcru.ab,ti. 
5 health care utilisation.mp
6 1 or 2 or 3 or 4 or 5
7 "Anti-Asthmatic Agents"/ 
8 Asthma/ 
9 asthma$.ti,ab.
10 Asthma, Exercise-Induced/
11 7 or 8 or 9 or 10
12 "Drug Administration Schedule"/
13 "Needs Assessment"/
14 "Severity of Illness Index"/ 
15 (severe$ or severity).ti,ab. 
16 (symptom$ adj3 control$).mp
17 (asthma adj3 control$).mp
18 exp disease management/
16 or/12-18 
17 6 and 11 and 16 
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Appendix 4
Systematic review of clinical effectiveness: 
data extraction and quality assessment forms
Study Treatment Participants Outcomes
continued
Random groups
Group A:
n = 15
Drug(s): BUD
Dose: 400 µg/day
Delivery: inhalation
Duration: I year
Group B: 
n = 15
Drug(s): FP
Dose: 250 µg/day
Delivery: inhalation
Duration: I year
A third control group
Group C: 
n = 30
Drug(s): NA
Dose: NA
Delivery: NA
Duration: I year
Run-in period: 
Duration: not reported
ICS: not reported
Relief: not reported
Additional treatment
allowed:
Relief: not reported
Other: not reported
Number randomised: 
30
Sample attrition/drop-out:
Not reported
Sample cross-overs:
Not reported
Inclusion/exclusion criteria:
• Not reported. The study sample
was children with moderate
asthma who were followed up by
the investigators. (Asthma was
diagnosed according to guidelines
for the diagnosis and management
of asthma from the National
Institutes of Health, National
Heart, Lung and Blood Institute)
Baseline characteristics:
Summarising groups A and B, without
including the third group C
• Age: mean (range) = 10.1
(6–13) years
• Male:female = 17:13
• Symptom score = 5.6 (0.5)
• Pulmonary functions: mean (SE or
SD)
– VC = 66.6 (8.7)
– PEF = 62.4 (5.5)
– FEV1 = 60.0 (9.4)
• Bone metabolism: mean 
– calcium (mg/dl) = 9.55
– phosphorus (mg/dl) = 4.35
– ALP (IU/l) = 468.5
– BMD (g/cm2) = 0.615
Primary measure:
• Anthropometric
measurements
– body mass index
– linear growth
– growth rate
• Symptom score
• Pulmonary functions
– FVC
– PEF
– FEV1
Secondary measures:
• Bone metabolism
– serum calcium
– serum phosphorus
– serum ALP
– BMD
• Adrenal functions (basal serum
cortisol level)
Method of assessing
outcomes:
Not reported
Length of follow-up:
1 year
Ref.: 204
Author:
Altintas et al.
Year:
2005
Country:
Turkey 
Study design:
Randomised trial 
Number of
centres:
1
Funding:
Not reportedAppendix 4
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Results
Outcomesa Group A Group B p-Value
(n = 15) (n = 15)
FEV1, % predicted values for height and age: assuming reported as mean (SD) 82.8 (10.0) 82.8 (10.0) NA
PEF, % predicted values for height and age: assuming reported as mean (SD) 82.5 (14.3) 82.5 (14.3) NA
SFDs
Nocturnal awakenings
Acute exacerbations
Use of systemic corticosteroids
Use of reliever medication
Mortality
QoL
AEs – n (%)b
Otherc
FVC, % predicted values for height and age: assuming reported as mean (SD) 85.3 (10.7) 85.3 (10.7) NA
Symptom score: mean (SE or SD) 4.2 (0.4) 4.2 (0.4) NA
a It looks incorrect as the symptom score and pulmonary functions before and after therapy for the two groups are identical
including the SE/SD; the outcome extracted are at the end-point (after treatment).
b Reported that the study did not observe any side-effects of ICs, and the study found that long term ICS treatment did not
cause any serious side-effects in children.
c Body mass index and weight percentiles did not change after one year in all groups (p > 0.05). The mean increase in linear
growth from the beginning to the first year of the therapy was statistically significant and similar in all groups (p < 0.05).
Growth rate (cm in 1 year) was 8.4 ± 4.6 cm (95% CI 6.07 to 10.73) in group A and 8.2 ± 6.2 (95% CI 5.06 to 11.34) in
group B (95% CIs were calculated by the reviewers assuming the reported values were presented as mean ± SD). Outcomes
which are not relevant to the review protocol are not extracted.
Methodological comments
• Allocation to treatment groups: reported as randomised trial, but no further details about randomisation and
allocation
• Blinding: not reported
• Comparability of treatment groups: symptom score and pulmonary functions (VC, PEF and FEV1) at baseline are
identical including SE or SD 
• Method of data analysis: used SPSS program for all statistical analysis. Analysis was performed by Mann–Whitney U and
Wilcoxon tests. A p-value <0.05 was considered significant
• Sample size/power calculation: not reported
• Attrition/drop-out: not reported
General comments
• Generalisability: applicable to children with moderate asthma, but not very clear as inclusion and exclusion criteria were
not reported
• Outcome measures: appropriate and objective
• Inter-centre variability: NA
• Conflict of interests: unknown
Quality criteria for assessment of experimental studies
1. Was the assignment to the treatment groups really random? Inadequate 
2. Was the treatment allocation concealed? Inadequate
3. Were the groups similar at baseline in terms of prognostic factors? Inadequate (appears
to be an error)
4. Were outcome assessors blinded to the treatment allocation? Inadequate
5. Was the care provider blinded? Inadequate
6. Was the patient blinded? Inadequate
7. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
8. Did the analyses include an ITT analysis? Unknown 
9. Were withdrawals and drop-outs completely described? Inadequate
ALP , alkaline phosphatase; FVC, forced vital capacity; NA, not applicable; QoL, quality of life; VC, velocity capacity.
From: NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: guidance for
those carrying out or commissioning reviews (Report 4). URL: http://www.york.ac.uk/inst/crd/report4.htm.Health Technology Assessment 2008; Vol. 12: No. 20
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Study Treatment Participants Outcomes
continued
Group A:
n = 101
Drug(s): FP/SAL
Dose: 100/50 µg b.d.
Delivery: Advair Diskus
Duration: 12 weeks
Group B:
n = 102
Drug(s): FP
Dose: 100 µg b.d.
Delivery: Flovent Diskus
Duration: 12 weeks
Run-in period: 
Duration: 2 weeks
ICS: baseline ICS was
continued
Relief: albuterol metered-
dose inhaler for rescue use
Additional treatment
allowed:
Relief: albuterol
Other: not
reported/unknown. (Oral
or parenteral
corticosteroids, cromolyn,
nedocromil, or LABA
were prohibited
throughout the study. Also,
the use of medications that
could affect the course of
asthma or interact with
study medications, such as
anticholinergics,
anticonvulsants, or 
-adrenergic blockers,
was prohibited throughout
the study)
Number randomised: 
203
Sample attrition/drop-out:
35 withdrawals; 19 (19%) were from group
A and 16 (16%) from group B. 7 of the 35
(2 vs 5) were due to worsening asthma
Sample cross-overs:
No 
Inclusion criteria:
For screening:
• Age 4–11 years with asthma (defined by
the American Thoracic Society criteria)
• History of asthma 2 months
• Were receiving ICS (BDP 252–336 µg;
triamcinolone acetonide 600–1000 µg;
flunisolide 1000 µg; FP 88–250 µg; or
BUD 200–400 µg, daily) at a consistent
dose for 1 month before screening
• FEV1 50–95% of the predicted for aged 
6–11 years
• PEF 50–95% of the predicted for aged
4–5 years
• An increase in FEV1 (for aged 6–11 years)
or morning PEF (for aged 4–5 years) of
12% within 30 minutes of inhalation of
2–4 actuations of albuterol (180–360 µg)
or to have a historical documentation of
12% reversibility within the previous
year
For randomisation: 
• A morning FEV1 50–95% of the predicted
for aged 6–11 years or a morning PEF
50–95% of the predicted for aged
4–5 years
• A daytime asthma symptom score of 1
(on a scale from 0 to 5) on 3 days or the
use of albuterol on 3 days during the
7 days before the randomisation visit
• Adequate compliance, defined as 70%
compliance with diary card completion
Exclusion criteria:
• A history of life-threatening asthma
• Hospitalisation due to asthma 2 times in
the previous year
• A significant concurrent disease (e.g. cystic
fibrosis, malignancy or immunological
compromise)
• Recent upper or lower respiratory tract
infection
• Current chickenpox or recent exposure
to chickenpox in a non-immune patient
• Severe milk protein allergy
• Hypersensitivity to beta2 agonist,
sympathomimetic or corticosteroid therapy
• Clinically significant abnormal laboratory
test results
• A history or present use of tobacco
Primary measure:
AEs
Secondary measures:
• Asthma exacerbations
or worsening asthma 
• 2-hour serial post-dose
FEV1 (for aged
6–11 years) or 2-hour
serial post-dose PEF
(for aged 4–5 years)
after the first dose of
study medication on
treatment day 1
• FEV1 (for aged
6–11 years)
• PEF (morning and
evening)
• Daytime asthma scores 
• 24-hour albuterol use
Method of assessing
outcomes:
• Clinic visit after 1, 2, 4,
8 and 12 weeks of
treatment
• Investigators were
responsible for the
detection,
documentation,
intensity evaluation and
causality evaluation of all
AEs
• Parents or guardians’
diary:
– PEF morning and
evening (measured
before taking a dose
of study medication or
albuterol)
– use of albuterol 
– daytime asthma
symptom scores: 0
(no symptoms) to 5
(severe symptoms
that prevented normal
daily activities)
Length of follow-up:
12 weeks
Ref.: 214
Author:
Malone et al.
Year:
2005
Country:
USA and Canada
Study design:
Randomised,
multi-centre,
double-blind,
active-controlled,
parallel-group
Number of
centres:
79
Funding:
GSKAppendix 4
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Study Treatment Participants Outcomes
a Evaluated at screening.
b The total daily dose of ICS was calculated in 93 patients in group A and 89 patients in group B.
Results
Outcomes Group A Group B p-Value
(n = 101) (n = 102)
FEV1, (litres) (for aged 6–11 years) at 12 weeksa 1.88 (n = 80 in this  1.77 (n = 83 in this 
age group)  age group)
Morning PEF (l/minute), mean (SE) change from baselineb 21.5 (±2.79) 16.9 (±2.85)
Evening PEF (l/minute), mean (SE) change from baselineb 21.5 (±2.43) 15.1 (±2.83)
Asthma symptom score, mean (SE) change from baselineb –0.6 (±0.10) –0.5 (±0.12)
% SFDs, mean (SE) change from baselineb 24.4 (±4.10) 21.2 (±4.09)
Nocturnal awakenings
Acute exacerbations: 
• Patients with exacerbation occurred, n (%) 3 (3) 8 (8)
• Withdrawal due to exacerbations, n (%) 2 (2) 5 (5)
Use of systemic corticosteroids
Use of reliever medication (puffs/24 hours), mean (SE) change  –0.5 (±0.22) –0.4 (±0.19)
from baselineb
Mortality
QoL
AEs – n (%)c:
• Any AE 60 (59) 58 (57)
• Patients experienced at least 1 potentially study drug-related AE 13 (13) 9 (9)
continued
• A history or current presence of glaucoma
or posterior subcapsular cataracts 
• Not to have used oral or parenteral
corticosteroids for 1 month before
screening, cromolyn or nedocromil for
1 week before screening, or LABA
within 48 hours of screening
Baseline characteristics:
• Age, mean = 8.05 years
– % 4–5 years = 20
– % 6–11 years = 80
• Male:female = 127:73
• White:black:other = 70:19:11
• Duration of asthma, mean = 5.2 years
• Aged 6–11 years
– FEV1 = 1.68 litres
– FEV1, mean, % predicted = 80.45
– FEV1, mean, % reversibility = 19.3
– historical reversibility, %a = 46
• Aged 4–5 years
– PEF = 142.5 l/minute
– PEF, mean, % predicted = 86.65
– PEF mean, % reversibility = 27.9
– historical reversibility, %a = 20 
• Run-in ICS regimen, patients/daily mean
doseb
– FP = 129/166.5 µg
– BUD = 45/380 µg
– BDP HFA = 2/240 µg
– BDP = 1/ 252 µg
– triamcinolone acetonide = 3/550 µgHealth Technology Assessment 2008; Vol. 12: No. 20
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Outcomes Group A Group B p-Value
(n = 101) (n = 102)
• Withdrawal due to AE 3 (3) 0 (0)
• Patients with oropharyngeal candidiasis occurred 4 (4) 0 (0)
Otherd
a Data taken from linked abstract.215
b Data taken from linked abstract.216
c Data on detailed types of AEs available in Table 2 in the paper.
d Not relevant.
Methodological comments
• Allocation to treatment groups: randomised allocation, but no further details
• Blinding: double-blind (the cardiologists accessing ECGs were blinded to treatment assignment)
• Comparability of treatment groups: reported as comparable at baseline with respect to patient demographics and
pulmonary function
• Method of data analysis: only that it was analysed on an ITT basis was reported
• Sample size/power calculation: no power calculations were performed (because it was a safety study), but estimated
that approximately 100 patients in each treatment arm were sufficient to evaluate the safety of the treatment for group A
compared with the treatment for group B.
• Attrition/drop-out: 35 withdrawals; 19 (19%) were from group A and 16 (16%) from group B. 7 of the 35 (2 vs 5)
were due to worsening asthma. ITT population (defined as all patients who were randomised and received at least one
dose of study drug) was used for all demographic and safety measures except for cortisol excretion
General comments
• Generalisability: relatively inclusive criteria; not applicable to ICS-naïve patients
• Outcome measures: appropriate and objective
• Inter-centre variability: not reported; unclear whether randomisation was stratified by centre
• Conflict of interests: study supported and 4 authors from GSK
Quality criteria for assessment of experimental studies
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were outcome assessors blinded to the treatment allocation? Unknown
5. Was the care provider blinded? Adequate
6. Was the patient blinded? Adequate
7. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
8. Did the analyses include an ITT analysis? Adequate
9. Were withdrawals and drop-outs completely described? Adequate
From: NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: guidance for
those carrying out or commissioning reviews (Report 4). URL: http://www.york.ac.uk/inst/crd/report4.htm.Appendix 4
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Study Treatment Participants Outcomes
a Values = combination of metered and delivered doses.
b Includes combinations of ICS/LABA and LABA.
continued
Group A:
n = 925
Drug(s): BUD/FF
Dose: 80/4.5 µg b.d. as
needed 
Children given half dose
Delivery: Turbuhaler 
Duration: 52 weeks
Group B:
n = 909
Drug(s): BUD/FF
Dose: 80/4.5 µg b.d.
plus terbutaline 0.4 mg
as needed
Children given half dose
Delivery: Turbuhaler
Duration: 52 weeks
Group C:
n = 926
Drug(s): BUD
Dose: 320 µg b.d. 
plus terbutaline 0.4 mg
as needed
Children given half dose
Delivery: Turbuhaler 
Duration: 52 weeks
Run-in period: 
Duration: 14–18 days
ICS: as previously
prescribed
Relief: terbutaline
Additional treatment
allowed:
Nasal glucocorticoids;
antihistamines (except
terfenadin); disodium
cromoglycate and/or
nasal nedocromil
sodium; immunotherapy
(at constant dose during
90 days pre-enrolment);
other medication given
at investigators’
discretion. Severe
exacerbations treated
with 10 days of oral
prednisone (30 µg/day)
Number randomised:
2760
Sample attrition/drop-out:
n = 412 (67 AEs; 111 eligibility criteria not
fulfilled; 47 lost to follow-up; 187 other)
Sample cross-overs:
Not reported
Inclusion criteria:
• Age 4 years
• 1 exacerbations in previous year
• Adults maintained on ICS
400–1000 µg/day and children
maintained on 200–500 µg/day in
previous year
• Constant dose of ICS 3 months
• FEV1 60–100% predicted
• Reversibility: FEV1 12
• For Rx 12 inhalations for adults and/or
8 for children during last 10 days of
run-in. 
Exclusion criteria:
• During run-in: 
• For Rx 10 inhalations reliever
medication on any one day (7 for
children)
• Additional exacerbations
Baseline characteristics:
• Mean age (range) = 36 (4–79) years
• Male:female = 1231:1529 
• 4–11 years, n (%): 341 (12%)
• Mean duration of asthma = 9 years
(range: 0–69)
• FEV1 (litres): 2.12 (range: 0.62–4.50)
• FEV1 % predicted: 73 (range: 43–108)
• FEV1 % reversibility: 21 (range: 2–89%)
• ICS dose at entry (µg/day): 598–620a
• LABA use at entry (n): 250–258 (28%)b
• Reliever use, number of inhalations/day:
1.69–1.74 (range: 0.0–9.4)
• Reliever use, number of
inhalations/night: 0.72 (range: 0–6.6)
• Asthma symptom scale score (0–6): 1.5
(range: 0.0–6.0)
• SFDs (%): 23.5 (range: 0.0–100)
• Reliever-free days (%): 8.4 (range:
0.0–100)
• Asthma control days (%): 5.6 (range:
0.0–90)
• Awakenings (% of nights): 20.9 (range:
0.0–100)
Primary measure:
Time to first severe
exacerbation (defined as
hospitalisation emergency
room treatment; oral steroid
treatment (or an increase in
ICS and/or other additional
treatment for children aged
4–11 years) or morning PEF
70% of baseline on 2
consecutive days)
Secondary measures:
• PEF (morning and evening)
• FEV1
• Time to first mild
exacerbation (defined as
morning PEF 80% of
baseline, 2 reliever
inhalations/day above
baseline or awakenings
caused by asthma)
• Asthma symptom scores
(day/night)
• Rescue medication use
(day/night)
• SFDs
• Rescue medication-free days 
• Asthma control days 
• Nocturnal awakenings
• Mild exacerbation days
• Height (children only)
• AEs
Method of assessing
outcomes:
• Clinic assessments at
beginning and end of run-in
and 1, 3, 6, 9, 12 months
– PEF (morning and evening)
Min-Wright PEF meter
• FEV1 (spirometry at clinic
visits)
• Daily patient diaries
(symptoms, awakenings,
effects and extra medication)
• Electrocardiogram, morning
plasma cortisol, vital signs (at
clinic visits)
• Height measured using local
procedures (before run-in, 6
and 12 months of treatment)
Length of follow-up:
None beyond 12-month
treatment period
Ref.: 198
Author:
O’Byrne et al.
Year: 
2005
Country:
International (22
countries)
Study design:
Randomised,
parallel group,
double-blind 
Number of
centres:
246
Funding:
AZ (Lund,
Sweden)Health Technology Assessment 2008; Vol. 12: No. 20
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Results
Outcomes Group A Group B Group C p-Value
(n = 925) (n = 909) (n = 926)
FEV1, meana over 12-month treatment period 2.51 2.43 2.41 <0.001b; <0.001c; 0.09d
PEF (l/minute), meana over 12-month treatment period <0.001b; <0.001c; <0.001d
Morning 355 346 339
Evening 360 349 345 <0.001b; <0.001c; <0.001d
SFDs (%), meana over 12-month treatment period 54 53 46 0.52b; <0.001c; <0.001d
Nocturnal awakenings (% of nights), meana over 9 12 12 <0.001b; <0.001c; 0.60d
12-month treatment period
Severe exacerbations including PEF falls: patients  16 27 28 <0.001b; <0.001c; 0.74d
with event (%)e
Severe exacerbations resulting in medical intervention:  11 21 19 <0.001b; <0.001c; 0.37d
patients with event (%)e
Use of reliever (inhalations/day), mean over 12 months 0.73 0.84 1.03 <0.001b; <0.001c; <0.001d
Use of reliever (inhalations/night), mean over 12 months 0.28 0.37 0.43 <0.001b; <0.001c; 0.003d
Use of systemic corticosteroids (courses per patient)
Children (4–11 years) 0.05 0.30 0.38
Adults (12–80 years) 0.19 0.42 0.25 NR
Mortality NR NR NR
QoL NR NR NR
1 AEs – n (%) 496 (54%) 475 (52%) 528 (57%) 0.58b; 0.99c; 0.03d
1 serious AEs – n (%) 46 (5%) 62 (7%) 48 (5%)
Pharyngitis – n (%) 88 (10%) 88 (10%) 86 (9%)  0.93b; 0.99c; 0.87d
Respiratory infection – n (%) 158 (17%) 144 (16%) 182 (20%) 0.49b; 0.15c; 0.03d
Rhinitis – n (%) 80 (9%) 72 (8%) 76 (8%) 0.61b; 0.80c; 0.86d
Bronchitis – n (%) 51 (6%) 61 (7%) 76 (8%) 0.29b; 0.02c; 0.25d
Sinusitis – n (%) 43 (5%) 39 (4%) 33 (4%) 0.74b; 0.29c; 0.47d
Headache – n (%) 31 (3%) 35 (4%) 42 (5%) 0.62b; 0.19c; 0.49d
Tremor – n (%) 20 (2%) 18 (2%) 19 (2%) 0.87b; 0.99c; 0.99d
Palpitation – n (%) 10 (1%) 11 (1%) 3 (<0.5%) 0.83b; 0.09c; 0.03d
Tachycardia – n (%) 5 (0.5%) 4 (<0.5%) 3 (<0.5%) 0.99b; 0.73c; 0.72d
Candidiasis – n (%) 9 (1%) 6 (1%) 10 (1%) 0.61b; 0.82c; 0.45d
Dysphonia – n (%) 11 (1%) 13 (1%) 12 (1%) 0.69b; 0.84c; 0.84d
Discontinuation due to respiratory events – n (%) 7 (1%) 15 (2%) 14 (2%) 0.80b; 0.13c; 0.85d
Other: asthma control days (%)f 45 44 37 0.64b; <0.001c; <0.001c
a Least squares mean from two-way ANOVA.
b Group A vs Group B.
c Group A vs Group C.
d Group B vs Group C.
e p-Values based on the instantaneous risk of experiencing at least one severe exacerbation (Cox proportional hazards
model).
f Defined as a day with no symptoms (day or night), no awakenings caused by asthma and no as-needed medication use.
Comments
• Time to first medically managed severe exacerbation was significantly longer in the BUD/FF maintenance + relief group
(group A) compared with the BUD/FF + SABA (group B) and BUD + SABA groups (group C); HR = 0.50 (95% CI 0.40
to 0.64) and 0.55 (95% CI 0.43 to 0.70), respectively.
• The RR of severe exacerbation requiring medical management was reduced by 53% for BUD/FF maintenance + relief
compared with BUD/FF + SABA; HR = 0.47 (95% CI 0.39 to 0.57) and by 46% compared with BUD + SABA; 
HR = 0.54 (95% CI 0.44 to 0.66). The effect of using BUD/FF for maintenance + relief remained constant over time.
continuedAppendix 4
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• Symptom measures improved in all groups compared with baseline in requirement for reliever medication treatment and
night-time awakenings 
• No clinically important differences in ECG, haematology, clinical chemistry or urinalysis were observed between the
treatment groups or over time
• Children in both the BUD/FF groups grew significantly more than those in the BUD + SABA group
Methodological comments
• Allocation to treatment groups: block randomisation by computer-generated list with treatment stratified by age
group in an 8:1 ratio (adults:children)
• Blinding: double-blind with respect to treatment group; unclear whether the outcome assessors were blinded
• Comparability of treatment groups: the groups are reported to be comparable with regard to demographic and
baseline disease characteristics. There appeared to be no baseline imbalance in patient characteristic across the treatment
groups
• Method of data analysis: the primary efficacy analyses of time to first severe asthma exacerbation was described using
Kaplan–Meier plots and a log-rank test, with analysis of instantaneous risk described using a Cox proportional hazards
model. Total numbers of severe exacerbations were compared using a Poisson regression model, with adjustments for
over-dispersion. Secondary efficacy end-points were evaluated by ANCOVA, with the baseline value as covariate and the
mean daily data over the 12-month treatment period as the treatment mean. All hypothesis testing was two-sided, with 
p-values of <5% considered significant
• Sample size/power calculation: designed to have 80% power to detect a 23% reduction in exacerbation rate in any of
the treatment groups
• Attrition/drop-out: all patients who received at least 1 dose of study medication were included in the ITT analysis (for
both efficacy and safety). The attrition rate was 15%, with 4% of randomised patients failing to meet the criterion for 
as-needed medication during the run-in period. Reasons for discontinuations were AEs 2% (n = 67), eligibility criteria not
fulfilled 4% (n = 111), lost to follow-up 2% (n = 47) and other (not specified) 7% (n = 187). The total n analysed for
primary end-point and safety was 2753, with LOCF for missing data. LOCF was not undertaken for three patients in
group A, one in group B and one in group C
General comments
• Generalisability: relatively inclusive eligibility criteria; not applicable to ICS-naïve populations or patients with mild
asthma
• Outcome measures: appropriately defined and objective
• Inter-centre variability: not reported; unclear whether randomisation was stratified by centre and whether centre was
analysed as a covariate in the ANOVA model
• Conflict of interests: study support and one author had received previous funding from AZ
Quality criteria for assessment of experimental studies
1. Was the assignment to the treatment groups really random? Adequate
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported
4. Were outcome assessors blinded to the treatment allocation? Unknown
5. Was the care provider blinded? Unknown
6. Was the patient blinded? Unknown
7. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
8. Did the analyses include an ITT analysis? Partial
9. Were withdrawals and drop-outs completely described? Partial
ANCOVA, analysis of covariance; ANOVA, analysis of variance; HR, hazard ratio; LOCF, last observation carried forward;
NR, not reported.
From: NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: guidance for
those carrying out or commissioning reviews (Report 4). URL: http://www.york.ac.uk/inst/crd/report4.htm.Health Technology Assessment 2008; Vol. 12: No. 20
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Study Treatment Participants Outcomes
a Measured before taking study medication or rescue salbutamol.
continued
Group A:
n = 125
Drug(s): FP/SAL
Dose: 100/50 µg b.d.
Delivery:
combination inhaler
(dry power inhaler)
Duration: 12 weeks
Group B:
n = 132
Drug(s): FP + SAL
Dose: 100 + 50 µg
b.d.
Delivery: concurrent
separate inhaler (dry
power inhaler)
Duration: 12 weeks
Run-in period: 
Duration: 2 weeks
ICS: continued to
take their regular
inhaled
corticosteroid
Relief: salbutamol
inhaler as required 
Additional
treatment allowed:
Relief: salbutamol as
required for
symptomatic relief
Other: any other
concurrent
medication provided
the dose remained
constant
Number randomised:
257
Sample attrition/drop-out:
10 (4%) with 5 (2%) in each group
Sample cross-overs:
Not reported
Inclusion criteria:
• Aged 4–11 years
• Reversible airways obstruction
• Remained symptomatic on ICS treatment alone
(BDP , BUD or flunisolide at dose of
400–500 µg/day, or FP at a dose of
200–250 µg/day for at least 4 weeks before the
start of the study run-in period)
• A symptom score (day- and night-time) of 1 on
at least 4 of the last 7 consecutive days of the run-
in period
• A mean PEF (morning) over the 7 days that was
50–85% of the PEF measured 15 minutes after
inhaled salbutamol (400 µg)
• PEF 50% of predicted normal
Exclusion criteria:
• Had changed asthma medication or had taken
salmeterol or any other long-acting beta2 agonists
or oral beta2 agonists in the 4 weeks before the
start of the run-in period
• Had a lower respiratory tract infection
• Had taken oral, depot or parenteral
corticosteroids during the 4 weeks before the run-
in period
• Had received 2 courses of oral, depot or
parenteral corticosteroids within 12 weeks of the
run-in period
• Had suffered an acute exacerbation of reversible
airways obstruction requiring hospitalisation
• Unable to use a mini-Wright peak flow meter
• Had known hypersensitivity to inhaled
corticosteroids, beta2 agonists, or lactose
• Had received any investigational drug within the
previous month
• Females who had reached menarche
Baseline characteristics:
• Mean age (range) = 7.6 (4–11) years
– 4–5 years = 27
– 6–7 years = 34
– 8–11 years = 67.5
• Sex (male:female) = 151:106
• Mean duration of asthma
– <1 years = 10.5
– 1–5 years = 72.5
– >5 years = 45.5
• Mean history of atopy, n = 84
• Mean clinic PEF (l/minute)
– % predicted = 243
– reversibility, % =10
• Concurrent asthma medication (ketotifen), n = 1
Primary measure:
• Mean PEF (morning
and evening)
Secondary measures:
• FEV1
• AEs
Method of assessing
outcomes:
• Clinic assessment at
beginning of the run-
in and treatment
periods, at 2, 4, 8 and
12 weeks during
treatment, and
2 weeks after study
treatment ended
• FEV1
a: when possible
at each clinic visit;
highest of three
readings on each
occasion
• Daily measurement
on a diary card:
– PEF (morning)a:
highest of three
readings on each
occasion; measured
with a mini-Wright
peak flow meter and
recorded
– day- and night-time
symptom scores
– any use of
salbutamol rescue
medication
• Compliance with
treatment: calculated
from the number of
doses used divided by
the expected use
Length of follow-up:
14 weeks
Ref.: 218
Author:
Van den Berg
et al.
Year:
2000
Country:
9 countries
Study design:
Randomised,
double-blind,
double-dummy,
parallel-group
design
Number of
centres:
35
Funding:
Glaxo Wellcome
Research and
DevelopmentAppendix 4
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Results
Outcomes Group A Group B p-Value
(n = 125) (n = 132)
FEV1
a, (litres): adjusted mean change from baseline at week 12 0.21 0.13 0.052
PEF, (l/minute): adjusted mean change from baseline at week 12
Morningb 33 28 0.103
Eveningc 29 25 0.164
SFDsd
Nocturnal awakenings
Acute exacerbations
Use of systemic corticosteroids
Use of reliever medicatione
Mortality
QoL
AEsf – n (%): patients  13 (10) 6 (5)
PEF (morning) predicted, %: adjusted mean change from baseline  15 13 0.361
at week 12
Patients had a median symptom score of zero, n (%): mean change 
from baseline at endpoint
Daytime 76 (61) 78 (59) 0.904
Night-time 97 (78) 100 (76) 0.799
a The difference between the two treatments was not significant at week 12 (–0.08 litres, 95% CI –0.14 to –0.01, p = 0.05)
or at any other time points.
b The adjusted change in mean morning PEF between the two treatment groups at other time intervals was similar to that
for weeks 1–12, except at week 2 there was a significant difference in favour of combination therapy (–9 l/minute, 95% CI
–15 to –3, p = 0.017).
c The adjusted change in evening PEF for most other periods were similar to that for weeks 1–12, except at week 2 there
was a significant difference in favour of combination therapy (–8 l/minute, 95% CI –13 to –2, p = 0.027).
d There was no significant difference between the two groups in median percentages of SFDs and SFNs during the 12 weeks.
e There was no significant difference between the two groups in rescue-free days and nights during the 12 weeks.
f  Considered by investigator to be drug-related (detailed AEs reported in Table 3 in the paper).
Methodological comments
• Allocation to treatment groups: stated as randomised trial, but no details reported
• Blinding: double-blind with respect to the interventions
• Comparability of treatment groups: reported as the two treatment groups were similar with respect to demographic
characteristics, history of asthma and baseline lung function
• Method of data analysis: treatment groups were defined as equivalent if the 95% CI for the difference between mean
PEF (morning) during combination and concurrent therapy was within ±15 l/minute. All tests were carried out at the
two-sided 5% level of significance. PEF and FEV1 values were analysed using ANCOVA, adjusting for baseline, age, gender
and country. Centres were grouped by country to avoid the effects of too few patients in any one centre. Symptom
scores and use of rescue medication were analysed using the Van Elteren extension to the Wilcoxon rank sum test
• Sample size/power calculation: not reported
• Attrition/drop-out: 10 (4%) patients withdrew with 5 (4%) from each treatment group; 2 (2%) patients withdrew
from each group due to AEs. Analyses were performed on an ITT basis
General comments
• Generalisability: relatively inclusive eligibility criteria; not applicable to ICS-naïve population
• Outcome measures: appropriate and objective
• Inter-centre variability: not reported; no stratification of randomisation by centre described
• Conflict of interests: supported by Glaxo Wellcome Research and Development and one author from it
continuedHealth Technology Assessment 2008; Vol. 12: No. 20
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Quality criteria for assessment of experimental studies
1. Was the assignment to the treatment groups really random? Unknown
2. Was the treatment allocation concealed? Unknown
3. Were the groups similar at baseline in terms of prognostic factors? Reported 
4. Were outcome assessors blinded to the treatment allocation? Unknown
5. Was the care provider blinded? Unknown 
6. Was the patient blinded? Adequate 
7. Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
8. Did the analyses include an ITT analysis? Adequate
9. Were withdrawals and drop-outs completely described? Adequate 
From: NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: guidance for
those carrying out or commissioning reviews (Report 4). URL: http://www.york.ac.uk/inst/crd/report4.htm. RCT
Pohunek P, Kuna P, Jorup C, De Boeck K.
Budesonide/formoterol improves lung function
compared with budesonide alone in children with
asthma. Pediatr Allergy Immunol 2006;17:458–65.
Systematic review
Pedersen S. Clinical safety of inhaled
corticosteroids for asthma in children: an update
of long-term trials. Drug Saf 2006;29:599–612.
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Appendix 5
Systematic review of clinical effectiveness: 
list of studies from updated literature search to 
be included in any future update of the 
assessment reportGeppe NA, Karpushkina AV, Kolossova NG, Yarovaya EB.
The effects of fluticasone propionate/salmeterole
50/100 µg bid in children with asthma versus
beclometasone propionate 200 µg BD and fluticasone
propionate 100 µg bid dry powder inhalers [Abstract].
Eur Respir J 2004;24:378s.
GlaxoSmithKline. A multicentre, randomised, double-blind,
double-dummy, parallel group comparison of three treatments:
(1) salmeterol/fluticasone propionate (SFC) (50/100 µg
strength) bd via DISKUS/ACCUHALER inhaler, (2)
fluticasone propionate 200 µg bd via DISKUS/ACCUHALER
inhaler, (3) fluticasone propionate 100 µg bd via
DISKUS/ACCUHALER inhaler in children aged 4–11 years
with asthma. URL: www.clinicalstudyresults.org. 2004.
Mokina NA, Geppe NA. The experience of study of
comparative efficiency of steroid fluticasone and becla
metasone at children [Abstract]. Eur Respir J 2004;
24:165s. 
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Appendix 6
Systematic review of clinical effectiveness: 
conference abstracts identified in the clinical
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Volume 1, 1997
No. 1
Home parenteral nutrition: a systematic
review.
By Richards DM, Deeks JJ, Sheldon
TA, Shaffer JL.
No. 2
Diagnosis, management and screening
of early localised prostate cancer.
A review by Selley S, Donovan J,
Faulkner A, Coast J, Gillatt D.
No. 3
The diagnosis, management, treatment
and costs of prostate cancer in England
and Wales.
A review by Chamberlain J, Melia J,
Moss S, Brown J.
No. 4
Screening for fragile X syndrome.
A review by Murray J, Cuckle H,
Taylor G, Hewison J.
No. 5
A review of near patient testing in
primary care.
By Hobbs FDR, Delaney BC,
Fitzmaurice DA, Wilson S, Hyde CJ,
Thorpe GH, et al.
No. 6
Systematic review of outpatient services
for chronic pain control.
By McQuay HJ, Moore RA, Eccleston
C, Morley S, de C Williams AC.
No. 7
Neonatal screening for inborn errors of
metabolism: cost, yield and outcome.
A review by Pollitt RJ, Green A,
McCabe CJ, Booth A, Cooper NJ,
Leonard JV, et al.
No. 8
Preschool vision screening.
A review by Snowdon SK, 
Stewart-Brown SL.
No. 9
Implications of socio-cultural contexts
for the ethics of clinical trials.
A review by Ashcroft RE, Chadwick
DW, Clark SRL, Edwards RHT, Frith L,
Hutton JL.
No. 10
A critical review of the role of neonatal
hearing screening in the detection of
congenital hearing impairment.
By Davis A, Bamford J, Wilson I,
Ramkalawan T, Forshaw M, Wright S.
No. 11
Newborn screening for inborn errors of
metabolism: a systematic review.
By Seymour CA, Thomason MJ,
Chalmers RA, Addison GM, Bain MD,
Cockburn F, et al.
No. 12
Routine preoperative testing: 
a systematic review of the evidence.
By Munro J, Booth A, Nicholl J.
No. 13
Systematic review of the effectiveness 
of laxatives in the elderly.
By Petticrew M, Watt I, Sheldon T.
No. 14
When and how to assess fast-changing
technologies: a comparative study of
medical applications of four generic
technologies.
A review by Mowatt G, Bower DJ,
Brebner JA, Cairns JA, Grant AM,
McKee L.
Volume 2, 1998
No. 1
Antenatal screening for Down’s
syndrome.
A review by Wald NJ, Kennard A,
Hackshaw A, McGuire A.
No. 2
Screening for ovarian cancer: 
a systematic review.
By Bell R, Petticrew M, Luengo S,
Sheldon TA.
No. 3
Consensus development methods, and
their use in clinical guideline
development.
A review by Murphy MK, Black NA,
Lamping DL, McKee CM, Sanderson
CFB, Askham J, et al.
No. 4
A cost–utility analysis of interferon 
beta for multiple sclerosis.
By Parkin D, McNamee P, Jacoby A,
Miller P, Thomas S, Bates D.
No. 5
Effectiveness and efficiency of methods
of dialysis therapy for end-stage renal
disease: systematic reviews.
By MacLeod A, Grant A, 
Donaldson C, Khan I, Campbell M,
Daly C, et al.
No. 6
Effectiveness of hip prostheses in
primary total hip replacement: a critical
review of evidence and an economic
model.
By Faulkner A, Kennedy LG, 
Baxter K, Donovan J, Wilkinson M,
Bevan G.
No. 7
Antimicrobial prophylaxis in colorectal
surgery: a systematic review of
randomised controlled trials.
By Song F, Glenny AM.
No. 8
Bone marrow and peripheral blood
stem cell transplantation for malignancy.
A review by Johnson PWM, Simnett SJ,
Sweetenham JW, Morgan GJ, Stewart LA.
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